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Abstract 
Background: Thyroid cancer is generally associated with an excellent 
prognosis, but there is significant long-term morbidity with standard treatment, 
and some sub-types have poor prognosis.  Metformin, an oral anti-diabetic 
drug is shown to have anti-cancer effects in several types of cancer (breast, 
lung and ovarian cancer).  Proposed mechanisms include activation of 
Adenosine Mono-phosphate-activated Protein Kinase (AMPK) pathway; 
inhibition of mTOR pathway; reduction in blood glucose and insulin levels by 
inhibiting hepatic gluconeogenesis and increasing peripheral glucose uptake. 
OCT1 (organic cation transporter 1) helps in the uptake of Metformin into liver 
cells. 
 
Aims: Explore the anti-cancer effect of Metformin on the growth and 
proliferation of thyroid cancer cell lines.  
 
Methods: The effects of Metformin on thyroid cancer cell lines (FTC-133, 
K1E7, RO82-W-1, 8305C and TT) and normal thyroid follicular cells (Nthy-ori 
3-1) were investigated using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl 
tetrazolium bromide) assay for cell proliferation; clonogenic assay; 
Fluorescence-activated Cell Sorting (FACS) analysis for apoptosis (using 
double staining with Annexin V-FITC stained early apoptotic cells and 
propidium iodide stained late apoptotic cells) and cell cycle (using propidium 
iodide staining); and H2A.X phosphorylation (γH2AX) assay for DNA repair. 
Immunocytochemistry was used to investigate OCT1 expression to evaluate 
the mechanism of action of Metformin.  The effects of Thyroid Stimulating 
Hormone (TSH), insulin and Insulin-like Growth Factor- 1 (IGF-1) on the 
response to Metformin treatment were also investigated.  Affymetrix assay 
was used for gene expression profiling of cell lines before and after Metformin 
treatment. 
 
Results: Metformin inhibited cell proliferation and colony formation at a 
minimum concentration of 0.03 mM and increased the percentage of apoptotic 
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cells at concentrations of 0.1 mM and above.  Metformin also induced cell 
cycle arrest in G0/G1 phase at minimum concentration of 0.3 mM.  Unlike 
previous reports, Metformin did not appear to affect response to DNA repair. 
OCT1 expression was observed in all thyroid cancer cell lines, but no 
significant difference was observed in the proportion and intensity of OCT1 
expression in Metformin treated and non-treated cells.  Anti-cancer effects of 
Metformin (cell proliferation and apoptosis) was amplified in the glucose-free 
medium compared to glucose-rich medium.  Metformin inhibited cell 
proliferation regardless of the presence of TSH, IGF-1 and insulin in the 
medium. Metformin modulated the expression of numerous genes and 
provided clues to the mechanism of action.  
Conclusion: Metformin suppresses thyroid cancer proliferation in vitro at 
concentrations within the therapeutic range for diabetic patients.  This effect 
appears to be independent of TSH, insulin, glucose and IGF-1. Further work 
is needed to determine the molecular mechanisms underlying the observed 
effects.  
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1.1 Introduction 
Thyroid cancer is a relatively uncommon malignancy (less than 1% of all cancers 
registered in the UK). However, it is the most common endocrine cancer, accounting 
for more than 90% of these tumours [1, 2].  The majority of thyroid cancer types have 
an excellent prognosis; but there are concerns over long-term morbidity associated 
with standard treatment regimes.  Some types and subtypes of thyroid cancer are 
associated with poor prognosis and novel treatment options are being tried. 
Metformin (N’, N’-dimethybiguanide) is an oral anti-diabetic drug of the Biguanide 
class and one of the most commonly prescribed drugs worldwide; accounting for 
nearly 120 million prescriptions a year [3].  It is the first drug of choice in most 
patients with type 2 diabetes and has been licensed for use in in UK since 1958 [4-
6].  Metformin has recently been investigated for possible anti-cancer effects by 
activating the Adenosine Mono-phosphate-activated Protein Kinase (AMPK) pathway 
in several types of cancer.  
1.2 Thyroid Gland 
1.2.1 Thyroid Gland Anatomy 
The thyroid gland is situated at the front of the neck (overlying the 2nd, 3rd, and 4th 
tracheal rings) and consists of two lateral pear-shaped lobes joined by an isthmus in 
the middle [7, 8].  Thyroid gland is very vascular; being supplied mainly by superior 
and inferior thyroid arteries.  Extensive anastomoses occur between the main thyroid 
arteries and branches of the tracheal and oesophageal arteries [7].  The veins 
draining thyroid gland are the superior, inferior and middle thyroid veins [7-9].  There 
is an extensive lymphatic network within the gland.  Although some lymph channels 
pass directly to the deep cervical nodes, the subcapsular plexus drains principally to 
the juxta-thyroidal (i.e. pretracheal and paratracheal) nodes and nodes around the 
superior and inferior thyroid veins before passing to the deep cervical and 
mediastinal groups of nodes [7]. 
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1.2.2 Thyroid Gland Physiology 
The thyroid gland secretes a number of thyroid hormones; of which thyroxine (T4) 
and Tri-iodothyronine (T3) are the most important (Figure 1.1).  Other hormones of 
little physiological significance include reverse T3, T1 and T2 [10].  The production 
and release of T3 and T4 in the thyroid gland is stimulated by Thyroid Stimulating 
Hormone (TSH) [7, 11] as part of the hypothalamo-pituitary-thyroid axis.  T4 is 
secreted in much larger amounts by the gland, but is converted by mono-
deiodination in the circulation and tissues to the more potent T3.  The conversion of 
T4 to T3 is decreased by many factors such as illness (cancer, heart diseases, liver 
diseases, kidney diseases and infections), drugs, injury, malnutrition and starvation.   
T3 and T4 are lipid soluble hormones and carried in the blood by proteins (thyroid 
binding globulin, transthyretin and albumin). They cross the cell membrane and bind 
to thyroid hormone receptors in the nucleus.  Thyroid-hormone receptors are nuclear 
acidic proteins associated with chromatin and bind to specific DNA sequences when 
activated [7].   
Thyroid hormones encourage various metabolic activities in most tissues in the body; 
thereby increasing the basal metabolic rate.  This increases oxygen consumption 
and body temperature.  Thyroid hormones enhance lipid metabolism, increase fatty 
acid oxidation in tissues and fatty acid concentration in plasma [12].  As a result 
blood cholesterol and triglyceride levels are decreased. Thyroid hormones stimulate 
gluconeogenesis and glycogenolysis.  Thyroid hormones are necessary for normal 
growth in children; therefore their deficiency causes growth retardation.  They also 
have effects on growth and development of nervous system (especially in foetal and 
neonatal brain) [13] and enhance the activity of the sympathetic nervous system - 
increase heart rate, cardiac contractility and blood flow. 
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Figure 1.1: Regulation of thyroid hormone synthesis and release. 
 
1.2.3 Thyroid Diseases 
Thyroid diseases are often classified on the basis of thyroid function – i.e. 
hyperthyroidism and hypothyroidism.  However, a significant number of thyroid 
pathologies are due to structural abnormalities where the patient is euthyroid, i.e. 
has normal thyroid function.  These can be categorised as a separate group (thyroid 
nodules and goitre). 
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1.2.3.1 Hyperthyroidism 
In hyperthyroidism the T4 and T3 levels are raised but TSH is low or undetectable.  
Occasionally, T3 levels alone (and not T4) can be raised.  Hyperthyroidism is much 
more common in women (~10 times).  The prevalence in women is 0.5-2%.  It is 
more common in iodine-deficient areas of the world [1].  In subclinical 
hyperthyroidism, serum thyrotropin (TSH) is low, but free thyroxine (T4) and serum 
T3 concentrations are normal [14]. 
Aetiology 
The common causes of hyperthyroidism are Graves’ disease (a form of autoimmune 
thyroiditis), multinodular goitre and autonomously functioning solitary thyroid nodule 
[14]. Rare causes include drugs (such as amiodarone and lithium), TSH secreting 
pituitary lesions, differentiated thyroid cancer and ectopic sources of thyroid 
hormones such as struma ovarii. 
Clinical features 
The clinical features are numerous and involve a number of different organ systems.  
They include 
1. General - weight loss with a normal or increased appetite, heat intolerance, 
fatigue, sweating, palmar erythema (redness), spider naevi (a dilated arteriole 
forming a red papule from which radiated prominent capillaries), onycholysis 
(separation of nail from its bed), alopecia (loss of hair), pigmentation 
(colouration of the skin), vitiligo (patches of loss of skin pigmentation), 
clubbing (nail become convex), pretibial myxoedema (dry firm waxy swelling 
of skin), gynaecomastia (enlargement of breast tissue in males), 
lymphadenopathy and osteoporosis (loss of bone tissue and liable to 
fracture). 
2. Gastrointestinal - diarrhoea and steatorrhoea (due to fat malabsorption), 
anorexia, vomiting. 
3. Cardiovascular - palpitations, sinus tachycardia, atrial fibrillation, increased 
pulse pressure, ankle oedema, angina and dyspnoea on exertion. 
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4. Respiratory - exacerbation of asthma. 
5. Muscular and nervous system - tremor and irritability, hyperreflexia, muscle 
weakness, proximal myopathy. 
6. Reproductive system - amenorrhoea/oligomenorrhoea, infertility, loss of libido, 
and impotence. 
7. Eyes - lid retraction, lid lag, excessive lacrimation, chemosis (conjuctival 
swelling), exophthalmos (protrusion of eyeballs), corneal ulceration, diplopia, 
papilloedema (swelling of retina) and loss of visual acuity.  
Investigations 
Thyroid function tests are used to diagnosis hyperthyroidism (Table 1.1 and Figure 
1.2).  TSH receptor antibody (TSHRAb) levels may be estimated to determine 
aetiology as in Graves’ disease [15].  In some patients (such as those with 
multinodular goitre) with hyperthyroidism, a radio-isotope scan will be required to 
determine if a specific nodule is the cause of the problem, as this may influence 
subsequent management [16]. 
Treatment 
Treatment is aimed at addressing the excess production and release of thyroid 
hormones.    Antithyroid drugs such as Carbimazole or Propylthiouracil are often 
used to render patients euthyroid in the first instance.  The relapse rate following 
cessation of anti-thyroid drugs is more than 50% and subsequent treatment options 
such as Radioactive Iodine (RAI) or surgery depend on response to anti-thyroid 
drugs, age, patient choice and local facilities [17].  
Radioactive iodine can be useful in patients who have recurrence of hyperthyroidism 
following surgery and patients with hyperthyroidism who are older than 40 years [18].  
Surgery is often preferred as definitive treatment in patients with large goitres, 
associated significant Graves’ ophthalmopathy and situations where RAI is 
contraindicated (such as pregnancy or lactation) or less preferred (women with 
young children) [19].  The surgical approach is usually a total thyroidectomy.  
Subtotal resections used to be performed in the past, but that was associated with 
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the risk of recurrence.  Disadvantages of surgery include complications such as 
hypoparathyroidism, recurrent laryngeal nerve injury, and the need for life-long 
thyroxine [20].   
 
1.2.3.2 Hypothyroidism  
Primary hypothyroidism is the most common form of hypothyroidism and is due to a 
primary pathology in the thyroid gland.  In primary hypothyroidism, free T3 (FT3) and 
free T4 (FT4) levels are low and the TSH is raised.  The prevalence of primary 
hypothyroidism is more common in women [14].  Secondary hypothyroidism is due to 
pituitary disease.  In secondary hypothyroidism FT4 is low and TSH is undetectable. 
Subclinical hypothyroidism: is defined by raised (TSH) and normal FT4.  The 
frequency of subclinical hypothyroidism and its impact on physiology and the risk of 
long-term complications are unclear [14]. Repeat measurements and monitoring is 
usually done before institution of treatment in symptomatic cases as the condition 
may be transient [14].  
Aetiology 
The most common cause of primary hypothyroidism is Hashimoto’s thyroiditis.  Other 
causes include spontaneous atrophic hypothyroidism, radio-iodine ablation (I¹³¹) and 
thyroid surgery. 
Clinical features 
In the early stages, patients are often asymptomatic and the diagnosis is made on 
routine biochemical testing.  Symptoms are often non-specific and diverse.  Clinical 
features include tiredness, weight gain, cold intolerance, hoarseness, goiter, poor 
hearing, non-pitting edema, myxedema, periorbital puffiness, anemia, bradycardia, 
hypertension, pericardial and pleural effusion, carpel tunnel syndrome and 
depression. 
Investigations 
Thyroid function tests are used to diagnose hypothyroidism (Table 1.1 and Figure 
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1.2).  FT3 levels are not routinely measured for the diagnosis of hypothyroidism as 
they correlate well with FT4 levels and do not independently influence management. 
Treatment  
Thyroid hormone replacement therapy; Thyroxine should be given as a single dose 
and is usually started at low doses (such as 50 µg per day).  Further dose 
escalations are titrated to TSH levels and symptoms and are done in increments of 
25 µg every few weeks to months. The optimal dose of thyroxine in most patients is 
the dose that restores serum TSH to the lower part of the normal reference range 
[21].  
Table 1.1: Thyroid function test results in thyroid diseases. 
Thyroid diseases FT3 FT4 TSH 
Hyperthyroidism  Raised Raised Low 
T3 thyrotoxicosis  Raised  Normal  Low 
Subclinical hyperthyroidism Normal Normal Low 
Primary hypothyroidism Low Low  Raised  
Secondary hypothyroidism Low Low  Low  
Subclinical hypothyroidism  Normal Normal  Raised  
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Figure 1.2: An algorithm to explain the diagnosis of thyroid dysfunction. 
This is based on biochemical measurements of TSH, FT4 and FT3 levels. The biochemical tests are 
shown in yellow boxes and the clinical conditions are shown in blue boxes.  
 
1.2.3.3 Thyroid Nodules and Goitre 
Thyroid nodules are very common in the population. The prevalence may be as high 
as 50%; but only up to 5% of patients presenting with thyroid nodules have cancer 
TSH
LowHighNormal
Euthyroid FT3, FT4
NormalHigh
FT4
Hyperthyroidism Subclinical
hyperthyroidism
Low Normal
Hypothyroidism Subclinical hypothyroidism
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[22].  In patients presenting with thyroid nodules, the most important question is 
whether the nodule is benign or malignant. 
Goitre is the term used to describe any single, diffuse or multinodular enlargement of 
thyroid. Its enlargement during puberty, pregnancy and lactation is called 
physiological goitre [14].  
Thyroid nodule(s) or pathological goitre may be due to a variety of benign and 
malignant conditions.  Benign thyroid neoplasms include follicular adenoma (colloid, 
simple, fetal, embryonal, and hurthle cell), hyperplastic nodules and rarely papillary 
adenoma.  Rare causes include teratoma, lipoma, c-cell adenoma and dermoid 
cysts.  Non-neoplastic thyroid abnormalities that may present as a thyroid 
nodule/goitre include colloid goitre, thyroiditis, thyroid cyst, hemi-agenetic thyroid, 
infections and granulomatous diseases (sarcoidosis).  Non-thyroidal lesions that may 
be considered in the differential diagnoses of a thyroid nodule include 
lymphadenopathy, thyroglossal cyst, laryngocele, lymphatic cysts, parathyroid cysts 
and rarely aneurysms. 
The vast majority of the above mentioned pathological conditions are independent of 
thyroid function (hypo- or hyperthyroidism).  Occasionally, some conditions such as 
thyroiditis present with both thyroid dysfunction and a thyroid mass/nodule. 
1.2.3.4  Thyroid cancer 
Thyroid cancer can be classified according to the cell of origin: 
a) Follicular cells 
 Differentiated Thyroid Cancer (DTC): Papillary Thyroid Cancer (PTC), 
Follicular Thyroid Cancer (FTC) and Hurthle Cell Cancer (HCC) 
 Undifferentiated Thyroid Cancer: Anaplastic Thyroid Cancer (ATC) 
b) Parafollicular C cells: Medullary Thyroid Cancer (MTC) 
c) Lymphocytes: Lymphoma 
d) Secondaries. 
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Figure 1.3: Percentage of thyroid cancer types. 
 (DTC = Differentiated Thyroid Cancer; MTC = Medullary Thyroid Cancer; ATC = Anaplastic Thyroid 
Cancer). 
 
1.2.3.5 Epidemiology of Thyroid Cancer 
As shown in figure 1.3, papillary thyroid cancer is the most common type of thyroid 
cancer [23, 24] and accounts for around 80% of all differentiated thyroid cancer [25].  
The relative proportions of other cancer subtypes are as shown in figure 1.3.  
Overall, the incidence of thyroid cancer has increased by 58% in many populations 
worldwide (Europe, Asia, Oceania and Americas), except in Sweden where the 
incidence of thyroid cancer decreased by 18% from 1973-2002 [26].  The incidence 
of thyroid cancer varies according to geographical distribution, age and sex.  The 
highest incidence of thyroid cancer was reported in USA [26, 27] and Israel and the 
lowest incidence was reported in Uganda from 1973-2002 [26] (Figure 1.4).  
The incidence of thyroid cancer in UK from 1976-2005 was 13.83/million, 
8.88/million, 8.71/million and 8.71/million person/year in Scotland, Northern and 
Yorkshire, north west and Wales respectively [28].  
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With regards to the subtypes, the incidence of papillary thyroid cancer has increased 
significantly over the last thirty years [23];  follicular thyroid cancer and medullary 
thyroid cancer have remained stable [23]; and the incidence of anaplastic thyroid 
cancer has remained stable [29] or decreased [23, 27].  The reason for the increase 
of papillary thyroid cancer is as yet not clear but suggested reasons include over 
diagnosis and increased exposure to radiation.   
 
Figure 1.4: Incidence of thyroid cancer. 
The figure shows the incidence of thyroid cancer per 100000 people and varied according to 
worldwide distribution from 1998 to 2002 in both sexes.   
The prognosis of papillary and follicular thyroid cancer is very good (>80% 10 year 
survival) when treated appropriately; that of medullary is intermediate (75% 10 year 
survival) and anaplastic thyroid cancer is poor (14% 10 year survival) [30].  
Anaplastic thyroid cancer accounts for 2% of all thyroid cancer but is the cause of up 
to 15% thyroid cancer mortality [31]. 
Thyroid cancer is more common in women than men [23, 32] but the mortality rates 
are higher in men than women [23].  The risk factors for thyroid cancer include 
radiation exposure and family history [33].   Radiation exposure can be in the form of 
external radiotherapy for treatment or exposure to a nuclear accident. 
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1.2.3.6 Thyroid cancer management 
General principles 
A patient with suspected thyroid nodule or cervical lymphadenopathy undergoes a 
detailed clinical assessment to enable a clinical diagnosis to be made.  A clinical 
diagnosis of a thyroid nodule has three components: 
1.  Structural/anatomical – is it a solitary nodule, dominant nodule in a 
multinodular goitre, multinodular goitre or a diffuse goitre? 
2. Physiological – is the patient clinically euthyroid, hypothyroid or hyperthyroid? 
3.  Pathological – is the nodule suspicious for cancer? 
 Investigations are done along the following lines: 
1. Blood tests (T4 and TSH) – this is to confirm or exclude thyroid dysfunction. 
Thyroid Peroxidase (TPO) is an enzyme found in thyroid follicular cells.  TPO 
catalyses important several steps in thyroid hormone synthesis. TPO antibody 
is formed in blood against TPO in patients with autoimmune thyroid disease. 
Thyroid peroxidase antibodies are often routinely performed in the 
investigation of patients with thyroid disease. A high result in a euthyroid 
patient could be an indication of subsequent hypothyroidism. 
2. Fine Needle Aspiration Cytology (FNAC): Fine-needle aspiration is currently 
the most accurate test in the preoperative diagnosis of thyroid cancer [34-37].  
FNAC can diagnose papillary thyroid cancer, medullary thyroid cancer and 
anaplastic thyroid cancer [24, 34-36]; however it cannot distinguish between 
follicular adenoma and follicular carcinoma.  Core needle biopsies are 
sometimes recommended when fine-needle aspiration test is suspicious of 
lymphoma or metastases [34].  The accuracy of fine needle aspiration test is 
related to the experience of the physician or the person who is performing and 
evaluating the fine-needle aspiration [34]; however, molecular marker 
analysis, particularly in indeterminate specimens, is beginning to play a more 
prominent role [24].  
3. Radiological imaging: Ultrasound of the neck is a good non-invasive and 
radiation-free imaging modality to investigate thyroid lumps; often used as 
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part of routine assessment in all patients presenting with thyroid nodules. It 
can differentiate solid from cystic lesions, identify associated 
lymphadenopathy in the neck and detect non-palpable nodules. Certain 
features on ultrasound such as vascularity, regularity of margins, presence 
and nature of calcifications can help differentiate benign from malignant 
nodules. 
Computerised Tomography (CT) of neck and mediastinum can be useful to 
evaluate thyroid cancer metastasis and to detect laryngeal invasion [34].  It is 
used in patients suspected of having locally invasive cancers, lymph node 
metastases and in patients with retrosternal goitre to assess the extent of 
retrosternal extension. Magnetic Resonance Imaging (MRI) of neck is also 
occasionally used to assess soft tissue invasion [34]. 
4. Preoperative screening for phaeochromocytoma and primary 
hyperparathyroidism should be performed if medullary thyroid cancer is 
suspected [34].  This enables detection and early treatment of these 
associated conditions in patients with MEN II (Multiple Endocrine Neoplasia 
type II) syndrome; of which medullary thyroid cancer is a component.  
1.2.3.6.1 Thyroid cancer staging 
American Joint Committee on Cancer (AJCC) has designed a staging system using 
the TNM classification (Table 1.2). 
Table 1.2: AJCC TNM staging 
 DTC  
< 45 years 
DTC  
>45 years 
ATC MTC 
Stage I 
 
Any T, any N, 
M0 
T1, N0, M0  T1, N0, M0 
Stage II 
 
Any T, any N, 
M1 
T2 - T3, N0, 
M0 
 T2-T4, N0, M0 
Stage III 
 
 T4, N0, M0 
Any T, N1,M0 
 Any T, N1, M0 
Stage IV 
 
 Any T, any N, 
M1 
All considered 
as stage IV 
 
Any T, any N, 
M1 
T= size and extent of the primary tumour (T1≤1cm; 1 cm<T2 ≤4 cm; T3 >4 cm; T4 direct invasion 
through the thyroid capsule); N = the absence (N0) or presence (N1) of regional node involvement; 
M= the absence (M0) or presence (M1) of metastases. 
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Management of specific cancer types: 
 
1. Differentiated Thyroid Cancer (DTC) 
 Surgery:  The surgical options are unilateral total lobectomy, total 
thyroidectomy and more extensive resection.  Patients with papillary thyroid 
cancer and follicular thyroid cancer >1 cm undergo a total thyroidectomy [34, 
38].  Lymph node dissection is usually performed only when the tumour has 
metastasised to lymph nodes [34]. Specific surgical complications include 
recurrent laryngeal nerve injury and hypoparathyroidism [34].   
 Radioiodine ablation (RIA): RIA is recommended in most patients following 
surgery for tumours >1 cm as an adjuvant to reduce risk of local and distant 
recurrence. Further doses of radio-iodine may be used in patients with 
residual or recurrent disease [24, 34].  However, an ongoing multi-centre trial 
in the UK aims to establish the need for RIA in low risk differentiated thyroid 
cancer. 
 TSH suppression therapy: The main goal of thyroxine therapy is to reduce the 
levels of TSH (that may act as a growth factor) in thyroid cancer patients [39], 
but potential long term morbidity can occur and these include atrial fibrillation, 
anxiety, osteopenia and other manifestations of hyperthyroidism. 
 External beam radiotherapy has a role in the treatment of differentiated 
thyroid cancer in advanced cases to provide symptomatic relief where surgery 
is not possible [2, 24].   
 Chemotherapy: Chemotherapy is of no value as an initial therapy in 
differentiated thyroid cancer and is not recommended [34]. 
 Follow up and monitoring:  Following definitive treatment with surgery, radio-
iodine ablation and TSH suppression, patients are usually monitored by 
regular physical examinations and biochemically by measuring TSH, Tg 
(thyroglobulin) levels and Tg-antibody levels.  An ultrasound scan of the neck 
is done routinely in some centres but more selectively in others, but only if 
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persistent or recurrent disease is suspected.  Recurrent disease may be 
treatment by one or more of the following – re-do surgery, RIA and external 
beam radiotherapy – depending on the presence of symptoms, extent of 
disease and likelihood of achieving cure. 
2. Medullary Thyroid Cancer (MTC) 
 As MTC arises from the parafollicular C-cells of the thyroid and not from 
thyroid follicular cells, RIA and TSH suppression do not play a role.  Surgery 
is the mainstay of treatment [40].  The extent of surgery depends on imaging 
findings and the presence and location of associated lymphadenopathy.  Total 
thyroidectomy (prophylactic or therapeutic) and central lymph node dissection 
is the standard surgical treatment for most patients with MTC. Ultrasound 
findings and calcitonin levels are helpful in deciding on the need for lateral 
neck dissection. RET (rearranged during transfection) proto-oncogene testing 
should be done in all patients with MTC at some stage in the treatment 
process.  If the patient is RET positive, all family members should be offered 
genetic testing and further appropriate management [34, 37, 41]. As most of 
the patients without a well-known family history of MTC, has a positive test of 
inherited RET. 
3. Anaplastic Thyroid Cancer (ATC) 
Anaplastic thyroid cancer carries a dismal prognosis and is considered as 
stage IV in the AJCC TNM staging (Table 1.2).  The disease is aggressive 
and curative surgery is often unlikely.  There are no effective chemo-
radiotherapy regimes available [31], but often a combination of various 
chemotherapeutic agents (including Doxorubicin, Cisplatin and Paclitaxel) and 
radiotherapy are employed.  Research is on-going into the role of tyrosine 
kinase inhibitors and vascular disrupting agents in improving response to 
systemic treatment [42] [43]. 
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1.2.3.7 Molecular pathology of thyroid cancer 
There are several genetic alterations involved in thyroid cancer progression and 
development.  They have potential as biomarkers as they may help in predicting 
biological behaviour and may serve as therapeutic targets.  
The commonly observed genetic alterations in thyroid cancer tissue include 
RET/PTC rearrangements, BRAF (B-type raf kinase) mutations, RAS (Rat sarcoma 
oncogene) mutations, PAX8/PPAR (Paired boxed gene 8/Peroxisome proliferator-
activated receptor gamma) rearrangements and genetic abnormality of P53 (tumour 
suppressor gene) deletion, point mutation and insertion. 
RET/PTC 
RET is a growth factor receptor tyrosine kinase that plays an important role in kidney 
development and neuronal differentiation.  It is located on chromosome 10q11.2. 
Chromosomal rearrangements involving the RET gene resulting in a fusion gene can 
occur by the juxtaposition of a foreign gene at the 5’ end of (or proximal to) the RET 
gene.  These are called RET/PTC rearrangements [44].  The first RET/PTC 
rearrangement was reported in 1987 and since then, 13 different types have been 
reported.  RET/PTC1 and RET/PTC3 are the most common types [44, 45].  
RET/PTC rearrangements have been identified in 13-46% of PTC [46-48].  The 
prevalence of RET/PTC rearrangements vary according to geographical distribution 
and are more common in radiation-induced PTC [47, 49].  The prognostic 
significance of RET/PTC is unclear.  Some authors have suggested that RET/PTC 
rearrangements are associated with increased tumour aggressiveness [50] but 
others suggested that this is associated with slow growth and lack of progression 
[51, 52].  
Point mutations of RET (a genetic abnormality that is different to the RET/PTC 
rearrangement described above) are identified in 40-50% of MTC [48]. 
BRAF 
BRAF is an intracellular signal transducer that links extracellular signals to cellular 
effects. BRAF plays an important role in cell differentiation, proliferation, apoptosis 
and survival [53].  More than 40 BRAF mutations have been identified.  BRAF V600E 
is the most common and accounts for up to 95% of all BRAF mutations [48].  BRAF 
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V600E mutations have been identified in around 45% of PTC [46-48].  BRAF 
mutations have been described in 25-50% and 12-17% of ATC and MTC 
respectively [47].  BRAF V600E mutation is associated with poor prognosis, disease 
recurrence and disease aggressiveness [48, 54].  
RAS 
RAS is also an intracellular signal transducer and plays an important role in 
regulating cell growth.  RAS is observed in around 30% of human tumours [53].  
There are three members of RAS oncogene family - Hras, Kras and Nras (located on 
chromosome 11p11, 12p12 and 1p13 respectively) [47-49].  Point mutations account 
for 40-50% of FTC tumours [46].  RAS point mutations have also been identified in 
ATC [55] and MTC [47].  RAS mutations are associated with poor prognosis and 
tumour aggressiveness in FTC, MTC and ATC [56]. 
PAX8-PPAR𝜸1 
Paired boxed gene 8 (PAX8) is a transcription factor and plays an important role in 
kidney organogenesis.  Peroxisome proliferator-activated receptor gamma (PPAR𝛾1) 
is a nuclear hormone receptor and is involved in the metabolism of differentiated 
adipocytes.  PAX8-PPAR𝛾1 rearrangements [at(2;3)(q13;p25) translocation] have 
been identified in around 36% of FTC [48] and are associated with favourable 
prognosis [57]. 
P53  
P53 gene acts as a tumour suppressor gene.  It is involved in cell cycle control and 
apoptosis and is altered in most human cancer cells.  It is located on chromosome 
17p13.  Genetic abnormalities of P53 (point mutations, deletions and insertions) are 
identified in 67-88% of ATC [47].  P53 mutations are also described in 17-38% of 
MTC [47], but only in 10% of PTC [58]. P53 mutations in thyroid cancer are 
associated with increased tumour aggressiveness [59]. 
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1.3 Metformin 
 
Metformin (N’, N’ -dimethybiguanide) is an oral anti-diabetic drug of the biguanide 
class and one of the most commonly prescribed drugs worldwide [3].  It is the first 
drug of choice in patients with type 2 diabetes and has been licensed for use in in 
UK since 1958 [4-6].   
 
1.3.1 Metformin structure 
The molecular formula of Metformin is C4H11N5 and molecular weight is 129.167 
g/mol and the structure formula shown as below [60]. (Figure 1.5) 
 
 
Figure 1.5: Structural formula of Metformin hydrochloride [60]. 
Metformin is also referred to as Dimethylbiguanidine, Dimethylguanylguanidine, 
glucophage and Metformin hydrochloride.   
 
1.3.2 Metformin indications dose and side effects 
Metformin has been licensed to use in type 2 diabetes mellitus and polycystic 
ovarian syndrome (PCOS).  
Metformin Hydrochloride Structure
N-C-NH-C-NH2 .HCL
NHNH
H3C
H3C
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 Diabetic mellitus: The initial dose of Metformin in diabetic patients (adult and 
child over 10 years old) is 500 mg with breakfast for at least 1 week, followed 
by 500 mg twice daily for a week. Subsequent increases may be up to 2 gm 
daily in divided doses [61].  
 Polycystic ovary syndrome: The doses used for PCOS are similar to that for 
diabetes; but the maximum recommended dose is up to 1.7 gm daily in 2-3 
divided doses [62].  
The side effects of Metformin include nausea, vomiting, anorexia, diarrhoea, 
abdominal pain, taste disturbance, erythema, pruritus, urticaria, decreased vitamin 
B12 absorption and rarely lactic acidosis [63, 64]. 
1.3.3 Pharmacokinetics of Metformin 
Metformin is administrated orally. The bioavailability of 500 mg Metformin is 40 to 
60% and the absorption is complete within six hours of ingestion [65]. Metformin is 
not metabolized in humans [66] and this distinguishes it from other biguanides. 
Metformin undergoes renal excretion, largely unchanged in the urine by active 
tubular process, with a mean plasma elimination half-life after oral administration of 
approximately 6.2 hours and blood elimination half-life approximately 17.6 hours [65, 
67, 68]. Approximately 90% of the absorbed Metformin is eliminated in the kidney 
within 24 hours and 10% of unabsorbed Metformin excreted in the faeces [68].  
Metformin is distributed into body tissues via several transporters such as Organic 
Cation Transports 1-3 (OCTs 1-3), Plasma membrane Monoamine Transporter 
(PMAT) and multidrug and toxin extrusion protein 1-2 (MATE 1-2) [69].  In the 
intestine PMAT, OCT1 and OCT3 has been identified to facilitate in Metformin 
uptake; PMAT localized to the tips of the mucosal epithelial layer [70], OCT1 and 
OCT3 are localized to the basolateral membrane [67, 71]. In the liver, Metformin 
uptake is mediated by OCT1 and probably by OCT3 and both transporters are 
expressed on the basolateral membrane of hepatocytes [67, 72-74]. However, 
Metformin uptake from the circulation into renal epithelial cells is facilitated by OCT2; 
expressed in the basolateral membrane of the cells [72]. The renal excretion of 
Metformin from tubule cells to the lumen is mediated through MATE1 and MATE2 
[75-78]. Both these transporters are expressed in the apical membrane of the renal 
proximal tubule cells [79].  OCT1 may also play an important role in Metformin 
reabsorption in the kidney tubules, which is expressed on the apical and sub-apical 
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domain side of both the proximal and the distal tubules in the kidney [80].  PMAT 
may play a role in the renal reabsorption of Metformin, which expressed on the 
apical membrane of renal epithelial cells [81]. 
 
 
1.3.4 Mechanism of action of Metformin 
The action of Metformin within the body is initiated in the liver and peripheral tissues 
and includes decreasing liver glucose production by liver and increasing glucose 
utilization by the peripheral tissues (muscle) [4]. Unlike other anti-diabetic drugs such 
as Sulfonylureas, Metformin does not produce hypoglycemia in either patients with 
type 2 diabetes or normal subjects and also does not cause hyperinsulinemia [82]. 
Metformin activates Adenosine Monophosphate-activated Protein Kinase (AMPK), 
which is a ubiquitously expressed sensor of cellular energy status [83]. AMPK 
reduces hepatic gluconeogenesis and fatty acid synthesis, whilst also increasing 
glucose uptake and fatty acid oxidation by peripheral tissues [84]. Furthermore, 
Metformin down regulates mitochondrial metabolism [85, 86]. 
 
Metformin has recently been investigated for its possible anti-cancer effects in 
several types of cancer either directly via the AMPK pathway or indirectly via its 
known ‘anti-diabetic’ effects. By reducing blood glucose, Metformin results in a 
reduction in circulatory insulin [87]. Insulin can act as a growth factor through 
stimulation of Insulin and insulin-like growth factor 1 (IGF-1) receptors (Figure 1.6) 
[88-90]. 
 
Although the molecular mechanism by which Metformin acts appears to be complex 
and is the topic of substantial debate, there is common agreement that Metformin 
administration induces phosphorylation and activation of AMP-activated protein 
kinase (AMPK) in the liver, which may lead to diverse pharmacological effects such 
as inhibition of lipid and glucose synthesis [91, 92]. The route of AMPK 
phosphorylation by Metformin remains unclear. The molecule LKB1 (liver kinase B1) 
has been shown to play important role in phosphorylation of AMPK in the presence 
of Metformin [92]. However, LKB1 and AMPK are not the direct targets of Metformin 
[93].  In a study using liver specific AMPK-knockout mice, Metformin was shown to 
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inhibit hepatic glucose production, suggesting that Metformin inhibits hepatic 
gluconeogenesis by LKB1 and AMPK in an independent manner [94].  Metformin 
inhibits complex 1 of the mitochondrial respiratory chain, suggesting activation of 
AMPK by increasing cellular AMP: ATP ratio [93, 95].   
 
Although AMPK is a major cellular regulator of glucose and lipid metabolism, up-
regulation of AMPK results in inactivation of many targets including mammalian 
target of rapamycin (mTOR), 3-hydroxy-3-methyle-glutargl-coenzyme A reductase  
(HMG-CoA reductase), acetyl-CoA carboxylase (ACC), and glycerol-3-phosphate 
acyltranferase 1 mitochondrial (GPAM) [92, 96].  Furthermore, AMPK increases 
glucose uptake in skeletal muscle by increasing glucose transporter type 4 (GLUT4) 
translocation activity [97]. The overall effect of AMPK activation in the liver includes 
inhibition of cholesterol and triglyceride synthesis with stimulation of fatty acid 
oxidation. The peripheral effects are stimulation of glucose uptake in skeletal 
muscles and fatty acid oxidation and also systemic increase in insulin sensitivity [95]. 
 
The detailed mechanism of action of Metformin in cancer is not well understood; 
however, studies on Metformin-mediated effects on gene/pathways in many cancer 
types are increasing with interesting findings. In breast cancer, Metformin has been 
shown to induce cell cycle arrest and activate AMPK and down-regulate cyclin D1 
[98, 99].  Metformin has also been shown to suppress overexpression of human 
epidermal growth factor receptor 2 (HER2) oncoprotein through inhibition of mTOR 
effector p70S6K1 in breast cancer cells [100]. Recently, a study on bladder cancer 
cells found that Metformin down-regulated cyclooxygenase-2 (COX2) and also signal 
transducer and activator of transcription 3 (STAT3) pathway, subsequently 
decreasing the expression of cyclin D1 and B-cell lymphoma 2 (Bcl-2) resulting in 
inhibition of cell proliferation and induction of apoptosis [101].  Metformin also has 
shown to have anti-cancer effects in ovarian cancer cells by the down-regulation of 
genes that associated with apoptosis regulation such as vascular endothelial growth 
factor (VEGF), Bcl-2, Bcl-2-associated X (Bax) and caspase-3 [102]. Furthermore, 
Metformin inhibited cell proliferation and induced apoptosis through the activation of 
AMPK and down-regulation of mTOR, protein kinase B (Akt) and P53 [103]. 
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Figure 1.6: The possible modes of action of Metformin. 
 
METFORMIN 
ANTI-CANCER EFFECTS 
Direct 
Activate AMPK (via LKB1) - inhibits 
mTOR pathway (which promotes 
growth and proliferation) 
Indirect 
Inhibition of hepatic gluconeogenesis (through activation of 
AMPK in the liver)+/- stimulation of peripheral utilisation of 
glucose --> reduction in blood glucose --> reduction of 
circulatory insulin --> reducation of growth-stimulating effect 
of insulin on insulin and IGF1 recptors 
HYPOGLYCEMIC EFFECTS BY: 
1. Reducing glucogenesis 
2. Increasing peripheral utilization of 
glucose 
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The molecular pathway of Metformin in thyroid cancer is not clear due to a lack of 
studies. In the last 5 years studies on thyroid cancer have found that Metformin 
altered the expression of several genes (Figure 1.7) [104-107].  The key findings 
were activation of AMPK and down-regulation of mTOR pathways resulting in 
inhibition of cell proliferation, colony formation, cell migration, promotion of apoptosis 
and induced cell cycle arrest [104-106].  Furthermore, Metformin induced AMPK 
activation in dose dependent manner and inhibited cyclin D1 and c-Myc expression 
through inhibition of mTOR pathways [105-107]. Moreover, knockdown of tuberous 
sclerosis complex 2 (TSC2) abolished the ability of Metformin to inhibit expression of 
cyclin D1, c-Myc and mTOR pathway [105]. However, loss of AMPK expression did 
not prevent Metformin from down-regulation mTOR pathway, cyclin D1 and S6K1 
[106]. This indicated that several pathways influenced by Metformin actions in thyroid 
cancer. Additionally, down-regulation of the mTOR pathways dampened the 
phosphorylation of its downstream effectors (4E-BP1, ribosomal protein S6 kinase 
beta 1 (S6K1) and cyclin D1), inhibiting cell proliferation and protein synthesis [105, 
106]. Furthermore, treatment with Metformin associated with decreased expression 
of extra cellular signal-regulated kinase (ERK) in thyroid cancer cells resulting in the 
inhibition of cell proliferation and induced cell cycle arrest [104, 106].  
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Figure 1.7: Potential anti-cancer pathways of Metformin in thyroid cancer. 
This figure shows that Metformin treatment altered the expression of several genes in thyroid cancer.  
Genes are either down-regulated (marked with inhibition arrow symbol ()) or genes are activated 
(marked with activation arrow symbol ()). 
 
Metformin
TSC2
AMPK
mTOR
ERK
4E-BP1S6K1cyclin D1c-Myc
Potential anticancer pathways of Metformin in thyroid cancer 
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1.3.5 Possible role of Metformin in Cancer 
 
1.3.5.1 Population based studies  
Several population-based studies have demonstrated the potential role of Metformin 
as a chemopreventative agent [108-110] in cancers. Evan et al [108] reported the 
first population based study demonstrating Metformin use to be associated with low 
cancer incidence among type 2 diabetic patients.  Several other reports have since 
been published to support the potential role of Metformin as an anti-cancer agent 
[88, 109, 111-117].  These include studies demonstrating reduced risk of breast 
cancer [112-114], prostate cancer [113, 118], gastric cancer [113, 119], lung cancer 
[112, 113, 119], pancreatic cancer [113, 119], and colorectal cancer [113].  There is 
also observational evidence that cancer-related mortality is reduced in patients on 
Metformin [111, 115, 117, 120].   
In retrospective cohort study of over 62,000 people in the UK, patients were 
categorized into 4 groups based on the treatment of diabetes. This study shows that 
patients on Metformin has a reduced risk of cancer such as colorectal and pancreas. 
Metformin has also been seen to reduce the risk of cancer progression. This study 
only included patients for whom treatment for diabetes was recently started. It could 
be that in patients with severe diabetes (requiring insulin treatment or treatment 
other than Metformin) have a different predisposition to cancer and that the glucose 
levels influence cancer risk. In addition there is potential in this study for under 
reporting of cancer [109].  
 
Another study reported by the same group [109], included patients in general 
practice who were diagnosed with cancer. Patients were categorized by the 
presence of diabetes and the nature of diabetes treatment. In over 110,000 patients 
this study demonstrated increased mortality of those with diabetes and also 
increased mortality in diabetics on sulfonylureas or insulin compared to Metformin 
therapy. This observation could be related to the diabetes as opposed to cancer and 
the severity of diabetes as opposed to treatment with non-Metformin therapies. The 
study did not present cause of death but only described all-causes of mortality [111]. 
 
44 
 
A further study was an observational cohort study of patients with type 2 diabetes 
who were on Metformin treatment, compared to patients who have never used 
Metformin in over 9,000 patients. Metformin use was associated with reduced risk of 
cancer after adjusting for age, sex, BMI, HbA1c, deprivation, smoking and other drug 
use.  It is possible that patients on Metformin had a different cancer risk profile and 
they may be other confounders such as ethnicity, age of onset that could have 
influenced the result [112]. Moreover, a study performed in the Netherlands looked at 
the pharmacy record and linked to hospital discharge data from 2.5 million people. 
The study found a lower risk of cancer in Metformin users compared to those on 
sulfonylureas. The study did not included diabetic patients treated with dietary or life 
style advice.  This study also limited by ‘reverse causality’. Data on cancer was only 
obtained from hospital discharge records and this may also have influenced the 
result. Other risk factors such as smoking and BMI were not adjusted for in this study 
[113]. 
 
Other population based studies focused on specific cancers such as breast cancer. 
A nested case-control study of type 2 diabetes patients in northern Denmark 
demonstrated that Metformin users were less likely have of breast cancer diagnosis 
compared to non-users [114]. This study reported 20% reduction in the risk of cancer 
for Metformin users and these results are consistent with several other similar 
studies [121, 122]. The limitation of case-control studies in general would apply to 
this study; in particularly, selection bias, ascertainment bias and bias due to 
confounding. In another study of the national Taiwanese database, from which up to 
half a million female patients with type 2 diabetes were followed up to evaluate 
breast cancer risk; patients were characterized into never-users and ever-users of 
Metformin. The study found that the Metformin use reduced breast cancer risk 
significantly. However, other confounders of cancer risk and details of cancer were 
not evaluated [123].  Similarly, in another retrospective cohort study of patients with 
ovarian cancer, patients with type 2 diabetes who used Metformin had a longer 
progression-free survival.  Again, this study is limited by small sample size in the 
various subgroups categorized by diabetic status and Metformin use and the data on 
the severity of diabetes was not evaluated [115]. Additionally, a study of 1448 
patients who received chemotherapy for triple negative breast cancer, 9% were 
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diabetic; of these, 48% were on Metformin during chemotherapy. The results of this 
study demonstrated that Metformin use does not significantly impact on survival, but 
Metformin users and non-diabetic patients were less likely to have distant diseases. 
As suggested before, this study has the usual limitations of a retrospective cohort 
design [116].  Finally, in a study of non-small cell lung cancer patients with pre-
existing diabetes, the role of Metformin on response to chemotherapy was studied. 
The data appeared to show that Metformin improved the response rate and survival. 
This study is limited by a small sample size and the analysis did not appeared to be 
adjusted for a number of other patient and disease related influences [117]. 
 
More specifically in relation to thyroid cancer, Chin et al. studied the risk of thyroid 
cancer in patients with type 2 diabetes in Taiwan. Of more than 1.5 million patients 
included over the three year period, Metformin use in patients with diabetes was 
associated with a reduced risk of thyroid cancer diagnosis. However, this study has a 
short follow up period. The details on the type of thyroid cancer and the possibility of 
cofounding factors such as the severity of diabetes, exposure to ionizing radiation, 
and reliability of the recorded diagnosis within the databases influencing the results 
should be considered [124] 
 
1.3.5.2 In vitro studies on cancers other than thyroid cancer. 
Metformin has also been studied extensively in vitro using a number of human 
cancer cell lines. The cancers studied include breast cancer [125, 126], gastric 
cancer [127], lung cancer [126], ovarian cancer [128] and thyroid cancer [106, 129].  
In a study of ovarian cancer cell lines (OVCAR-3 OVCAR-4); cells were treated with 
various concentrations of Metformin (1, 5, 10, 15, 20, 50 and 100 mM) at several 
time points (24, 48,72 and 96 hours). The study showed that Metformin inhibited cell 
growth of both cell lines in a time-dependant and concentration-dependent manner. 
The study also shows up-regulation of phosphorylation of AMPK pathway and down-
regulation of p70S6K and S6K.  The strengths of this study was that cells were 
exposed for long duration of time and various concentrations of Metformin were 
used. However, the concentration of Metformin used was supra-physiological [128]. 
In a study of breast cancer cell lines (MCF-7, MCF-7/713, BT-474 and SKBR-3); 
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cells were treated with various concentrations of Metformin (2,10 and 50 mM) for 72 
hours. Metformin decreased cell proliferation in concentration-dependent manner 
and reduced expression and activation of erbB2 protein. In addition, reduction in 
phosphorylation (but not expression) of Mitogen Activated Protein Kinase (MAPK) 
and Protein Kinase A (Akt) was observed. Metformin reduced levels of both mTOR 
and P-mTOR. The study limitations were that the concentration of Metformin used 
was high and cells were studied at one time point only [125]. In another study on 
breast cancer cell lines (BT474, SKBR3, BT474-HR20, SKBR3-pool2); cells were 
treated with Metformin concentrations (0.02, 0.1, 1, 5 and 10 mM) for 72 hours. 
Metformin inhibited cell proliferation in concentration–dependent manner and 
reduced expression and activation of erbB2/ Insulin-like growth factor-1 receptor 
(IGF-1R) complexes. These effects were observed in resistant sub-lines only but not 
in the parental cells. The strength of this study was various concentration of 
Metformin were used but cells were studied at one time point only [130].  
Additionally, in a further study, breast cancer and lung cancer cell lines (MCF-7 and 
A549 respectively) were treated with Metformin concentrations (1, 5, 10, 25 and 50 
mM) for two different durations - 48 and 72 hours.  Metformin inhibited cell 
proliferation of both cell lines. Inhibition was significant at the concentration of 10 
mM. Metformin also increased phosphorylation of AMPK but phosphorylation of 
mTOR, 4EBP1 and P70S6K was reduced [126]. In another study on breast cancer 
cell lines (MDA-MB-231, MCF-7 and MCF-10A); cells were treated with Metformin 
(50 and 75 mM) for 12 hours. Metformin inhibited cell proliferation and cell migration 
and decreased phosphorylation of mTOR and P70-S6K [131]. The last three studies 
[126, 127, 131] were limited by the fact that only high concentrations of Metformin 
were used. Finally, in a study on gastric cancer cell lines (MKN1, MKN45, and 
MKN74); cells were treated with various concentrations of Metformin (1,5 and 10 
mM) for several time points (24, 48 and 72 hours). Metformin inhibited cell 
proliferation, blocked cell cycle in G0-G1 phase and this was associated with a 
significant reduction of G1 cyclins especially cyclin D1, cyclin-dependent (Cdk) 4 and 
Cdk6. The phosphorylation of retinoblastoma protein (Rb) and the expression of 
epidermal growth factor receptor (EGFR) and IGF-1R was reduced [127]. 
Until recently, there have been few studies of Metformin in thyroid cancer [129].  In a 
study on Metformin in human anaplastic thyroid cancer cell lines (HTh74, SW1736, 
47 
 
C643), human follicular thyroid cancer cell line FTC 133, doxorubicin-resistant 
thyroid cancer cell line HTh74Rdox, and a rat thyroid normal epithelial cell line 
(FRTL-5) [129]; cells were treated with various concentrations of Metformin (0.1, 0.5, 
1, 2.5, 5,10, 20 and 40 mmol/L) for different periods of time (24, 48, and 72 hours).  
The findings of this study showed that Metformin decreased growth of these cell 
lines in a concentration-dependent and time-dependent manner.  The anti-
proliferative effect of Metformin was more obvious in HTh74Rdox compared to 
HTh74. FTC 133 was more sensitive to Metformin compared to other wild types of 
thyroid cancer cell lines.  Further experiments on the same cell lines showed that 
Metformin induced cell cycle arrest in G1 phase.   In a separate experiment in the 
same study, insulin significantly enhanced the growth of all human thyroid cancer 
cell lines described above. When Metformin was added, the insulin-induced increase 
in cell proliferation was negated.  This group have also shown that Metformin 
enhances the anti-proliferative effect of Doxorubicin and Cisplatin.  Moreover, 
Metformin increased phosphorylation of AMPK at Thr-172 in all human thyroid 
cancer cell lines.  It was noted however that the concentrations of Metformin used 
are higher than normal human plasma concentrations.  It would have been of value 
to have observed the effects of lower concentrations of Metformin at longer periods 
of time. 
Another study on Metformin in human MTC cell lines (TT and MZ-CRC-1) [106], cells 
were exposed to various concentrations of Metformin (0.5, 1, 2.5, 5 mmol/L) for 
different periods of time (24, 48, 72 hours).  This study showed that Metformin 
inhibited cell growth in both cell lines (TT and MZ-CRC-1) in time-dependent and 
dose-dependent manner and reduced expression of cyclin D1 in dose-dependent 
manner.  Metformin decreased phosphorylation of ERK, p70S6K and pS6 in TT and 
MZ-CRC-1 cell lines but increased phosphorylation of AMPK in TT cell lines only.  In 
this study, various concentrations of Metformin have been used for three different 
periods of time, but again the concentration of Metformin is too high compared to 
normal human plasma concentration. 
The findings of the above in vitro studies indicate that Metformin inhibits cell growth 
in a time-dependent and concentration-dependent manner.  The concentrations of 
Metformin used were much higher than normal human plasma concentrations [132].  
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This therefore limits the extrapolation of these findings to clinical practice.  Also, it is 
not clear from these studies whether the cells were seeded in different 
concentrations to evaluate the effects of Metformin on factors such as confluence. 
 
1.3.5.3 In vivo studies  
The possible anti-cancer effect of Metformin has been studied in animal models 
alongside of population-based study and in vitro studies.  In a mouse model 
experimental study, each mouse was inoculated in the flank by human 
cholangiocarcinoma cells (HuCCT-1).  The animals were then divided into two 
groups (Metformin treated and PBS treated control). The injection was given 
intraperitoneally (2 mg/kg of Metformin or PBS) five times per week for 4 weeks.  
The study found that Metformin inhibited tumour growth by 36% compared to control 
group [133]. In another study of a xenograft model, human pancreatic 
adenocarcinoma cells (CFAC-1) were subcutaneously injected into the anterior 
armpit of nude mice.  20 injected mice were subdivided into 4 groups (treated with 
normal saline, Metformin treated 200 mg/kg/day, Gemcitabine treated and 
combination therapy of Gemcitabine and Metformin). The study findings show that 
Metformin and combination therapy were associated with smaller size and weight of 
xenografts compared to control group [134].  
 
In a more recent study, oesophageal squamous cell carcinoma cells (KYSE450) 
were injected into mice subcutaneously.  After 10 days, 10 mice with the same size 
of xenograft tumours were selected and divided into two groups.  One group was 
treated with Metformin (35.7 mg/kg/day by intraperitoneal injection) and the other 
group received normal saline for 15 days.  The tumour size was reduced by 70% in 
the Metformin treated group compared to the control group along with an increase in 
the area of necrosis and apoptotic rate.   Furthermore, Metformin inhibited the 
expression of S6K1 and 4EBP1 [135].  The anti-tumour effect of Metformin on 
pancreatic cancer cell growth was also studied in an experimental xenograft model. 
Mice were divided into two groups (Gemcitabine treated only, Gemcitabine + oral 
Metformin (20 mg/kg/day diluted in the drinking water) from the time of injection of 
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pancreatic cancer cells in the flank for 4 weeks.  The data show that Metformin 
treatment inhibited xenograft tumour size [136]. 
 
More specifically, the anti-tumour effect of Metformin on papillary thyroid cancer cells 
was also studied in an experimental xenograft model, BHP10-3SC cells were 
injected subcutaneously into dorsal skin of mice at 4 different places. Mice were 
treated with Metformin 0-100 mg/mL in drinking water for four weeks.  The study 
found that Metformin significantly inhibited tumour growth at day 10 for the dose 50 
mg/mL and marginally significant at day 30 for the dose 10 mg/mL. Metformin (at a 
dose of 50 mg/mL) significantly increased the necrotic area, increased AMPK 
phosphorylation and down regulated mTOR and Akt expression compared to control 
group [137]. In another xenograft experimental model, mice were implanted with 
SW579 thyroid cancer cells and then divided into two groups (Metformin treated 100 
mg/kg/day orally and vehicle alone control).  After tumour size was measured from 
days 0-45, the study found that Metformin inhibited tumour size in a time-dependent 
manner [105]. 
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1.3.5.4 Clinical trials of Metformin in chemoprevention and therapy of 
human cancer 
Recently, few clinical trials have been done to investigate the anti-tumour 
effect of Metformin in patients with breast cancer [138-140]. In a randomised 
controlled clinical trial, 47 non-diabetic women with operable primary invasive 
breast cancer were randomised pre-operatively to receiving Metformin (500 
mg/day for a week and then 1 g/day until surgery) or no drug.  Core biopsies 
from the breast tumour before randomisation and two weeks later at surgery 
were done.  Ki67 immunohistochemistry, transcriptome analysis on formalin-
fixed paraffin-embedded cores and serum insulin levels were performed 
blinded to treatment.  This was considered to be a “window of opportunity” 
trial, whereby the anti-cancer effects of drugs can be studied in patients who 
are exposed to the drugs in the period between having a diagnostic tissue 
biopsy and surgical resection.  This study found significant reduction in Ki67 
expression in the Metformin group with no change in the control arm; 
providing evidence for anti-proliferative effects of Metformin [138].  Mean 
serum insulin levels remained stable in patients receiving Metformin but rose 
in control patients. One limitation of this study was that the participants were 
treated with Metformin only for a short period of time; limiting the opportunity 
to study the effects of Metformin in the longer term.  Some would argue that 
the sample size of this study was relatively small; however the study was not 
powered to detect differences in clinical outcomes. 
 
In another randomised pre-surgical trial, 200 non-diabetic women with 
operable breast cancer were divided into two groups of 100 patients – one 
group received 850mg Metformin twice a day and the other received a 
placebo for four weeks.  There were no significant changes on Ki67 
expression in Metformin group compared to the placebo group [139].  The 
sample size in this study was higher compared to the previous study [138].  
Despite no overall differences in the Ki67 expression between the groups, the 
effects of Metformin seemed to be different when patients were subdivided in 
accordance with insulin resistance. As the study showed that Metformin 
decreased cell proliferation in patients with insulin resistance and increased 
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cell proliferation in patients without insulin resistance. 
In a ‘single arm’ clinical trial on 39 non-diabetic women with early stage of 
breast cancer, Metformin showed anti-proliferative effects and increased 
apoptosis as reflected by Ki67 and TUNEL assay respectively [140].  The 
weaknesses of this study are small sample size, absence of control arm and 
short duration of Metformin treatment. Finally, a double-blind randomised 
controlled trial study is currently underway to determine the effects of 
Metformin in the prevention of colorectal polyps [141].  This is based on 
previous observations that Metformin suppresses polyp formation in a murine 
model of FAP [142]. Metformin has also been demonstrated to suppress 
colorectal aberrant crypt foci (ACF) in humans [143].  ACF is thought to be a 
risk factor for colorectal cancer [144].  
From the above studies, it is apparent that Metformin is being increasingly 
investigated as chemo-preventative as well as adjuvant therapeutic agent in 
human cancer.  
 
1.3.6 Metformin and its effect on TSH 
 
Another effect of Metformin on thyroid disease is a decrease in Thyroid 
Stimulating Hormone (TSH) level without change in FT4.  The TSH lowering 
effect of Metformin was reported in a retrospective case study of 4 
hypothyroid patients (three patients with type 2 diabetes and one patient with 
steatohepatitis) [145]. The level of TSH increased again in all patients after 
Metformin was discontinued.  The sample size of this study was too small but 
the findings can serve as a basis to investigate further the role of Metformin 
on TSH synthesis and release. 
In a pilot study, 11 patients with type 2 diabetes and hypothyroidism on stable 
thyroxine doses, were treated with Metformin for 6 months [146]. A 
significantly decreased TSH level was observed after 6 months of treatment. 
In a second study performed by the same group [146], 29 patients with 
hypothyroidism on thyroxine (group 1), 18 patients with subclinical 
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hypothyroidism (group 2) and 54 euthyroid patients (group 3) were treated 
with Metformin for 1 year.  Metformin decreased the TSH level in group 1 and 
group 2 but not in group 3; without changes in FT4.  The sample size of the 
study was relatively small and there was no information regarding the dose of 
Metformin used in this study.  
 
The mechanism of TSH lowering effect in patients who received Metformin is 
not clear and requires further research.  In the studies reported so far, the 
effect of Metformin on TSH level appeared independent of thyroxine treatment 
[145, 146].  However, Metformin treatment was not associated with major 
changes in TSH level in patients with an intact thyroid axis [146]. In a single 
blind randomized clinical trial [147] of 50 non-diabetic patients with DTC (46 
patients with papillary thyroid cancer and 4 patients with follicular thyroid 
cancer); the dose of Metformin was 500 mg/day for 3 months. Thyroid 
hormones and TSH were measured in the beginning and after 3 months of 
Metformin treatment. The data indicated that 500 mg/day did not decrease the 
level of TSH. The study has limitations of small sample size and short 
administration of Metformin and low dose of Metformin (Metformin dose in 
diabetic patients 500-2500 mg/day) In another study [148], 66 women with 
small benign  thyroid nodules and insulin resistance were divided in to 4 
groups (Group 1 received Metformin alone, group 2 received Metformin + 
levothyroxine, group 3 received levothyroxine alone and group 4 did not 
receive either drug) and followed up for 6 months.  Patients treated with 
Metformin showed a decrease in nodule size in association with reduced TSH 
levels; but this effect was best seen in combination with levothyroxine 
treatment. In a recent study on patients diagnosed with differentiated thyroid 
cancer (patients on thyroxine treatment), Metformin treatment was associated 
with smaller tumour size and low TSH level.   These findings were based on 
clinico-pathological data of 34 diabetic patients treated with Metformin 
compared to 21 diabetic and 185 non-diabetic patients not treated with 
Metformin [149]. 
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1.4 Need for this research and implications for 
patients 
 
In patients with DTC, the prognosis is in general good to excellent.  TSH 
suppression using high doses of thyroxine is an objective of treatment. 
However, this is associated with side effects [150].  Metformin has a good 
long term safety profile and may serve a dual role – anti-cancer effect and 
reduced need for overtreatment with thyroxine – this has potential to 
significantly reduce treatment-related morbidity in thyroid cancer. The 
prognosis in certain types of thyroid cancer (such as MTC, and ATC) is poor.  
New adjuvant treatment options are invaluable for these types of thyroid 
cancer.  Given recent information on the role of Metformin as an anti-cancer 
agent, there is potential for Metformin to be used as adjuvant treatment in 
these cancer subtypes.  
To facilitate the development of Metformin as a potential clinically useful anti-
cancer drug, a detailed understanding of the molecular mechanisms of its 
effects on thyroid cancer is essential.  In addition, its effects on thyroid cancer 
cell lines at concentrations relevant in the clinical setting, its interactions with 
TSH and the influence of glucose in the environment needs to be studied.  
This will be the focus of this research project. 
 
Hypothesis: Metformin inhibits the growth and proliferation of different types 
of thyroid cancer. 
Aims: The aims of this project are to 
 Explore the role of Metformin in thyroid cancer cell growth and 
proliferation 
● Compare the effect of Metformin on thyroid cancer cell lines in different 
environments 
- Glucose-free and glucose-rich media 
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- With and without influence of insulin, IGF-1 and TSH 
● Investigate the role of Organic Cation Transporter 1 (OCT1) in thyroid 
cells on the anti-proliferative effect of Metformin on thyroid cancer cells. 
● Study the effects of Metformin on gene regulation in thyroid cancer cell 
lines
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CHAPTER TWO 
 
Materials & Methods 
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2.1 Materials 
2.1.1 Basic laboratory equipment 
In this section the basic materials used in the research are summarized in the 
following two tables below (Table 2.1). 
 
Table 2.1: Basic laboratory equipment. 
Item  Supplier  
Hoods (class II microbiological sterile safety 
cabinet) 
UniMAT – BS, medical air technology, 
Oldham, UK 
CO2 Incubator  Sanyo electric, Japan  
Centrifuge  Sanyo harrier 18/80, UK 
Micro centrifuge  MSE, UK 
Cell viability analyser  Vi-CELLTM XR, Beckman coulter, USA 
Light microscope Olympus optical, Japan 
Fluorescent microscope Zeiss axioscop 
Nikon glipse TS100 microscope  Nikon, Japan 
Cesium137 irradiator CIS Bio International 
R100/TW rotates shaker Luckham, UK 
Autovortex mixer SA2 Stuart scientific, UK 
Dry heating block Techne 
Pipettes (P2, P10, P20, P200 & P1000), pipetting 
aid 
Gilson, France 
Pipette tips, sterile eppendrof 1.5 ml tubes, 
cryogenic vials 1.8 vial 
Star lab 
Disposable serological 5ml pipettes Fisherbrand 
Disposable serological 10 ml and 25 ml pipettes, 
Sterile 6 well and 96 well plates 
Costar 
Specimen tubes (15ml, 20ml, 50ml), cryopure 1.8 
ml tubes 
Sarstedt 
Fluostar Galaxy (Plate reader) BMG labtech, Germany 
NanoDropTM ND-1000 spectrophotometer Thermo fisher scientific, Wilmington, USA 
PCR Sensoquest, Germany 
TC20TM Automated Cell Counter BIO RAD, Singapore 
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Item  Supplier  
T25, T75 cm2 culture flasks, Sterile petri dish 10 
cm 
NuncTM 
2 well silicone insert chambers Ibidi 
Coverslips (22x22/40/50 mm) Scientific laboratory supplies 
Microscope slides  VWR 
Aluminium foil  Robinson young, UK 
Exam gloves Micro flex 
Distilled water Gibco 
Industrial Methylated Spirit (I.M.S) BP 70% V/V Adams healthcare, UK 
Methanol, absolute ethanol and Acetone  BDH Analar 
Effective disinfectant tablets PreseptTM 
 
 
2.1.2 Other materials  
 
In this section the other materials (reagents and antibodies) used in the 
experiments are summarized (Table 2.2). 
 
Table 2.2: Other materials used in the experiments described. 
Item  Supplier  
Foetal Bovine Serum (FBS) was stored at -20°C in 50 ml 
aliquots. 
Lonza. BioWhittaker 
Dulbecco’s Phosphate Buffered Saline (DPBS) 
Trypsin/EDTA, Fungizone, Glutamine, Penicillin/streptomycin. 
Dulbecco’s Modified Eagle’s Medium (DMEM) with 4.5 g/L 
Glucose, L-glutamine and without Na Pyruvate. The medium 
was stored at -4°C. 
Dulbecco’s Modified Eagle’s Medium Ham’s F-12 (1.1 MIX) 
(DMEM F12) with 15 Mm Hepes, L-Glutamine. The medium 
was stored at -4°C. 
Roswell Park Memorial Institute (RPMI) 1640 medium. The 
medium was stored at -4°C. 
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Item  Supplier  
Minimum Essential Medium Eagle (EMEM), Non-Essential 
Amino Acids (NEAA) solution 100x, Sodium Pyruvate (NaP), 
Molecular, Cellular and Developmental Biology 105 (MCDB 
105) medium, Dimethyl Sulfoxide (DMSO) and Triton X-100 
(Sigma-Aldrich, UK). 
Sigma-Aldrich 
Primary antibody anti-SLC22A1 (OCT1) and secondary 
antibody (goat anti-rabbit, biotinylated). 
D-(+)-Glucose solution (45%), human TSH (T8785), human 
Insulin (I2643-50MG). 
Agarose powder, Ethidium bromide, Thiazolyl blue tetra 
zolium bromide, ˃= 97.5% TLC, 1g stored at 4°C and Triton-
X-100. 
Sigma 
FITC Annexin V Apoptosis Detection Kit I (Cat. 556547): The 
kit contents were; FITC Annexin V, Propidium Iodide (PI), 
10X Annexin V Binding Buffer 
BD Biosciences 
DNeasy blood and tissue kit: The kit contents were; 
Proteinase K, buffer AL, buffer AW, buffer AW2, buffer AE, 2 
ml collection tubes and DNeasy mini spin columns 
QIAGEN, Germany 
RNeasy Mini Kit (50) 
Rneasy mini kit (50): 50 RNeasy Mini Spin Columns, 
Collection Tubes (1.5 ml and 2 ml), RNase-free Reagents 
and buffers 
Trypan Blue Dye 0.4% solution (Cat. 145-0013), counting 
slides, dual chamber for cell counter (Cat. 145-0011)  
BIORAD, USA 
Mounting medium with 4',6-DiAmidino-2-Phenylindol (DAPI), 
normal goat serum and VECTASTAIN ABC kit 
Vector laboratories 
Inc. 
Metformin (1,1-Dimethylbiguanide. Hydrochloride, 5g stored 
at 4°C. 
Enzo 
Propidium iodide 1 mg/ml (ab14083) Abcam 
Methylene blue 70% alcohol (I.M.S) BDH, England 
Human IGF-1 (Cat. AF-100-11) Peprotech 
BRAF forward and BRAF reverse Eurofins genomics 
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Item  Supplier  
Immolase DNA polymerase kit  BIOLINE 
Paraformaldehyde (PFA) Fisher scientific, UK 
Primary antibody (Phospho-Histone H2A.X (Ser139) (20E3) 
rabbit mAb) 
Cell signalling 
technology  
Secondary antibody (Cy3 goat anti-rabbit IgG)  InvitrogenTM USA 
 
2.1.3 Cell lines and medium  
The cell lines used in the projects included: 
1. Nthy-ori 3-1 (human thyroid follicular epithelium immortalised by 
transfection with a plasmid containing an origin-defective SV40 
genome (SV-ori)) 
2. K1E7 (a subclone of K1 cell line from primary papillary thyroid cancer)   
3. FTC-133 (derived from primary follicular thyroid cancer) 
4. RO82-W-1 (derived from metastases of follicular thyroid cancer) 
5. 8305C (derived from primary anaplastic thyroid cancer) 
6. TT (derived from primary medullary thyroid cancer) 
7.  MCF7 (established from pleural effusion in patient with metastatic 
breast adenocarcinoma) 
8. h-TERT-RPE-1 (retinal pigmented epithelial cells immortalized with 
hTERT ) 
Nthy-ori 3-1, FTC-133, K1E7, MCF7 and h-TERT RPE-1 were obtained from 
department of Oncology, University of Sheffield.  RO82-W-1, 8305C and TT 
were authenticated and purchased from the European Collection of Cell 
Culture (ECACC).   
These cell lines were sub-cultured in specific media. The media used for the 
different cell lines were as follows: 
1. Nthy-ori 3-1 - DMEM supplemented with 10% FBS, 1% fungizone and 
1% penicillin/streptomycin. 
2. K1E7 and FTC-133 - DMEM F-12 supplemented with 10% FBS, 1% 
fungizone and 1% penicillin/streptomycin and 1% glutamine.   
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3. RO82-W-1 – DMEM:Ham’s F12:MCDB 105 (2:1:1) supplemented with 
10% FBS, 1% fungizone and 1% penicillin/streptomycin and 1% 
glutamine.   
4. 8305C – EMEM (HBSS) supplemented with 10% FBS, 1% fungizone 
and 1% penicillin/streptomycin, 1% Non-Essential Amino Acids and 1% 
glutamine. 
5. TT – Ham’s F12 supplemented with 10% FBS, 1% fungizone and 1% 
penicillin/streptomycin, 1% Non-Essential Amino Acids, 1% Sodium 
Pyruvate (NaP) and 1% glutamine. 
6. MCF7 and h-TERT-RPEI – RPMI supplemented with 10% FBS, 1% 
fungizone, 1% penicillin/streptomycin and 1% glutamine.   
DMEM with 2 gm/L (10 mM) of glucose was chosen for all experiments as 
standardized medium (see section 3.2.2). 
Morphology of thyroid cells: The morphology of K1E7, FTC-133, RO82-W-1 
and TT cell lines are similar to normal thyroid cell line (Nthy-ori 3-1). These 
are all differentiated cells and resemble normal thyroid follicular epithelium. 
The shapes are variable and ranged from spindle to polygonal. The 8305C 
cell line is much more undifferentiated; the nucleo-cytoplasmic ratio is high 
and there is significant variability in the shape of these cells. 
 
2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 General cell culture 
All tissue culture procedures were carried out in a class II microbiological 
safety sterile cabinet (UniMAT – BS, Medical Air Technology Ltd., UK).  
Before commencing work, the cabinet was switched on and sterilized with 
70% Industrial Methylated Spirit I.M.S (Adams healthcare, UK) and left for 15 
minutes.  All necessary reagents and equipment were cleaned and sterilized 
with 70% I.M.S during work.  
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2.2.1.2 Defrosting and recovery of cells from liquid nitrogen 
Cells were taken from liquid Nitrogen storage and quickly defrosted in a water 
bath at 37°C.  Cells were then transferred to a universal tube and 9 ml of 
medium was added.  The pellet was obtained by centrifuging the universal 
tube at 1000 rpm for 5 minutes.  The pellet was cultured in T75 flasks and 
incubated at 37 °C in a humidified atmosphere of 95% and 5% CO2 for 
approximately 3-5 days. The medium was renewed twice a week (until the 
cells were 70-80% confluent).  
 
2.2.1.3 Subculture/cell split 
Cells were observed under the light microscope (Olympus optical, Japan) until 
they were 70-80% confluent.  They were then washed twice with 5 ml of PBS 
and incubated with 5 ml of trypsin for 2 minutes.  The detached cells were 
observed under the light microscope and the process of trypsinization was 
halted by adding 5 ml of medium.  Cells were collected in a sterile universal 
tube and centrifuged at 1000 rpm for 5 minutes (at 21 °C).  The supernatant 
was discarded and the cells were re-suspended as pellet in 10 ml of medium.  
The re-suspended cells were cultured in T75 flasks at 37°C in a humidified 
atmosphere of 95% and 5% CO2. 
 
2.2.1.4 Frozen storage of the cells 
The cells were frozen between experiments to maintain cell integrity.  After 
the cells were 70-80% confluent, they were washed twice with PBS and then 
5 ml of trypsin added for 2 minutes.  5 ml of medium was added to stop the 
action of trypsin and centrifuged at 1000 rpm for 5 minutes (21°C).  The pellet 
was re-suspended in 1 ml of freezing solution (10% DMSO and 90% foetal 
bovine serum) and transferred to 1.8 ml cryogenic vial.  The cells were 
labelled and placed in ultra-low temperature freezers at -80°C (Sanyo, Japan) 
for 24 hours before being stored in liquid nitrogen for long periods of time.  
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2.2.1.5 Authentication of cell lines 
There are several methods to identify and authenticate cell lines such as 
Short Tandem Repeat (STR), karyotyping, Human Leukocyte Antigen (HLA) 
typing and isoenzyme analysis. Karyotyping analysis is used to investigate the 
number and structure of the chromosomes. It is able to detect numerical 
chromosomal abnormalities, genomic instability and chromosomal 
rearrangements including deletions, translocations, duplications and 
inversions. Isoenzyme analysis is a simple, rapid method that is able to define 
a range of intracellular enzymes from species to species [151].  Both 
isoenzyme analysis and karyotyping are able to confirm species of origin and 
detect cross-contamination of cell lines in the early stages [152]. HLA typing is 
another method to authenticate cell lines and is able to detect variation in 
human leukocyte antigen genes. Short Tandem Repeat (STR) profiling is now 
commonly used to authenticate cell lines and it is now an internationally 
approved and recommended method [153, 154].  Short tandem repeats are 
repeat sequences of 2-7 base pair nucleotides found in the particular regions 
(loci) of the genome [155] .  These can be amplified by Polymerase Chain 
Reaction (PCR) and detected.  A number of STRs specific to an individual or 
cell line is referred to as their ‘STR profile’.  The principle of STR profiling is to 
be able to determine the genetic identity by determining the STR at various 
loci of an individual cell line.  The numbers of loci at which the STRs are 
identified and detected vary, but typically include the following: THO1, 
D21S11, D5S818, D13S317, D7S820, D16S539, CSFIPO, AMEL, vWA and 
TPOX.  STR profiling has many advantages over the other methods such as 
reliability, accuracy, sensitivity [156, 157], rapidity and cost [155, 157]; 
however the disadvantage of STR is that it does not provide information on 
the origin of tissue [156]. In this study Short Tandem Repeat (STR) profiling 
has been used to authenticate three human thyroid cell lines (FTC-133, K1E7 
and Nthy-ori 3-1) that were being maintained in house.  This was to ensure 
that the results of our study of these cell lines would be reliable. The other cell 
lines with a known STR profile; RO82-W-1, 8305C and TT were purchased 
from the European Collection of Cell Culture (ECACC) and were not subject 
to STR profiling. 
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2.2.1.5.1 DNA extraction for STR profiling 
The cell lines Nthy-ori 3-1, K1E7 and FTC were sub-cultured in T75 flask and 
cell confluence were checked frequently under the microscope.  Cells were 
centrifuged again at 1000 rpm for 5 minutes and re-suspended in 200 µl of 
PBS.  20 µl of ‘proteinase K’ and 200µl of ‘Buffer AL’ were added, mixed by 
vortexing and incubated at 56°C for 10 minutes. 200 µl of 100% ethanol was 
added.  This was left for 1 minute before being mixed by vortexing and 
transferred to a mini spin column placed in 2 ml collection tube.  This was 
spun at 8000 rpm for 1 minute and the 2ml collection tube was discarded.   A 
mini spin column was placed in a new 2 ml collection tube before adding 500 
µl of ‘Buffer AW1’.  This was centrifuged at 8000 rpm for 1 minute.  The 2 ml 
collection tube was then discarded.  The mini spin column placed in a new 2 
ml collection tube.  500 µl of ‘Buffer AW2’ was added and then centrifuged at 
14000 rpm for 3 minutes before transferring the filter with the DNA to a 1.5 ml 
or 2 ml microcentrifuge tube.  200 µl of ‘Buffer AE’ was added and incubated 
at room temperature for 1 minute.  The solution was centrifuged for 1 minute 
at 8000 rpm. The pellet containing the extracted DNA was sent to core 
genomic facility, University of Sheffield for STR profiling.  The concentrations 
of DNA extracted from the Nthy-ori 3-1, K1E7 and FTC-133 cell lines and 
estimated using NanoDropTM ND-1000 Spectrophotometer method was 
157.35 ng/µl, 84.37 ng/µl and 79.23 ng/µl respectively and considered as a 
good concentration.  
2.2.1.5.2 STR profiling 
STR profiling was done by the picogreen method. This is briefly described.  
The picogreen reagent was warmed up at room temperature before use.  TE 
buffer solution (its components 10 mM Tris-HCL and 0.1 mM 
Ethylenediaminetetraacetic acid (EDTA) 8.0 PH) was used to dilute DNA 
samples and quantify picogreen reagent. The working concentration of 1x TE 
buffer was prepared by diluting 20x TE buffer stock concentration in distilled 
water.  The aqueous working solution of the picogreen reagent was prepared 
by diluting picogreen reagent 200 fold in TE buffer (200 µl of Picogreen 
reagent diluted in 39.8 ml of TE buffer) in a plastic container and protected 
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from light by an aluminium foil cover.  2 µg/mL DNA was mixed and incubated 
at room temperature with 1.0 ml of the aqueous working solution of picogreen 
reagent for 5 minutes in plastic test tube covered by foil.  The fluorescence 
was read via microplate reader at emission 520 nm and excitation 480 nm.  
Following this, 0.84 ng DNA was added to each reaction (the reaction also 
contains a primer pair mix and an enzyme mix (one-step addition of Taq DNA 
polymerase, dNTPs, MgCl2) plus water to final volume) before PCR cycling.   
The amplified DNA was then subjected to fragment analysis on a 3730 DNA 
analyser.  The results were analysed using Genemapper 4.0 software to give 
genotyping results that can be matched to information in an STR database for 
cell identification. 
   
2.2.2 Cell proliferation assay (MTT assay) 
2.2.2.1 Principles of MTT assay 
MTT (3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyldetrazolium bromide is a 
colorimetric metabolic activity assay that assesses the viability of cells. The 
yellow tetrazolium MTT dye in living cells is reduced by cellular reductive 
enzymes to form insoluble formazan, which is purple in colour [158].  
Insoluble purple formazan is dissolved to form a coloured solution by DMSO.  
The absorbance of the colour solution can be measured by 
spectrophotometer by using 500-600 nm wavelengths. 
In this study, the effect of Metformin on thyroid cancer cell growth at time 
periods ranging from 1 to 6 days was investigated via MTT assay; all 
experiments were repeated in triplicate.  The concentration of Metformin used 
ranged between 0.03 mM to 20 mM; this includes therapeutic concentrations 
of Metformin in humans [132].  The effect of Metformin on breast cancer cells 
(MCF7) and retinal pigmented epithelial cells (h-TERT RPE-1) was also 
studied and compared to thyroid cells.  
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2.2.2.2 Methodology of MTT assay 
Cell line preparation: Cells were defrosted and cultured for 3 days in T75 
flasks.  Cells were seen attached to the base of the flask and were dividing. 
The target was 70% confluence but if this target was not achieved in 3 days, 
the culture media was changed and the cells left for a few more days.  The 
medium was aspirated with a Pasteur pipette (new for each flask), and then 
washed twice with 5 ml of PBS.  The PBS was aspirated and 5 ml of trypsin 
added.  This was then incubated for 2 minutes to completely detach the cells.  
The solution was then pipetted up and down and transferred to a falcon tube 
before being centrifuged at 1000 rpm for 5 minutes.  The supernatant was 
aspirated and 10.5 ml of medium added.  500µl was aspirated for counting 
cells with a cell viability analyser (vi-cell XR, Beckman coulter, USA).   
As initial standardisation procedure, cells were seeded into a 96 well plate in 3 
different concentrations (1.5x10⁴, 1x10⁴ and 0.5x10⁴ cells per well in 100 µl of 
medium – 15 wells each).  The concentrations were chosen to reflect the 
optimal growth for up to 144 hours.  We decided to choose 0.5x10⁴ cells per 
well as they showed optimum growth yet still retained space for further growth 
in the 96 well plate.  
Day 1: Cells were seeded into a 96 well plate using 0.5x10⁴ cells per well in 
100 µl of medium. They were then incubated at 37°C in a humidified 
atmosphere of 95% and 5% CO2 for 24 hours. 
Day 2: The cells were treated with various concentrations of Metformin (0.03 
mM, 0.1 mM, 0.15 mM, 0.3 mM, 1 mM, 5mM, 10 mM and 20 mM) in triplicate; 
they were then incubated for certain time points (24, 48, 72, 96,120 and 144 
hours) at 37°C in a humidified atmosphere of 95% and 5% CO2. 
Day3: At each time point, 100 µl of MTT (1 mg/ml) was added to each well 
and incubated for 3 hours at 37°C in a humidified atmosphere of 95% and 5% 
CO2 and protected from light by foil.  MTT and the media were aspirated and 
100 µl of DMSO added to each well.  This was incubated for 30 minutes at 
37°C in a humidified atmosphere of 95% and 5% CO2.    
The absorbance was read via plate reader (Fluostar Galaxy, BMG labtech, 
Germany) at 570 nM.  
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2.2.2.2.1 Cell proliferation assay (MTT) to study the interaction of 
Metformin with glucose, TSH, IGF-1 and insulin. 
 
The principles and methodology of MTT assay have been described 
previously. The following modifications were made to study the effects of 
glucose, TSH, IGF-1 and insulin. 
1. Glucose: 
Day 2: Cells were treated with Metformin concentrations (0.3 mM and 10 mM) 
in the DMEM glucose free medium and DMEM medium containing 10 mM of 
glucose; they were then incubated for 6 days at 37°C in a humidified 
atmosphere of 95% and 5% CO2. 
2. TSH: 
Day 2:  Cells were treated with various concentrations of Metformin (0.3 mM 
and 10 mM) in triplicate with and without 5 mIU/ml of TSH in the medium; they 
were then incubated for 6 days at 37°C in a humidified atmosphere of 95% 
and 5% CO2. 
3. IGF-1 
Day 2:  Cells were treated with Metformin concentrations  (0.3 mM and 10 
mM) in triplicate with and without 100 ng/ml of IGF-1 in the medium; they were 
then incubated for 6 days at 37°C in a humidified atmosphere of 95% and 5% 
CO2. 
4. Insulin 
Day 2:  Cells were treated with Metformin concentrations (0.3 mM and 10 
mM) in triplicate with and without 10 μg/ml of insulin in the medium; they were 
then incubated for 6 days at 37°C in a humidified atmosphere of 95% and 5% 
CO2. 
2.2.3 Cell proliferation assay (trypan blue assay) 
2.2.3.1 Principles of trypan blue assay 
This assay was used to validate the results of MTT assay. Trypan blue 
solution (0.4%) is prepared in 0.81% sodium chloride and 0.06% potassium 
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phosphate dibasic. Trypan blue solution is a traditional technique, which is 
used in proliferation assays and cytotoxicity. Trypan blue is a vital stain, which 
is absorbed by dead cells but is not absorbed by live cells. Live cells are 
excluded from the staining and the method is referred to as the dye exclusion 
method. The dead cells are stained blue in colour while the live cells are 
colourless and bright under the microscope. Trypan blue has been used for 
years in academic research and laboratory-based work. Traditionally, in 
trypan blue exclusion method the cells are routinely counted manually via 
haemocytometer but in recent research, the trypan blue method has been 
replaced by a quick modern automated method of high quality image and   
ability of sample handling.  The automated cell counter (BIO RAD TC20) 
counted the percentage of viable cells. 
 
2.2.3.2 Methodology of trypan blue assay 
Cell preparation: Similar to that described previously in MTT assay. 
Day 1: Cells were seeded into a 24 well plate using 0.5x10⁴ cells per well in 1 
ml of medium then they were incubated at 37°C in a humidified atmosphere of 
95% and 5% CO2 for 24 hours. 
Day 2: The cells were treated with various concentrations of Metformin (0.03 
mM, 0.1 mM, 0.15 mM, 0.3 mM, 1 mM, 5 mM, 10 mM and 20 mM) in triplicate; 
they were then incubated for 6 days at 37°C in a humidified atmosphere of 
95% and 5% CO2. 
Day 3: At each time point, 10 µl of cell-trypan blue mixture solution (10 µl of 
cell suspension was mixed with 10 µl of trypan blue to make 20 µl of cell-
trypan blue solution) was added to the one side of outer opening slide 
chambers.  The percentage of viable cells on the slide chambers was counted 
via automated cell counter BIO RAD TC20. 
 
 68 
2.2.4 Clonal formation assay 
2.2.4.1 Principles of Clonal formation assay 
This is a proliferation assay that is used to assess the ability of single cells to 
form a colony.  Cells may grow and divide to form a few cells counted as a 
colony or remain as a single cell, which was counted as a dead cell.  The aim 
of this assay was to investigate the number and the morphology of colonies 
after cells were treated with various concentrations of Metformin.  
Cells were treated with concentrations between 0-5 mM, which include the 
normal therapeutic concentration of Metformin. The other toxic concentrations 
of Metformin 10 mM and 20 mM were used in the pilot study but the cells 
unable to form colonies due to the high toxicity of Metformin. In the previous 
published study similar concentrations of Metformin were used but different 
thyroid cancer cell lines were investigated [104]. 
 
2.2.4.2 Methodology of clonal formation assay 
 
Cell preparation: Cells were cultured in T75 flasks and constantly checked 
under the microscope for confluence until the cells were approximately 70% 
confluent.  
Day 1: When the cells approximately were 70% confluent, they were washed 
twice with 5 ml PBS and trypsinised with 5 ml of trypsin.  The cells were 
suspended in medium and trypsin in a universal tube.  Cells were centrifuged 
at 1000 rpm for 5 minutes and re-suspended as a pellet in 10 ml of medium.  
The total number of viable cells was counted via cell viability analyser (Vi-
CELLTM XR, Beckman coulter, USA).  Cells were seeded 500 cells per 10 cm 
petri dishes and incubated with 10 ml of medium for 24 hours at 37°C, 
humidified atmosphere of 95% and 5% CO2. 
Day 2: Cells were treated with various concentrations of Metformin in triplicate 
(control, 0.03 M, 0.1 mM, 0.3 mM, 1 mM and 5 mM) and incubated for 14 
days at 37°C, humidified atmosphere of 95% and 5% CO2. 
Day 14: After this period, cells were washed twice with PBS and then fixed 
with 5 ml of a solution of methanol/acetone solution at a ratio of 1:1. The 
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dishes were washed again with PBS, colonies stained with methylene blue 
70% alcohol (I.M.S) and incubated at room temperature for 40 minutes.  After 
a final wash with distilled water, the dishes were left to dry overnight. 
Day 15: Formed colonies were counted by using an inverted microscope for 
FTC-133, K1E7, RO82-W-1 and Nthy-ori 3-1 cell lines in three independent 
experiments for each concentration of Metformin (control, 0.03 M, 0.1 mM, 0.3 
mM, 1 mM and 5 mM) in triplicate.  
 
2.2.5 Cell migration or scratch assay 
2.2.5.1 Principles of Scratch assay 
This assay investigated the movements of cell growth under the effect of an 
anti-proliferative agent. The process of movement of cells in a particular 
direction is known as cell migration. The assay helps to determine if drugs 
such as Metformin stop or enhance cell migration in vitro.   
Two concentrations of Metformin were used in this experiment, the 
therapeutic concentration 0.3 mM and one toxic concentration 10 mM, which 
was previously studied [105].  
 
2.2.5.2 Methodology of Scratch assay 
Cells were cultured with silicone inserts to ensure a defined cell-free gap in 
each chamber.  The cells were then incubated for 24 hours at 37°C, 
humidified atmosphere 95% and 5% CO2. After 24 hours, the silicone insert 
was removed and the medium changed with medium containing Metformin 
(control, 0.3 mM and 10 mM) and incubated for 24 hours. This experiment 
was repeated three times independently and in triplicate at different Metformin 
concentrations. After 24 hours, pictures were taken of untreated cells and 
cells treated with Metformin (0.3 mM and 10 mM) using the Nikon glipse 
TS100 microscope at 4x magnification.  
ImageJ software was used to measure the gap closure and to calculate the 
remaining separation gap between two populations of cells on removal of the 
partition in control cells and Metformin treated cells (0.3 mM and 10 mM).  
About 20 horizontal lines were drawn across the edge of the cells and the 
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measurements of the length of the drawn lines were taken and the percentage 
of the closed area was calculated. These steps were repeated for each cell 
line. 
 
2.2.6 Flow cytometric analysis for apoptosis assay 
2.2.6.1 Principle of apoptosis 
Apoptosis also called programmed cell death is a biochemical consequence 
resulting in cell characteristic changes (morphology).  Annexin V is a family of 
calcium-dependent phospholipid-binding proteins, which bind to 
phosphatidylserine (PS) on the cell membrane of apoptotic cells, as PS 
translocates to the extracellular membrane in apoptotic cells.  This assay is 
able to characterize cells into three populations: - The viable cells (annexin V 
negative, propidium iodide (PI) negative), necrotic cells (annexin V positive, PI 
positive) and early apoptotic cells (annexin V positive, PI negative).  
In this study both low concentrations of Metformin including therapeutic 
concentrations of Metformin and high concentrations of Metformin, similar to 
those used as in the previous study were investigated [104]. 
 
2.2.6.2 Methodology of apoptosis assay 
10X Annexin V Binding Buffer: 0.1 M Hepes/NaOH (pH 7.4), 1.4 M NaCl, 25 
mM CaCl2. For a 1X working solution, dilute 1 part of the 10X Annexin V 
Binding Buffer to 9 parts of distilled water. 
Cell preparation: Cells were cultured in T75 flasks and constantly checked 
under the microscope for confluence until the cells were approximately 70% 
confluent. 
Day 1: When the cells were 70% confluent, they were washed twice with 5 ml 
PBS, trypsinised with 5 ml of trypsin and suspended in medium in a universal 
tube.  Cells were centrifuged at 1000 rpm for 5 minutes and re-suspended as 
a pellet in 10 ml of medium.  The total number of viable cells was counted via 
cell viability analyser (Vi-CELLTM XR, Beckman coulter, USA).  Cells were 
seeded 4 x 105 cells per 6 cm dishes and incubated with 10 ml of medium for 
24 hours at 37°C, humidified atmosphere of 95% and 5% CO2. 
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Day 2: Cells were treated with various concentrations of Metformin (control, 
0.1, 0.3 mM, 1 mM and 10 mM) in triplicate and incubated for 144 hours at 
37°C, humidified atmosphere of 95% and 5% CO2. 
Day 3: The medium was transferred from 6 cm dishes to labelled tubes. Cells 
were washed with PBS twice and then incubated with 2 ml of trypsin for 2 
minutes at 37°C, humidified atmosphere of 95% and 5% CO2.  Cells were 
collected in correspondence labelled tubes and centrifuged at 1000 rpm for 5 
minutes (at 21°C).  The supernatant was discarded and the cells were re-
suspended as pellet in 5 ml of ice PBS.  Cells were centrifuged again at 1000 
rpm for 5 minutes (at 21°C) and the cells were re-suspended as pellet in 10% 
buffer (2 ml of buffer + 18 ml of distilled water) to get a concentration of 2 x 
106 cells per ml (by dilution of cells in buffer). 100 µl of cells were transferred 
into FACS tubes (2 X 106 cells).  5 µl of FITC anexin V and 5 µl of propidium 
iodide (PI) were added to each FACS tubes and incubated at room 
temperature for 15 minutes.  400 µl of 10% buffer added to each samples and 
then the percentage of apoptotic cells analysed with flow cytometer (FACS) 
(BD Biosciences) via Cell Quest Pro software (Figure 2.1).  
 
 
Figure 2.1: Flow cytometry gating strategies for apoptosis assay. 
This figure shows the selection of FTC-133 cell population (R1 which is red in colour) used for 
analysis of the apoptosis assay. 
 
Flow cytometry scatter plots and gating strategies for cell viability
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2.2.7 Flow cytometric analysis for cell cycle assay 
2.2.7.1 Principles of cell cycle assay 
In this assay flow cytometry can differentiate cells in various cell cycle phases.  
Cells were treated with fluorescent dye (propidium iodide), which stains DNA.  
The certain wavelengths of fluorescent intensity in stained cells associated 
with the amount of DNA in the cells.  Based on the amount of DNA, flow 
cytometry identified the percentage of cell population in cell cycle phases.   
2.2.7.2 Methodology of cell cycle assay 
Cells were cultured in 6 well plates (4 x 105 cells per well) and incubated for 
24 hours.  Cell were treated with different concentrations of Metformin 
(control, 0.3 mM, 1 mM and 10 mM) and incubated for 6 days, fixed with 70% 
ethanol and left overnight at 4°C.  50 µl of ribonuclease (100 µg/mL solution) 
was added to the cells for 15 minutes at room temperature, followed by 200 µl 
of propidium iodide (PI) and left for 2 hours at 4°C.  The samples were 
analysed with flow cytometer (FACS) (BD LSRII) using FACSDiva 7.0 
software (Figure 2.2). For each cell line, the experiment was performed in 
one well and on 3 occasions. 
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Figure 2.2: Flow cytometry scatter plots and gating strategies for cell cycle 
analysis. 
This shows the gating strategy for the flow cytometry cell cycle assay and shows the 
population of cells in different phases of the cell cycle (G1, S &G2). The side scatter (SSC) 
shows the granularity of the cells and forward scatter (FSC) shows the size of the cells. 
 
2.2.8 γH2AX assay for DNA repair 
2.2.8.1 Principles of γH2AX assay 
Histone proteins are alkaline proteins. H2A.X is a member of the H2A histone 
protein family and is packed along with DNA to form the subunit of the 
chromatid (nucleosome).   
H2A.X protein (gamma-H2A.X) phosphorylation in cells is a sensitive target 
for looking at double-strand breaks (DSBs)  [159]. In response to double 
strand breaks-DNA (DSBs-DNA), ataxia telangiectasia mutated (ATM) and 
DNA dependent protein kinase (DNA-PK) are activated and play an essential 
role in phosphorylation of H2A.X protein (γH2AX) [160].  Subsequently, 
nuclear microscopically visible foci in the nucleus form as a result of DSBs. 
Flow cytometry scatter plots and gating strategies for cell viability
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These therefore can be used as biomarkers of DNA damage and repair [161] 
(Figure 3.11). The γH2AX foci can be visualised with an immunofluorescence 
microscope after staining with specific primary antibody (Phospho-Histone 
H2A.X (Ser139) (20E3) Rabbit mAb).  In order to induce DNA-DSBs in FTC-
133, K1E7 and Nthy-ori 3-1, cells were irradiated (IR) or treated with 
Metformin or treated with both.  The quantitative assessment of γH2AX foci 
were used to assess DNA damage and repair in thyroid cancer cell lines 
treated with and without radiation and/or Metformin and Metformin alone. 
 
2.2.8.2 Methodology of γH2AX assay 
Cell preparation: Cells were cultured into T75 flasks and checked under the 
microscope daily until they were approximately 70% confluent.   
Day 1: Cover slips 22 X 22mm were immersed in absolute methanol and left 
for 10 minutes until they were dried.  The cover slips were then placed in the 6 
well plates.  Cells were trypsinised with 5 ml of trypsin and incubated for 2 
minutes.  Cells were re-suspended in 5 ml of medium and collected in 
universal tube.  The cells in the universal tube were centrifuged for 5 minutes 
at 1000 rpm.  A cell viability analyser (Vi-CELLTM XR, Beckman coulter, USA) 
was used to count viable cells. Viable cells were seeded (5 x 10⁴ cells per 
coverslip) in each well and 2 ml of medium was carefully added to each well 
without disturbing cells on the coverslips.  The plates were incubated for 24 
hours at 37°C, 95% humidification and 5% CO2. 
Day 2: The wells were labelled for different combinations of treatments for 
each cell lines:-  
a) Metformin (20 mM) + radiation (2 Gy IR). 
b) Metformin (0.1 mM) + radiation (2 Gy IR). 
c) Radiation (2 Gy IR). 
d) Metformin (20 mM). 
e) Metformin (0.1 mM). 
f) Control (not treated with either Metformin or IR) 
Cells labelled with Metformin were treated with medium containing Metformin 
(0.1 mM and 20 mM) for 144 hours prior to radiation.  
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Day 8: Cells labelled with IR were irradiated with 2 Gy IR using Cesium137 
irradiator (CIS Bio International).  The cells were incubated for certain time 
points (0.5 hour, 1 hour and 2 hours) which allowed the recovery of cells after 
DNA damage.  The medium was discarded at each time point (0.5 hour, 1 
hour and 2 hours) and washed twice with PBS.  The cells were fixed by 
adding 1.5 ml of 4% PFA to each well and incubated for 10 minutes at room 
temperature.  After incubation, the 4% PFA was discarded and the cells were 
washed twice with PBS.  After this, 2 ml of 0.2% Triton X-100 in PBS was 
added to each washed well, incubated for 5 minutes at room temperature (for 
permeation of primary antibody) and then washed twice with PBS.  Cells were 
blocked by adding 1.5 ml of blocking buffer (10% normal goat serum in PBS) 
to each well and incubated for 1 hour at room temperature and then washed 
twice with PBS.  100 µl of phospho-histone rabbit anti-у-H2A.X was added on 
each coverslip and incubated for 24 hours at 4°C in a humidity chamber. 
Day 9: Cells were washed 3 times with PBS (5 minutes wash on the rotate 
shaker).  They were incubated with 100 µl of Cy3 goat anti-rabbit IgG in the 
dark for 1 hour at room temperature.  Following incubation, the cells were 
washed 3 times with PBS (5 minute wash on the shaker and protected from 
light).  The coverslips were then placed with 4',6-DiAmidino-2-Phenylindol 
(DAPI) (Vector laboratories Inc., USA) onto the centre of microscope slides.  
The edges of coverslips were fixed with a small drop of nail varnish and the 
slides were left to dry before being stored at 4°C in the dark. 
Day 10: The numbers of γH2AX foci were counted using Cytovision software 
(Newcastle upon Tyne, UK) in 100 cells per slide via fluorescent microscope 
with CCD camera at 100x magnification. The foci were detected as red 
fluorescent signals inside the blue background stained DAPI cells.   
 
This experiment was performed in triplicate and the entire experiment was 
repeated in three independent experiments. The rationale for using the 2 Gy 
IR radiation dose in this experiment was that is considered as a therapeutic 
dose of radiotherapy [162]. In addition, the 2 Gy radiation-induced high DNA 
damage previously reported by the Rare Tumour Research Group (RTRG) 
within the department of Oncology, University of Sheffield. 
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2.2.9 Immunocytochemistry for OCT1 expression 
2.2.9.1 Principles of immunocytochemistry 
Immunocytochemistry is a common technique used in the laboratory to detect 
and localize a specific antigen or protein.  In order to visualize protein under 
the fluorescent microscope, a specific primary antibody were used and then 
treated with a secondary antibody to bond with the primary antibody.  
Immunocytochemistry was used to investigate the expression of OCT1 in 
thyroid cancer cells. 
2.2.9.2 Methodology of Immunocytochemistry 
In a pilot study a serial dilution for the primary antibody as tested (1:25, 1:50, 
1:100 and 1:200) and 1:50    20 µl of SLC22A1 in 1000 µl of 2% goat sera 
was chosen as this distinguished OCT1 staining in HepG2 cells-the positive 
control. 
Cell preparation: Slides were soaked in absolute ethanol for at least 10 
minutes. Slides removed with forceps and leant against the side of a large 
petri dish to allow the ethanol to completely evaporate. Once dried, forceps 
were used to place the slides into the petri dish so they were completely flat 
and the lid is replaced.  Cells were then prepared for counting.  Cells were 
then seeded at a concentration of between 10,000-15,000/0.5 ml of media 
and placed onto each slide.  After 24 hours, 25 ml of media containing 
different concentrations of Metformin (0-10 mM) added and incubated for two 
time points (24 and 48 hours).  Once the cells were ready, the media was 
removed and the slides were washed in the petri dish with PBS 4 times.  
Slides were transferred to a slide rack and submerged into ice-cold 
methanol/acetone 50:50 for 10 minutes. The methanol/acetone was prepared 
1 hour before use and stored in a – 20 °C freezer. Slides were removed from 
methanol/acetone and left to dry in fume cupboard.  Once completely dry, the 
slides were stored in a container in the – 20 °C freezer until further use. 
 
SLC22A1 antibody stain for OCT1: The slides were removed from the – 20 
°C freezer and allowed to warm up to room temperature.  The ImEdge 
hydrophobic barrier pen was used to mark an area on the slides by drawing 
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around the cells and washed in PBS for 5 minutes. Slides were soaked in 
H2O2/methanol at room temperature (30 ml H2O2 + 270 ml methanol) for 5 
minutes and then washed on the shaker very gently for 5 minutes and 
repeated twice.  After this, 10% blocking serum (400 µl goat sera in 4 ml of 
PBS) was added, left for 20 minutes and then tipped off.  Cells were 
incubated with 200 µl of primary antibody (SLC22A1) at 4°C overnight (using 
the dilution of 1:50 of primary antibody; 20 µl of SLC22A1 in 1000 µl of 2% 
goat sera).  The next day, cells were washed with PBS on a shaker very 
gently for 5 minutes and repeated twice.  Cells were incubated at room 
temperature with 200 µl of secondary antibody (goat anti-rabbit, Biotinylated) 
for an hour.  Secondary antibody was diluted 1:200 in 2% goat sera (10 µl to 2 
ml 2% goat sera).  Cells were washed again with PBS 3 times (each time for 5 
minutes) and then incubated with ABC reagent (for 5 ml of reagent, 2 drops A, 
2 drops B and 5 ml PBS were mixed well and allowed to stand for 30 minutes 
before being used) for 30 minutes.  Cells were washed again with PBS 3 
times, each for 5 minutes.  The sections were incubated in peroxidase 
substrate (DAB) solution (for 5 ml of DAB, 2 drops buffer, 4 drops DAB, 2 drop 
H2O2 are mixed with 5 ml distilled water; this is usually only prepared 
immediately before use) until desired stain intensity developed; usually 
around 10 minutes. Slides were washed in tap water for 2 minutes and then 
counterstain in haematoxylin gills for 30 seconds. Slides were then rinsed in 
tap water until the water ran clear and washed in Scott’s tap water substitute 
for 10 seconds. 
 
Dehydrate, clear and mount:  Slides were soaked in increasing 
concentrations of ethanol - 70% ethanol for 3 minutes, 90% ethanol for 3 
minutes, 95% ethanol for 3 minutes, 100% ethanol for 3 minutes and 100% 
ethanol for 3 minutes. This was followed by mounting on Xylenel1 for 3 
minutes and Xylenel2 for 3 minutes (or until wax from the wax pen has 
cleared).  The slides were mounted and dried overnight.  The proportion and 
intensity of OCT1 expression were estimated using the Allred score. Allred 
score is a scoring method to estimate the percentage of cells that are stained 
(on the scale of 0-5) and then to determine the intensity of that stain (on the 
scale of 0-3) and the total scoring will be ranged 0-8.  
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This experiment was repeated once for each concentration of Metformin but 
the entire experiment was repeated in three independent experiments. In this 
experiment a breast cancer cell line (MDA-MB-231) were used as a control 
because the MCF7 cells had issues with recovery. 
 
2.2.10 Affymetrix assay 
2.2.10.1 Principles of Affymetrix assay 
The Affymetrix gene chip microarray is to detect a wide range of genomic 
expression of each sample (high quality extracted RNA) by using specific 
probes.  The genomic expression profile can be then translated to 
understanding specific diseases, molecular diagnostic tests and improving 
therapeutic targets.  
2.2.10.2 Methodology of Affymetrix assay 
Prior to starting: Preparing Buffer RPE working solution by adding 4 volume 
of 96-100% ethanol to Buffer RPE. 
RNA extraction: Cells were harvested to a maximum 1x 107 cells then 600 µl 
of buffer RLT was added and mixed with 600 µl of 70% ethanol.  700 µl of the 
sample was transferred to RNeasy Mini spin column and placed in a 2 ml 
collection tube then centrifuged at ≥8000 x g for 15 seconds.  After that 700 µl 
of Buffer RW1 added to the RNeasy spin column and centrifuged at ≥8000 x g 
for 15 seconds.  500 µl of Buffer RPE added to the RNeasy spin column and 
centrifuged at ≥8000 x g for 15 seconds then 500 µl of Buffer RPE added to 
the RNeasy spin column and centrifuged at ≥8000 x g for 2 minutes.  The 
RNeasy spin column were placed in a new 1.5 ml collection tube and 50 µl 
RNase-free water was added before centrifuged at ≥8000 x g for 1 minute to 
elute the RNA.  The quality of RNA samples was checked by the microarray 
core facility, University of Sheffield, UK before proceedings to analysis on the 
Agilent Bioanalyser. 
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2.2.11 Statistical analyses  
All the data was non-parametric  (not normally distributed) and the statistical 
analyses were performed using Graphpad Prism software v. 6 for Mac.  
Kruskal-Wallis test was used for multiple comparisons of more than two 
groups for example to compare the results of the experiments for the treated 
(cells treated with different concentrations of Metformin) and untreated (cells 
not treated with Metformin) groups. Mann-Whitney test was used to compare 
two groups for example cells treated with single concentration of Metformin 
and cells not treated with Metformin (control).  P value < 0.05 was considered 
as a statistically significant.  
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3 CHAPTER THREE 
CHAPTER THREE 
 
Effect of Metformin on thyroid cancer 
cell growth and behaviour
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3.1 Introduction 
 
Several population-based studies have demonstrated the potential of Metformin as a 
chemo-preventative agent in cancer (including breast cancer [112-114], prostate 
cancer [113, 118], gastric cancer [113, 119], lung cancer [112, 113, 119], pancreatic 
cancer [113, 119], and colorectal cancer [113]).  Recently, a few clinical trials have 
been done to investigate the anti-tumour effect of Metformin in patients with breast 
cancer [138-140]. These showed significant reduction in Ki67 expression in the 
Metformin group and changes in the control arm; providing evidence for anti-
proliferative effects of Metformin and increased apoptosis as reflected using the 
TUNEL assay.  
 
Furthermore, investigations of the anti-cancer effects of Metformin in vitro, using a 
number of human cancer cell lines (including breast cancer [125, 126], gastric 
cancer [127], lung cancer [126], ovarian cancer [128] and thyroid cancer [104, 106]) 
have shown that Metformin inhibited cancer cell proliferation and induced apoptosis.  
The response to Metformin has been shown in these studies to be dependent on 
duration of exposure and concentration of drug in the media.  In relation to thyroid 
cancer, Metformin has been suggested to have anti-cancer effect on anaplastic 
thyroid cancer cell line HTh74 by inducing cell cycle arrest and apoptosis and also 
Metformin inhibited cell proliferation on anaplastic (HTh74, C643 and SW1736) and 
follicular thyroid cancer cell lines (FTC-133) [104].  In another study, Metformin 
inhibited medullary thyroid cancer cell proliferation (TT and MZ-CRC-1 cell lines) and 
also Metformin up-regulated the AMPK pathway (TT cell line) [106].  The anti-cancer 
effects of Metformin are in dose and time dependent manner in thyroid cancer cell 
lines [104, 106].  The concentrations of Metformin used in these studies were much 
higher than normal human plasma concentrations (0.01-0.3 mM) [132, 163], limiting 
the extrapolation of these findings to clinical practice.  
 
Metformin in thyroid cancer has also been investigated in vitro in combination with 
other agents such as Doxorubicin and Cisplatin [129]. The anti-proliferative effect 
when Metformin was given in combination with either Doxorubicin or Cisplatin was 
more effective than single agent treatment. In a study of Metformin in combination 
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treatment with Paclitaxel in breast and lung cancer cell lines (MCF7 and A549) [126], 
there was significant inhibition of cell proliferation (MCF7 and A549) compared to 
Paclitaxel treatment only. Furthermore, Metformin boosts the anti-cancer effects of 
Paclitaxel by increasing AMPK phosphorylation and inhibited mTOR, p70S6K and 
4E-BP1 [126]. The findings of these studies showed that Metformin amplified the 
effect of anti-cancer agents on some types of cancer in laboratory studies.  In this 
study the effect of Metformin on DSBs was investigated as a single agent and in 
combination with radiotherapy.  Radioiodine ablation is recommended in most 
patients following surgery to decrease the risk of recurrence of differentiated thyroid 
cancer [24].  However, radiation is also a risk factor to induce thyroid cancer 
because it causes DSBs-DNA [164].  γH2AX plays an essential role in DNA repair by 
the recruitment and activation of DNA repair proteins, chromatin remodelling and 
check points around the site of DNA damage that might cause DNA repair or cell 
cycle arrest and apoptosis [165]. DNA is repaired by one of two pathways - 
homologous recombination (where the DNA is accurately repaired by using the sister 
chromatid as template) and non homologous end joining pathway (where the DNA is 
repaired without a template) [166]. To facilitate the development of Metformin as a 
potential clinically useful anti-cancer drug for thyroid cancer, a detailed 
understanding of its effects on different types of thyroid cancer and the underlying 
mechanisms are required.  The aim of this study is to determine its effects on the 
growth and proliferation of several thyroid cancer and normal cell lines at 
concentrations relevant to clinical settings. 
 
In this chapter the effects of Metformin on the growth of normal thyroid follicular 
epithelium (Nthy-ori 3-1) and cancerous thyroid cell lines (K1E7, FTC-133, RO82-W-
1, 8305C and TT) were studied. The cells were exposed to low concentrations of 
Metformin that are relevant to clinical practice for longer periods of time (up to 14 
days).  In order to understand the mechanism of any observed effects, a number of 
different experiments including cell apoptosis, cell cycle arrest and cell migration 
were performed.  
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3.2 Results 
3.2.1 Cell line authentication  
The three thyroid cell lines (Nthy-ori 3-1, K1E7 and FTC-133) were recovered from 
liquid Nitrogen, and were then checked for STR profiling in order to validate the cell 
lines. The other cell lines (RO82-W-1, 8305C and TT) were purchased from the 
European Collection of Cell Culture (ECACC) with a known STR profile; hence a 
repeat authentication experiment was not performed. 
The original STR profile for each cell line was available from ECACC general cell 
collection, which was recorded on 9 loci. The observed STR profiles for Nthy-ori 3-1, 
K1E7 and FTC-133 cell lines were matched with the expected STR profiles. Table 
3.1 shows expected (black) and observed (red) STR profiles at the 10 loci (THO1, 
D21S11, D5S818, D13S317, D7S820, D16S539, CSFIPO, AMEL, vWA and TPOX).  
The number of STRs at each locus is represented as one or two peaks. The number 
of observed STRs was equivalent to the expected STR profiles for all cell lines.  For 
example the table shows that at the THO1 loci for Nthy-ori 3-1, STR occured 7 times 
on one chromosome 11 and 9.3 times on the other chromosome 11.  At the D21S11 
loci, the STR was 29 on one chromosome 21 and 30 on the other chromosome 21.  
 
3.2.2 Thyroid cells growth (MTT assay) 
In order to determine the most appropriate growth medium for the cell lines, cells 
were grown in various media.  Figure 3.1 demonstrates the growth curves of K1E7, 
FTC-133, RO82-W-1, 8305C, TT and Nthy-ori 3-1 cell lines in the different media.  
Tested all cell lines demonstrated more robust growth in DMEM with 2 gm/L and 
RMPI medium, compared to DMEM without glucose and DMEM F-12 medium.  
DMEM with 2 gm/L (10 mM) glucose was chosen for all further experiments, 
ensuring consistency of the growth environment across the various experiments. In 
the chapter four (section 4.2.1) the effects of glucose concentrations in the medium 
on cell proliferation were studied.  In each cell lines, there were significant statistical 
differences of cell growth between different mediums. The significant differences of 
cell growth among different mediums was DMEM with glucose vs DMEM F-12 (p = 
0.01) at day 3 and DMEM with glucose vs DMEM without glucose (p = 0.01) at day 4 
in K1E7 cells, RPMI vs DMEM F-12 (P = 0.03) at day 1 and DMEM with glucose vs 
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DMEM without glucose (p = 0.01) at day 3 in FTC-133 cells, DMEM F-12 vs DMEM 
with glucose (p = 0.02) at day 2 and DMEM with glucose vs DMEM without glucose 
(p = 0.01) at day 4 in RO82-W-1 cells, DMEM with glucose vs DMEM without 
glucose (p = 0.03) at day 3 in 8305C cells, RPMI vs DMEM without glucose (p = 
0.03) at day 4 and DMEM with glucose vs DMEM without glucose (p = 0.01) at day 5 
in TT cells, RPMI vs DMEM without glucose (p = 0.03) at day 3 and DMEM with 
glucose vs DMEM without glucose (p = 0.01) at day 4 in Nthy-ori 3-1 cells.  
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Table 3.1: STR profiling for Nthy-ori 3-1, K1E7 and FTC-133 thyroid cancer cell lines. 
  
  
TH01 D21S11 D5S818 D13S317 D7S820 D16S539 CSFIPO AMEL vwA TPOX 
Chromosome 
number 
11 21 5 13 7 16 5 X, Y 12 2 
Nthy-ori 
3-1 
Expected 7, 9.3  11 11 7, 12 12, 13 12 X 16, 18 9 
Observed 7, 9.3 29, 30 11 11 7, 12 12, 13 12 X 16, 18 9 
K1E7 Expected 6, 9  10, 11 11, 14 11 11, 12 11, 12 X, Y 17, 18 8 
Observed 6, 9 30, 31.2 10, 11 11, 14 11 11, 12 11, 12 X, Y 17, 18 8 
FTC-133 Expected 9.3  12 11 9, 10 11 10 X 15, 18 9 
Observed 9.3 32.2 12 11 9, 10 11 10 X 15, 18 9 
 
The observed STR profile was performed by the sequencing core facility, University of Sheffield on 10 loci as shown in red. The expected STR profile is 
shown in black, which is recorded on 9 loci  (available on ECACC website).  
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Figure 3.1: The growth curve of thyroid cell lines. 
Each data point represents the mean of three independent experiments performed in triplicate for 
each cell line. In each experiment, cells were cultured in various media (DMEM without glucose, 
DMEM with glucose 2 g/L (10 mM), DMEM F-12 and RPMI) for 6 time points (1-6 days). At each time 
point, the absorbance of cells in the medium was recorded.  Error bars show the standard error of 
mean (SEM). Kruskal-Wallis test were used for multiple comparisons of more than two groups. 
Statistics are not included on the figure due to noise but are included in text. Each thyroid cell line is 
shown in a separate graph 
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3.2.3 Cell proliferation assay (MTT assay) 
As this study was the first detailed investigation undertaken in the study of thyroid 
cancer cells. Metformin was used in wide dose range and included doses used in 
previously published studies [104-106, 149]. In order to assess the cell proliferation 
by the MTT assay, cells were cultured with various concentrations of Metformin for a 
number of different time points (section 2.2.2.2). For each time evaluated (1-6 days), 
the percentage of cell proliferation for Metformin concentrations was determined by 
using Fluostar Galaxy (plate reader).  
 
This assay evaluated thyroid cancer cell growth and proliferation of 5 thyroid cancer 
cell lines (K1E7, FTC-133, RO82-W-1, 8305C and TT) and a ‘normal’ thyroid 
follicular epithelial cell line (Nthy-ori 3-1). Other cell lines including a breast cancer 
cell line (MCF7) and a normal retinal pigmented epithelial cells (h-TERT-RPE-1) 
were also studied. MCF7 was used as a positive control in this study because it has 
shown a good response to treatment with Metformin in previous studies [125, 126, 
131]. The h-TERT-RPE-1 cells were used alongside of Nthy-ori 3-1 cells to boost 
accuracy of the control arm in this study.  
 
The results showed that Metformin inhibited K1E7 cell proliferation from the day 1 for 
all concentrations (0.03 mM, 0.1 mM, 0.15 mM, 0.3 mM, 1 mM, 5 mM, 10 mM and 20 
mM) but the inhibition did not reach statistical significance (p value > 0.05).  On day 
2, the inhibition approached marginal significance at 20 mM (p value = 0.05).  
Increasing the duration of incubation of K1E7 cells with Metformin decreased the 
minimum concentration of Metformin required to inhibited K1E7 cell proliferation 
significantly.  The minimum significant concentration of Metformin that inhibited K1E7 
cell proliferation was 5 mM on day 3, 4, 5 and 6 (p values were 0.019, 0.031, 0.009 
and 0.008 respectively) (Figure 3.2).   
 
In FTC-133 cells, the minimum significant concentration of Metformin that inhibited 
FTC-133 cell proliferation was 5 mM (p = 0.044) after an incubation period of 3 days.  
Following longer periods of incubation, the minimum significant concentration of 
Metformin remained at 5 mM at days 4, 5 and 6 (p values were 0.044, 0.044 and 
0.05 respectively) (Figure 3.2).  
 88 
At day 1 Metformin did not appear to significantly inhibit RO82-W-1 cell proliferation 
at any concentration.  At day 2, Metformin inhibited RO82-W-1 cell proliferation 
significantly at a minimum concentration of 20 mM (p = 0.027).   After cells were 
incubated with Metformin for longer periods of time, Metformin significantly inhibited 
RO82-W-1 cells at minimum concentrations of 5 mM at days 4, 5 and 6 (p values 
were 0.037, 0.027 and 0.019 respectively) (Figure 3.2).  
In 8305C cells, Metformin did not result in significant inhibition of cell proliferation 
from days 1 to 3 (p > 0.05).  However, cell proliferation was significantly inhibited at a 
minimum Metformin concentration of 5 mM at day 4, 5 and 6 (p values were 0.027, 
0.008 and 0.022 respectively) (Figure 3.2). 
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Figure 3.2: Cell proliferation assay  (MTT assay) 
Each bar represented the mean of three independent experiments (each done in triplicate).  Error bars show the standard error of mean (SEM).   In each 
experiment, cells were treated with various concentrations of Metformin (control, 0.03mM, 0.1 mM, 0.15 mM, 0.3 mM, 1 mM, 5 mM, 10 mM and 20 mM as 
shown in different colours) and incubated for different periods (horizontal axis). Statistical analysis was performed by Graphpad Prism software v. 6 for Mac, 
Kruskal-Wallis test were used for multiple comparisons of more than two groups. * P value < 0.05 vs control. 
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The TT cells results show that Metformin inhibited TT cell proliferation from day 1 
and this reached statistical significance at minimum concentration of 10 mM at day 2 
(p = 0.027).  After further incubation of TT cells with Metformin for longer period of 
time, minimum significant concentration of Metformin decreased to 5 mM that 
inhibited TT cell proliferation at days 3, 4, 5 and 6 (p values were 0.019, 0.021, 0.032 
and 0.011 respectively) (Figure 3.3).  
 
The normal thyroid cell lines (Nthy-ori 3-1) also showed response to the anti-
proliferative effect of Metformin.  Metformin inhibited Nthy-ori 3-1 cell proliferation 
from the day 1 and this reached statistical significance at minimum concentration of 
20 mM at day 2 (p = 0.014).  The minimum significant concentration of Metformin 
decreased when Nthy-ori 3-1 cells were incubated with Metformin for longer periods 
of time.  The minimum significant concentration of Metformin was 5 mM at days 4, 5 
and 6 (p values were 0.029, 0.014 and 0.044 respectively) (Figure 3.3). 
 
The other non-thyroid cell lines (MCF7 and h-TERT RPE-1) also responded to anti-
proliferative effects of Metformin.  The results showed that Metformin inhibited MCF7 
cells proliferation significantly at minimum concentration of 5 mM from day 1 (p = 
0.037).  Metformin also inhibited h-TERT RPE-1 cell proliferation significantly from 
day 1 at minimum concentration of 10 mM (p = 0.044) and 5 mM at day 2 (p = 0.032) 
(Figure 3.3). 
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Figure 3.3: Cell proliferation assay (MTT assay). 
Each bar represented the mean of three independent experiments (each done in triplicate).  Error bars show the standard error of mean (SEM).   In each 
experiment, cells were treated with various concentrations of Metformin (control, 0.03mM, 0.1 mM, 0.15 mM, 0.3 mM, 1 mM, 5 mM, 10 mM and 20 mM as 
shown in different colours) and incubated for different periods (horizontal axis). Statistical analysis was performed by Graphpad Prism software v. 6 for Mac, 
Kruskal-Wallis test were used for multiple comparisons of more than two groups. * , p value < 0.05 vs control.  
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The anti-proliferative effects of Metformin on all cell lines were enhanced at higher 
concentrations (Figure 3.2, Figure 3.3 & Figure 3.4). Even at low physiological 
doses (0.3 mM), longer exposure reduced proliferation, although this was not shown 
to be statistically significant (Figure 3.4). There were some differences between cell 
lines in their response to Metformin. As shown, the minimum statistically significant 
concentration of Metformin that inhibited cell proliferation was 5 mM, at day 3 for 
K1E7 (p = 0.01), FTC (p = 0.04) and TT (p = 0.01); 5 mM at day 4 for 8305C (p = 
0.02), Nthy-ori 3-1 (p = 0.02) and RO82-W-1 (p = 0.02); 5 mM at day 1 for MCF7 (p = 
0.03); and 5 mM at day 2 for h-TERT RPE-1 (p = 0.03).   
 
In all thyroid cancer cell lines Metformin inhibited cell proliferation in a concentration 
dependent manner with small differential effects of Metformin between cell lines 
(Figure 3.4). The differential effects of Metformin was only significant at 
concentrations of 1 mM and 5 mM in K1E7 vs RO82-W-1 cells (p = 0.02 and p = 
0.04 respectively) and at concentration of 20 mM FTC-133 vs TT (p = 0.01). 
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Figure 3.4: Cell proliferation assay (MTT assay). 
Each data point represents the mean of three independent experiments performed in triplicate for 
each cell line (shown in different colours).  Panel A shows thyroid cell proliferation after six days with 
various concentrations of Metformin (horizontal axis).  Panel B and C show cell proliferation at supra-
physiological concentration (20 mM) and physiological concentrations (0.3 mM) of Metformin at 
several time points (horizontal axis). Kruskal-Wallis test were used for multiple comparisons of more 
than two groups. 
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The growth inhibitory effect of Metformin on two of the above thyroid cancer cells 
was also studied by the trypan blue cell viability assay. The results are comparable 
to the MTT assay (Figure 3.5).  After cells treated with Metformin for 6 days, 
Metformin inhibited cell viability of K1E7 and FTC-133 cells in a concentration 
dependent manner. The other thyroid cell lines were not studied. In FTC-133 cells, 
Metformin inhibited cell proliferation in a concentration dependent manner and 
reached borderline significance at 1 mM Metformin (p = 0.051). The minimum 
concentration of Metformin that significantly inhibited cell proliferation was 10 mM (p 
= 0.02). In K1E7 cells Metformin inhibited cell proliferation in a concentration 
dependent manner and reached borderline significant level at concentration 10 mM 
(p = 0.06). However, at 20 mM Metformin cells were significantly inhibited (p = 0.02). 
Furthermore, the statistical analysis shows that there are no differential effects of 
Metformin in FTC-133 vs K1E7 cell proliferation for the same concentrations of 
Metformin. 
 
 
Figure 3.5: Cell viability assay (trypan blue). 
Each data point represents the mean of three independent experiments for FTC-133 and K1E7 cells 
(shown in blue and red colours respectively).  In each experiment, cells were treated with various 
concentrations of Metformin (as shown in the horizontal axis) in triplicate for 6 days. Error bars show 
the standard error of mean (SEM).  Kruskal-Wallis test were used for multiple comparisons of more 
than two groups. * , P value < 0.05 vs control. 
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3.2.4 Clonal formation assay 
Clonal formation assay was chosen to observe the anti-cancer effect of various 
concentrations of Metformin on cell growth and ability to form colonies over longer 
periods of time (14 days) compared to the MTT assay. The toxic concentrations of 
Metformin 10 mM and 20 mM were also studied in the pilot study, but the cells were 
unable to form colonies, due to the highly toxic effects of Metformin. 
 
Cells were treated with concentrations of 0-5 mM Metformin, which include the 
therapeutic concentration of Metformin. The rationale for Metformin concentrations 
used in this clonal formation assay were discussed in the method and materials 
(section 2.2.4.1). The cells were cultured in petri dishes for 14 days then the number 
of colonies was counted.  Inhibition of colony formation was evident at Metformin 
concentrations of 0.03 mM.  The minimum statistically significant concentration of 
Metformin that was demonstrated to inhibit colony formation was 1 mM for K1E7 (p = 
0.02), FTC-133 (p = 0.02), RO82-W-1 (p = 0.03) and 8305C (p = 0.02) and 5 mM for 
Nthy-ori 3-1 cells (p = 0.005) (Figure 3.6a & Figure 3.7). Colony formation was 
further decreased by increasing the concentration of Metformin and almost abolished 
at concentration of 5 mM (Figure 3.6b).  The study also found significant differential 
effects of Metformin on colony formation between FTC-133 vs 8305C cells at 
concentrations of 0 mM (p = 0.01), 0.03 mM (p = 0.01), 0.1 mM (p = 0.02) and 0.3 
mM (p = 0.03). The differential effects of Metformin on colony formation also were 
demonstrated in K1E7 vs 8305C cells reaching statistical significance at 0.3 mM 
concentration (p = 0.04). The clonogenic assay was also studied on the TT cell line 
but the TT cells did not form colonies.  
  
 96 
 
Figure 3.6: Clonal formation assay. 
Panel A demonstrates percentage of cells that formed colonies (y-axis) in various thyroid cancer cell 
lines at 14 days over a range of concentrations of Metformin (x-axis). Panel B shows microscopic 
morphology of colony formation of FTC-133.  After 14 days, pictures of colonies were taken of 
untreated cells and cells treated with Metformin (5 mM) using the Nikon glipse TS100 microscope at 
4x magnification. Error bars show the standard error of mean (SEM).  Kruskal-Wallis test were used 
for multiple comparisons of more than two groups. * , P value < 0.05 vs control. 
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Figure 3.7: Clonal formation assay. 
This figure shows the macroscopic morphology of colonies after cells were treated with various concentrations of Metformin for 14 days. 8305c cell line (not 
shown).
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3.2.5 Cell migration (Scratch assay) 
The effects of Metformin on cell migration were observed in five thyroid cell lines 
(K1E7, FTC-133, RO82-W-1, 8305C and Nthy-ori 3-1).  Cells were cultured with 
silicone inserts to ensure a defined cell-free gap in each chamber.  The cells were 
then treated with two concentrations of Metformin (0.3 mM and 10 mM) and 
incubated for 24 hours to provide a snap shot with therapeutic and toxic doses 
(section 2.2.5.1). 
 
After 24 hours of exposure of thyroid cancer cells to Metformin at concentration of 
0.3 mM, cell migration was inhibited (Figure 3.8 & Figure 3.9).  At high 
concentration of Metformin (10 mM), there was further inhibition of cell migration. All 
cell lines responded to Metformin in concentration dependent manner.   Metformin 
has shown similar anti migration effect on all cell lines. Metformin significantly 
inhibited cell migration at minimum concentration of 0.3 mM in FTC-133 (p = 0.01), 
K1E7 (p = 0.004), 8305C (p = 0.001) and Nthy-ori 3-1 (p = 0.0001) cell lines. In 
RO82-W-1 cells the anti migration effect of Metformin was not significant at 
concentration of 0.3 mM (p = 0.12). However, all cell lines significantly responded to 
anti-migration effect of Metformin at concentration of 10 mM (p  0.0001). The 
process of quantification for migration assay was done by ImageJ software as 
discussed in section 2.2.5.2. 
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Figure 3.8: Quantification of scratch assay (migration assay). 
This figure shows the percentage of remaining gap between the edges of control cells and Metformin 
treated cells. In all cell lines ImageJ software (using 20 repeatitive) was used to measure the gap 
closure and to calculate the remaining clear area after 24 hours time point. Kruskal-Wallis test were 
used for multiple comparisons of more than two groups. * , P value < 0.05 vs control. 
 
K1E7 cells demonstrated cell migration in the control, but in the presence of 
Metformin cell migration was decreased in a concentration dependent manner and 
with fewer cells seen at 10 mM (Figure 3.9). In contrast to the other cell lines, FTC-
133 cell growth was slow with minimal cell migration observed in control cells whilst 
Metformin inhibited the growth at 0.3 mM and cell death was seen at 10 mM. RO82-
W-1 cells were also able to migrate to fill the gap in the control cells, but Metformin 
inhibited cell migration at 0.3 mM with less cells observed in the cells treated with 10 
mM Metformin. In 8305C cells, cell migration was observed within the gap in the 
control group, but Metformin inhibited cell migration at 0.3 mM and 10 mM with fewer 
cells after treatment with Metformin.  For Nthy-ori 3-1 cells, migration was observed 
in control cells but migration decreased in Metformin treated cells with cell death at 
10 mM. 
 
Therefore for all lines, migration was inhibited by 10 mM and there was visual 
evidence of toxicity. 
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Figure 3.9: Scratch assay (migration assay) 
After 24 hours, pictures of cells were taken of untreated cells and cells treated with Metformin (0.3 
mM and 10 mM) using the Nikon glipse TS100 microscope at 4x magnification.  
 
 
 101 
3.2.6 Flow cytometric analysis for apoptosis assay 
Figure 3.10 & 3.11 shows that at concentrations of 0.1 mM and above, apoptosis 
was observed in all cell lines (K1E7, FTC-133, RO82-W-1, 8305C, TT & Nthy-ori 3-1) 
and this increased in a dose dependent manner.  
 
In K1E7 cells, Metformin significantly promoted apoptosis at 10 mM and the 
percentage of viable cells, apoptosis and necrotic cells was 74.2  3.38, 24.25  3.24 
& 1.55  0.31 respectively (p = 0.01). In FTC-133 cells, the significant effect of 
Metformin-induced apoptosis was observed at concentration of 10 mM and the 
percentage of viable cells, apoptosis and necrotic cells was 24.21  16.4, 68.09  
14.45 & 7.68  2.12 respectively (p = 0.007). In RO82-W-1 cells, Metformin slightly 
induced apoptosis but not reached significant level and at 10 mM the percentage of 
viable cells, apoptosis and necrotic cells was 92.35  4.5, 5.87  3.0 & 1.77  1.48 
respectively (p > 0.9).  In 8305C cells, Metformin significantly induced apoptosis at 
concentration of 10 mM and the percentage of viable cells, apoptosis and necrotic 
cells was 55.08  23.34, 38.73  24.25 & 6.18  5.07 respectively (p = 0.01). The TT 
cells had higher levels of apoptosis before treatment with Metformin compared to 
other cells.  At TT cell lines Metformin significantly induced apoptosis at minimum 
concentration of 10 mM and the percentage of viable cells, apoptotic cells and 
necrotic cells was 19.61  1.42, 79.55  1.57 & 0.83  0.21 respectively (p = 0.01). 
 
It is also of interest that the Nthy-ori 3-1 normal thyroid cells appeared less 
responsive, with apoptosis only marginally significant at 10 mM (p = 0.04) and the 
percentage of viable cells, apoptosis and necrotic cells was 94.22  1.81, 4.46  1.16 
& 1.31  0.8 respectively.  
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Figure 3.10: Flow cytometric analysis for apoptosis assay. 
Each bar represents the mean of three independent experiments (each done in triplicate).  In each 
experiment, cells were treated with various concentrations of Metformin for 6 days (horizontal axis). 
The % of apoptotic, necrotic and viable cells shown in different patterns. Error bars show the standard 
error of mean (SEM).   Kruskal-Wallis test was used for multiple comparisons of more than two 
groups. *, p value < 0.05 vs control. 
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Figure 3.11: Flow cytometry scatter plots for apoptosis assay. 
Plot of cells that positive to annexin v FITC against PI. Each square shows population of viable cells 
(LL), apoptosis (LR), necrotic (UL) & a mix of apoptotic and necrotic cells (UR).  
Flow cytometric analysis for apoptosis assay
K1E7 (Control) K1E7 (0.3 mM) K1E7 (1 mM) K1E7 (10 mM)
FTC-133 (Control) FTC-133 (0.3 mM) FTC-133 (1 mM) FTC-133 (10 mM)
RO82-W-1 (Control) RO82-W-1 (0.3 mM) RO82-W-1 (1 mM) RO82-W-1 (10 mM)
8305C (Control) 8305C (0.3 mM) 8305C (1 mM) 8305C (10 mM)
TT (Control) TT (0.3 mM) TT (1 mM) TT (10 mM)
Nthy-ori 3-1 (Control) Nthy-ori 3-1 (0.3 mM) Nthy-ori 3-1 (1 mM) Nthy-ori 3-1 (10 mM)
 104 
3.2.7 Flow cytometric analysis for cell cycle assay 
Figure 3.12 and 3.13 shows that Metformin increased the percentage of cells in 
G0/G1 phase in a concentration dependent manner.  This is probably due to cell 
cycle arrest in G0/G1 phase.  The results were statistically significant at 
concentrations of 10 mM in all thyroid cell lines except Nthy-ori 3-1.  The percentage 
of thyroid cells in G0/G1 phase for the concentrations of Metformin used in the study 
(control, 0.3 mM, 1 mM and 10 mM) was 34.4%, 43.3%, 43.3% and 51.3% 
respectively in K1E7 cells, 57.9%, 65.5%, 72.7% and 74.3% respectively in FTC-133 
cells, 56.5%, 62.5%, 70% and 77.3% respectively in RO82-W-1 cells, 56.7%, 63.9%, 
69.8% and 71.4% in 83O5C cells and 58.8%, 69.8%, 95.3% and 95.6% respectively 
in TT cells 
 
In Nthy-ori 3-1 cells, the percentage of G0/G1 cells remained unchanged with 
Metformin treatment. The percentage of Nthy-ori 3-1 cells following treatment with 
Metformin ((control, 0.3 mM, 1 mM and 10 mM) was 53.4%, 53.9%, 55.3% and 
56.2% respectively. 
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Figure 3.12: Flow cytometric analysis for cell cycle assay. 
Each bar represented the mean of three independent experiments (each done in triplicate). In each 
experiment, cells were treated with various concentrations (as shown in horizontal axis). The 
percentage of viable cells in different phases shown in different patterns and colors. Error bars show 
the standard error of mean (SEM).    
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Figure 3.13: Flow cytometry plots for cell cycle assay. 
This figure shows number of cells in different phases of cell cycle (G1, S and G2) 
 
 
3.2.8 γH2AX assay for DNA repair 
 
Previous studies reported that Metformin induced double strand breaks and could 
affect DNA repair in nasopharyngeal carcinoma cells and mammalian cells [167, 
168]. To confirm if Metformin had any DNA-damaging properties, its effects in 
combination with radiation have been explored. Radiation is used to treat some 
thyroid cancers and other thyroid cancers may arise due to radiation exposure. 
Metformin treatment could increase the effectiveness of radiation or produce 
damaging side effects if DSB occurs.  
 
In untreated cells (control), and cells treated with Metformin (0.1 mM and 20 mM) 
very low levels of phosphorylation of γH2AX foci were detected at the comparable 
post irradiation time points for all cell lines (Figure 3.14 & 3.15). Following radiation 
for the K1E7 cell line, the percentage of cells with more than 10 γH2AX foci was 
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99.6% at 30 minutes, 83% at 1 hour and 76% at 2 hours.  Similar results were 
observed in FTC-133, RO82-W-1, 8305C and TT; In FTC-133 cell line, 97.66% at 30 
minutes, 85.33% at 1 hour and 74% at 2 hours; In RO82-W-1 cell line, 98.33% at 30 
minutes, 88% at 1 hour and 80% at 2 hours; In 8305C cell line, 97.33% at 30 
minutes, 85% at 1 hour and 79% at 2 hours; In TT cell line, 97% at 30 minutes, 
85.33% at 1 hour and 80% at 2 hours. 
 
Following radiation for the Nthy-ori 3-1 cell line, the percentage of cells with more 
than 10 γH2AX foci was In Nthy-ori 3-1 cell line, 87% at 30 minutes, 56.33% at 1 
hour and 31% at 2 hours. 
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Figure 3.14: The effect of Metformin on DSBs and DNA repair in thyroid cells. 
γH2AX assay shows DSBs-DNA and DNA repair in KIE7, FTC-133, RO82-W-1, 8305C, TT and Nthy-ori 3-1 cells. Each bar represented the mean of three 
independent successful experiments. Cells were either treated with Metformin (0.1 mM and 20 mM) for 144 hours or treated with Metformin for 144 hours and 
followed by radiation 2 Gy IR (0.1 mM + IR and 20 mM + IR) or cells irradiated with 2Gy IR only (IR). Kruskal-Wallis test was used for multiple comparisons of 
more than two groups. NS (not significant) P value > 0.05. 
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Following radiation the γH2AX foci appear as a small immunofluorescence stained 
red dotted in blue background cell stained with DAPI and by time the number of 
γH2AX foci was decreased (Figure 3.15). 
 
 
Figure 3.15: Formation of radiation-induced YH2AX foci in K1E7. 
γH2AX assay shows formation of radiation-induced γH2AX foci in K1E7 cells. The picture was taken 
via immunofluorescence microscopy at 100x magnification.  Panel A shows no γH2AX foci formation 
in control cells.  Panel B shows ˃ 10 γH2AX foci formation at 0.5 hour after irradiated cells with 2 Gy 
IR.  Panel C shows a decrease the number of γH2AX foci formation at 2 hours after irradiated cells 
with 2 Gy IR. 
 
 
 
Data variability was assessed while training for the γH2AX assay, the γH2AX score 
was determined in real time a second independent observer did not score the 
results.
Formation of radiation-induced γH2AX foci in K1E7 cells
A B C
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3.3 Discussion 
Human cancer cell lines play a critical role in the study of cancer biology and 
therapy.  Historically, HeLa is the oldest established human cell line and was 
derived from human cervical cancer [144].  Several factors can contribute to 
cross-contamination and misidentification of human cell lines. These include 
mislabelling of cell lines during sub-cultures, using same pipettes for different 
cell lines, unplugged pipettes, sharing reagents and media between cell lines 
[156, 169], mutations after several passages [155] and incorrect diagnoses by 
pathologists [157].  HeLa cell line cross-contamination with other cell lines, 
was first reported in 1960 [170] and 1962 [171].  In a study on 100 human cell 
lines, 18.8% of cell lines in the national cell bank of Iran were cross-
contaminated [155]. The German collection of microorganisms and cell culture 
reported that misidentification or contamination occurred in 18% of 252 cell 
lines used [143].  In a study on 6 human adenoid cystic carcinoma cell lines, 
all 6 cell lines were found to be contaminated with other cell lines [172].  
Shweppe et al (2008) evaluated 40 human thyroid cancer cell lines; many of 
them are commonly used in thyroid cancer studies.  The findings of this study 
showed that 50% of these cell lines were cross-contaminated or misidentified 
[173].  These misidentified cell lines had been used in a large number of 
publications thereby raising doubts about the validity of their findings.   
 
In this study, to validate the thyroid cell lines, ten STR loci were studied for 
Nthy-ori 3-1, K1E7 and FTC-133.  The observed STR profiles for the cell lines 
were then compared with culture collections in Public Health England website 
(http://www.hpacultures.org.uk) and matched with their specific STR profiling 
(Table 3.1). This demonstrates that these cell lines (Nthy-ori 3-1, FTC-133 
and K1E7) are valid and are not cross-contaminated or misidentified. The 
other cell lines (RO82-W-1, 8305C and TT) were purchased from the 
European Collection of Cell Culture (ECACC) with a known STR profile; 
hence a repeat authentication experiment was not performed. 
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The aim of this study was to investigate the effect of Metformin and explain 
the observations of the clinical studies where Metformin reduced the risk of 
cancer. Some of the data presented here repeats an earlier investigation in 
which high doses of Metformin was used, but this study specifically set out to 
examine the effects of Metformin within a therapeutic range, and for the first 
time explore the effect over a longer time frame.  
 
The cell lines evaluated in this project represent different types of thyroid 
cancer seen in clinical practice. Initially, proliferation of all cell lines (normal 
thyroid, thyroid cancers and breast cancer cell line MCF-7) was studied 
following exposure to a broad range of Metformin concentrations ranging from 
sub-physiological to supra-physiological concentrations (0.3 mM – 20 mM).  
Our findings demonstrated that Metformin reduced proliferation, supporting 
earlier investigations on thyroid cancer [106, 129] and the control breast 
cancer cell line MCF-7 [125, 126].  In previous studies however, cells were 
treated with high concentrations of Metformin for relatively short periods of up 
to 3 days [104]. In this study, Metformin was tested at therapeutic doses over 
a longer time period (1 -14 days). These results suggest that at lower 
physiological doses (0.01-0.3 mM) [132, 163], Metformin does dampen cell 
proliferation in cancer and normal cell lines (Figure 3.4).   
 
The clonogenic assays demonstrated that Metformin inhibited colony 
formation from a low concentration of 0.3 mM and almost abolished colony 
formation at 5 mM.  When combining the observations on cell proliferation 
with those of the clonogenic assays (Figure 3.6), the dampening effect 
appeared enhanced over time, with the lowest significant dose (affecting 
proliferation) dropping from 5 mM at day 3 to 1 mM Metformin at day 14 
(Figure 3.2, 3.3 & 3.6).  The effects of Metformin on clonogenicity have been 
intensively investigated in other cancers and also thyroid cancer cell lines.  As 
with these earlier studies [104, 125, 130] we found that supra-physiological 
concentrations of Metformin (1 mM and 5 mM) virtually obliterated colony 
formation for some cell lines (8305C and FTC -133) (Figure 3.6).  
Furthermore, we found that at concentrations above 5 mM no colonies were 
formed and cells were dead at 14 days (data not shown).  The action of 
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Metformin appears wide ranging, and whilst only high doses clearly affect 
proliferation at 24hrs in MTT assay (Figure 3.4) its effect on other processes 
is evident even at lower doses, with 0.3 mM inhibiting migration in the scratch 
assay (Figure 3.8 & 3.9), suggesting that Metformin targets different 
pathways to varying degrees.  The limitations for the migration assay were 
that only 1 time point was used to investigate the influence of Metformin on 
cell migration. The TT cell line was not recovered at that time and so it was 
not possible to investigate the effects of Metformin on the migration of TT 
cells. It was clear that high dose Metformin 10 mM affected both viability and 
proliferation of the cells and far fewer cells were left in the wells after 10 mM 
treatment; the more highly proliferative lines should potentially be able to fill 
the gap quicker.  
 
How does Metformin exert its action on thyroid cancer cells? This is unclear 
but it is thought that the growth inhibitory effect of Metformin on cancer cell 
proliferation may be through the activation of AMPK (via LKB1). This in turn 
causes inhibition of mammalian target of rapamcycin (mTOR) pathway (which 
promotes growth and proliferation) [85, 174].  In numerous human cancers, 
mTOR is associated with increased cell growth and proliferation [175].  In 
addition to the above, it has been suggested that the growth inhibitory effect 
of Metformin on tumour growth may be indirect - by a decrease in circulatory 
tumour growth factors such as glucose [4, 87], insulin [87] and TSH [145, 
146].  Insulin and glucose may play a critical role in tumour growth and 
malignant transformation through stimulation of insulin and IGF-1 receptors 
[88-90, 176].  As TSH has been shown to specifically promote thyroid cancer 
growth in rat [177] and mouse models [178], it may be suggested that 
Metformin would be specifically effective against thyroid cancers, as previous 
studies have reported that Metformin decreased TSH level without change in 
FT4 [145, 146].  In term of Metformin doses is unclear whether higher doses 
of Metformin may act via a different mechanism but this need further 
investigations.  
 
This study also demonstrated that Metformin induced apoptosis and cell cycle 
arrest in thyroid cancer cells, increasing both the percentage of apoptosis 
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cells and accumulating cells in G0/G1 phase (Figure 3.10 & 3.12).  Similar 
findings were reported in other studies on different cancers, including thyroid 
[104, 179, 180].  It is however of interest that the normal thyroid cell line Nthy-
ori 3-1 appeared relatively unaffected by Metformin even at doses of 10 mM 
at 6 days. These cells only showed low levels of apoptotic cells, negligible 
necrosis and no change to the percentage of cells in GO/G1 (Figure 3.10 & 
3.12).   
 
Furthermore, colony formation for all thyroid cancer cell lines was inhibited at 
1 mM; but for the Nthy-ori 3-1 cell line, it was significant only at 5 mM.  In 
contrast, TT (medullary thyroid cancer cell line) had naturally high levels of 
apoptosis, which increased dramatically on exposure to Metformin.  At 10 
mM, Metformin virtually obliterated TT cell division and stalled the majority of 
the cells in G0/G1 (Figure 3.12).  The observations of apoptosis and cell 
cycle assist in explaining the varying responses of the different thyroid 
cancers to Metformin. For example it seems that the high natural rate of 
apoptosis in TT means that it is the most sensitive to low doses (Figure 3.3 & 
3.4) and that high doses will have a catastrophic effect even at day 1 (Figure 
3.4) that tips the balance in favour of apoptosis and stalls the remainder of the 
cells in G0/G1 (Figure 3.4 and 3.10 & 3.12).  As only one medullary thyroid 
cancer cell line was studied, it is not possible to say if this subtype is 
particularly sensitive, or whether the naturally high level of apoptosis affects 
its response to Metformin.  Recently, it has been reported that the RET 
induced medullary thyroid cancers show increased apoptosis in response to 
therapy targeting the RET oncogene [181, 182] with inhibition of the MAPK 
and mTOR pathways.  Another study suggested that Metformin targets these 
pathways in medullary thyroid cancer [105]. These observations in 
combination with our findings suggest that some subtypes of thyroid cancer 
may be more sensitive to Metformin than others. However, it is too early to 
say if these differences are clinically relevant. Variation in the response to 
Metformin among the different sub-types of thyroid cancer may explain why a 
recent study has not found any decreased risk of developing thyroid cancer 
for Metformin users [183].  
 
 114 
How Metformin exerts its action on thyroid cancer cells is unclear, but unlike 
previous investigations [168] this study did not find that exposure to Metformin 
induced DNA damage; even treatment with 20 mM of Metformin for 6 days 
(prior to measuring DNA damage) although significantly reducing proliferation 
did not increase DSBs-DNA in the absence of IR (Figure 3.14).  In this study, 
the kinetics of formation and loss of γH2AX foci were investigated in K1E7, 
FTC-133, RO82-W-1, 8305C, TT and Nthy-ori 3-1 cells.  The findings 
demonstrated very low DSBs-DNA in non-irradiated cells (with or without 
Metformin) compared to cells irradiated with 2Gy IR.  We found high DNA 
damage in all cell lines at 30 minutes after cells were irradiated with 2 Gy IR 
compared to control. In Nthy-ori 3-1 cells, there was a relatively rapid 
elimination of γH2AX foci at 1 hour and 2 hours after radiation compared to 
thyroid cancer cells. The results show that Nthy-ori 3-1 was able to repair 
DSBs faster compared to cancer cell lines.  DNA repair is essential to 
reproduce correct sequences and avoid malignant transformation [184, 185].  
Normal cells have low levels of genetic instability as opposed to cancer cells; 
in addition cancer cell lines are more sensitive to radiation compared to 
normal cell lines.  Ataxia-telangiectasia mutated (ATM) [186] and  DNA-
dependent protein kinase (DNA-PK) [187] genes are mutated in cancer cell 
lines; resulting in reduced phosphorylation of H2A.X, thus impairing the ability 
to repair DSBs.  These findings suggest that Metformin neither induces DSBs-
DNA nor promotes DNA repair.  Similar findings were reported in a study on 
human lymphocytes, where oxidative stress induced DNA damage and the 
influence of Metformin was investigated. The findings demonstrated that DNA 
damage was not prevented by Metformin at concentrations of 0.01 to 0.05 
mM [188]. 
 
This is the first in vitro study that looks at longer-term exposure to low dose 
Metformin in thyroid cancer.  This investigation has demonstrated that the 
cumulative effects of Metformin increase over time for all types of thyroid 
cancer, and suggests that even sub-physiological doses alters behaviour and 
can act to dampen down the proliferative response. In combination, our 
results possibly explain why prolonged exposure to therapeutic doses, as 
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occurs in diabetic patients, may account for the observed longer disease free 
survival from thyroid cancer in these populations [189].  
 
3.4 Is Metformin selectively affecting thyroid cancer 
over normal thyroid tissues?  
 
The current investigations found that Metformin inhibited cell proliferation in all 
cell lines in a concentration and time dependent manner. However, some 
variations were observed in cancer cell lines compared to normal cells in 
response to Metformin treatment.  Metformin inhibited cell proliferation 
significantly at 5 mM at day 3 in cancer cells and day 4 in normal cells 
(section 3.2.3). Similar observations were reported in a previous study where 
normal lines were less sensitive to Metformin treatment compared to cancer 
lines [104]. The minimum significant concentration of Metformin to inhibit the 
colony formation was decreased from 5 mM to 1 mM in cancer cells but 
normal cells remained at 5 mM (section 3.2.4). In addition, Metformin 
significantly induced apoptosis and cell cycle arrest in cancer cells at 10 mM 
but normal lines were less sensitive to Metformin in terms of apoptosis and 
also cell cycle (section 3.2.6 & 3.2.7).  Furthermore, the normal lines 
demonstrated more rapid DNA repair compared to cancer lines following 
radiation (section 3.2.8). The overall findings suggested that Metformin was 
selectively affected cancer cells over normal tissues.  The findings of this 
current study are therefore in broad agreement with other investigations on 
numerous cancer types that suggest normal tissues, although responding to 
Metformin treatment are overall less sensitive [104, 106]. 
 
3.5 Conclusions 
In summary, Metformin inhibited cell proliferation in a concentration and time 
dependent manner. Metformin also inhibited colony formation, cell migration, 
induced apoptosis and cell cycle arrest in a concentration dependent manner.  
Metformin does not induce or prevent DSBs-DNA and does not promote DNA 
repair in thyroid cancer cells. The study demonstrated high level of DSBs-
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DNA in thyroid cancer cell lines after radiation followed by a reduction with 
time.  Further work will be aimed at understanding the molecular mechanisms 
of the above effects of Metformin and its interactions with TSH, insulin, IGF-1 
and glucose in the environment. 
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4 CHAPTER FOUR 
CHAPTER FOUR 
 
Modulating the anti-cancer effects 
of Metformin 
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4.1 Introduction 
Metformin is effective in the treatment of diabetes by decreasing blood 
glucose, through prevention of glucose production in the liver, whilst 
increasing the sensitivity of muscle and fat cells to insulin [5]. The action of 
Metformin may be influenced by regulatory factors, which are altered as a 
consequence of the disease.  Indeed, in the previous chapter, the anti-cancer 
effect of Metformin on a number of different thyroid cancer cell lines was 
investigated only after standardization of the amount of glucose to be included 
in the media (section 3.2.2). In this chapter, the effects of glucose and 
regulators important in controlling diabetes (insulin, IGF-1) were explored in 
more depth.  Furthermore, the modulation by TSH was also studied, as TSH 
suppression therapy is currently used for the treatment of thyroid cancer post-
surgery and the main goal of thyroxine therapy is to reduce the levels of TSH 
(that may act as a growth factor) in thyroid cancer patients [39],  TSH actions 
may be synergistic or antagonistic to Metformin.  
 
Glucose (C6H12O6) is a simple monosaccharide that is the main source of 
energy used by cells within the body, and is metabolized in the cytosol by 
glycolysis, either aerobically or anaerobically [190]. The importance of glucose 
on promoting cancer growth and proliferation has been extensively studied in 
many cancer types for example breast, colon, pancreatic and thyroid [191-
199] and universally increases growth. Furthermore, the epidemiological data 
on several types of cancer has shown that high blood glucose associates with 
an increased risk of cancer [200, 201]. The effect of glucose on the action of 
Metformin has also been studied. A recent study on breast cancer cell lines 
(MDA-MB-231) showed that the anti-cancer effect of Metformin was highly 
dependent on glucose concentration [192]. The study showed that Metformin 
inhibited MDA-MB-231 cell growth in the medium containing 5 mM of glucose, 
but the anti-cancer effect of Metformin was abolished in medium containing 25 
mM of glucose, as determined by the MTT assay after 48 and 96 hours 
incubation. The amount of glucose in the medium may also influence the anti-
cancer effect of Metformin on thyroid cancer cells. A recent study on the 
thyroid cancer cell line (FTC-133) showed that the anti-cancer effects of 
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Metformin depends on the glucose concentration in the medium [195],  with 
Metformin inhibiting thyroid cancer cells in a dose dependent manner when 
the medium contained no glucose; but Metformin was less effective when the 
medium contained 5 mM and 20 mM of glucose.   
 
Glucose levels are regulated by insulin, a hormone, which is secreted from 
beta cells of the pancreas.  Insulin secretion by the pancreas is increased in 
response to high levels of glucose in the blood, and enhances glucose 
absorption by various cells in the body such as fat cells, muscle cells and red 
blood cells. In the case of low levels of glucose in the blood, insulin secretion 
by the pancreas is decreased to maintain the normal level of glucose in the 
blood. The effect of insulin on cancer has also been investigated in population 
based studies; Hemkens and colleagues conducted a cohort study by using 
records of German health insurance between 1998-2005 of 127,000 patients 
treated with insulin and noted the incidence for cancer [202].  They found that 
treatment with insulin is associated with an increased risk of cancer. The 
findings of this study can be given more weight, because of the large numbers 
of patients involved.  However, the study had limitations as information on the 
body mass index and duration of diabetes was not available.  The effect of 
insulin on cancer cell proliferation has also been studied in vitro. A study on 
colon cancer cell lines (Caco-2 and HT-29) treated with various concentration 
of insulin (10-14, 10-12, 10-10, 10-8 and 10-6 mol/L) for 3 days [203], found that 
insulin promoted cell proliferation. Similar findings were observed in a study 
for prostate cancer cell lines (LNCaP, C4-2 and P69), but in contrast insulin 
has no effect on cell proliferation in other prostate cancer cell lines in the 
same study (M12 and PC3) [204]. Of more relevance to the current 
investigation, a study in which anaplastic thyroid cancer cell lines (HTh74 and 
HTh74Rdox), were treated with insulin in the presence and absence of 
Metformin (10 μg/ml of insulin only, 5 mM or 10 mM of Metformin only and 
Metformin + insulin) for 3 days [104], insulin promoted cell proliferation and 
induced ERK phosphorylation.  Furthermore, the study also found that 
Metformin abolished the effect of insulin on cell proliferation and extra cellular 
signal-regulated kinase (ERK) phosphorylation. Insulin promotes cancer cell 
proliferation through the activation of phosphoinositol-3 kinase/Akt (P13K-Akt) 
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pathway and inhibition of insulin growth factor binding protein 1 and 2 (IGFBP-
1 & IGFBP-2), leading to the release of free IGF-1 and activation signalling via 
IGF1-receptor [205]. P13K/Akt signaling pathways play an important role in 
cell growth [206] and cell cycle entry at G1/S [207] and inhibition of apoptosis 
[208, 209]. 
 
Insulin-like growth factor 1 (IGF-1) has a similar function and molecular 
structure to insulin, and equally plays an important role in growth and 
development. The importance of IGF-1 in cancer was investigated in many 
studies [210-214]. For example the relationship between IGF-1 and risk of 
breast cancer has been studied in a case control study [215] on 397 women 
diagnosed with breast cancer and 620 matched controls, between1989-1990, 
and found a positive relationship between high IGF-1 plasma concentration 
and breast cancer in premenopausal women. However, the study 
demonstrated no relationship between high plasma concentration of IGF-1 
and risk of breast cancer in postmenopausal women. The effect of IGF-1 on 
cancer cell growth and proliferation was also investigated in in vitro studies.  
In a study on colon cancer cell lines (HTC116 cells), cells were treated with 
the following concentrations of IGF-1 (0, 50, 100 and 200 ng/ml) for 3 days 
[216] and IGF-1 was associated with increased cell proliferation and 
decreased apoptosis.  
 
TSH, also known as thyrotropin, is secreted from the pituitary gland and plays 
an important role in the production and release of T3 and T4 from the thyroid 
gland [7, 11] as part of the hypothalamo-pituitary-thyroid axis. The relationship 
of serum TSH concentration and risk of thyroid cancer were studied in a 
retrospective cohort study [217].  Serum TSH was measured preoperatively 
for 843 patients with thyroid nodules between 1994-2007. The data showed 
that increasing the concentration of serum TSH increased the probability of 
cancer. Furthermore, another study confirmed that the likelihood of cancer 
diagnosis increased in patients with TSH in the upper three quartiles 
compared to patients with TSH in the lower quartiles [218]. TSH has also 
shown to promote thyroid cancer growth in rat [177] and mouse models [178]. 
The mechanism of TSH promoted cell proliferation in cancer cells remains 
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unclear. However, the possible effects of TSH on cancer cell growth has been 
investigated in vitro, with follicular thyroid cancer cell lines (HTC TSHr) and 
hurthle cell (XTC), treated with TSH for 48 hours [219], finding that TSH 
increased vascular endothelial growth factor (VEGF) mRNA production. In this 
chapter the focus will be to examine the effect of Metformin on thyroid cancer 
cell in combination with other modulators (glucose, insulin, IGF-1 & TSH).  
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4.2 Results  
4.2.1 The influence of glucose on Metformin’s anti-
proliferative and apoptotic effects 
 
Previously it was shown that increasing glucose promoted thyroid cancer 
growth (section 3.2.2), and the standard for glucose to be included in the 
media was set at 10 mM, as some cell lines had poor growth in glucose-free 
media.  The action of Metformin has thus been explored against the standard 
of 10 mM glucose in vitro (chapter 3) but here as part of the investigations into 
factors that could modulate the anti-proliferative action of Metformin the 
findings in glucose-free and glucose containing medium are presented in 
more detail (Figures 4.1 & 4.2).  Higher levels of glucose of more than 10 mM 
were not included here because the cells over grow and it makes it difficult to 
measure inhibition of growth in an accurate manner (section 3.2.3).  As 
before, glucose increased mean cell growth in the absence of Metformin 
(Figure 4.1 and 4.2). The addition of Metformin however decreased cell 
growth not only in the glucose-free medium group but also in the glucose-rich 
medium group in a concentration (Figure 4.1) and time dependent manner 
(Figure 4.2). At six days (Figure 4.1) 0.3 mM Metformin reduced growth to a 
level comparable to that of glucose-free media, but the presence of glucose 
(10 mM) moderated this effect. No significant differences were seen for 10 
mM Metformin in glucose and glucose free medium, but this concentration is 
toxic (section 3.2.3) and shows that although glucose can modulate the anti-
proliferative effects of Metformin it does not overcome its toxic effects at high 
doses. 
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Figure 4.1: The effect of glucose on control of thyroid cancer 
proliferation by Metformin at 6 days. 
This figure shows the absorbance (y-axis) of thyroid cells at day 6 following incubation at 
different Metformin concentrations (x-axis) in glucose and glucose-free media. The columns 
represent the mean of three independent experiments, each of which was done in triplicate. 
Error bars show the standard error of mean (SEM). The different pattern of bars shows the 
different media (black dotted represented DMEM containing 10 mM of glucose (2 g/L) and 
white dotted shows glucose-free DMEM) used in the experiments. Kruskal-Wallis test was 
used for multiple comparisons of more than two groups. * P value < 0.05 vs control within the 
same medium. 
 
Over 6 days, (Figure 4.2) the anti-proliferative effect of 0.3 mM Metformin in 
glucose-free medium was greater than its effects on medium containing 
glucose.  
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Figure 4.2: The effect of glucose and 0.3 mM Metformin on thyroid cell 
proliferation over time. 
The figure shows the absorbance (y-axis) of cells in different time points (x-axis) after cells 
were treated with 0.3 mM (M+) of Metformin for 6 days in glucose-free medium (G-) and 
medium containing 10 mM of glucose (G+).  The data points represent the mean of three 
independent experiments, each of which was done in triplicate.  Error bars show the standard 
error of mean (SEM).  Statistics are not included on the figure due to noise but are included in 
text. Each thyroid cell line is shown in a separate graph.  
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p = 0.04, p = 0.04 and p = 0.01 respectively) and at day 4 for RO82-W-1 and 
Nthy-ori 3-1 (p = 0.05 and p < 0.01 respectively).  As had been found 
previously (section 3.2.3) the findings would seem to suggest that thyroid cell 
lines are more susceptible to the anti-proliferative action of Metformin than the 
normal control Nthy-ori 3-1, but that in higher concentrations of glucose this 
effect is reduced.  
 
Metformin was previously shown to promote apoptosis (section 3.2.6), but 
here, just as was found with proliferation, glucose similarly moderated the 
induction of apoptosis by Metformin (Figure 4.3), in those cell lines where 
apoptosis was a feature.  
 
 
Figure 4.3: The effect of glucose on control of thyroid cell apoptosis by 
Metformin. 
This figure shows the percentage of apoptotic cells (y-axis) for cell lines treated with 0.3 mM 
of Metformin (x-axis) for 6 days in both glucose-rich (10 mM) and glucose-free media. The 
columns represent the mean of three independent experiments, each of which was done in 
triplicate. Error bars show the standard error of mean (SEM).   Mann-Whitney test was used 
to compare two groups. * , P value < 0.05.  
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The effect of either Metformin or glucose deprivation independently has 
similar results in terms of both proliferation and apoptosis.  But in combination 
glucose will modulate the effect of Metformin, as seen in the previous chapter 
(section 3.2.2, 3.2.3, 3.2.6 & 4.2.1). 
 
The difference between the percentages of apoptotic cells in glucose-free 
medium compared to glucose-rich medium after adding 0.3 mM of Metformin 
for 6 days was significant for FTC-133, RO82-W-1, 8305C, Nthy-0ri 3-1 and 
MCF7 cell lines (p = 0.004, p = 0.004, p = 0.008, p = 0.001 and p = 0.029 
respectively) but not significant for K1E7 and TT cell lines (p = 0.097 and p = 
0.673 respectively). TT has high levels of apoptosis anyway, (section 3.2.6), 
and the same was observed here with apoptosis not significantly altered 
regardless of the inclusion of glucose. For K1E7, there was no significant 
difference between induction of apoptosis by Metformin with or without 
glucose, and these findings mirror those found in chapter 3 (section 3.2.6) 
whereby only high and toxic levels of Metformin were found to increase 
apoptosis for K1E7. RO82-W-1 cell line like the TT line also has high 
apoptosis as a result of Metformin treatment, but unlike TT the addition of 
glucose blocks the action of Metformin and reduces apoptosis to a lower level.  
The other cell lines (FTC-133, 8305C, Nthy-ori 3-1 & MCF7) all had a similar 
response with a high level of apoptosis as a result of Metformin treatment in 
the glucose-free medium. Hence these findings clearly indicate that the 
presence of glucose in the media modified the anti-cancer effects of 
Metformin in vitro.  
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4.2.2 The influence of insulin on the anti-proliferative effects 
of Metformin on thyroid cancer cell lines 
The next studies were carried out in the glucose-rich medium, as the cell lines 
would not grow in the medium without glucose (section 3.2.2). Increasing 
concentrations of Metformin in the media without the addition of growth 
factors inhibits thyroid cancer growth (section 3.2.3).  Here, the difference in 
anti-proliferative action of Metformin on thyroid cells was assessed at 6 days 
after growth in media containing insulin (10 μg/ml) as a previous study used 
the same insulin concentration, allowing comparison of our data with Chen et 
al results [104] and compared to media without insulin.  As shown in figures 
4.4 and 4.5, the addition of 10 μg/ml of insulin in the medium showed no 
significant effects on thyroid cell proliferation, and Metformin significantly 
inhibited cell proliferation in all thyroid cell lines (K1E7, FTC-133, RO82-W-1, 
8305C and Nthy-ori 3-1) regardless of the inclusion of insulin.  The TT cell line 
was not tested in this experiment as frozen stocks of the cell line had failed to 
recover for these investigations.  
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Figure 4.4: The effect of insulin on control thyroid cancer proliferation 
by Metformin. 
MTT assay shows the absorbance (y-axis) of thyroid cells, which were treated for 6 days with 
different concentrations of Metformin in mM (x-axis).  The media either contained 10 μg/ml of 
insulin (+insulin) or did not contain insulin (-insulin).  The columns represent the mean of 
three independent experiments, each of which was done in triplicate. Error bars show the 
standard error of mean (SEM). Mann-Whitney test was used to compare two groups. NS (not 
significant) P value > 0.05. Each thyroid cell line is shown in a separate graph.  
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Figure 4.5: The effects of Metformin & insulin on thyroid cell 
proliferation over a period of 6 days. 
MTT assay shows the absorbance /cell proliferations (y-axis) of thyroid cells under different 
conditions control (blue), 10 μg/ml of insulin (red), 10 mM of Metformin + 10 μg/ml of insulin 
(green) and 10 mM Metformin (purple), for several time points (x-axis).  Each data point 
represents the mean of three independent experiments done in triplicate. Error bars show the 
standard error of mean (SEM). Mann-Whitney test was used to compare two groups. NS (not 
significant) P value > 0.05. Each thyroid cell line is shown in a separate graph. 
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4.2.3 The influence of IGF-1 on the anti-proliferative effects of 
Metformin on thyroid cancer cell lines 
 
The importance of IGF-1 on the regulation of cancer growth has been 
extensively studied in many types of cancer, showing a positive stimulation 
[210-214]. However, the presence of IGF-1 in combination with Metformin has 
not previously been investigated and by adding IGF-1 to the media the anti-
cancer effects of Metformin on thyroid cancer cells maybe modulated. As 
shown in figure 4.6 IGF-1 concentrations (50 ng, 100 ng and 200 ng) in the 
medium for up to 6 days did not affect thyroid cell proliferation in any of the 
cell lines studied (K1E7, FTC-133, RO82-W-1, 8305C and Nthy-ori 3-1). For 
all cell lines, similar findings were also obtained overtime on days 0-5 (the 
data not shown).  
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Figure 4.6: Effect of IGF-1 on thyroid cell proliferation. 
MTT assay shows the absorbance /cell proliferation of thyroid cells (y-axis) after cells were 
treated with various concentrations of IGF-1 (x-axis) for 6 days.  The columns represent the 
mean of three independent experiments, each of which was done in triplicate. Error bars 
show the standard error of mean (SEM).    Each cell line is represented by a separate graph. 
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100 ng/ml is within the concentrations used in the previous study [216], so our 
results are comparable with their findings. All media contained glucose (10 
mM) and the TT cell line was not included due to failure to recover. 
 
Figure 4.7: The effect of IGF-1 on control of thyroid cancer proliferation 
by Metformin. 
MTT assay shows the absorbance (y-axis) of thyroid cells after cells treated for 6 days with 
different concentrations of Metformin in mM (x-axis).  Growth was in medium with 100 ng/ml 
of IGF-1 (+IGF-1) or without IGF-1 (-IGF-1).  Each column represents the mean of three 
independent experiments done in triplicate. Error bars show the standard error of mean 
(SEM).  Mann-Whitney test was used to compare two groups. NS (not significant) P value > 
0.05. Each thyroid cell line is shown in a separate graph. 
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4.2.4 The influence of TSH on Metformin’s anti-proliferative 
effects 
Previous studies on TSH have shown high serum TSH is associated with 
cancer growth and risk of cancer [217, 219, 220]. However, its action in the 
presence of Metformin has not previously been investigated. As shown in 
figure 4.8 various concentrations of TSH (5 mIU, 10 mIU and 50 mIU) in the 
media for up to 6 days did not influence cell proliferation for any of the cell 
lines studied (K1E7, FTC-133, RO82-W-1, 8305C and Nthy-ori 3-1). Similar 
findings were observed on days 0-5 (the data not shown).  
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Figure 4.8: Effect of TSH on thyroid cell proliferation. 
MTT assay shows the absorbance of thyroid cells (y-axis) after treatment with various 
concentrations of TSH (x-axis) for 6 days.  The columns represent the mean of three 
independent experiments, each of which was done in triplicate. Error bars show the standard 
error of mean (SEM).    
 
 
 
Control 5mIU 10mIU 50mIU
0.0
0.5
1.0
1.5
TSH concentrations
A
b
s
o
rb
a
n
c
e
RO82-W-1
Control 5mIU 10mIU 50mIU
0.0
0.5
1.0
1.5
TSH concentrations
A
b
s
o
rb
a
n
c
e
Nthy-ori 3-1
Control 5mIU 10mIU 50mIU
0.0
0.5
1.0
1.5
TSH concentrations
A
b
s
o
rb
a
n
c
e
FTC-133
Control 5mIU 10mIU 50mIU
0.0
0.5
1.0
1.5
TSH concentrations
A
b
s
o
rb
a
n
c
e
8305C
Control 5mIU 10mIU 50mIU
0.0
0.5
1.0
1.5
TSH concentrations
A
b
s
o
rb
a
n
c
e
K1E7
 135 
Furthermore, as shown in figure 4.9 Metformin inhibited cell proliferation in 
both TSH free medium (-TSH) and TSH rich medium (+TSH) for all thyroid 
cell lines.  This suggests that Metformin has anti-proliferative effects 
regardless of TSH (5 mIU) in the medium (this TSH concentration is within the 
concentrations used in the previous study [219]), and all cell lines (K1E7, 
FTC-133, RO82-W-1, 8305C and Nthy-ori 3-1) had similar responses in the 
TSH free medium and TSH rich media. All the above observations were 
performed in medium containing glucose (10 mM) and the TT cell line was not 
included as it had failed to recover. This data shows that TSH in the medium 
does not inhibit the action of Metformin on thyroid cancer cell lines over a 
period of 6 days.  
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Figure 4.9: The effect of TSH on control of thyroid cancer proliferation 
by Metformin. 
MTT assay shows the absorbance (y-axis) of thyroid cells after treatment for 6 days with 
different concentrations of Metformin (x-axis) in TSH containing (5 mIU/ml) and TSH free 
media. The columns represent the mean of three independent experiments, each of which 
was done in triplicate.  Error bars show the standard error of mean (SEM). Mann-Whitney test 
was used to compare two groups. NS (not significant) P value > 0.05. Each thyroid cell line is 
shown in a separate graph. 
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4.3 Discussion 
 
Previous studies on thyroid cancer found that glucose and insulin both 
modulated the anti-cancer effects of Metformin in thyroid cancer cells [104, 
195].  
4.3.1 Glucose deprivation promotes the anti-cancer effects of 
Metformin in thyroid cancer cells.  
In the previous chapter, it was demonstrated that Metformin inhibited cell 
proliferation in the medium containing 10 mM of glucose.  Numerous factors 
may influence the anti-cancer effects of Metformin. Previous studies reported 
that the anti-cancer effects of Metformin were highly dependent on the 
glucose concentration in the media [192, 221].  A study on breast cancer cells 
has shown that increasing concentrations of glucose (0-17 mM) in the media 
promoted cell proliferation, colony formation, cell migration, up-regulation of 
pro-oncogenic signalling such as AKT, mTOR and ERK and also reduced cell 
apoptosis in breast cancer cell lines [221]. Furthermore, the concentrations of 
glucose at 10 mM or greater abolished the anti-cancer effects of Metformin on 
breast cancer cell lines [221].  In a study on breast cancer cell line (MDA-MB-
231), Metformin inhibited cell proliferation and activated the AMPK pathway in 
the normoglycemic (5 mM) condition only, while the anti-cancer effects of 
Metformin on MDA-MB-231 cells was abolished in hyperglycemic condition 
(25 mM) [192].  
 
In this study the modulation of Metformin by 10 mM glucose in thyroid cancer 
cells was investigated. Evidence from previous investigations consistently 
shows that increasing glucose in the medium counteracts the action of 
Metformin on in thyroid cancer cells [195]. Here lower doses of Metformin (0.3 
mM) were used over a longer period of time (6 days), but similarly confirmed 
that glucose counteracts the inhibitory action of Metformin on thyroid cancer 
cells (Figure 4.1 & 4.2). Whereas Bikas et al study on thyroid cancer, high 
concentrations of Metformin were used (1 mM and 5 mM) for shorter period 
time (48 hours), so toxicity maybe an issue [195]. Certainly, the action of 
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Metformin without glucose in the medium is not useful, as the cells are unable 
to grow and there cannot be a true measure of Metformin inhibition, hence, as 
shown in figure 4.2 the absence of glucose has the same results as just 
treating with Metformin. The normal serum glucose levels in non-diabetic 
individuals is maintained in between 70 and 100 mg/dl (4 to 5.5 mM) and also 
in cases of prolonged nutrient deprivation the glucose level dropped to 55 – 
65 mg/dl [222].  The amount of glucose used in this study was 10 mM (180 
mg/dl). This is within the range of glucose used in the published previous 
studies (0 mM – 50 mM), and was also shown to maintain the growth of 
thyroid cell lines, but at lower than 10 mM of glucose, growth was retarded 
(section 3.2.2).  
The data also verifies previously reported findings on breast cancer cell lines 
demonstrating pro-apoptotic effects of Metformin were observed in low 
glucose medium but not in the medium containing high glucose [221]. 
Similarly another study on breast cancer also found that Metformin induced 
extensive cell-death in the glucose-deprived microenvironment [223]. 
 
Consistent with previous reports [221, 223], the current study demonstrated 
that the pro-apoptotic activity of Metformin on thyroid cancer cells increased in 
glucose depleted medium (0 mM) compared to the medium containing 10 mM 
glucose. Furthermore, a recent study on thyroid cancer cells, demonstrated 
that Metformin induced cellular morphological changes and cell death in low 
glucose conditions (5 mM) compared to the medium containing high glucose 
(20 mM) [195]. These findings are also in agreement with the current 
observations on colony formation, where Metformin treatment associated with 
changes in the morphology of colonies (section 3.2.4). 
 
The inhibition of Metformin by glucose provides clues to the pathways by 
which Metformin suppresses thyroid tumour growth, and the various possible 
mechanisms and molecular pathways whereby glucose counteracts the anti-
cancer effects of Metformin have been reported in previous studies.   
Metformin treatment was observed to become more cytotoxic by decreasing 
ATP production and increased AMPK phosphorylation in a medium which 
contained low glucose (2.5 mM) compared to medium which contained 25 mM 
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of glucose [224]. In another study on ovarian cancer cell lines (HeyA8, Tyk-
nu, DOV13 and ID8), Metformin increased AMPK phosphorylation in medium 
contained 5.5 mM of glucose but this anti-cancer effect of Metformin was 
again found to be inhibited in medium containing 25 mM of glucose [225].   Of 
more relevance a recent study on thyroid cancer cells (FTC133) and 
Metformin found that glucose deprivation also increased AMPK 
phosphorylation and down-regulated phopho-pS6 [195].  Taken together 
these findings suggest that Metformin may inhibit up-regulation of the AMPK 
pathway and that glucose is capable of modulating this response. 
 
4.3.2 The anti-cancer effects of Metformin on thyroid cancer 
cells in the presence of insulin, IGF-1 and TSH in the 
media.  
 
Many factors potentially contribute to the development and progression of 
cancer. These include hyperinsulinemia and insulin-like growth factor I, and 
hyperglycaemia [221, 226]. Epidemiological studies have shown that 
hyperinsulinemia and hyperglycaemia associated with type 2 DM are linked 
to an increased risk of several types of cancer, especially the liver and 
pancreas [200-202]. Hyperinsulinemia and the exposure of liver to high insulin 
concentrations in the portal circulation play a major role in cancer 
development. This is because insulin binds to and activates the related 
insulin-like growth factor-I (IGF-I) receptor (80% homology with insulin 
receptor). This leads to more potent mitogenic and transforming activities. 
Moreover, insulin decreases IGF-I-binding proteins (IGF-BP1) resulting in 
increased free IGF-I, the biologically active form of the growth factor [227].  
 
In addition to the influence of glucose on the anti-cancer action of Metformin, 
the effects on thyroid cell proliferation were also investigated in media 
containing insulin, IGF-1 or TSH. In contrast to evidence from previous 
studies, that showed increasing insulin in the medium increased cell 
proliferation [104, 203, 204], here, insulin in the medium (10 μg/ml) did not 
affect cell proliferation (Figure 4.4 & 4.5). It is possible that differences in 
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these findings reflect the use of the various cell lines used as Cheng et al 
[104] studied anaplastic thyroid cancer cells (HTh74 & HTh74Rdox), whereas, 
in this present study, four different thyroid cancer cell lines (K1E7, FTC-133, 
RO82-W-1 and 8305C) and one normal thyroid cell line (Nthy-ori 3-1) were 
tested, but one of these lines 8305c is also an anaplastic thyroid cancer, so 
subtype may not be accountable for the differences. Certainly Doron et al. 
[204] in a previous investigation on prostate cancer found that insulin 
promoted growth of 3 cell lines (LNCaP, C4-2 & P69) but had no effect on two 
other cell lines (M12 & PC3) [204]. These variations were found after cells 
were treated with various concentration of insulin (0, 5, 50, 100, 500 ng/ml) for 
48 hours, and measured using the MTT assay and the results were obtained 
from three independent experiments. In contrast to Doron et al. another study 
on the same prostate cell lines (PC3) found that insulin (3 nM at 48 hours) 
enhanced cell proliferation [226]. Variations among studies could be explained 
by the use of different cell lines and different experimental procedures. 
Despite these variations this investigation did find similar results to Cheng et 
al where insulin increased cell proliferation, but in the presence of Metformin 
the increase in phosphorylation of ERK induced by insulin was prevented and 
thereby reducing growth [104].  In the current study it was found that insulin 
did not increase growth as such, with growth matching the control. To explain 
differences in these findings both human and animal insulin was studied but 
produced the same results. The study by Chen et al had found that insulin 
increased growth, however the information on the type of insulin and medium 
was not provided [104], and despite contacting the author differences in 
insulin could not be confirmed. The findings from this current investigation 
provide further clues to the pathways whereby Metformin exerts its effects, as 
both this study and that of Chen et al, found that Metformin inhibited cell 
growth and proliferation in the presence and absence of insulin. Chen et al 
indicated that ERK phosphorylation increases with insulin and so the 
MAPK/ERK pathway may also be targeted by Metformin. 
 
This present study also demonstrated that IGF-1 and TSH had no effects on 
thyroid cell proliferation and no influence on the anti-cancer effects of 
Metformin (Figures 4.7 & 4.9). This is again in contrast with previous 
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investigations that reported increasing the concentrations of IGF-1 and TSH 
increased cell proliferation in breast and colon cancers cell lines [228-230].  In 
a breast cancer cell line (MCF7) IGF-1 (100 ng/ml) up-regulated P13K/Akt 
pathway and increased cell proliferation [228]. Koenuma et al [229] found that 
insulin and IGF-1 (0-100 ng/ml) for 5 days increased colon cancer cell 
proliferation in a time and concentration dependent manner. Furthermore, 
Koenuma et al showed that NL-44 cells were less sensitive to growth 
stimulation of insulin and IGF-1 than NL-17 cells [229]. This provided 
evidence of variation in the degree of response from different cell lines to the 
growth stimulatory effects of insulin and IGF-1.  It maybe that the 
concentration of glucose affected the results, here 10 mM of glucose were 
used for all investigation but in the other studies up to 25 mM of glucose was 
used [228, 229]. 
 
Several epidemiological studies have suggested that higher serum TSH 
concentrations, even within the normal TSH range, associate with a thyroid 
cancer diagnosis in patients presenting with thyroid nodules [218, 231, 232]. 
Furthermore, a study on 843 patients in the United States suggested that the 
likelihood of thyroid cancer increases, with higher serum TSH levels and also 
higher serum TSH levels are associated with a more advanced stage of 
differentiated thyroid cancer [217]. These findings indicated that TSH might 
play an important role in thyroid cancer progression and/or development. 
Furthermore, in animal models (tumourigenic clone of papillary thyroid cancer 
cells were implanted in nude mice), TSH promoted tumour growth by 
promoting tumour angiogenesis and macrophage recruitment in the 
microenvironment mediated by overexpression of VEGF [233]. Thus, TSH 
suppression therapy by administering exogenous thyroid hormone treatment 
may inhibit the growth and development of thyroid nodules [234]. Additionally, 
therapy with suppressive doses of thyroxine (T4) are associated with 
favourable outcomes in differentiated thyroid cancer patients [235] and 
retrospective studies have shown that a lesser degree of TSH suppression is 
associated with an increased risk of recurrence of differentiated thyroid cancer 
[236]. Moreover, prospective studies have suggested that aggressive TSH 
suppression therapy associated with superior outcomes in thyroid carcinoma-
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related death and relapse in high-risk patients [237, 238]. In this current study 
we found that treatment by TSH had no effect on thyroid cancer proliferation 
or modulated the effects of Metformin (Figures 4.9). Consistent with these 
observations, a study on 86 newly diagnosed breast cancer patients shows 
that thyroid hormone (FT3, FT4 and TSH) levels were not found to be 
correlated to cell proliferation (Ki67) and tumour size [239].   
 
4.3.3 Exploring the differences in observations of Insulin, IGF 
and TSH on thyroid cancer proliferation. 
 
In the most of the above-mentioned studies, cells were cultured in H6 
medium, which is rich with growth factors. The H6 medium is a DMEM 
medium supplemented with a mixture of six hormones (DMEM medium + 10 
μg/ml insulin + 5 μg/ml human transferrin + 10 ng/ml somatostatin + 10 ng/ml 
glycyl-L histidyl-L-lysine acetate + 10 nm hydrocortisone + 1 nm TSH) [229, 
240].  In the present study, we tested the effect of TSH, IGF-1 and insulin on 
thyroid cells in the DMEM medium without adding growth factors as 
mentioned.  These differences may account for why this investigation is 
different to previous studies of TSH, insulin and IGF-1 in thyroid cancer cells.  
In addition, the variation in the current observations on insulin, IGF and TSH 
could be because of different cell lines and different experimental procedures. 
As mentioned earlier, in one study three prostate cancer cell lines responded 
to insulin-induced cell proliferation, whereas the other two cell lines did not 
respond to insulin [204]. Moreover, insulin-induced proliferation in prostate 
cancer cell lines (PC3) was reported in one study [226] while in other study no 
effects were found on the same cell line [204]. 
 
This however is the first study that investigated the anti-cancer effect of 
Metformin (therapeutic dose) with and without modulators (IGF-1 and TSH) in 
the medium. It is of interest that previous studies on thyroid cancer cells with 
TSH (1 nm) and IGF-1 (100 ng/ml) were found to decrease the Forkhead box 
O 1 (FOXO1) protein levels; FOXO1 act as tumour suppressor for thyroid 
malignancy [240]. The study also found that TSH and IGF-1 activated P13K 
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pathway via up-regulated of Akt phosphorylation.  In this current study no 
modulation of the action of Metformin was found by either TSH or IGF-1, but it 
remains to be determined if Metformin exerts its effects by inhibiting pathways 
such as the P13K and the expression of FOXO1. Finally the data suggests 
that TSH may be part of the change from differentiated to de-differentiated 
status, therefore it would be interesting to see if this alters the ability to form 
colonies or migration. Evidence from an in vivo study show that TSH is 
associated with overexpression of VEGF [233]. However, VEGF activation is 
associated with promoting growth and invasion of differentiated thyroid cancer 
cells in culture and in in vivo models [241]. 
 
The effect of insulin, IGF and TSH on apoptosis was not explored, as time 
was limited, and as the data from the proliferation assays were essentially 
negative. It could of course be that any observed effects of insulin, IGF and 
TSH may relate to an effect on apoptosis, which was not explored here.  
 
4.4 Conclusion  
To summarize, the anti-cancer actions of Metformin can be abrogated or 
reduced in the presence of glucose, but are not modulated by insulin, IGF-1 
and TSH.   Therefore it could be assumed in patients that treatment with 
Metformin would work in combination with TSH and would not be affected by 
other factors in non-diabetic patients. Furthermore the interaction of Metformin 
with these modulators has provided evidence for the pathways that are up-
regulated as part of its anti-cancer response, and these aspects are explored 
further later. 
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5 CHAPTER FIVE 
CHAPTER FIVE 
 
Potential methods of action of 
Metformin in thyroid cancer 
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5.1 Introduction 
 
In the previous chapters (chapter 3 & 4) Metformin was shown to have anti-
cancer effects on thyroid cancer cells. The possible methods of action of 
Metformin as an anti-cancer drug in thyroid cancer cell lines are however 
unclear. This current study aims to understand the mechanism by which 
Metformin enters into the thyroid cells and then the genes and pathways it 
modulates.  Organic Cation Transporter 1 (OCT1) plays a role in the cellular 
uptake of Metformin in liver cells and is highly expressed in the kidney and 
intestine [242, 243]. Similarly OCT1 maybe expressed by thyroid cancer cells 
and therefore play an important role in facilitating the anti-cancer effect of 
Metformin. The presence and absence of OCT1 in thyroid cancer cells was 
investigated via immunocytochemistry in this study.  
 
In addition to the potential importance of OCT1 to the uptake of Metformin by 
thyroid cancer cells, this study aimed to demonstrate the genes targeted and 
the pathways involved in the anti-cancer effects of Metformin.  Several non-
thyroid cancer studies have shown the importance of some genes and 
pathways that may be targeted as a result of the anti-cancer actions of 
Metformin, such as in breast cancer [244], ovarian cancer [128], oesophageal 
squamous cell carcinoma [245], pancreatic cancer [246] and thyroid cancer 
[104-106].   
 
In a study on breast cancer cells (MCF7) Metformin inhibited proliferation and 
induced apoptosis via promotion of P53 up-regulation, increasing 
phosphorylation of AMPK and decreasing phosphorylation of mTOR  [125, 
244].   Another study on breast cancer cells (MCF7) found that Metformin 
inhibited cell growth and induced cell cycle arrest via reduced expression and 
activation of erbB2 protein [125], decreased phosphorylation of a Protein 
Kinase (Akt) and decreased phosphorylation of mTOR [125].  In addition to 
breast cancer cells, in oesophageal squamous cell carcinoma cells (OSCC), 
Metformin induced cell cycle arrest and decreased cell growth via up-
regulation of AMPK, p27cip1, p21kip1 and p53 and down-regulation of 
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cyclinD1 [245]. In other investigations of ovarian cancer cells (OVCAR-3 and 
OVCAR-4), Metformin up-regulated the AMPK pathway and down-regulated 
p70S6K and S6K [128].  Finally in pancreatic cancer cells (BxPC3 and PANC-
1), Metformin inhibited cell growth through down-regulation of Bcl2 and Mcl-1 
(both anti-apoptotic proteins), and also decreased phosphorylation of mTOR, 
S6K, 4EBP1, ACC and STAT3 whilst increasing phosphorylation of AMPK 
[246].  The actions of Metformin therefore appear to target a number of 
pathways, but these studies in others cancers seem to suggest that up-
regulation of the AMPK pathway and down-regulation of mTOR are consistent 
features.  
 
In order to understand the potential methods of action of Metformin, the 
Affymetrix expression assay was chosen because it provides information on 
the expression of a large number of genes, including targets (AMPK and 
mTOR) identified in other investigations.  The two thyroid cancer cell lines 
(K1E7 and FTC-133) and one normal thyroid cell line (Nthy-ori 3-1) were 
chosen for the Affymetrix array, the other cell lines were not studied because 
of financial issues. 
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5.2 Results 
5.2.1 Immunocytochemistry assay. 
A positive control line (HepG2 liver cancer cell line) and a breast cancer cell 
line (MDA-MB-231) were also tested in addition to the thyroid cancer cell 
lines.  OCT1 was strongly expressed by the control HepG2 (known 
expression of OCT1) and equally by all thyroid cell lines (K1E7, FTC-133, 
RO82-W-1 and 8305C), but was not expressed by the breast cancer cell line 
MDA-MB-231, which acted as the negative control (Figure 5.1 & 5.2).  The 
pattern of staining for OCT1 in thyroid cells showed a robust diffuse staining 
localized to the plasma membrane (Figure 5.1 & 5.2). The proportion and 
intensity of OCT1 expression was estimated using the Allred score (range 0-
8) [247] as detailed in the material and methods chapter in section 2.2.9.  
Metformin did not influence the proportion and intensity of OCT1 expression in 
thyroid cells, and all thyroid cancer cell lines strongly expressed OCT1 
regardless of treatment with Metformin  (Table 5.1).  
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Figure 5.1: OCT1 expression in thyroid cancer cell lines. 
Low magnification images using x4 objective of the results of the immunocytochemistry assay 
showing OCT1 expression in thyroid cancer & normal cells (K1E7, FTC-133, RO82-W-1, 
8305C and Nthy-ori 3-1) and compared to HepG2 (positive control & negative control without 
antibody). The figure only shows thyroid cells treated with 0.3 mM of Metformin for 48 hours 
(M+) and cells not treated with Metformin (M-). 
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Figure 5.2: OCT1 expression in HepG2, FTC-133 & MDA-MB-231 cells. 
Immunocytochemistry assay comparing OCT1 expression in FTC-133, HepG2 and MDA-MB-
231 using high magnification images x40.  Cells treated with 0.3 mM (+ Metformin) for 48 
hours compared to the cells not treated with Metformin (- Metformin).  + ve control = HepG2 
cells were incubated with 200 µl of primary antibody (SLC22A1) and – ve control = HepG2 
cells were not Incubated with primary antibody (SLC22A1).  
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Table 5.1: Results of the immunocytochemistry assay showing OCT1 
expression in thyroid cells with & without Metformin. 
 
The Immunocytochemistry assay shows the results of quantification of OCT1 expression in 
thyroid cells (K1E7, FTC-133, RO82-W-1, 8305C and Nthy-ori 3-1).  Cells were treated with 
different concentrations of Metformin (0 mM, 0.3 mM, 1 mM and 10 mM), for two different 
time points 24 and 48 hours (Only 48hr time point shown because there was no difference 
between time points). The Allred score was used to score the proportion and intensity of 
OCT1 expression.  
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5.2.2 Results of changes in gene expression using the 
Affymetrix expression array.  
 
The Affymetrix expression array was only performed using three paired 
thyroid cancer cell lines (K1E7, FTC-133 and Nthy-ori 3-1) and compared the 
expression of a total of 53617 genes for all cell lines, before and after 
Metformin treatment (cells were treated with 0.3 mM Metformin for 6 days). 
Due to the financial considerations it was not feasible to perform the analysis 
on all the thyroid cancer cell lines, so only K1E7, FTC-133 and Nthy-ori 3-1 
were investigated. Furthermore it was not possible to perform independent 
repeats. Nthy-ori 3-1 was studied to investigate gene expression in normal 
cells and the cell lines K1E7 and FTC-133 were selected because they 
represent the common types of thyroid cancer.  Metformin significantly up-
regulated and down-regulated a wide range of genes for all cell lines (K1E7, 
FTC-133 and Nthy-ori 3-1). To evaluate, a targeted approach was taken and 
the genes with either a 1 fold change up or down in expression, following 
Metformin treatment, were chosen for further evaluation.  This approach is a 
standard approach established by the core facility in the department of 
Neuroscience, University of Sheffield (Dr Paul Heath). However, as seen 
(Figure 5.3) this initial screen still found there were a large number of genes 
altered in response to Metformin treatment.  
 
 
5.2.3 Overview of the findings on gene expression following 
Metformin treatment. 
 
Previous studies have taken a more focused approach when assessing the 
potential targets and pathways that Metformin could regulate.  This study 
found that the effects of Metformin were wide ranging, with 9.3% genes up-
regulated in the lines and 8.3% down-regulated. In all these instances there 
was at least a one-fold change. In previous studies using the Affymetrix array 
the level considered as relevant for analysis varied among different studies, 
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but mainly ranged between 1-2 fold [248-252]. In these other investigations 
(not exploring Metformin but looking at the action of other drugs) a similar 
approach was taken, but the level of alteration induced was far less than 
found in this current study as a response to Metformin. Therefore although the 
fold changes found using the Affymetrix array were comparable between this 
investigation and others, there was a much higher degree of modulation 
produced by Metformin than reported for other drugs.  Dr Heath (Department 
of Neuroscience, University of Sheffield), was surprised at how much changed 
was induced by Metformin treatment particularly for K1E7. 
 
 
Figure 5.3: Overview of the level of altered genes expression in thyroid 
cells, following Metformin treatment using the Affymetrix array assay. 
The numbers of genes that were up or down-regulated by at least 1 fold, using the Affymetrix 
assay, after Metformin treatment (0.3 mM) in the K1E7, FTC-133 and Nthy-ori 3-1 cell lines is 
summarised. 
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The K1E7 cell line had the most variation in the number of genes that were 
significantly up-regulated (3563 genes) and down-regulated (3430 genes) 
following Metformin treatment.  The protein phosphatase 1 regulatory subunit 
10 gene (PPP1R10), was the top up-regulated gene with an increased 
expression of 18.39 fold compared to the expression of the control. The 
PPP1R10 gene plays an important role in cellular processes, such as the cell 
cycle [253].  The small nucleolar RNA, C/D box 115-5 gene (SNORD115-5) 
was the top down-regulated gene and decreased expression by 16.3 fold 
compared to control (Table 5.2). 
 
Table 5.2: Results of the Affymetrix array assay- identification of the top 
10 up-regulated and down-regulated genes after K1E7 cells were treated 
with 0.3 mM of Metformin for 6 days. 
Numbers 
Gene Symbol Upregulated 
Expression Gene Symbol 
Down 
regulated 
Expression 
1 PPP1R10  18.396358 SNORD115-5  -16.309266 
2 IPW  18.180253 LOC100272216  -15.106969 
3 HCG8  13.96817 SNORD32B  -9.661779 
4 IER3  10.379987 SNORA38  -9.284843 
5 FLJ22447  8.675055 SNORD117  -8.509836 
6 C6orf47  8.49042 HSPA1A  -7.513288 
7 PPT2-EGFL8  8.417027 TAF1D   -7.095325 
8 MTRF1L  7.367797 SNORD52  -6.96934 
9 LOC100132167  7.181866 SNORD48  -6.498743 
10 LINC01000  6.776727 SNORD116-3  -6.014839 
 
Selected up-regulated or down-regulated genes discussed later have been highlighted in the 
table. 
 
 
The FTC-133 cell line, demonstrated the fewest altered genes, with 153 up-
regulated genes, and 109 down-regulated.  The top up-regulated gene was 
the solute carrier family 18 member A3 (SLC18A3), and expression was 
increased by 2.91 fold compared to the control. The top gene that was down-
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regulated was small nucleolar RNA, C/D box 99 (SNORD99) decreased by 
3.13 fold expression compared to control (Table 5.3). 
 
Table 5.3: Results of the Affymetrix array assay- identification of the top 
10 up-regulated and down-regulated genes after FTC-133 cells were 
treated with 0.3 mM of Metformin for 6 days. 
Numbers Gene Symbol Expression Gene Symbol Expression 
1 SLC18A3  2.914271 SNORD99  -3.138417 
2 SERTAD4  2.912107 SNORA66  -2.819541 
3 DIO1  2.60728 DUSP5  -2.722006 
4 RP4-791M13.3  2.410873 SNORD75  -2.721084 
5 LINC01037  2.3793 SNORD103A  -2.64968 
6 LOC102723919  2.288908 RNU6-773P  -2.567926 
7 HIST2H4B  2.23496 SNHG12  -2.34524 
8 IKBKE  2.166837 HMGN2  -2.241845 
9 PARS2  2.159519 CIART  -2.200218 
10 BICC1  2.056973 MIR554  -2.149709 
 
Selected up-regulated or down-regulated genes discussed later have been highlighted in the 
table. 
 
In the Nthy-ori 3-1 cell line acting as the normal thyroid control, 1315 genes 
were significantly up-regulated and 931 genes down-regulated following 
Metformin treatment.  The top up-regulated gene was the complement 
component 4 gene (C4B) and the expression was increased by 17.13 fold 
compared to control. The top down-regulated gene was the SNORD32B and 
the expression was decreased by 6.25 fold compared to control (Table 5.4). 
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Table 5.4: Results of the Affymetrix array assay- identification of the top 
10 up-regulated and down-regulated genes after Nthy-ori 3-1 cells were 
treated with 0.3 mM of Metformin for 6 days. 
Numbers Gene Symbol Expression Gene Symbol Expression 
1 C4B  17.1382 SNORD32B  -6.252246 
2 SNAR-C2  8.260474 SNORD3B-1  -4.47315 
3 PPP1R10  8.143419 TAF1D -4.209673 
4 IER3  7.378793 SNORD24  -3.419105 
5 PDE4DIP  6.931958 ID3  -3.208322 
6 PTPRQ  6.519714 TNC  -2.803944 
7 SNORA38  6.10198 CGB8  -2.80279 
8 CEACAMP7  5.237918 RNU6-767P  -2.694614 
9 LINC00963  4.722674 HIST1H2BM  -2.672788 
10 PRKXP1  4.617178 ERVK-7  -2.670674 
 
Selected up-regulated or down-regulated genes discussed later have been highlighted in the 
table. 
 
5.2.4 Common genes regulated by Metformin treatment of 
thyroid (normal and cancer cell lines). 
 
It was observed that genes amongst the top 10 significantly up and down-
regulated genes were common to both K1E7 and Nthy-ori 3-1 cells.  Two up-
regulated genes (IER3 and PPP1R10) and two down-regulated genes 
(SNORD32B and TAF1D) were common altered in both K1E7 and Nthy-ori 3-
1 cells. In fact, other members of the SNORD family of non-coding small 
nucleolar RNAs were altered in all cell lines tested (Table 5.2, 5.3 & 5.4). 
 
When comparison of the findings on all cell lines were made (including those 
genes where expression was altered more than 1 fold, but not among the top 
candidates), there was also 15 significantly up-regulated genes and 3 
significantly down-regulated genes that were shared between all cell lines 
(K1E7, FTC-133 and Nthy-ori 3-1)  (Table 5.5 & 5.6, Figure 5.4). 
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Table 5.5: The commonly up-regulated genes shared between K1E7, 
FTC-133 & Nthy-ori 3-1 cells, found using the Affymetrix array assay. 
Numbers Gene Symbol Nthy-ori 3-1 FTC-133 K1E7 
1 TOE1  1.113663 1.251928 1.557604 
2 S1PR1  1.334568 1.486556 1.304211 
3 SLC16A1-AS1  1.307473 1.065338 1.4398 
4 LOC102723919  1.174772 2.288908 1.351293 
5 C1orf220  1.060775 1.694529 1.026326 
6 SERTAD4  1.58121 2.912107 3.696954 
7 FBXO28  1.055935 1.083433 1.797531 
8 COG2  1.155445 1.513195 1.410165 
9 Unknown1 2.05395 1.576519 1.285898 
10 TSPAN2  1.150647 1.365549 1.848103 
11 Unknown2 1.264119 1.289381 1.613705 
12 RP4-791M13.3  1.375516 2.410873 2.561201 
13 PIGM  1.27974 1.104949 1.66414 
14 BICC1  1.546207 2.056973 1.539705 
15 STOX1  1.842854 1.166804 1.462698 
 
Selected up-regulated or down-regulated genes discussed later have been highlighted in the 
table. 
 
Table 5.6: Affymetrix Array assay- The commonly down-regulated genes 
shared between K1E7, FTC-133 & Nthy-ori 3-1 cells. 
Numbers Gene Symbol Nthy-ori 3-1 FTC-133 K1E7 
1 RABGGTB -1.350999 -1.495314 -1.087615 
2 Unknown -1.058718 -1.160969 -1.545412 
3 FAM72C  -1.599743 -1.015477 -1.177497 
 
As the expression of these genes was altered in all 3 cell lines, it suggests 
that common pathways maybe implicated in all thyroid tissues, whether 
normal or cancer, however the most significantly altered genes shared by the 
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two cancer cell lines (K1E7 & FTC-133.) were not of significance in the normal 
Nthy-ori 3-1 control.  These findings would therefore suggest that there is a 
different mode of action by Metformin specifically in thyroid cancer.  
 
A summary of the overview of commonly altered genes in the lines is 
presented in figure 5.5. 
 
Figure 5.4: Overview of the results of the Affymetrix array assay and the 
common involved genes in K1E7, FTC-133 & Nthy-ori 3-1 cells. 
Results of the Affymetrix array assay showing the number of genes for which changes in 
expression were shared in all cell lines (K1E7, FTC-133 and Nthy-ori 3-1 cells).  Also the 
genes that were shared between the cancer cell lines (K1E7 and FTC-133), and finally the 
genes shared by  the cancer cells, but unchanged in the normal Nthy-ori 3-1 cells.  The 
findings demonstrate that there is a large amount of change in expression of genes that is 
specific to the cancer cell lines. 
 
 
In addition to looking at individual target genes, it is possible to look at what 
pathways are implicated and show significant change. A large number of 
genes were identified as potentially of interest from the initial screen.  The 
data produced by the Afffymetrix Array can be refined using the Database for 
Annotation, Visualization and Integrated Discovery (DAVID) to identify the top 
10 significantly involved pathways in K1E7, FTC-133 and Nthy-ori 3-1 cells 
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following Metformin treatment. DAVID uses a comprehensive set of functional 
annotation tools, to refine the results for the systematic and integrative 
analysis of the gene lists (https://david.ncifcrf.gov/summary.jsp). DAVID 
allows for an integrated approach to be taken to the analysis and identifies 
any relationship between up and down-regulated genes to reveal pathways 
implicated by treatment with Metformin.  
  
Following the submission of the results of the expression arrays to DAVID, 
several involved pathways were found for each of the cell lines.  In total 468, 
24 and 151 functional annotation clusters (implying linked pathways) were 
found as a result of the up-regulated genes for K1E7, FTC-133 and Nthy-ori 
3-1 respectively.  Furthermore 88, 13 and 41 functional annotation clusters 
were revelaed in relation to the down-regulated genes for K1E7, FTC-133 and 
Nthy-ori 3-1 respectively.  The top 10 fucnctional annotation clusters based on 
the p-value were selected for K1E7, FTC-133 and Nthy-ori 3-1 (Table 5.7 & 
5.8).  The study did not find any commonly affected pathways between all 
three cell lines among the top 10 significant either up or down-regulated 
pathways. 
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Table 5.7: Findings of analysis with DAVID, to analyse the top 10 
functional annotation clusters of up-regulated genes in the cell lines; 
following treatment with Metformin (0.3 mM) for 6 days. 
No. 
K1E7  
(10 out of 468 clusters) 
FTC-133 
 (10 out of 24 clusters) 
Nthy-ori 3-1 
 (10 out of 151 clusters) 
Annotation 
clusters 
P-
value 
Annotation 
clusters 
P-
value 
Annotation 
clusters 
P-
value 
1 Transferase 3.6E-
10 
Lipid metabolism 8.0E-3 Response to 
hypoxia 
8.7E-6 
2 Metal-binding 7.4E-9 Mitochondrial part 1.6E-2 Positive regulation 
of cell migration 
4.2E-6 
3 Ubl conjugation 
pathway 
4.3E-9 Flavoprotein 1.8E-2 Response to 
oxygen levels 
1.5E-5 
4 Zinc 1.8E-8 Golgi membrane 1.9E-2 Domain:Anaphylat
oxin-like 
3.2E-5 
5 Zinc-finger 7.1E-8 Golgi apparatus 
part 
2.2E-2 Anaphylatoxin 9.5E-5 
6 Nucleus 2.5E-
12 
FAD 2.2E-2 Complement 
C3a/C4a/C5a 
anaphylatoxin 
9.5E-5 
7 Serine/threonine 
protein kinase-
related 
4.7E-7 Glycoprotein 
metabolic process 
2.3E-2 Antiviral defense 3.3E-5 
8 Serine/threonine-
protein kinase 
5.9E-7 Fatty acid 
metabolism 
3.0E-2 Regulation of cell 
motion 
1.0E-4 
9 Apoptosis 1.7E-6 Protein amino 
acid glycosylation 
3.1E-2 Regulation of cell 
migration 
1.0E-4 
10 Protein kinase, 
core 
1.2E-6 Glycosylation 3.1E-2 Response to 
nutrient levels 
1.3E-4 
 
The P-value (or EASE score generated by DAVID) examines the significance of the entire 
gene list and compares altered expression, whether up or down for individual genes, to relate 
such changes to pathway.  On this basis the analysis can detemine which pathways are most 
altered
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Table 5.8: Findings of analysis with DAVID, to analyse the top 10 
functional annotation clusters of down-regulated genes in the cell lines; 
following treatment with Metformin (0.3 mM) for 6 days. 
No. 
K1E7  
(10 out of 88 clusters) 
FTC-133 
 (10 out of 13 clusters) 
Nthy-ori 3-1 
 (10 out of 41 clusters) 
Annotation 
clusters 
P-
value 
Annotation 
clusters 
P-
value 
Annotation 
clusters 
P-
value 
1 Olfactory receptor 2.2E-9 Cytosolic part 2.7E-4 Metal ion-
binding site:Zinc; 
catalytic 
9.6E-4 
2 Olfaction 4.6E-9 S_TKc 6.9E-4 Extracellular 
region 
9.1E-3 
3 Olfactory receptor 
activity 
6.4E-9 Kinase 8.8E-4 Cell motion 1.2E-2 
4 Sensory 
perception of 
smell 
1.1E-8 Cell cycle 9.9E-4 Secreted 1.3E-2 
5 GPCR, 
rhodopsin-like 
superfamily 
2.0E-8 Binding site:ATP 1.4E-3 Extracellular 
region part 
1.4E-2 
6 7TM GPCR, 
rhodopsin-like 
2.0E-8 Serine/threonine 
protein kinase 
3.1E-3 Metalloprotease 1.4E-2 
7 Sensory 
perception of 
chemical stimulus 
8.6E-8 Nucleotide 
phosphate-
binding 
region:ATP 
6.0E-3 Response to 
organic 
substance 
1.8E-2 
8 Olfactory 
transduction 
1.1E-7 Nucleotide 
binding 
9.0E-3 Regulation of 
protein complex 
assembly 
2.1E-2 
9 G-protein coupled 
receptor 
3.7E-7 Serine/threonine 
protein kinase, 
active site 
9.2E-3 Actin binding 2.1E-2 
10 Nucleosome core 6.0E-7 Serine/threonine 
protein kinase-
related 
9.6E-3 Signal 3.2E-2 
 
The P-value (or EASE score generated by DAVID) examines the significance of the entire 
gene list and compares altered expression, whether up or down for individual genes, to relate 
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such changes to pathway.  On this basis the analysis can detemine which pathways are most 
altered. 
 
Using DAVID, genes up-regulated and down-regulated were highlighted and 
their expression was clustered to provide relationships that point to the 
pathways implicated (Table 5.7 & 5.8). To verify and further analyse the data, 
the functional annotation clusters were examined to see if individual genes 
within the pathways, rather than the pathways, were common targets amongst 
all cell lines. It was hoped that this analysis might reveal which gene /genes 
were specifically responsive to Metformin. To do this, targets originally 
identified without the use of DAVID were crossed referenced with the 
clustered data.  Furthermore genes repeated as part of clusters on more than, 
or equal to 5, occasions (out of the top ten significant pathways) were 
identified.  For all 3 cell lines the number of genes repeated as part of different 
clusters were 83 up-regulated and 35 down-regulated.  However, there was 
such a significant cross over, that it was not possible to determine if any 
particular gene was the target for Metformin action (data included in the 
appendix table 7.1, 7.2 & 7.3).  The genes originally identified as most highly 
up-regulated or down-regulated (Tables 5.2, 5.3 & 5.4) were also not 
identified within the top ten most significant clusters. The findings therefore 
provide evidence for pathways that are either up-regulated or down-regulated 
in response to Metformin, such as apoptosis (Table 5.9), but equally identifies 
individual target genes whose action maybe specific, such as PPP1R10. 
Genes such as PPP1R10, were not identified as part of the clustering data 
from DAVID as they do not belong to pathways with a high number of genes 
that showed commonality of expression changes.   
 
The data overall not perhaps surprisingly found that Metformin modulated 
several pathways including pathways related to cancer, such as the up-
regulation of apoptosis and down-regulation of the cell cycle (Table 5.9, 5.10 
& 5.11). Other pathways were however highlighted that appeared to have no 
relationship, in particular the olfactory pathway which appears to have no 
bearing on the cancer behaviour or modulation of the thyroid cancer cell lines 
by Metformin.   
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Table 5.9: The list of involved genes identified using the Affymetrix array 
present in the apoptosis and cell cycle pathways following Metformin 
treatment in K1E7 cells. 
Pathways Apoptosis Cell cycle 
Down 
regulated  
genes 
TPT1, NDUFA13, CASP1, MEF2C, 
PPP2R2B, ROCK1P1, COL18A1, 
HSPA1A, HSPA1B, ID3, IFI6, 
NEUROD1, RPS3A, SNCB, TP53I3 
HORMAD1, PRDM9, CNTROB, GFI1, 
MNS1, MND1, MSH5 
Up 
regulated 
 genes 
DHCR24, API5, ALMS1, BCL10, BAG2, 
BCL2L13, BNIP3L, DFFA, DRAM1, 
EP300, FASTKD2, FASTKD3, FAF1, 
GPR65, GSPT1, GULP1, JAK2, KLF11, 
KCNIP3, NCKAP1, NAIP, PTK2B, 
ARHGEF6, RASGRF1, RRAGC, 
ARHGEF12, ARHGEF18, ARHGEF2, 
SLTM, SH3GLB1, SLK, STEAP3, TIAM1, 
TIA1, TAX1BP1, AIMP2, AATF, AHR, 
CASP2, F3, CUL1, DAPK1, DOCK1, 
DNASE2, ERN1, FEM1B, FGF2, GLRX2, 
GREM1, GADD45A, HRK, HIPK2, 
HIPK3, IER3, IL1A, IL1B, IL24, IL6, JUN, 
LIG4, LITAF, MUL1, MEF2A, NGF, 
NET1, NME6, NFKB1, PAK2, PTRH2, 
PMAIP1, PREX1, PEA15, PHLDA1, 
PDCD4, PDCD6IP, PSME3, PRUNE2, 
RABEP1, RIPK1, RIPK2, RTN4, 
RNF144B, SEMA3A, SQSTM1, STK17A, 
ROCK1, SIRT1, SOS1, SOS2, SGMS1, 
SGPL1, SGPP1, TCTN3, TRIB3, 
TNFRSF10D, TNFRSF12A, TP53BP2, 
UBE4B, KRAS, MYC, ZMAT3 
DHCR24, BLM, CDC14A, CSRP2BP, 
CHTF8, CABLES1, DCLRE1A, 
EP300, E2F3, E2F8, GPS2, G0S2, 
GSPT1, HAUS6, KAT2B, LATS1, 
MPHOSPH8, MIS12, NEK3, NEK4, 
NIPBL, PDS5A, RAD17, RAD50, 
RB1CC1, ARHGEF2, SH3BP4, 
STEAP3, SENP5, TAF2, ZWILCH, 
ACVR1, APPL2, APBB2, ANAPC13, 
ANAPC1, AVPI1, AHR, BCAT1, 
BRCA2, CDC6, CGRRF1, CEP120, 
SKA3, SKA1, CUL1, CUL3, CUL5, 
CCND1, CCNT1, CINP, CDK6, 
CLASP2, DSCC1, DUSP1, DMWD, 
EML4, EVI5, ERN1, EGFR, 
ERBB2IP, ESCO1, ESCO2, EIF4G2, 
FOXN3, GSK3B, GADD45A, HDAC3, 
INHBA, JMY, LMLN, LIG4, MCM8, 
MAP3K8, NEDD1, NPAT, PARD3, 
PARD6B, PHGDH, PKD2, PDCD6IP, 
PA2G4P4, PSMD11, PSMD5, 
PSME3, PPM1D, PPP3CA, PPP6C, 
PTP4A1, PRUNE2, RBBP8, RNF2, 
SEPT7P2, SESN2, SESN3, SGOL1,, 
SPAST, SPIN1, STAG1, STAG2, 
TNKS, TXNL4B, TOP3A, TFDP2, 
TBRG1, TUBE1, TP53BP2, MYC, 
VPS4B, ZMYND11 
 
Selected up-regulated or down-regulated genes discussed later have been highlighted in the 
table. 
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Table 5.10: The list of involved genes identified using the Affymetrix 
array present in the apoptosis and cell cycle pathways following 
Metformin treatment in FTC-133 cells. 
Pathways Apoptosis Cell cycle 
Down 
regulated 
genes 
NUAK2, GADD45A, IL24, 
MEF2D, NGF 
CDK1, CKS1B, G0S2, NEK2, 
RAD54L, GADD45A, PHGDH, PLK3, 
RGS2 
Up 
regulated 
genes 
BCL10, CDKN2C, PAFAH2 
CDC14A, NSL1, ASPM, BTRC, 
CDKN2C, FMN2, ZMYND11 
 
Selected up-regulated or down-regulated genes discussed later have been highlighted in the 
table. 
 
 
Table 5.11: The list of involved genes identified using the Affymetrix 
array present in the apoptosis and cell cycle pathways following 
Metformin treatment in Nthy-ori 3-1 cells. 
Pathways Apoptosis Cell cycle 
Down 
regulated 
genes 
CD24, BIRC2, CGB8, LGALS1, 
SRGN, SGK1, TNFRSF21, BTG2, 
CD44, GSTP1, ID3, TXNIP 
 
Up 
regulated 
genes 
DAPK1, DRAM1, DDIT4, NAIP, 
PTK2B, RASGRF1, ARHGEF2, 
AHR, C5, FUS, HRK, IER3, IFI6, 
IL6, OLR1, RNF144B, SEMA3A, 
SQSTM1, SGPL1, TRIB3, 
TNFRSF11B 
CSRP2BP, CABLES1, DDIT3, 
E2F8, KAT2B, ARHGEF2, 
XRCC2, AHR, BRCA2, DSCC1, 
DUSP1, EGFR, PARD3B, PKD2, 
PA2G4P4, BRCC3, CITED2, 
BMP4, EDN1, HEXIM1 
 
Selected up-regulated or down-regulated genes discussed later have been highlighted in the 
table. 
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Among the genes significantly implicated in the apoptosis pathway, one gene 
was commonly regulated by Metformin in K1E7 and FTC-133 cells (BCL10) 
and 16 genes were shared between K1E7 and Nthy-ori 3-1 (AHR, ARHGEF2, 
BCL2, DAPK1, DRAM1, HRK, IER3, IL6, NAIP, PTK2B, RASGRF1, 
RNF144B, SEMA3A, SGPL1, SQSTM1 and TRIB3) (Figure 5.5 & Table 5.9, 
5.10 & 5.11).  Metformin also commonly down-regulated one gene in the 
K1E7 and Nthy-ori 3-1 cell lines (ID3) (Table 5.9 & 5.11).  
  
 
Figure 5.5: Pattern of shared genes involved in the apoptosis pathway 
identified using the Affymetrix assay in K1E7, FTC-133 & Nthy-ori 3-1 
cells. 
This figure shows the number of shared genes that were up-regulated (panel A) and down-
regulated genes (panel B) in the apoptosis pathway in K1E7 cells (red circle), FTC-133 cells 
(yellow circle) and Nthy-ori 3-1 cells (green circle). 
 
For the cell cycle pathway, 2 significantly up-regulated genes were shared by 
K1E7 and FTC-133 (CDC14A and ZMYND11), but more down-regulated 
genes were shared between K1E7 and Nthy-ori 3-1 (AHR, ARHGEF2, BCL2, 
BRCA2, CABLES1, CSRP2BP, DSCC1, DUSP1, E2F8, EGFR, KAT2B, 
PA2G4P4 and PKD2) (Figure 5.6 & Table 5.9, 5.10 & 5.11).  
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Figure 5.6: Pattern of shared genes involved in the cell cycle pathway 
identified using the Affymetrix assay in K1E7, FTC-133 & Nthy-ori 3-1 
cells. 
This figure shows the number of shared genes that were up-regulated (panel A) and down-
regulated genes (panel B) in the cell cycle pathway in K1E7 cells (red circle), FTC-133 cells 
(yellow circle) and Nthy-ori 3-1 cells (green circle). 
 
 
When looking at the patterns of pathways it appears that more pathways are 
affected in the thyroid cancer lines compared to the normal Nthy-ori 3-1(Table 
5.9 & Figures 5.5 & 5.6).  These findings would need to be explored further, 
but seem to validate some of the data from chapter 3 and 4  (sections 3.2.6 & 
3.2.7) that suggest Metformin is acting more effectively on thyroid cancer, and 
that these lines they may be more sensitive. 
 
5.2.5 Does Metformin regulate genes specifically in thyroid 
cancer but not normal tissue? 
 
In this section specific comparison of the two cancer lines (K1E7 and FTC-
133) was undertaken to see identify target was selectively affected in cancer 
only.  The current study found that 55 significantly up-regulated genes and 14 
significantly down-regulated genes were common between K1E7 and FTC-
A
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133 cells (Table 5.12 & 5.13).  Furthermore, It is clear that when the genes 
were commonly up or down-regulated in the thyroid cancer cell lines, the 
change in the level of expression was broadly comparable for both lines 
(Table 5.12 & 5.13). These findings may suggest that major pathways 
modulated by Metformin are essential to all tissues (both normal and cancer), 
such as cell cycle and apoptosis, whilst other pathways are also implicated in 
cancer cells and provide additional targets for modulation.  
 
Table 5.12: The commonly up-regulated genes shared between K1E7 
and FTC-133 cells, found using the Affymetrix array assay. 
 Numbers 
Gene Symbol 
Expression in FTC-
133 Expression in K1E7 
1 FAM213B  1.074924 1.015541 
2 UBE4B  1.11957 1.349833 
3 DNAJC16  1.103066 1.879633 
4 RAB42  1.152434 1.330498 
5 ZMYM4  1.038411 1.423858 
6 ZNF691  1.17977 1.159623 
7 TOE1  1.251928 1.557604 
8 CPT2  1.659833 1.605741 
9 ROR1  1.132694 1.557849 
10 CACHD1  1.219443 1.104747 
11 AGL  1.623054 1.751588 
12 CDC14A  1.403379 1.50894 
13 S1PR1  1.486556 1.304211 
14 SLC16A1-AS1  1.065338 1.4398 
15 LOC102723919  2.288908 1.351293 
16 MAN1A2  1.086991 1.831226 
17 NBPF25P  1.258747 1.229284 
18 PRUNE  1.027419 1.078087 
19 FLG-AS1  1.424351 1.454022 
20 SLC25A44  1.76949 1.08994 
21 C1orf220  1.694529 1.026326 
22 RGL1  1.21664 1.228333 
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 Numbers 
Gene Symbol 
Expression in FTC-
133 Expression in K1E7 
23 SERTAD4  2.912107 3.696954 
24 LOC100287497  1.172272 1.949758 
25 FBXO28  1.083433 1.797531 
26 RAB4A  1.626263 1.572824 
27 COG2  1.513195 1.410165 
28 Unknown1 1.576519 1.285898 
29 C1orf233  1.144269 1.243295 
30 SYNC  1.166014 1.006925 
31 BCL10  1.063442 1.236285 
32 LRIF1  1.432328 1.903429 
33 TSPAN2  1.365549 1.848103 
34 Unknown2 1.289381 1.613705 
35 RP4-791M13.3  2.410873 2.561201 
36 THEM4  1.12133 1.238752 
37 PIGM  1.104949 1.66414 
38 EDEM3  1.494628 1.126477 
39 RAB29  1.064365 1.246003 
40 ZMYND11  1.225645 1.406281 
41 BICC1  2.056973 1.539705 
42 TET1  1.079681 1.91316 
43 STOX1  1.166804 1.462698 
44 KAT6B  1.04286 1.648313 
45 LOC642361  1.044005 1.066369 
46 TSPAN14  1.073806 1.397822 
47 IFIT5  1.312251 1.528192 
48 Unknown3 2.191284 1.655302 
49 WBP1L  1.135208 1.060112 
50 HTRA1  1.166512 1.81714 
51 PTPRE  1.704732 1.041017 
52 ST8SIA6  1.123277 2.265311 
53 CASC10  1.495583 1.222906 
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 Numbers 
Gene Symbol 
Expression in FTC-
133 Expression in K1E7 
54 ZNF248  1.172855 1.047531 
55 C10orf25  1.318821 1.258493 
 
Selected up-regulated or down-regulated genes discussed later have been highlighted in the 
table. 
 
The table 5.13 represents those genes that have altered expression in the 
cancer cell lines (FTC-133 & K1E7), but may still be changed less significantly 
in normal tissues.  
 
Table 5.13: The commonly down-regulated genes shared between K1E7 
and FTC-133 cells, found using the Affymetrix array assay. 
Numbers Gene Symbol FTC-133 K1E7 
1 RNU6ATAC27P  -1.09637 -2.554632 
2 RNU11  -1.760812 -3.019247 
3 RNU6-753P  -1.286647 -1.703753 
4 RNU4-61P  -1.053955 -1.781177 
5 RABGGTB   -1.495314 -1.087615 
6 Unkown1 -1.160969 -1.545412 
7 Unkown2 -2.394764 -1.693968 
8 PRAMEF11  -1.036984 -1.573027 
9 SNORD103A  -1.32484 -1.361419 
10 SNORA55  -1.385548 -1.225207 
11 FAM72C  -1.015477 -1.177497 
12 NBPF20  -1.737692 -1.206808 
13 SNORA14B  -1.933805 -3.893102 
14 RNU6-1067P  -1.202275 -2.642413 
 
Selected up-regulated or down-regulated genes discussed later have been highlighted in the 
table. 
 
169 
 
The findings suggest that Metformin acts on certain shared targets. In some 
instances up / down-regulated genes in the cancer lines are modulated at 
higher levels, but are unaffected in normal thyroid cells. The expression of B-
cell lymphoma/leukemia 10 (BCL10) decreased by 1.06 & 1.23 fold in FTC-
133 and K1E7 cell lines respectively but were unaffected in Nthy-ori 3-1 cell 
lines (- 0.05 fold change). Small nucleolar RNA, C/D box 103A (SNORD103A) 
was down-regulated at comparable levels in both thyroid cancer lines (1.32 & 
1.36 fold down-regulation in FTC-133 & K1E7 respectively), but was 
unaffected in the Nthy-ori 3-1 cell line (0.12 fold change) (Table 5.13).  
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5.3 Discussion. 
5.3.1 OCT1 is ubiquitously expressed and is likely to promote 
uptake of Metformin by thyroid cancer cells.  
Several transporters play an important role in Metformin uptake in the 
intestine, kidney and liver. In the intestine, the plasma membrane monoamine 
transporter (PMAT), OCT3 (SLC22A3) and OCT1 (SLC22A1) contribute to 
Metformin uptake [67, 70, 71]. In the liver Metformin uptake is mediated by 
OCT1 and probably by OCT3 and both transporters are expressed on the 
basolateral membrane of hepatocytes [67, 72-74]. In the kidney Metformin 
uptake from the circulation into renal epithelial cells is facilitated by OCT2 
(SLC22A2) [72]. The renal excretion of Metformin from tubule cells to the 
lumen is mediated through MATE1 (SLC47A1) and MATE2-K (SLC47A2) [75-
78], and studies in healthy individuals have suggested that they contribute to 
the renal excretion of Metformin [79]. Furthermore, OCT1 and PMAT 
(SLC29A4) may play important roles in the reabsorption of Metformin in the 
kidney tubules [80] [81].  
 
In the current study, the presence and absence of OCT1 in thyroid cancer 
cells were examined, because the antibody for OCT1 was already available 
within the department and the importance of OCT1 in facilitating the anti-
cancer effects of Metformin had already been reported in studies on ovarian 
cancer cell lines [254].  All thyroid cancer cell lines and normal thyroid cells 
were found to strongly express OCT1 even before treatment with Metformin 
(Figure 5.1 & Table 5.1). Furthermore, the OCT1 expression was not altered 
in gene expression array data and this is consistent with the OCT1 expression 
results found by Immunocytochemistry. 
 
Previous studies have reported that Metformin has an anti-cancer effect by 
activation of the AMPK pathway [105, 245].  The presence of OCT1 in the 
thyroid cells is maybe essential for Metformin to enter the cells and activate 
AMPK [97], as previous studies have suggested this maybe the case.  In 
ovarian cancer cell lines (SKOV-3 and OVCAR-3), OCT1 was shown to be 
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essential for the anti-cancer effects of Metformin in order for the activation of 
specific targets inside the cells such as activation of AMPK [254]. The study 
also found that Metformin induced-activation of AMPK decreased when the 
expression of OCT1 was blocked in both ovarian cell lines. Unlike, previous 
studies the expression data here on thyroid cancer did not show clear 
evidence for the activation of AMPK and mTOR pathways (section 5.2.3).  It 
is possible that this is because the cells were treated with low doses 
(therapeutic dose) of Metformin, whilst previous studies have used toxic 
concentrations of Metformin. Due to time and financial constraints blocking of 
OCT1 expression or investigation of other previously studied transporters was 
not undertaken.  
 
It is of course possible that other transporters are important in the uptake of 
Metformin by the cells, as here the expression data identified clear up-
regulation of both the solute carrier family 18 member A3 (SLC18A3) in FTC-
133 and SLC16A1-AS1 in all 3 lines tested (Tables 5.3 & 5.5). Consistent 
with current observations, Metformin treatment associated with 
overexpression of SLC18A3 in an animal study, where Metformin was 
investigated as a promising therapeutic agent for stroke therapy [255]. In 
addition to considerations about Metformin treatment, a study on chronic 
myeloid leukemia patients found that OCT1 expression was a useful 
biomarker for Imatinib therapy [256].  Patients failed to respond to Imatinib 
therapy, due to OCT1 down-regulation, and it is possible that OCT1 
expression by all thyroid cancer cell lines in this study may equally prove of 
value as a therapeutic biomarker.  
 
5.3.2 Metformin modulated a large number of genes that point 
to the pathways implicated in thyroid cancer. 
This is the first study that has used the Affymetrix array to investigate the anti-
cancer effect of Metformin in thyroid cancer. In this study, after Metformin 
treatment a large number of genes were modulated in thyroid cells (Figure 
5.3). In the literature, several genes (cyclin D1, c-Myc, AKT, ERK, TSC2, 4E-
BP1 and S6K1) have already been reported as associated with the role of 
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Metformin in thyroid cancer [104-106, 149].  There is consistent evidence in 
thyroid cancer to suggest that the AMPK pathway is up-regulated and the 
mTOR is down-regulated. A study on thyroid cancer cell lines found that 
Metformin inhibited cell growth and cell migration via up-regulation of the 
AMPK pathway and down-regulation of mTOR pathway, resulting in 
decreased expression of cyclinD1 and c-myc, subsequently decreasing the 
phosphorylation of S6K and 4E-BP1 [105].  However, the dose of Metformin 
was much higher than used here in these expression studies. In 2 studies 
using different thyroid cancer lines, found that Metformin increased AMPK and 
down-regulated mTOR, as well as decreasing the phosphorylation of P70S6K, 
PS6, cyclin D1 and ERK [106, 149]. Furthermore, Chen, in a study on 
anaplastic thyroid cancer cells (HTh74), found that Metformin inhibited thyroid 
cell growth, by increasing phosphorylation of AMPK and decreasing 
phosphorylation of mTOR and ERK [104]. 
 
As previously mentioned this current investigation did not show any evidence 
for the activation of AMPK and mTOR pathways (section 5.2.3).  For all 3 cell 
lines no fold changes for AMPK and mTOR were detected by Affymetrix. The 
molecular mechanisms behind the anti-cancer effects of Metformin in thyroid 
cancer are not clear, as there has been limited study.  In this investigation 
thousands of genes were up and down-regulated following Metformin 
treatment of the 3 different thyroid cell lines (Nthy-ori 3-1, K1E7 and FTC-133) 
(Figure 5.3).  The top up-regulated genes in K1E7, FTC-133 and Nthy-ori 3-1 
cells were PPP1R10, SLC18A3 and C4B respectively (Table 5.2, 5.3 and 
5.4). The PPP1R10 gene is thought to play an important role in cellular 
process such as cell cycle [253].  Whereas SLC18A3 encodes vesicular 
acetyl-choline (Ach transporter), and may represent an alternative transporter 
for the uptake of Metformin as discussed previously [257]. SLC18A3 has been 
associated with recessive congenital myasthenic syndrome [258]. The 
complement component 4 gene (C4B), is involved in the complement system 
and assists with important functions such as immunity, tolerance and 
autoimmunity in combination with the other numerous components [259]. Its 
importance in the context of this study is not yet clear.  What however was 
173 
 
clear was the evidence implicating the SNORD family as most commonly 
regulated genes across all lines (Table 5.2, 5.3 and 5.4). Among the top 10 
significantly up-regulated or down-regulated genes, mutual genes were found 
in K1E7 and Nthy-ori 3-1 cells; two up-regulated genes (IER3 and PPP1R10) 
and two down-regulated genes (SNORD32B and TAF1D) (Table 5.2 & 5.4).  
Furthermore from the initial screen members of the SNORD family were 
consistently down-regulated across all lines. The SNORD family has been 
found to be over expressed in tumour cells [260], but there is very limited data 
on the family in cancer.  In relation to SNORD32B it is a small nucleolar RNA 
a member of SNORD family and with little information available on the 
databases. TAF1D (TATA-box binding protein associated factor), plays a role 
in RNA polymerase 1 transcription) [261] but again with very little evidence for 
its role in cancer.  Of particular interest is IER3 (Immediate early response 3), 
also known as IEX-1 (Immediate early gene X-1). IER3 plays an important 
role in cell growth control and acts as a negative regulation of apoptosis [262]. 
IER3 is activated to protect cells from stimuli induced cell apoptosis such as 
stress, radiation and viral infection or therapies such as Metformin [263]. The 
IER3 cell survival function is in response to stimuli inducing cell death and is 
obtained upon ERK activation pathway [264]. As IER3 is a top gene up-
regulated in this study it suggests that there is ERK activation as a response 
to Metformin, which may mean that indeed there is some modulation of the 
AMPK and mTOR pathways here, but that there are so many other potentially 
more important findings it was not identified in this study as significant. The 
protein phosphatase 1 regulatory subunit 10 (PPP1R10) plays an important 
role in cellular process such as cell cycle, by protecting chromosome de-
condensation [253], and links into the current findings by suggesting that the 
stalling of the cell cycle observed here (Figure 3.12) may require increased 
expression of PPP1R10 to maintain chromosome integrity whilst stalled and 
slowed by Metformin. 
 
Although mutual genes were shared by all 3 cell lines, the study found no 
shared mutual genes in the top 10 significantly up and down-regulated genes 
between FTC-133 and the other two cell lines.  However, among all significant 
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genes approximately 15 mutual genes were observed to be up-regulated and 
3 genes to be down-regulated in K1E7, FTC-133 and Nthy-ori 3-1 cells (Table 
5.5 & 5.6). The effect of some of these genes is not known, and for all these 
genes there is no evidence to suggest a possible role in thyroid cancer or for 
treatment by Metformin.  
 
Using DAVID, the most significant of the pathways modulated by Metformin 
can be identified. It is however, important to remember that in these pathways 
indicated genes maybe up or down-regulated. But the overall effect is a down-
regulation or up-regulation of the pathways. The selected pathways provide a 
better understanding of the findings in chapter 3 related to apoptosis and cell 
cycle (section 3.2.6 & 3.2.7) as here (Table 5.9, 5.10 & 5.11) there is 
evidence to show up-regulation of apoptosis and down-regulation of the cell 
cycle, and thus confirming that the anti-cancer effects of Metformin in thyroid 
cancer result in increased apoptosis and stalling of the cell cycle.  This study 
shows several genes that were up-regulated and down-regulated in apoptosis 
and cell cycle pathways that were not previously reported in thyroid cancer 
[104-106, 149] and these targets (cyclin D1, c-Myc, AKT, ERK, TSC2, 4E-BP1 
and S6K1) have already been discussed.   
 
There was however some confusing evidence relating to data on the olfactory 
clusters, which was a top target among the down-regulated genes (section 
5.2.4 & Table 5.8). The modulation of the olfactory clusters was found only in 
the K1E7 cell line, and comprises 26 down-regulated genes. It is possible that 
this was a bystander change brought about because of the large number of 
other pathways altered in the K1E7 cell line (556 pathways), and there is no 
evidence for a possible role in the Metformin regulation of thyroid cancer in 
the literature.  Furthermore, as Metformin modulation of K1E7 produced so 
much more alteration than for the other cell lines, it is possible that the results 
for this line are less robust when specifically compared to the other annotated 
clusters, and may suggest that was unreliability of the data for these clusters.  
The experiments would need to be repeated to confirm these possible 
pathways as implicated.   
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5.3.2.1 Metformin-induced regulation of apoptosis and cell cycle arrest 
in thyroid cells. 
 
The current study found that Metformin modulated several genes that play an 
important role in apoptosis and cell cycle (Table 5.9, 5.10 & 5.11), Metformin 
decreased the expression of Cyclin-dependent kinase 1 also known as CDK1 
by 1.04 fold in FTC-133 cells (section 5.2.4 & Table 5.10). CDK1 plays an 
important role in cell cycle regulation [265]. More recently, a study on non-
small cell lung cancer cells found that knockdown of CDK1 resulting inhibition 
of cell proliferation, cell migration, and induced cell cycle arrest and enhanced 
cell apoptosis [266].  
 
In addition to CDK1, Metformin altered the expression of the NUAK2 gene. 
NUAK2 expression decreased by 1.39 fold following Metformin treatment of 
FTC-133 cells. NUAK2 is known as SNF1-like kinase 2 and plays an 
important role in cell cycle regulation and growth of melanoma cells [267]. A 
study on melanoma cells found that knockdown NUAK2 resulting inhibition of 
cell proliferation, cell migration, and also induced apoptosis and cell cycle 
arrest [268]. Furthermore, knockdown of NUAK2 decreased the expression of 
cyclin D1, cyclin D3, cyclin-dependent kinase 2 and down-regulated the 
expression of mTOR [268].  
 
Recently, a study reported that the tumour suppressor p53 is required for 
Metformin-inhibited cell proliferation [269] and Metformin-induced apoptosis in 
breast cancer [244]. In this investigation, Metformin modulated the expression 
of the TP53BP2 gene in K1E7 cells increasing its expression by 1.45 fold 
(section 5.2.4 & Table 5.9). TP53BP2 gene, also known as tumour 
suppressor p53-binding protein 2 (TP53BP2) or apoptosis-stimulating p53 
protein 2 (ASPP2) [270], is a tumour suppressor gene which promotes 
damage-induced apoptosis through activation with p53 [271]. TP53BP2 
controls p53 by boosting the DNA binding and transactivation function of p53, 
on the promoters of pro-apoptotic genes in vivo [272].   Moreover, the down-
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regulation of TP53BP2 associates with increased cell proliferation, tumour 
metastasis and poor prognosis in human cancers [273, 274], and can result in 
increased resistance to gemcitabine treatment [275]. TP53BP2 expression 
however enhanced sensitivity of chemotherapy-induced apoptosis in colon 
cancer cells [276].  
 
In this current study, tumour protein translationally-controlled 1 (TPT1) also 
known as TCTP, was found to decrease by 1.62 in K1E7 (section 5.2.4 & 
Table 5.9) Metformin treated cells compared to control (non-Metformin treated 
cells). It is thought that TCTP plays an important role in cell growth and 
protects cells from apoptosis.  In other studies, the expression of TCTP 
decreased during tumour suppression associated with the activation of the 
tumour suppression gene (p53) in human monocytic leukemia cells [277]. The 
knockdown of TCTP, in primary mammary tumour cells from ErbB2 transgenic 
mice, results in activation of p53 and inhibits cancer cell growth [278]. More 
recently, in vivo and in vitro data shows that the knockdown of TCTP in lung 
cancer cells results in the inhibition of cell proliferation, colony formation and 
cell migration and also induces apoptosis (by altering apoptosis regulatory 
proteins such caspase-3, p53 and BCL2) and cell cycle arrest [279]. The 
findings here on TCTP in K1E7 mirror those discussed on TP53BP2, and 
suggest that down-regulation of an inhibitor of p53 matched with up-regulation 
of an activator are related and ultimately through p53 increase apoptosis.   
 
In this study, Metformin treatment increased the expression of Caspase 2 
(CASP2) by 1.14 fold in K1E7 cells compared to non-treated cells (section 
5.2.4 & Table 5.9). CASP2 is an enzyme encoded by the CASP2 gene in 
humans and is one of the hallmarks of apoptotic cell death [280].  A study on 
prostate cancer cell lines (PC-3 and LNCaP) and the anti-cancer effects of 
Ferulic acid, found that Ferulic acid inhibited cell proliferation and induced cell 
apoptosis as reflected by activation of CASP2 [281]. Alternatively, knock down 
of CASP2, inhibited Docetaxel-induced apoptosis in prostate cancer cells 
(PC3), the data indicated that premitochondrial activation of CASP2 was 
required for Docetaxel-induced apoptosis in prostate cancer cells [282]. 
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Similar to the current findings on thyroid cancer, a previous study using 
Metformin found that it inhibited cell proliferation and induced apoptosis 
through activation of the caspase family and AMPK in cholangiocarcinoma 
cells [269]. In addition, overexpression of CASP2 in the current study might be 
through the potential activation of the AMPK pathway, as previous reports 
suggest that the AMPK pathway is involved in CASP2-modulated autophagy 
[283, 284]. 
 
In the current study, the expression of the death associated protein kinase 1 
(DAPK1) gene increased following Metformin treatment in K1E7 and Nthy-ori 
3-1 cells by 2 and 1.49 fold respectively (section 5.2.4, Table 5.9 & 5.11). 
DAPK1 is a calcium/calmodulin (Ca2+/CaM)-dependent serine/threonine 
kinase encoded by DAPK1 gene in humans [285]. DAPK1 acts as a tumour 
suppressor gene and plays an important role in apoptosis and cell cycle arrest 
[286].  A study on human neuroblastoma cell lines (U251) shows that 
overexpression of DAPK1 induces apoptosis and G2/M cell cycle arrest; 
whilst knockdown of DAPK1 inhibited apoptosis and cell cycle arrest [287]. In 
another study on pancreatic cancer cells (BxPC-3), overexpression of DAPK1 
in BxPC-3 cells significantly inhibited cell proliferation, cell migration and 
activation of caspase-3, which was followed by down-regulation of AKT and 
ERK phosphorylation [288]. The study suggested that overexpression of 
DAPK1 in pancreatic cancer cells inhibited cell proliferation through 
P13K/AKT and ERK pathway.  Furthermore, as previously mentioned Chen, 
reported that Metformin inhibited ERK phosphorylation and the mTOR 
pathway in thyroid cancer cells [104]. The overexpression of DAPK1 in the 
current study suggests that Metformin could be targeting the MAPK/ERK 
pathway in thyroid cancer cells, but needs further investigation.  
 
The regulation of other genes in this investigation also supports the potential 
of Metformin to induce apoptosis and regulate the cell cycle. The expression 
of B-cell lymphoma/leukemia 10 gene (BCL10) increased by 1.23 and 1.06 
fold in K1E7 and FTC-133 cells respectively but no changes was observed in 
Nthy-ori 3-1 cells (section 5.2.4, Table 5.9 & 5.10). B-cell 
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lymphoma/leukemia 10 protein is encoded by the BCL10 gene [289] and wild 
type BCL10 expression acts as a tumour suppressor with BCL10 
overexpression inducing apoptosis [290]. A study using breast cancer cell 
lines (MCF7 and T47D) shows that an anti-cancer agent, Benzene-poly-
carboxylic acid complex, induced cell apoptosis, as determined by over 
expression of BCL10 [291].  The expression of HORMA domain containing 
protein 1 (HORMAD1) was decreased by 1.13 fold in K1E7 cells following 
Metformin treatment (section 5.2.4 & Table 5.9). (HORMAD1) is a protein 
encoded by the HORMAD1 gene in humans and play an important role in cell 
cycle regulation [292, 293]. In vitro and in vivo studies on ovarian cancer cells 
found that silencing HORMAD1 gene enhanced Docetaxel-induced apoptosis 
and reduced tumour weight [294].  
 
The specific gene regulation following Metformin treatment clearly indicates 
that Metformin treatment is associated with cell cycle arrest and induces 
apoptosis (Figure 5.7).  
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Figure 5.7: Metformin alters specific genes in the apoptosis and cell 
cycle pathways. 
 
The findings here of the expression array all serve to support the previous 
findings of Metformin inhibiting cell proliferation, induced cell cycle arrest, and 
accelerated apoptosis presented in chapter 3 (section 3.2.3, 3.2.6 and 3.2.7 
respectively). 
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5.3.2.2 Evidence for modulation of the action of Metformin by other 
regulators. 
 
In this study, presented in chapter 4, TSH and IGF-1 had no effect on the 
ability of Metformin to control cell proliferation of the thyroid cell lines (section 
4.2.3 & 4.2.4).  It has been previously reported that TSH and IGF-1 activate 
the P13K/Akt signaling pathway and show down-regulation of FOXO1 (act as 
a tumour suppressor) in thyroid cancer cells [240]. Examination of the array 
data here (section 5.2.3) only found a slight increase in the expression of 
FOXO1 in K1E7 cells by 0.42 fold.  Of course as the study was not performed 
with TSH and IGF-1 it is not possible to say if their inclusion would affect the 
regulation of FOXO1 by Metformin. Furthermore, in a study on endometrial 
cancer cells, Metformin inhibited cell growth via FOXO1 and AMPK activation 
[295]. In the current study, FOXO1 was slightly up-regulation by Metformin 
suggesting another way of controlling thyroid cancer cells. It remains to be 
determined if Metformin exerts its effects by inhibiting pathways such as the 
P13K/Akt pathway and the expression of FOXO1. 
 
5.3.2.3 Specific gene expression in thyroid cancer cell lines, is BCL10 
induced by Metformin?  
As previously mentioned expression of the BCL10 gene, involved in 
apoptosis, was increased by 1.06 and 1.23 fold in FTC-133 and K1E7 (thyroid 
cancer cells) but not normal cells (section 5.2.5).  This may suggest that 
although apoptosis is up-regulated in all thyroid cells its action may be 
increased in thyroid cancer specifically.  Unfortunately the TT cell line, which 
had the highest level of apoptosis, was not investigated by the array, and it 
would have been interesting to make a comparison with the expression of 
BCL10 post Metformin treatment. 
 
Finally the data suggests that Metformin action in cancer is wide ranging and 
targets multi-signalling pathways and further investigation is required to 
181 
 
understand the molecular action of Metformin in depth.  The thyroid cancer 
cell lines showed variation in the number of genes modulated, as did the 
normal control, potentially reflecting characteristics of the subtypes of thyroid 
cancer responding to modulation by Metformin in a different manner. 
 
5.3.2.4 Other regulatory pathways associated with Metformin. 
 
The gene expression data detailed above included many targets of interest as 
part of the pathways that are possibly modulated by Metformin. However 
other targets have previously been suggested to be the focus for the action of 
Metformin in cancer.  These include GLUT4, COX-2, ACC, STAT3, GPAM, 
Bax, Ki67, RET [101, 102, 181, 182].   Unfortunately although the array 
included information on over almost 54,000 genes the above were not part of 
the array, and it was not possible to confirm if they were the subject of 
modulation by Metformin. 
 
5.4 Conclusions 
OCT1 was ubiquitously expressed in thyroid cells even prior to treatment with 
Metformin, suggesting it can facilitate the anti-cancer effects of Metformin and 
possibly that thyroid cancer may be more responsive than other cancers. 
Metformin treatment significantly modulated thousands of genes and 
hundreds of pathways in thyroid cell lines, but findings confirmed the 
importance of both apoptosis and cell cycle regulation by low dose Metformin.  
 
In the current study the gene expression data was obtained from medium 
containing 10 mM of glucose, as this had been shown to produce good growth 
of all the cell lines.  The level of glucose chosen here could however prevent / 
reduce AMPK activation, in favour of alternative pathways. Metformin 
treatment has been shown to become more cytotoxic by decreasing ATP 
production and increasing AMPK phosphorylation in a medium which 
contained low glucose (2.5 mM) compared to medium which contained 25 mM 
of glucose [224]. AMPK pathway activation induces p53 up-regulation [296], 
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and the current study found Metformin-induced activation of TP53PB2 (P53 
activator) in K1E7 cells (Table 5.9) suggesting the potential activation of the 
AMPK pathway. In this study the lower doses of Metformin present in a higher 
concentration of glucose is different to previous investigations, and it is 
possible that the response to Metformin in this investigation still activates 
AMPK but that other pathways maybe more important.   
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6 CHAPTER SIX 
CHAPTER SIX 
 
General discussion
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6.1 Background to project and summary of findings. 
 
At the start of this project, a literature search found population-based studies 
that suggested the potential anti-cancer effects of Metformin in several types 
of cancer [109, 111, 112].  Furthermore, other studies found that Metformin 
treatment in type 2 diabetes patients was associated with a reduced risk of 
cancer, decreased cancer recurrence and reduced cancer mortality [111, 115, 
117, 120]. Metformin had also been studied in vitro [125, 128], with 
investigations confirming Metformin’s anti-cancer properties on different 
cancer cells such as breast, pancreatic, ovarian, colorectal, lung, 
oesophageal, and specifically on thyroid cancer [104-106, 149].  At the 
beginning of the current study, there were few studies on the anti-cancer 
effects of Metformin in thyroid cancer; but currently, there are in excess of 
more than 20 studies on thyroid cancer [104-107, 124, 137, 147, 149, 183, 
189, 195, 297-305] including our own based on the results of chapter 3. 
These include investigations based on in vitro, in vivo and clinical data. 
 
Despite the evidence supporting the anti-cancer action of Metformin, the 
molecular mechanisms through which it modulates cancers have not been 
well characterized.  Although both the AMPK and mTOR pathways are 
targeted in a number of cancers [85, 105, 174, 306], this study has not found 
clear evidence from the gene expression data, that in thyroid cancer the 
AMPK and the mTOR pathways are modulated by Metformin (section 5.2.2).  
The current study did however find strong evidence in favour of the anti-
cancer effects of Metformin in thyroid cancer, and the main findings are 
summarized in figure 6.1.  
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Figure 6.1: Summary of the anti-cancer findings of Metformin in thyroid 
cancer cell lines. 
This figure shows the anti-cancer effects of Metformin in chapter 3 (black), chapter 4 (blue) 
and chapter 5 (green).  
 
Consistent with the previous reports, Metformin inhibited thyroid cancer cell 
proliferation and clonal formation as analysed by MTT assay and clonal 
formation assay (chapter 3) [104, 195].  At the doses of Metformin considered 
to be within normal therapeutic concentrations in diabetic patients (< 0.3 mM) 
[132, 163], the effects were not statistically significant over 6 days on thyroid 
cells. However, the relationship could explain the significant anti-cancer 
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effects when Metformin is used for longer periods, as with diabetic patients.   
This investigation standardized all tests in 10 mM glucose, as the growth for 
all cell line was good. However previous studies on thyroid cancer have used 
other concentrations of glucose in a variety of media with different additives.  
Thereby the action of Metformin could be modulated in these studies by the 
higher glucose used or the additional additives [240]. 
 
6.2 How modulation of the anti-cancer action of 
Metformin may alter patient response. 
The anti-cancer effects of Metformin on thyroid cell proliferation were 
modulated by the amount of glucose in the medium (section 4.2.1). Without 
glucose, cells did not grow and the action of Metformin was strongest. High 
levels of glucose (10 mM) however abrogated the action of Metformin.  It is 
important to consider that the oxidation of 1 molecule of glucose under 
aerobic conditions can produce 38 molecules of ATP, whilst in anaerobic 
conditions only 2 molecules of ATP are produced [190]. The findings in an 
earlier study that Metformin treatment decreased ATP production and 
increased AMPK phosphorylation in a low glucose medium may also help with 
the translation of the use of Metformin to the clinic [224].  Since, glucose 
metabolism in cancer cells occurs mainly under anaerobic conditions; cancer 
cells need more glucose to grow and replicate. In this study the thyroid cancer 
cells were cultured in aerobic conditions and it can be counted as one of the 
limitations of this study, but if Metformin does decrease ATP production its 
anti-proliferative effects, as reported in this study, may be augmented in the 
patient under hypoxic conditions and with a low glucose diet, by further 
restricting the production of ATP. Unfortunately it was not possible during this 
current investigation to look at the effect of Metformin in hypoxic conditions. 
The action of other possible modulators affecting the response in patients was 
also studied. Investigation into the role of TSH, Insulin and IGF on cell 
proliferation under defined circumstances demonstrated no effect (chapter 4).  
Further studies are required to investigate the influence of other modulators in 
more detail. Once again differences between this study and past 
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investigations may reflect variation in other factors included in the media that 
may have additionally modulated the findings [240]. 
 
6.3 The uptake of Metformin by thyroid cancer cells. 
All the effects as a consequence of treatment with Metformin have yet to be 
determined. Unlike previous investigations [168], this study found that 
exposure to Metformin did not induce DNA damage (section 3.2.8); even at 
high concentrations of Metformin for prolonged periods (up to 20 mM of 
Metformin for up to 6 days). Another recent study has confirmed our findings 
[188].  It is thought that the growth inhibitory effect of Metformin on cancer cell 
proliferation may be through the activation of AMPK via activation of LKB1 
[85], which causes inactivation of mTOR pathway [174].  In ovarian cancer 
lines, OCT1 was shown to facilitate uptake of Metformin and when knocked 
down AMPK was inactivated, suggesting this is the method whereby 
Metformin is internalized [254]. All thyroid cancers (and the normal thyroid cell 
line) in this study expressed OCT1, which may indicate that they are involved 
in the action of Metformin. Furthermore, as OCT1 expression appears to be 
linked to Metformin activating AMPK [254], it suggests that in thyroid cancers, 
the AMPK would be activated and mTOR down-regulated. The findings in 
chapter 5 found unclear evidence for the modulation of the common target 
genes in the AMPK and mTOR pathways. Why this should be is unclear, but 
this study used therapeutic doses, whilst others studies used doses known to 
be toxic, and this may be the explanation for different responses.  The 
activation of AMPK may therefore be a response to toxic conditions. 
Alternatively, as mentioned in chapter 4 (section 4.2.1) it may be down to the 
fact that in this current study glucose was used in the medium and OCT1 
modulation of AMPK may be under situations of low glucose only [254].    
 
Unfortunately because of time constraints blocking OCT expression or 
investigation of other previously studied transporters was not undertaken. It is 
of course possible that other transporters are important in cellular uptake of 
Metformin, as here the expression data identified clear up-regulation of both 
solute carrier family 18 member A3 (SLC18A3) in FTC-133 and SLC16A1-
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AS1 in all 3 lines tested (Tables 5.3 & 5.5). Consistent with current 
observations, Metformin treatment was associated with overexpression of 
SLC18A3 in an animal study investigating Metformin as a promising 
therapeutic agent in stroke therapy [255]. However, the expression array was 
performed only once and repeats are important to validate the data and 
undertake further research on the genes that are consistently up or down-
regulated.  
 
6.4 What pathways does Metformin act on to produce 
its anti-cancer effect in thyroid cancer?  
 
As mentioned before, evidence in this study did not find direct up-regulation of 
the AMPK pathway.  Importantly however, the current study has found that 
low dose of Metformin treatment (0.3 mM) for 6 days altered the expression of 
several specific genes that previously have not been identified in studies of 
Metformin and thyroid cancer, such as TP53BP2, NUAK2, CASP2, DAPK1, 
TCTP, BCL10 and HORMAD1 (Table 5.9, 5.10 & 5.11).  Additionally, some of 
these specific genes have been investigated before as targets for therapy in 
several types of cancer [267, 268, 275, 276, 279, 281, 282, 287, 288, 290, 
294], and in the context of this study they can help to improve the 
understanding of the mechanisms by which Metformin produces its anti-
cancer actions. 
 
It has been previously reported that p53 is required for Metformin to inhibit cell 
growth and induce apoptosis [244]. AMPK pathway activation induces p53 up 
regulation [296], and the current study found Metformin induced activation of 
TP53PB2 (P53 activator) in K1E7 cells (Table 5.9), suggesting the potential 
activation of AMPK pathways. In the current study, low dose of Metformin 
increased the expression of TP53BP2 by 1.45, 0.36 and 0.37 fold in K1E7, 
FTC-133 and Nthy-ori 3-1 cells respectively. TP53BP2 expression has been 
shown to enhance sensitivity of chemotherapy-induced apoptosis in colon 
cancer cells [276]. If TP53BP2 were increasing sensitivity to chemotherapy-
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induced apoptosis, then maybe treatment with Metformin to up-regulate 
TP53BP2 before giving chemotherapy in thyroid cancer would be a possibility. 
Furthermore, Metformin inhibited cell proliferation and induced apoptosis 
through activation of the caspase family and AMPK in cholangiocarcinoma 
cells [269]. Overexpression of CASP2 in the current study might be through 
the potential activation of AMPK pathway, as it has been previously reported 
that AMPK is involved in CASP2-modulated autophagy [283, 284].  
 
This study suggests that the potential activation of AMPK pathways at low 
dose (non-toxic) Metformin in thyroid cancer cell lines is through the activation 
of other AMPK-target genes, that are linked to and interact with this pathway. 
Similarly, although there was no direct evidence that the mTOR pathway was 
down-regulated by Metformin, the current study did find that Metformin 
decreased the expression of NUAK2 in FTC-133 cells (Table 5.10).  Evidence 
suggests that knockdown of NUAK2 decreases the expression of cyclin D1, 
and down-regulates the expression of mTOR [268]. The MAPK/ERK pathway 
is another pathway that may be targeted by Metformin. As previously 
mentioned, Chen, reported that Metformin inhibited ERK phosphorylation and 
mTOR pathways in thyroid cancer cells [104]. The overexpression of DAPK1 
in pancreatic cancer cells inhibited cell proliferation through P13K/AKT and 
ERK pathway [288]. The overexpression of DAPK1 in the current study 
suggests that Metformin could be targeting the MAPK/ERK pathway in thyroid 
cancer cells, but needs further investigation. 
 
However, although direct activation of AMPK and down-regulation of the 
mTOR pathways was not found in this study, importantly there was 
consistency of findings between those of chapter 3 and the experimental data 
in chapter 5, that suggests Metformin induces apoptosis and stalls cell cycle 
(section 3.2.6, 3.2.7).  Observations from chapter 3 on the up-regulation of 
apoptosis and blocking of the cell cycle were confirmed in section 5.2.4 with 
both thyroid cancer and normal cell lines demonstrating modulation of the 
expression of genes in these pathways. Importantly the expression data from 
this study shows that Metformin has a wide-ranging action (chapter 5). 0.3 
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mM of Metformin was enough to significantly modulate 53617 genes in K1E7, 
FTC-133 and Nthy-ori 3-1.These findings suggest that there is still much to 
learn about how Metformin acts in cells and the pathways and targets of its 
actions. There is consistency in this study however between genes up or 
down-regulated for all cell lines, and there are also genes targeted specifically 
in the thyroid cancers compared to the normal Nthy-ori 3-1 cell line (section 
5.2.5). Differences between the top genes and pathways altered between 
Nthy-ori 3-1 and the thyroid cancer lines suggest that there are genuine 
differences in response to Metformin. This mirrors and support the 
observations of chapter 3 where apoptosis and cell cycle arrest was more 
evident in the thyroid cancer lines (section 3.2.6 & 3.2.7) Why certain genes 
and pathways are targeted needs to be explored further. The SNORDs family 
looks a promising angle, and there have been links to cancer but the 
relationship is unclear [260]. Other pathways such as the members of 
olfactory pathways in KE17 are so far unrelated to the Metformin use or 
cancer, so the relevance of these findings warrants further exploration.   
 
Furthermore, the differences in the expression of the transporters could 
explain increased uptake in the thyroid cancer lines resulting in more 
apoptosis than Nthy-ori 3-1 cells.  In addition, as mentioned in section 5.2.4 
Metformin modulates more genes in cancer lines (120 & 133 genes 
modulated in apoptosis and cell cycle pathways respectively) compared to 
Nthy-ori 3-1 cells (34 & 21 genes modulated in apoptosis and cell cycle 
pathways respectively), consistent with the finding that cancer cell lines 
demonstrated more apoptosis and cell cycle arrest (section 3.2.6 & 3.2.7). 
 
The CDK1 expression was increased in FTC-133 cells following Metformin 
treatment. CDK1 plays an important role in cell cycle progression and itself is 
activated by A-type cyclins and is in complex with cyclin B1 to facilitate the 
onset of mitosis [265]. The exquisite control of CyclinB1/Cdk1 activity peaking 
at metaphase is necessary for a successful G2/M transition. Previous studies 
on thyroid cancer cells found that Metformin induced AMPK activation in a 
dose dependent manner and inhibited cyclin D1 through inhibition of mTOR 
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pathways [105, 106]. Cyclin D1 plays an important role in cell cycle 
progression through the G1/S phase via binding to the cyclin dependent 
kinase 4 (cdk4), acting to phosphorylate and inactivate the retinoblastoma 
protein, and release E2F transcription factors to transcribe genes required for 
entry into S phase of cell cycle [307]. Comparison of the findings from this and 
other studies suggests that Metformin treatment is associated with arrest in 
different phases of the cell cycle; since the data presented here, indicates that 
the action of Metformin is wide ranging and affects different targets acting on 
other phases of the cell cycle.  Alternatively the action of Metformin could vary 
among different types of cell lines in terms of cell cycle arrest, as a response 
to the cells own biology.  
 
6.5 Study limitations  
The main limitations to this current study were the logistical and financial 
constraints. More cell lines could have been studied with the Affymetrix 
expression array to identify patterns across all 5 thyroid cancer lines. 
Furthermore, the Affymetrix assay was done on the 3 thyroid cell lines only 
once (not triplicate), potentially affecting results and allow variability. 
Repetition of the expression data would hopefully narrow the targets by 
confirming genuine changes in expression that are consistent rather than as a 
result of variability in the quality of the array data.  Such findings would 
confirm if there are real differences in the way thyroid cancers and normal 
thyroid tissues respond to Metformin.  Finally, evidence also suggests that 
hypoxia may influence the response to Metformin, so it would have been good 
to look at the effect of hypoxia at low doses.  Another limitation in the current 
study was the TT cell line was not tested for the influence of insulin, IGF-1 
and TSH. This was due to technical issues limiting the recovery of the cell line 
for further investigation.  Insulin, IGF-1 and TSH were also only studied in the 
proliferation assay and not in the assays investigating apoptosis, cell 
migration and colony formation. Despite the array being detailed and including 
many targets of interest, as part of the pathways possibly modulated by 
Metformin, the array was not however totally inclusive of some interesting 
targets e.g. RET, so other potential targets could not be studied. 
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6.6  Study strengths   
This study clearly demonstrated the anti-cancer effects of Metformin on 
different thyroid cancer subtypes in vitro.  Several thyroid cell lines (5 thyroid 
cancer cell lines and 1 normal thyroid cell line) were chosen to represent the 
different thyroid cancer types and study the anti-cancer effects of Metformin.  
Unlike other studies, the study used a wide range of Metformin concentrations 
including its therapeutic dose in diabetic patients (0.3 mM).  In this study all 
experiments were performed in the same medium (DMEM contained 10 mM 
of glucose) because this study observed that the growth patterns were 
different in different media such as DMEM 4.5g/L, DMEM F-12 and RPMI.  As 
such the different investigations undertaken here can be compared in a 
manner that is not always possible when relating to previous published work.  
 
Furthermore, this is the first study, to my knowledge, that investigated the 
modulatory effects of IGF-1 and TSH on the Metformin treatment of thyroid 
cancer. In addition, the consistent expression of OCT1 by thyroid cancer cells 
suggested that Metformin could be readily up-taken in thyroid cancer, a novel 
finding that has previously not been reported elsewhere.  
 
The Affymetrix data has shown the wide-ranging effects of Metformin on the 
thyroid cancer cell lines. Low dose Metformin modulated thousands of genes 
including several important genes that play key roles in cancer therapy.   The 
data also implicated specific genes for further investigation that might help in 
gaining a better understanding of the molecular pathways influenced by 
Metformin, but these require further investigation. 
 
6.7 On-going and future work  
 
In order to better understand the role of Metformin in thyroid cancer, further 
research may involve one or more of the following components:  
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 Repetition of the results of the expression array on the same cell lines 
in triplicate to confirm which targets were consistently up and down-
regulated following Metformin treatment. Study of other cell lines to 
identify common genes and variations across cancer types would also 
be valuable.  
 Study of cation transporters other than OCT1 such as OCT2 
(SLC22A2), OCT3 (SLC22A3), PMAT (SLC29A4), MATE1 (SLC47A1) 
and MATE2-K (SLC47A2) would be useful.  SLC18A3 expression has 
been demonstrated in FTC-133 cells. Additionally, blocking of OCT1 
expression to study its influence on the anti-cancer effect of Metformin 
is also important.  
 TSH, IGF-1 and insulin did not alter the proliferation of the cells in the 
cell proliferation assay (MTT assay). Their role on apoptosis could also 
be explored.  
 Human thyroid cancer tissue obtained from bio-banks could also be 
investigated for the expression of markers involved in pathways 
affected by Metformin should be done.  
 The role of Metformin on animal models of thyroid and other cancers 
could also be investigated. In addition to observing the effects of 
Metformin on the tumours in vivo, changes in expression of relevant 
proteins with treatment as investigated in other in vitro and in vivo 
studies that could be studied (S6K1 and 4EBP1 [135]).  
 
6.8 Conclusion 
This in vitro study confirmed that Metformin has anti-cancer effects on thyroid 
cancer cell lines.  Based on these findings, it is important to undertake further 
research along the lines described above. These could subsequently lead to 
clinical trials of Metformin treatment in the management of thyroid cancer.  
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Table 7.1: Affymetrix assay- genes repeated in ≥ 5 top 10 significant 
pathways for K1E7 cells. 
Grand Total: 269 
Number of repeated 
genes: 26 
Repeat  
Grand Total: 2096 
Number of repeated 
genes: 72 
Repeat 
Down regulates genes Up regulated genes 
OR10A2, OR10G8, 
OR10H2, OR11H12, 
OR13C2, 
OR1D2,OR1D5, OR1L4, 
OR2T4, OR3A1, OR3A3, 
OR4M1, OR4N5, 
OR51A4, OR51B4, 
OR52M1, OR52N2, 
OR5AC2, OR5AN1, 
OR5AP2, OR5D18, 
OR5F1, OR5H2, OR6T1, 
OR9A2 
9 
ACVR1, ACVR2A, 
ASH1L, BAZ1B, BMP2K, 
BMPR1A, BMPR2, 
CASK, CDK8, CDK9, 
CDKL5, CHUK, CNOT4, 
CREBBP, DAPK1, 
ESCO1, ESCO2, HIPK1, 
HLTF, KLF11, LATS1, 
MAP3K15, MAP3K8, 
MUL1, MYCBP2, NEK3, 
NEK7, NSD1, NUAK1, 
OXSR1, PIAS2, PLK4, 
POLR1B, POLR3B, 
PRKAA1, PRKAA2, 
PRKACB, PSKH1, 
RCHY1, RIPK1, RIPK2, 
RNF111, RNF144B, 
RNF2, RPS6KA3, 
RPS6KB1, SIK2, SIK3, 
SLK, SQSTM1, TESK1, 
TRIM33, TSSK3, ZMAT3, 
ZRANB1 
8 
OR6P1 7 
CDC42BPA, PRKD3, 
ROCK2 
7 
EP300, ERN1, HIPK2, 
HIPK3, MAP3K2, 
MKNK2, NEK4, NLK, 
6 
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Grand Total: 269 
Number of repeated 
genes: 26 
Repeat  
Grand Total: 2096 
Number of repeated 
genes: 72 
Repeat 
Down regulates genes Up regulated genes 
PAK2, RPS6KA5, 
STK17A, STK38 
PRKCI, ROCK1 8 
 
Table 7.2: Affymetrix assay- genes repeated in ≥ 5 top 10 significant 
pathways for FTC-133 cells. 
Grand Total: 70 
Number of repeated 
genes: 5 
Repeat  
Grand Total: 49 
Number of repeated 
genes: 6 
Repeat 
Down regulates genes Up regulated genes 
CDK1, NEK2, PLK3 9 
ACADM, ACADSB, 
COG2, MAN1A2, 
ST6GALNAC5, 
ST8SIA6 
5 
 
 
Table 7.3: Affymetrix assay- genes repeated in top 10 significant 
pathways for Nthy-ori 3-1 cells. 
No. 
Grand Total: 125 
Number of repeated 
genes: 4 Repeat  
Grand Total: 105 
Number of repeated 
genes: 5 Repeat 
Down regulates 
genes 
Up regulated genes 
1 ADAMTS6 6 
  
2 
ADAM12, CD44, 
CPA4 
5 EDN1, PDGFB, PTK2B,  5 
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Table 7.4: List of genes that 1 fold down regulated in Nthy-ori 3-1 cells 
following Metformin treatment (0.3 mM) for 6 days. 
Gene Symbol Expression Gene Symbol Expression Gene Symbol Expression Gene Symbol Expression 
SNORD32B  -6.252246 RNA5SP25  -1.652925 FSCN1  -1.395712 RNU6-1125P  -1.239692 
SNORD3B-1  -4.47315 AOX1  -1.649277 CD24  -1.392565 RAP1GAP2  -1.236415 
TAF1D -4.209673 SNORA23  -1.64583 DPYSL3  -1.388522 SMAGP  -1.232379 
SNORD24  -3.419105 APOBEC3C  -1.64251 RPSAP52  -1.386029 RP11-91H12.4  -1.227397 
ID3  -3.208322 SNORD65  -1.637415 MT-TN  -1.385114 SNORD36C  -1.217121 
TNC  -2.803944 RNU6-577P  -1.631045 RNU7-12P  -1.37752 SNORD4B  -1.216727 
CGB8  -2.80279 SNORD114-3  -1.625387 
RP11-
171A24.3  
-1.369992 RP11-3G21.1  -1.21596 
RNU6-767P  -2.694614 SLC16A14  -1.619389 SRGN  -1.368837 TRPM4  -1.214193 
HIST1H2BM  -2.672788 MIR130B  -1.611842 SNORD114-22  -1.367522 RNA5SP309  -1.211722 
ERVK-7  -2.670674 TSPAN13  -1.600066 SNHG24  -1.367469 RNA5SP46  -1.211372 
RNU5D-1  -2.66551 FAM72C  -1.599743 DDB2  -1.367435 TRBJ2-4  -1.210529 
ABHD17A  -2.526654 SLC16A2  -1.593783 RNA5SP228  -1.36172 SNORD14A  -1.208134 
SNORD80  -2.504472 SNORD114-14  -1.567084 SNORD47  -1.351289 RNU4ATAC  -1.20542 
SNORD50A  -2.453068 RNU5F-1  -1.566105 RABGGTB  -1.350999 SNORD42A  -1.202428 
RNY4P19  -2.434782 SNORD72  -1.56458 RNU6-741P  -1.348792 DNAPTP3  -1.198375 
RNA5SP221  -2.432818 
SPACA5  // 
SPACA5B  
-1.564578 HIST1H2AJ  -1.339102 RNU6ATAC14P  -1.193569 
KRTAP2-3  -2.313304 RNVU1-14  -1.536307 FAM219A  -1.338774 SERINC2  -1.193263 
CD44  -2.282199 CLCA2  -1.535355 MIR3136  -1.336508 ZNF843  -1.187885 
SNORD70  -2.275284 LINC00842  -1.534089 SH3BGRL3  -1.332106 AC012593.1  -1.186309 
SNORD114-1  -2.21372 SNORD58A  -1.53365 SNORD59B  -1.322598 RNU7-18P  -1.185012 
SNORD114-9  -2.194289 SAT1  -1.528811 FKBP11  -1.316025 EMB  -1.184947 
RNU5A-8P  -2.174159 LOC101927501  -1.526218 MSMO1  -1.315332 SNORD74  -1.183046 
IL23A  -2.171254 TUBB4A  -1.524568 RNU6-219P  -1.310385 CCDC112  -1.178864 
SNORD60  -2.088342 EBPL  -1.51845 SNORD27  -1.307994 COX6B1  -1.1733 
SNORD91B  -2.085502 RNU6-1075P  -1.507815 HMGCS1  -1.297247 ZNF415  -1.172944 
RNU6-900P  -2.074324 SNORA18  -1.496646 LGALS1  -1.293349 SNORD3D  -1.169899 
ID1  -2.071566 SMAD9  -1.490794 PSTPIP2  -1.292115 LOC101928947  -1.167635 
SNORD41  -2.061413 RNU6-57P  -1.490772 SNORD104  -1.289459 RP11-400D2.2  -1.16599 
RNVU1-15  -2.059525 SNORD114-16  -1.485214 PLIN3  -1.288176 QSOX1  -1.162317 
SNORD114-13  -2.051996 TAGLN  -1.482171 LOC100507316  -1.285146 MIR1253  -1.157783 
SNORD14C  -1.997306 NPPB  -1.480666 CBR3  -1.281856 GLIPR1  -1.157032 
FGF5  -1.994547 SEC24D  -1.480282 MIR197  -1.279294 TRDJ3  -1.151964 
TGFBI  -1.985938 SNORD45C  -1.47149 PCAT6  -1.277143 RNU6-387P  -1.148672 
SNORD3C  -1.963041 SNORD114-12  -1.469167 RN7SKP185  -1.274226 GCNT1  -1.146185 
CTB-151G24.1  -1.957957 SNORD15B  -1.463465 RNA5SP265  -1.27123 RPS4Y2  -1.143632 
SNORD14B  -1.957166 MIR4290  -1.463122 SNORD1C  -1.27009 LTA4H  -1.142623 
SNORD114-11  -1.926553 PLAUR  -1.459269 RNU6-1286P  -1.269935 PRAMEF2  -1.140896 
218 
 
Gene Symbol Expression Gene Symbol Expression Gene Symbol Expression Gene Symbol Expression 
RNU2-63P  -1.875984 CD68  -1.446662 RP11-897M7.1  -1.269924 SNORD95  -1.14074 
LINC00707  -1.868693 SNORD100  -1.445072 RP11-410L14.2  -1.269278 LINC01314  -1.138541 
SEPW1  -1.866265 RNU6-564P  -1.434174 SNORD57  -1.264677 HSPA6  -1.138181 
RNA5SP465  -1.846296 RNU6-778P  -1.434112 RNA5SP193  -1.264175 MIRLET7A1  -1.134684 
TIMP1  -1.829922 SNORA21  -1.427784 RNU6-60P  -1.263645 GSTA1  -1.133967 
ADAMTS6  -1.815131 MSN  -1.41933 
RP11-
501C14.5  
-1.258491 SNORD15A  -1.133651 
SNORD114-10  -1.796657 SNORA76C  -1.416062 RNU12  -1.257208 MIR4420  -1.131832 
CPA4  -1.761465 SNORD11  -1.41123 PSMB3  -1.251856 SNORD46  -1.13183 
SNORD68  -1.72812 RNU6-986P  -1.408445 MIR1302-6  -1.249674 RNU1-122P  -1.130378 
RNU1-59P  -1.701769 ADAM12  -1.400133 RNU1-46P  -1.249095 MIR29B1  -1.127195 
SNORA24  -1.658283 SNAI2  -1.399514 TRIM55  -1.248619 RNA5SP174  -1.12266 
LCE1F  -1.653459 KRT34  -1.395766 SNORD121A  -1.243922 DPP3  -1.118481 
NDUFA1  -1.117683 RNU6-916P  -1.051538 NCEH1  -1.005179 SH3RF2  -1.02471 
SGK1  -1.117636 BCAS4  -1.050713 MT1L  -1.004677 UQCRB  -1.023579 
MVD  -1.117347 RNU6-102P  -1.050657 RNU7-103P  -1.00413 RNU6-176P  -1.020438 
MT-TA  -1.117114 BIRC2  -1.050645 SNORD101  -1.003045 PPA1  -1.020201 
SNORD21  -1.114064 RN7SKP33  -1.050285 MTRNR2L10  -1.002552 MIR4781  -1.019665 
CTB-140J7.2  -1.11212 NR1D1  -1.049781 WASF3-AS1  -1.002114 MIR520C  -1.019203 
SNORD22  -1.110616 ENPP1  -1.048843 HBG2  -1.001469 GSTP1  -1.019073 
RNU6ATAC11P  -1.104427 C12orf75  -1.046191 TPM4  -1.00108 SNORD81 -1.017243 
DCXR  -1.100228 SEC61G  -1.045251 LMBR1L  -1.000677 IDH1-AS1  -1.017094 
AC006262.4  -1.100128 RNU6-612P  -1.042316 RNU6-1191P  -1.067299 AC124944.3  -1.016199 
CORO1A  -1.0987 SCARNA18  -1.041066 EML1  -1.066192 AC011284.3  -1.015702 
SPRYD3  -1.098458 KRTAP10-5  -1.039706 PRSS50  -1.064648 
RP11-
124N14.3  
-1.015572 
MIR302D  -1.096536 ZNF563  -1.038518 RP1-288L1.4  -1.063974 TMED9  -1.015388 
SUMO1P3  -1.096453 C6orf205  -1.03714 RNF122  -1.062042 CASC22  -1.014826 
AC005324.7  -1.095319 SNORD55  -1.036882 RP11-550C4.6  -1.060734 TMEM158  -1.012336 
MIR4461  -1.094127 SNORD99  -1.033106 BEX1  -1.059926 CST5  -1.012302 
SCARNA9L  -1.093795 TXNIP  -1.030712 SIX4  -1.058897 SCARNA5  -1.012038 
OSTF1  -1.093734 ROMO1  -1.030542 RNA5SP22  -1.058702 GPI  -1.01147 
RNU2-25P  -1.093671 SNORD114-20  -1.030133 ARPC3  -1.057886 LOC101928119  -1.011192 
C4orf48  -1.092101 SNORD35A  -1.029789 CCBE1  -1.054383 TNFRSF21  -1.009372 
P4HA1  -1.09009 ABHD17AP3  -1.029186 RNU4-80P  -1.052953 SDF2L1  -1.00838 
RNA5SP495  -1.089334 IFFO2  -1.029036 VIM-AS1  -1.052454 ZFC3H1  -1.006191 
AC079354.5  -1.087107 RRAS  -1.029031 RNA5SP476  -1.051857 MPP4  -1.005939 
HOMER2  -1.086766 SNORD58C  -1.028742 RNA5SP214  -1.080108 RNA5SP505  -1.07442 
RP11-14I17.2  -1.086715 LOC101928271  -1.026824 BTG2  -1.078784 KRT18P39  -1.072027 
ALMS1P  -1.086406 SNORD45A  -1.026324 CIART  -1.076079 MGC12916  -1.067621 
RNU2-24P  -1.083184 TRBV5-6  -1.081456 RNU6-110P  -1.081668 
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Table 7.5: List of genes that 1 fold up regulated in Nthy-ori 3-1 cells 
following Metformin treatments (0.3 mM) for 6 days. 
Gene Symbol Expression Gene Symbol Expression Gene Symbol Expression Gene Symbol Expression 
C4B  17.1382 RNU6-294P  2.591221 EEF1DP3  1.985241 KCTD16  1.746045 
SNAR-C2  8.260474 AC104135.3  2.589646 PLEKHS1  1.979516 BMP4  1.744037 
PPP1R10  8.143419 ANKRD20A9P  2.583029 OLR1  1.976276 IL18  1.742196 
IER3  7.378793 RNU6-433P  2.573448 NSAP11  1.972319 SPG20OS  1.739636 
PDE4DIP  6.931958 LINC01293  2.569288 RN7SKP103  1.969026 RP11-465N4.4  1.73358 
PTPRQ  6.519714 FTX  2.554234 RN7SKP198  1.964488 RNU6-789P  1.731081 
SNORA38  6.10198 NCOA5  2.521023 CTB-147C13.1  1.958482 RP11-110I1.12  1.720515 
CEACAMP7  5.237918 KCNH1  2.514307 FJX1  1.955495 MIR3189  1.717637 
LINC00963  4.722674 DHRS3  2.511312 SNORA38B  1.946578 ITGB4  1.715645 
PRKXP1  4.617178 DLGAP1-AS2  2.435514 FRY  1.946477 CXCL8  1.715208 
ZBTB12  4.56794 ANKRD30B  2.433121 MT-TL2  1.939348 PDE1A  1.714236 
LOC100132167  4.448485 PPIP5K1  2.416842 RTKN2  1.938739 TAS2R14  1.71316 
LOC100506870  4.094731 RP11-34P13.7  2.408226 FZD1  1.930788 ACKR3  1.710937 
PROS1  3.726661 C7orf69  2.400004 RNU6-1316P  1.923258 IFIT1  1.709172 
PIEZO2  3.724022 AC005392.13  2.387354 PTX3  1.914646 MAMDC2  1.690717 
PLCE1-AS1  3.641091 RNU6-957P  2.3866 MUC1  1.912818 RASEF  1.687939 
LINC01111  3.556213 RASGRP3  2.357029 DKK1  1.909815 LOC285500  1.683698 
DUXAP10  3.555711 CD177P1  2.354582 ZNF451  1.902315 ICAM1  1.681669 
LOC441956  3.5445 C3  2.316679 MIR554  1.900519 
RP11-
314N13.3  
1.681607 
MAT2A  3.511004 MID1IP1-AS1  2.313057 KCNIP1  1.897427 MIR1205  1.675004 
RP11-3L8.3  3.369322 TAS2R46  2.304925 LOC102724425  1.870754 LOC100507477  1.674654 
PDZK1  3.291508 ADAMTS5  2.290615 NUPR1  1.864618 ZBTB2  1.672993 
SNORD62A  3.228056 PSAT1  2.28173 PARD3B  1.864002 CTD-2269F5.1  1.668163 
SSX2B  3.22444 RNU6-530P  2.267139 LOC728339  1.861989 RGS7  1.657907 
JRKL-AS1  3.214572 FAM86EP  2.252485 HIF1A-AS2  1.855248 CTAGE11P  1.655691 
RP11-745L13.2  3.214332 MIR3671  2.232056 LOC100506895  1.849859 RNU6-1255P  1.651551 
CLSTN2  3.20284 SORBS2  2.225418 STOX1  1.842854 VLDLR-AS1  1.648177 
KCNH7  3.179391 MIR181B2  2.215367 RNA5SP346  1.831347 FAM198B  1.645376 
LOC374443  3.161608 ASS1  2.209457 IFI44  1.830416 PDE1C  1.633017 
NEAT1  3.154257 LINC00476  2.206139 ZBTB20  1.827317 NPNT  1.63039 
LOC284344  3.153381 LOC400743  2.204532 LOC100507577  1.824106 RP11-360F5.3  1.629866 
MIR548I2  3.145784 C4A  2.19773 LINC00883  1.823087 RNU6-1147P  1.629023 
SNAR-B2  3.111688 MX1  2.190525 RNU6-1287P  1.814964 DDIT4  1.628775 
SSX1  3.09608 CLDN1  2.098145 HNRNPH1P1  1.813023 RP11-757O6.1  1.627755 
ARHGAP23P1  3.038614 SDHAP2  // LINC00969  2.094141 IFIT3  1.811479 HNRNPA1L2  1.626685 
AC093642.4  3.001863 SMA4  2.090716 MIR181A2HG  1.808694 TOB2P1  1.624983 
ZNF807  2.965392 MIR616  2.086582 LINC00965  1.805758 IFI44L  1.624648 
PROSP  2.947028 SHISA9  2.057963 DDR2  1.803474 HTR1D  1.622015 
GPNMB  2.92643 PRICKLE1  2.056931 C5  1.80135 ADAMTS12  1.618574 
LOC645553  2.92015 ITGB8  2.053967 MIRLET7F1  1.794816 CHAC1  1.61421 
CDKN2B-AS1  2.7412 C4BPB  2.050059 TTC9  1.792215 RP11-70J12.1  1.613685 
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CLDN16  2.726477 COL8A1  2.039397 RP11-551L14.4  1.775679 LINC00328  1.613244 
SLC7A11  2.713641 DRAM1  2.032892 ALPK2  1.772302 NCKAP5  1.612351 
NABP1  2.641271 PTGES  2.031756 DAPK1-IT1  1.76844 ZNF75A  1.610115 
PA2G4P4  2.639227 MCOLN3  2.022122 TMC3  1.767519 PLAU  1.609967 
ARHGAP23  2.622482 MEGF9  2.013654 TMEM178B  1.766052 NPR3  1.609118 
VLDLR-AS1 2.59891 RNU7-80P  2.011094 KRCC1  1.758719 RNU4ATAC18P  1.608476 
FLJ38717  2.595691 IPO5P1  2.01017 LOC729987  1.757916 IL6ST  1.605092 
CTIF  1.000797 MIR421  1.987304 ZNF37BP  1.750578 AC093110.3  1.603878 
PIGL  1.598371 RP11-685N10.1  1.44098 LOC728323  1.357176 RNU6-522P  1.30355 
LINC01239  1.595554 LOC101928565  1.44056 RNU7-187P  1.354375 MIR644A  1.300386 
RP11-154D6.1  1.587637 SMAD2  1.440079 CPA3  1.353976 LOC101929787  1.300114 
ZNF252P  1.587553 MIR4668  1.437956 LOC101928324  1.353589 FAM111B  1.298518 
RPL23AP32  1.585392 RP11-389O22.1  1.43759 LINC01355  1.353542 LOC100288637  1.297532 
SERTAD4  1.58121 KRT80  1.436258 SETBP1  1.352872 DDIT3  1.295563 
LOC100130169  1.580202 RP11-818F20.5  1.436252 E2F8  1.351677 MX2  1.293169 
RBM26-AS1  1.577715 SRGAP1  1.433345 MIR27B  1.350116 ANKRD20A11P  1.291922 
PRSS23  1.563625 NXPH2  1.432957 MEIS3P1  1.347742 ERBB4  1.291726 
LIMCH1  1.563526 IL6  1.428327 ZNF337  1.347141 LOC101929475  1.29141 
VEGFA  1.559916 GS1-600G8.5  1.425364 TSPY2  1.346743 FAM133CP  1.290896 
LOC101927287  1.553069 ZCCHC8  1.424573 FAM66E  1.346103 SCN9A  1.290819 
PPARGC1A  1.547066 KCNMB3  1.42302 TNS3  1.345822 RNF157  1.290665 
BICC1  1.546207 LOC101930275  1.422015 ERCC6  1.345797 AC007879.7  1.290508 
TAS2R20  1.544782 LOC100506929  1.421573 AHR  1.344931 METAP1D  1.289994 
NBPF1  1.544242 HRK  1.420232 RNU6-872P  1.344545 LAMP3  1.289594 
LOC90784  1.542143 NAIP  1.418763 LOC101927184  1.342217 SLC4A2  1.288211 
MIR548H3  1.535778 LOC100129034  1.417076 LOC440028  1.336957 SLC38A1  1.2855 
LOC101928020  1.535777 TRAK2  1.416008 TMEM194B  1.336454 FAM66C  1.285029 
MAL2  1.532748 TRIB3  1.414132 NMNAT2  1.334855 PKD2  1.284717 
PPP3CB-AS1  1.531101 RNU6-215P  1.413309 S1PR1  1.334568 NCOA7  1.284452 
ADAMTS15  1.526897 LMBRD2  1.412615 PDGFB  1.334297 ANKRD1  1.282192 
RNU6ATAC16P  1.524537 NCKAP5-IT1  1.412572 LOC728613  1.329268 LOC101927097  1.280171 
CTNS  1.521223 DSC3  1.410669 ABI3BP  1.329234 DLEU2  1.279964 
TTLL1  1.518174 RN7SKP95  1.410293 LOC101928054  1.328904 PIGM  1.27974 
RP11-807H7.2  1.51753 
LOC101928706  // 
LOC101929823  
1.409177 LINC01004  1.328859 TMSB4X  1.276145 
LOC340581  1.515399 EPSTI1  1.40632 GS1-124K5.2  1.3268 BRWD3  1.276118 
GEN1  1.514843 IRS1  1.403744 NAV2  1.322888 GCSHP3  1.275784 
PARP14  1.51052 MKRN9P  1.401434 ZNF66  1.322301 
RP11-
152P17.2  
1.2734 
TIMP3  1.510448 LOC100130691  1.393899 RNU6-82P  1.321761 LOC100129518  1.271978 
SRSF6  1.508137 FAM13B  1.393436 MIR570  1.320256 LOC284581  1.271737 
SLC16A6P1  1.503976 RNU6-302P  1.392839 LINC00886  1.319909 MIR3621  1.271113 
RP3-368A4.5  1.503508 SECTM1  1.386099 TNFRSF11B  1.319753 PSMD5-AS1  1.270698 
GAS5-AS1  1.502007 RP11-585F1.10  1.38016 DPY19L3  1.319454 CLEC2D  1.270614 
221 
 
Gene Symbol Expression Gene Symbol Expression Gene Symbol Expression Gene Symbol Expression 
LOC102724851  1.498241 AJUBA  1.379192 CDC42EP3  1.31871 BRCC3  1.268692 
DAPK1  1.496929 EPAS1  1.378037 MYLIP  1.317689 PRKAA2  1.267353 
DNAJC6  1.490659 RNU6-998P  1.377231 METTL7A  1.31665 RP11-49O14.2  1.26733 
HERC2P9  1.490397 RP4-791M13.3  1.375516 TYRP1  1.314589 STON2  1.259321 
NOV  1.486634 LOC100289455  1.375117 PTK2B  1.314278 UAP1L1  1.256256 
SLC35F6  1.486548 ANK2  1.374528 CIRBP  1.31413 RNA5SP355  1.255741 
LOC102724077  1.483174 AC009229.5  1.372961 RNU6-697P  1.312449 IGFBP3  1.255272 
AC099850.1  1.47714 TPCN1  1.372098 SLC43A3  1.311266 GPC6  1.25525 
AC002117.1  1.458931 DDX58  1.371331 RASSF3  1.309805 LINC00342  1.253275 
RNU6-1284P  1.454859 BCL2  1.369705 AP000704.5  1.308858 RPS6KA5  1.253262 
WISP2  1.451802 CLGN  1.364957 SLC16A1-AS1  1.307473 RNU6-316P  1.251013 
KCNJ2-AS1  1.450935 ZSCAN16  1.363844 SLC35A5  1.306221 PKP2  1.248811 
RP11-436H11.5  1.449994 AP001059.5  1.361519 LOC100294341  1.305715 TAS2R31  1.247655 
ULBP1  1.447452 RP11-692D12.1  1.36037 ANKRD20A5P  1.305117 CABLES1  1.247532 
PTPN21  1.445818 LOC100653515  1.359744 KIF24  1.303892 ZNF620  1.245263 
RP4-657D16.3  1.24426 SRSF1  1.188428 RNU4ATAC16P  1.147163 SNORD114-18  1.108048 
RNU6-1162P  1.241597 PTGIS  1.187631 MTSS1L  1.144627 CCDC30  1.107174 
RNU6-206P  1.241238 LOC100131826  1.18735 HAVCR1P1  1.144284 RP11-94I2.1  1.105633 
ABLIM1  1.240065 MIR573  1.186534 LINC00969  1.144153 CHST15  1.105242 
ZNF658  1.239775 MIR454  1.185638 DSCC1  1.143246 FOXE1  1.103903 
ZNF385B  1.238092 ANKRD36BP2  1.183821 RP6-206I17.1  1.141838 AC138035.1  1.103577 
RASGRF1  1.236543 RP11-123O10.4  1.18367 CCDC125  1.14092 POLR3B  1.103326 
NALCN  1.236464 RNU7-182P  1.183381 SGPL1  1.140486 TMEM67  1.103295 
LINC01285  1.235605 SLC29A2  1.18216 ADAL  1.140351 RNU6-466P  1.102967 
ZNF473  1.23508 RP11-1166P10.1  1.178751 ADAM1A  1.140267 RRAGD  1.101206 
AC017002.2  1.234908 POLR3C  1.177247 LCMT2  1.138523 MGC27345  1.100245 
LOC101929287  1.234455 HSF2BP  1.177016 RAPGEF1  1.137723 
RP11-
522M21.3  
1.099854 
LOC441454  1.234383 CHAC2  1.17627 TCEAL3-AS1  1.137535 FLJ43681  1.099529 
MTMR8  1.232008 IFIT2  1.176171 LOC101929964  1.137321 RP11-274J7.2  1.099336 
TIGD2  1.231396 LOC102723919  1.174772 CTC-325J23.3  1.137082 FUS  1.095798 
RP5-1050D4.2  1.228234 ZDHHC21  1.174542 RNA5SP37  1.136595 GBAP1  1.095666 
WBP4  1.227558 SERPINB9  1.173427 GNB5  1.136213 MIR4659A  1.095269 
PDGFC  1.227168 STC2  1.173369 UCP2  1.136148 CEP128  1.095195 
SLC1A4  1.223744 CARF  1.17267 TRAPPC2  1.135638 AP3M2  1.093371 
ARNT2  1.222963 SH3YL1  1.172056 RNU7-62P  1.133752 TBL1XR1  1.093213 
LOC100132705  1.222601 SLC38A4  1.170982 MIR4258  1.132806 ARHGEF2  1.091631 
ZC3H12B  1.22035 LOC100288842  1.170683 BACH1-IT2  1.131931 SNORD18B  1.090821 
RP11-50E11.3  1.219928 RRN3P3  1.170477 PSG9  1.130682 SLC16A7  1.090624 
SORL1  1.219495 ERCC6L2  1.166397 FOXRED2  1.130378 LOC101929464  1.090259 
RNU6-1045P  1.218309 C9orf64  1.166303 RNF144B  1.129961 USP40  1.089867 
ZC3HAV1  1.216662 PTN  1.164695 CLCN7  1.128654 FRMD4A  1.088945 
POGLUT1  1.215986 LOC102723672  1.162983 
RP11-
283C24.1  
1.128624 CTC1  1.088372 
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FNDC1  1.213659 PCBD2  1.162312 ZNF230  1.128476 UGCG  1.088124 
LOC100131802  1.212476 CREG1  1.16118 RAD51D  1.125235 MAP3K14  1.087469 
FRMPD4  1.21002 LRCH3  1.159974 LURAP1L  1.125081 SLC35E2  1.086693 
ITFG2  1.206646 EIF5  1.159705 TRIOBP  1.125065 MIR4295  1.086574 
AC159540.1  1.206089 RNU6-606P  1.158293 SLC6A9  1.123094 FAM106CP  1.085609 
IFI6  1.205403 SEMA3A  1.15753 LOC101927841  1.122726 
CTD-
2116N20.1  
1.084531 
FAM49A  1.201638 VDR  1.157512 BST2  1.121072 RP1-239B22.5  1.084103 
PATZ1  1.200338 RNU6-817P  1.157008 LOC653513  1.119441 LPAR4  1.083757 
KLHL42  1.198931 RN7SKP56  1.155846 EYA4  1.117332 KGFLP1  1.083365 
bP-21201H5.1  1.197715 C22orf46  1.155585 CYP4F35P  1.116906 IGFN1  1.083183 
PLEKHG7  1.19703 COG2  1.155445 RNU6-834P  1.116729 TNFAIP2  1.082978 
RP1-313L4.3  1.195673 LOC102725076  1.154587 SLC27A2  1.116193 MEPCE  1.081599 
FHDC1  1.195167 GREB1L  1.153339 ZC3H12C  1.116089 SLC30A6  1.081109 
RNU4-31P  1.195081 DAGLA  1.152792 HEXIM1  1.114872 SPPL2A  1.080276 
GOLGA1  1.194451 SAMD9L  1.15258 LINC00882  1.114782 LYPD6B  1.079471 
IFIH1  1.192943 LRRC8D  1.151838 GLYR1  1.113724 AC017006.2  1.079367 
RP11-435D7.3  1.191314 MIR645  1.151708 TOE1  1.113663 MIR924  1.079 
ZBED3  1.190627 CLMN  1.150778 ZNF829  1.112881 RN7SKP173  1.07866 
B3GALT6  1.190101 TSPAN2  1.150647 LOC101927506  1.112068 LPA  1.07812 
CITED2  1.189508 TSTD2  1.149533 TMEM52B  1.111751 MYO1B  1.077404 
RP5-864K19.4  1.189368 DGCR8  1.148644 
RP11-
385D13.1  
1.111404 DENND2A  1.077358 
ZNF572  1.188757 RNU6-890P  1.147317 TRAM2  1.110926 CYP20A1  1.077031 
NUAK1  1.077012 LINC00472  1.054031 PARP12  1.026287 XRCC2  1.055714 
RNU6-1163P  1.076513 LOC101928173  1.05343 MTHFD1  1.025802 TRPM7  1.055625 
BRCA2  1.075807 C2CD3  1.052163 ZFX  1.025542 RNA5SP511  1.055171 
LINC01123  1.075339 OPN3  1.051686 ANKRD36B  1.024849 MIR548V  1.054068 
EGFR  1.074873 ING3  1.051417 GAS6-AS2  1.024457 ETS2  1.029904 
TMEM220  1.074837 ZDHHC15  1.05035 EXPH5  1.024438 CCL2  1.029158 
SLC7A1  1.074488 ARHGEF39  1.050243 KMO  1.023208 ADM  1.029051 
RP11-101E14.3  1.074461 SNAR-H  1.050102 EPHA5-AS1  1.023117 ZNF250  1.027561 
LOC284926  1.074127 EDN1  1.050019 STX11  1.022692 ZSWIM7  1.056776 
RP11-33B1.3  1.073511 RP1-102E24.8  1.049861 PSPH  1.022481 LINC00152  1.056563 
HELQ  1.072892 DCLK2  1.049802 LINC-PINT  1.022048 GPX3  1.05611 
ELAVL2  1.071984 MYO16-AS1  1.049683 CBS  1.021246 FBXO28  1.055935 
DOLK  1.071815 CYTH3  1.048133 LOC101927978  1.021055 PTS  1.055918 
RNU6-895P  1.069716 PSPC1  1.047847 TAF15  1.020676 MT1E  1.032474 
FAM86MP  1.069264 NOTCH2NL  1.046593 KIAA1217  1.020653 PHF14  1.032414 
RN7SKP88  1.068616 HIST1H4H  1.045594 TAS2R50  1.019401 
RP11-
398K22.12  
1.031467 
ZNF770  1.068417 NEAT1  // MIR612  1.044994 FAM122A  1.019392 SLC22A5  1.031289 
LOC100133315  1.06826 DVL3  1.044985 SNORA10  1.019245 DLGAP1-AS1  1.030452 
GUSBP1  // 1.067155 RNU4-9P  1.044216 CSRP2BP  1.018788 FAT3  1.00514 
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LOC100996497  
TBX20  1.066464 LOC101927533  1.043809 LINC00240  1.017978 HNRNPA0  1.004366 
RP11-417O11.5  1.066286 MBTD1  1.040547 RNU6-971P  1.016805 RNU6-301P  1.003262 
LOC553103  1.066102 SDCBP2-AS1  1.040532 
RP11-
344N10.5  
1.016626 URB2  1.002368 
VEZF1  1.065327 KIAA1614-AS1  1.039552 MIR4298  1.01541 ST7L  1.001178 
VGLL3  1.064534 SECISBP2  1.039178 TGFB2-AS1  1.015181 KAT2B  1.007396 
TAS2R13  1.063851 MIR761  1.03894 RNU6-1102P  1.014535 OCLN  1.007071 
ZNF782  1.063725 SLC16A13  1.038719 POLR1A  1.013486 CLIP4  1.006042 
QPRT  1.063629 SQSTM1  1.038667 CYP1B1  1.013136 RNU6-968P  1.034024 
RNU6-1263P  1.061946 MGC70870  1.038267 RNU6ATAC18P  1.012234 RNU6-1223P  1.033789 
LTBP1  1.061865 ZNF45  1.037896 SASH1  1.011566 RNU6-1029P  1.03366 
LOC283140  // 
LOC100506870  
1.061848 DUSP1  1.037756 CREBBP  1.011503 
RP11-
798M19.3  
1.058282 
DNMT3B  1.061358 RP11-773D16.1  1.037567 
RP11-
107M16.2  
1.010346 DSE  1.057635 
C1orf220  1.060775 HLA-B  1.03721 LPP-AS2  1.009355 LOC101927116  1.0574 
AMIGO2  1.060662 RNU6-954P  1.036963 ECM2  1.009253 SLC7A5  1.05874 
RNU4-36P  1.06037 GLRB  1.03599 LOC100506325  1.008527 RNU6-923P  1.034229 
RNA5SP283  1.059605 CPVL  1.035675 PLSCR1  1.008422 RNA5SP444  1.007597 
RP4-
633O19__A.1  
1.058824 MIR33B  1.035533 RNU6-220P  1.007692 
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Table 7.6: List of genes that 1 fold down regulated in FTC-133 cells 
following Metformin treatments (0.3 mM) for 6 days. 
Gene Symbol Expression Gene Symbol Expression Gene Symbol Expression 
SNORD99  -3.138417 TUFT1  -1.494788 RN7SKP160  -1.15334 
SNORA66  -2.819541 ATP6V0B  -1.48684 UCK2  -1.127401 
DUSP5  -2.722006 RGS2  -1.486511 MIR3671  -1.125274 
SNORD75  -2.721084 NAMPT  -1.48637 RP11-384C4.7  -1.123829 
SNORD103A  -2.64968 SLC19A2  -1.392155 NRBF2  -1.123661 
RNU6-773P  -2.567926 PFDN2  -1.391322 ENO1  -1.121763 
SNHG12  -2.34524 SNORA55  -1.385548 SCARNA1  -1.112795 
HMGN2  -2.241845 OTUD1  -1.328859 PPP1R15B  -1.109595 
CIART  -2.200218 G0S2  -1.293682 FAM129A  -1.098725 
MIR554  -2.149709 RNU6-753P  -1.286647 RNU6-693P  -1.098367 
GAS5  -2.142077 DYRK3  -1.283458 THAP3  -1.097863 
SNORA14B  -1.933805 OR2L3  -1.27309 RNU6ATAC27P  -1.09637 
RPS27  -1.911409 ZBTB18  -1.268312 RNU6-885P  -1.093934 
ATF3  -1.906255 TIMM23B  -1.256248 RAD54L  -1.09338 
KCNH1-IT1  -1.87971 RNU7-45P  -1.231558 OCLM  -1.076606 
IL24  -1.854969 RNU6-946P  -1.215508 TOMM20  -1.076182 
MIR1278  -1.7632 RPL21P28  -1.211071 SRGAP2  -1.064688 
RNU11  -1.760812 MEF2D  -1.204484 NEK2  -1.058935 
GNG5  -1.744586 RNU6-805P  -1.202467 RNU4-61P  -1.053955 
NBPF20  -1.737692 RNU6-1067P  -1.202275 CKS1B  -1.052173 
HKDC1  -1.70373 GADD45A  -1.201438 NUAK2  -1.051206 
RPS24  -1.68706 RNU7-70P  -1.194104 PHGDH  -1.047373 
ARL5B  -1.681324 YRDC  -1.188103 RNU6-1274P  -1.043247 
MIR4742  -1.65024 PLK3  -1.182211 CDK1  -1.041123 
LOC284561  -1.621344 RNA5SP45  -1.181792 PRAMEF11  -1.036984 
MIR3115  -1.547067 SLC22A15  -1.176196 FAM72C  -1.015477 
RP11-545I10.2  -1.538732 RP11-275I14.4  -1.175123 EMBP1  -1.002409 
RABGGTB  -1.495314 NGF  -1.161649 RP11-295G20.2  -1.001638 
 
Table 7.7: List of genes that 1 fold up regulated in FTC-133 cells 
following Metformin treatments (0.3 mM) for 6 days. 
Gene Symbol Expression Gene Symbol Expression Gene Symbol Expression 
SLC18A3  2.914271 EPHX4  1.325457 WBP1L  1.135208 
SERTAD4  2.912107 C10orf25  1.318821 ROR1  1.132694 
DIO1  2.60728 IFIT5  1.312251 IPO13  1.128392 
RP4-791M13.3  2.410873 ACADM  1.308962 LOC100133331  1.12656 
LINC01037  2.3793 LCE1A  1.302852 ST8SIA6  1.123277 
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Gene Symbol Expression Gene Symbol Expression Gene Symbol Expression 
LOC102723919  2.288908 ACP6  1.296792 THEM4  1.12133 
HIST2H4B  2.23496 PEX11B  1.295167 UBE4B  1.11957 
IKBKE  2.166837 NBPF1  1.292538 ABCB10  1.118556 
PARS2  2.159519 LINC01139  1.285893 MAB21L3  1.112222 
BICC1  2.056973 INTS3  1.284189 PIGM  1.104949 
LRRC39  2.001026 PIK3R3  1.272465 DNAJC16  1.103066 
RNU5E-4P  1.904593 CCDC18  1.263084 GNAI3  1.101555 
SLC25A44  1.76949 RP5-1061H20.4  1.260614 LOC729970  1.100031 
RP11-148B18.4  1.747115 NBPF25P  1.258747 MAN1A2  1.086991 
PTPRE 7 1.704732 TOE1  1.251928 FBXO28  1.083433 
LOC101927435  1.703138 HMCN1  1.249894 TET1  1.079681 
C1orf220  1.694529 RNU7-165P  1.248054 SYT11  1.078852 
CPT2  1.659833 RP11-284F21.7  1.243934 RNVU1-19  1.078367 
EIF4EBP2  1.629283 MR1  1.237218 RNU1-122P  1.076841 
ST6GALNAC5  1.627499 STPG1  1.230525 TCEANC2  1.076051 
RAB4A  1.626263 ZMYND11  1.225645 FAM213B  1.074924 
AGL  1.623054 MTFR1L  1.222258 TSPAN14  1.073806 
ASPM  1.607022 CACHD1  1.219443 SCYL3  1.071649 
PER3  1.587773 RGL1  1.21664 SDHC  1.069283 
PMVK  1.58397 NPPA-AS1  1.20978 SLC16A1-AS1  1.065338 
SLC35E2  1.554891 BTRC  1.206915 RAB29  1.064365 
FAM231D  1.5356 GS1-174L6.4  1.201096 BCL10  1.063442 
BTBD8  1.530597 FMO4  1.190572 NFYC-AS1  1.047256 
COG2  1.513195 ZNF22  1.184752 FAM63A  1.045453 
LOC102724425  1.512033 ZNF691  1.17977 LOC642361  1.044005 
NSL1  1.507203 ARV1  1.179298 MIR4677  1.043843 
CASC10  1.495583 ZNF248  1.172855 KAT6B  1.04286 
EDEM3  1.494628 LOC100287497  1.172272 ZMYM4  1.038411 
S1PR1  1.486556 SKIDA1  1.168877 RP11-80B9.1  1.034924 
FMN2  1.438571 TRMT1L  1.168654 LINC00702  1.031723 
ACOT11  1.435883 IPP  1.168561 DLEU2L  1.031639 
LRIF1  1.432328 STOX1  1.166804 PRUNE  1.027419 
KLHL20  1.429742 HTRA1  1.166512 PAFAH2  1.025468 
FLG-AS1  1.424351 SYNC  1.166014 LDLRAP1  1.014443 
ZFP69B  1.419879 CDKN2C  1.163997 PRTFDC1  1.013846 
CDC14A  1.403379 KCNT2  1.156313 FAM178A  1.013687 
KIAA1107  1.394029 MIR4480  1.155348 RCAN3  1.006583 
DNAJC11  1.38977 SPAG17  1.153368 TBX15  1.005901 
PHTF1  1.38927 RAB42  1.152434 ACADSB  1.00337 
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TAF1A-AS1  1.386637 RP11-815M8.1  1.151448 INPP5A  1.002899 
ABCD3  1.372124 NMNAT2  1.148806 TARS2  1.001082 
TSPAN2  1.365549 C1orf233  1.144269 MTHFR  1.000777 
DNM3  1.348495 THNSL1  1.140079 
  CFH  1.330521 ZNF436  1.138494 
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Table 7.8: List of genes that 1 fold down regulated in K1E7 cells 
following Metformin treatments (0.3 mM) for 6 days. 
Gene Symbol Expression Gene Symbol Expression Gene Symbol Expression Gene Symbol Expression 
SNORD115-5  -16.309266 RNU6-1072P  -3.282342 MIR574  -2.812188 SNORA6  -2.556597 
LOC100272216  -15.106969 SNORD41  -3.268312 RNU6-1095P  -2.802889 MIR4481  -2.556056 
SNORD32B  -9.661779 SNORD17  -3.266657 RNA5SP415  -2.785281 RNU6ATAC27P  -2.554632 
SNORA38  -9.284843 SNORA36B  -3.255055 RNU6-1167P  -2.780826 RNU6-487P  -2.537045 
SNORD117  -8.509836 RNU1-14P  -3.241755 RNU1-138P  -2.777218 SNORD116-1  -2.526007 
HSPA1A  -7.513288 RNU5D-1  -3.241036 SNORD115-1  -2.770826 RNU6-702P  -2.521976 
TAF1D  // 
SNORA8 -7.095325 MIR1185-2  -3.235616 SNORA71D  -2.767418 RNU6-739P  -2.50272 
SNORD52  -6.96934 SNORA54  -3.223583 RNA5SP176  -2.765666 RNU5F-2P  -2.502156 
SNORD48  -6.498743 ZNF474  -3.197887 RNA5SP87  -2.76331 SNORD84  -2.493576 
SNORD116-3  -6.014839 SNORD14C  -3.197487 RNU6-804P  -2.752915 SNORD24  -2.481144 
RNU1-13P  -5.679428 RNU1-42P  -3.159696 HIST1H4B  -2.745049 SNORD115-47  -2.475927 
RNU6-540P  -5.348021 RNU1-32P  -3.150842 MIR514A1  -2.742492 SNORD83A  -2.474204 
HSPA1B  -5.207419 SNORA61  -3.14295 SNORD100  -2.740214 RNU6-279P  -2.46995 
ANKRD20A11P  -5.111095 
SNORD81  // 
SNORD79 -3.133315 RNU6-572P  -2.740106 RNU6-60P  -2.468641 
SAPCD1  -4.796992 SCARNA7  -3.109645 SCARNA10  -2.739802 SNORD94  -2.468167 
RNU1-38P  -4.796858 PTMA  -3.097041 RNA5SP455  -2.733891 SNORA21  -2.467629 
MIR933  -4.627214 SNORD115-4  -3.070124 SNORA52  -2.727871 RP13-401N8.1  -2.466919 
SNORD3B-1  -4.53475 MICA  -3.067721 MYH16  -2.727384 SNORD58C  -2.465 
SNORA72  -4.40927 SNORA37  -3.062438 DDR1-AS1  -2.722995 SNORD9  -2.46127 
SNORA60  -4.360123 SNORD92  -3.057987 SNORD103A  -2.722838 RNA5SP132  -2.459834 
SNORA75  -4.358876 SCARNA4  -3.03576 RNU6-560P  -2.718242 RNA5SP28  -2.453412 
RNU1-41P  -4.32181 HIST1H2BG  -3.031223 RNU6-580P  -2.714142 MIR548A1  -2.450984 
RNA5SP221  -4.303338 RNU6-294P  -3.022542 ROCK1P1  -2.71103 MT-TA  -2.43403 
LOC102724689  -4.299147 RNU11  -3.019247 RNU6-151P  -2.710437 SPANXA1  -2.430698 
SNORD116-5  -4.181892 RNA5SP90  -3.01892 SNORA11  -2.707471 TRAJ59  -2.428491 
MIR4650-1  -4.034786 RNU6-816P  -3.014013 MIR4673  -2.69465 RNU6-471P  -2.425134 
SNORA1  -4.003489 SNAR-C2  -3.013218 RNU1-136P  -2.673831 HLA-DQB1-AS1  -2.418987 
MIR3156-2  -4.002237 RNA5SP106  -3.007132 RNA5SP478  -2.669549 RNU6-412P  -2.41486 
SNORA59B  -3.920698 RNU6-363P  -3.003897 MIR4461  -2.666637 SNORA7B  -2.408545 
SNORA14B  -3.893102 ABHD17A  -3.002514 KSR2  -2.6537 RNU6-971P  -2.404938 
RNU6-407P  -3.871328 RNU4-8P  -2.988792 SCARNA8  -2.65233 RNA5SP399  -2.385912 
RNU5E-4P  -3.861107 SNORA46  -2.980917 SCARNA11  -2.651717 SNORA15  -2.38209 
RNVU1-15  -3.835796 RNA5SP116  -2.980795 RNU6-801P  -2.643595 RNA5SP432  -2.381482 
SNORD115-17  -3.803325 RNU5F-1  -2.975267 RNU6-1067P  -2.642413 LOC388692  -2.370153 
RNU6-271P  -3.735883 SCARNA17  -2.933124 MT-TS1  -2.642356 SNORA80E  -2.368253 
RASA4  -3.648009 RN7SK  -2.92742 RNU6-392P  -2.632402 RNU1-143P  -2.360234 
SNORA71B  -3.64304 SNORA20  -2.922946 SNORA76C  -2.625838 SNORA57  -2.357718 
SNORA33  -3.628663 RNU6-1257P  -2.90714 MIR3156-1  -2.624937 SNORD60  -2.354844 
RNA5SP361  -3.622943 SNORA11D  -2.887514 SCARNA9  -2.619746 SNORD104  -2.35343 
SNORD116-2  -3.602833 HIST1H2BH  -2.883166 RNU6-1005P  -2.612075 SNORA45B  -2.351086 
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RNA5SP199  -3.536739 RNU6ATAC2P  -2.873024 RNU6-1112P  -2.611464 RN7SKP173  -2.346026 
RNU6-1295P  -3.483577 SCARNA6  -2.87094 SCARNA5  -2.611094 SLC25A3  -2.34435 
RNU1-95P  -3.45923 RNU6ATAC  -2.86167 SNORA38B  -2.606791 RNU1-83P  -2.339703 
RNA5SP233  -3.426408 RNA5SP265  -2.850359 RNU6-431P  -2.60088 RNA5SP473  -2.339101 
RNA5SP100  -3.422696 RNU6ATAC10P  -2.847578 SNORA26  -2.58933 RNU6-371P  -2.318944 
RNA5SP390  -3.400606 SCARNA3  -2.847194 RNU6-159P  -2.586944 HCG27  -2.310892 
RNA5SP150  -3.383379 SNORD3C  -2.84445 RNA5SP234  -2.57822 RNU6-925P  -2.309352 
MIR328  -3.351308 RNU6-353P  -2.842194 RNU1-46P  -2.573426 SNORD116-13  -2.304643 
SNORD14E  -3.332556 RPS3A  -2.83085 RNU5B-1  -2.572817 RNU1-119P  -2.303358 
RNA5SP368  -2.298712 SNORD15A  -2.128625 RPPH1  -1.946808 RNA5SP295  -1.837402 
RNU1-18P  -2.294431 VTRNA2-1  -2.127092 SNORA67  -1.944677 RNU6-981P  -1.83449 
RNU6ATAC23P  -2.283364 SNORD123  -2.122878 SNORA17  -1.944532 LOC100133050  -1.834378 
LOC101926975  -2.282944 RNU6-1270P  -2.113297 SNORD11  -1.944171 RNA5SP484  -1.832296 
RNA5SP99  -2.275895 RNU4-80P  -2.100296 SNORD45C  -1.94385 RN7SKP37  -1.831333 
SCARNA9L  -2.269301 RNU6-1010P  -2.098603 RNA5SP195  -1.938964 RNU1-56P  -1.827755 
RNU6-1071P  -2.265162 SNORD12  -2.096778 RNU6-317P  -1.935518 RNU1-63P  -1.825954 
MIR934  -2.26459 SNORD57  -2.096214 MIR4740  -1.934637 RNA5SP282  -1.820687 
SNORA36C  -2.260952 SNORA24  -2.085881 AC004070.1  -1.934028 RNA5SP388  -1.819342 
RNU4ATAC15P  -2.256292 SNORD38A  -2.081733 SNORA5C  -1.933919 RP1-32B1.4  -1.811797 
RNU6-1080P  -2.255347 HERC2  -2.079987 MT-TW  -1.929517 RNU6-732P  -1.808263 
RNU6-1230P  -2.252197 SNORD14A  -2.075876 SNORD58A  -1.927008 MT-TP  -1.80595 
SNORA41  -2.249595 RNA5SP85  -2.075766 SNORD45B  -1.923262 SCARNA18  -1.805803 
RNU6-893P  -2.244721 RNU5E-9P  -2.072398 KRTAP6-2  -1.92287 RNA5SP119  -1.803166 
DKC1  -2.24359 RNU6-933P  -2.066228 SCARNA20  -1.922358 RNA5SP363  -1.802836 
RNU5A-8P  -2.241657 RNU1-62P  -2.064661 SNORD119  -1.92191 RNU6-959P  -1.801375 
SNORD14B  -2.23937 RNU6-1227P  -2.057292 RNU6-544P  -1.918849 RNA5SP441  -1.800967 
RNU6-760P  -2.239142 FCGR1C  -2.033002 RNA5SP188  -1.91703 LINC00616  -1.800464 
RNU6-223P  -2.23589 SCARNA22  -2.031877 MIR1321  -1.913079 SNORD1B  -1.800157 
SNORA32  -2.231905 RNA5SP88  -2.021019 SNORA4  -1.912519 SNORD36C  -1.798092 
RNU1-122P  -2.217655 LOC439994  -2.018923 HIST1H3H  -1.912025 RP11-363G2.4  -1.796242 
SNORD116-21  -2.208704 RNU6-1181P  -2.018403 SNORD91B  -1.909351 HIST1H4D  -1.795959 
RNU6ATAC28P  -2.208457 RNU6-1293P  -2.011114 RNU4-26P  -1.906635 RNU6-613P  -1.794056 
MIR2861  -2.200948 RNA5SP405  -2.00633 SNORD35A  -1.905245 RNA5SP54  -1.794046 
SNORA9  -2.197746 RNA5SP264  -2.006043 RNA5SP46  -1.905056 RP11-146D12.2  -1.794024 
RNU6-906P  -2.197278 RNA5SP51  -2.004032 RNU6-1031P  -1.904337 RNU6-684P  -1.790579 
MIR3975  -2.195479 RNU6-200P  -2.003848 RNU6-178P  -1.902775 SNORD115-45  -1.790301 
SNORD115-44  -2.190598 RNA5SP428  -2.000271 RNA5SP403  -1.8989 RNA5SP262  -1.785159 
RNU6-1286P  -2.188832 RNU6-59P  -1.999345 RNU1-16P  -1.896598 RNA5SP156  -1.782644 
SNORA65  -2.180797 SNORD102  -1.998049 SNORA36A  -1.895575 SNORD70  -1.78187 
MXD1  -2.180071 SNORA74B  -1.996461 RP11-232D9.2  -1.884806 RNU6-1058P  -1.781547 
RNU6-930P  -2.175602 RNU6-1289P  -1.979633 RNU6ATAC25P  -1.883359 RNU4-61P  -1.781177 
RNU1-40P  -2.170926 SNORA5A  -1.976612 SNORD4A  -1.88227 RNU6-1122P  -1.778243 
SCARNA2  -2.168486 SCARNA21  -1.975441 LOC101928102  -1.880779 LINC01154  -1.777961 
SNORD21  -2.167341 RNU6-213P  -1.975388 SNORA80A  -1.875736 SNORD80  -1.764386 
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SNORD111  -2.161571 SNORD83B  -1.971923 RNA5SP86  -1.87495 SNORA51  -1.762644 
RNU1-86P  -2.159854 SNORA14A  -1.970671 SNORA47  -1.874449 LPA  -1.760009 
SNORD67  -2.153906 SNORD11B  -1.970083 RNA5SP419  -1.873979 TRAJ23  -1.759962 
RNVU1-3  -2.152492 RNU6-876P  -1.969062 MIR520C  -1.873021 RNU6-524P  -1.759008 
RNU4-7P  -2.152265 MIR1185-1  -1.968936 RNU6-179P  -1.870824 RP11-436M15.3  -1.757691 
RNU6-266P  -2.150576 RNU6-65P  -1.967313 RNU6-219P  -1.86278 SCARNA23  -1.753972 
RNU6-878P  -2.150275 SNORA2A  -1.962677 RNA5SP183  -1.860075 RNU1-44P  -1.751182 
SNORA25  -2.148306 SNORD38B  -1.961139 SNORD115-25  -1.860027 RP11-384C4.2  -1.751052 
SNORD59A  -2.146387 SNORD6  -1.956828 SNORD116-29  -1.85904 RNU6-986P  -1.749525 
RNU6-1288P  -2.142437 TERC  -1.956213 SNORD74  -1.852386 RNU1-7P  -1.749484 
RNA5SP129  -2.141479 RNU6-444P  -1.95587 RNA5SP471  -1.852178 RNU4ATAC  -1.74758 
RNU4ATAC12P  -2.135352 SNORA12  -1.95074 SNORA71C  -1.851086 RNU6-650P  -1.747298 
AC008694.3  -2.132194 RNU6-646P  -1.949713 RNA5SP172  -1.850653 RNU6-952P  -1.746967 
SNORA10  -2.128812 RNU6ATAC3P  -1.947002 RNU1-74P  -1.84285 SPANXC  -1.745337 
MIR4668  -1.745319 MIR4287  -1.654832 SNORD124  -1.592247 RPS4Y2  -1.537847 
RNU6-1105P  -1.73486 SNORD71  -1.65438 RNU6-645P  -1.590186 RNU6-249P  -1.537681 
RNU6-28P  -1.732488 RNU6-428P  -1.653494 RNU6-669P  -1.58926 SNHG8  -1.536176 
MIR520B  -1.728716 TM4SF1  -1.651839 MIR4420  -1.589146 SNORA18  -1.535553 
RNA5SP300  -1.728043 RNA5SP215  -1.647872 SNORD35B  -1.589123 RNU7-133P  -1.534627 
RNU6-899P  -1.727855 RN7SKP123  -1.647067 RN7SKP1  -1.588341 TCEB3CL2  -1.534605 
RNU6-1127P  -1.727765 RNU6-295P  -1.645547 RN7SKP118  -1.587931 MIR548AD  -1.5322 
CTD-2340D6.2  -1.727161 DRD4  -1.645524 SNORD32A  -1.586824 RNU6-1123P  -1.531933 
LINC00343  -1.725998 OR6P1  -1.644748 MIR4694  -1.583608 SNORD8  -1.52932 
RP11-
261C10.1  -1.724787 SNORD116-20  -1.642067 TRBV4-2  -1.583042 AP000459.7  -1.527184 
HMGA1P4  -1.72122 AC073094.4  -1.640226 IGKJ5  -1.578056 MTRNR2L4  -1.526437 
MIRLET7A2  -1.718426 RNU6-497P  -1.637396 LOC101059948  -1.576825 ATHL1  -1.526266 
RP11-
719N22.1  -1.718273 SNORD88A  -1.634531 RNU6-722P  -1.57456 KRTAP5-9  -1.525133 
RNU6-632P  -1.715534 SNORD88C  -1.633195 PRAMEF11  -1.573027 RNA5SP380  -1.524708 
MIR514B  -1.714329 SNORD116-30  -1.629164 MND1  -1.569824 RNU12  -1.523706 
CACNA1C-AS2  -1.712641 SNORD2  -1.62846 RNU6-415P  -1.568759 RP11-61A14.1  -1.52339 
RN7SKP203  -1.707453 MIR519A1  -1.627665 RNU6-754P  -1.566849 SNORD116-23  -1.522815 
SNORD26  -1.70678 RNU6-176P  -1.627187 SNORD115-27  -1.566111 HMGCS1  -1.521286 
FGF5  -1.704957 RN7SKP230  -1.627104 SNORD116-14  -1.565756 SNHG19  -1.520681 
RNU6-753P  -1.703753 RNU6-425P  -1.62341 RNA5SP298  -1.564891 RNA5SP459  -1.520107 
RNA5SP19  -1.701584 RN7SKP168  -1.622885 SNORD59B  -1.563351 OR4N5  -1.518233 
SNORA23  -1.700459 RNU6-1335P  -1.622372 CASC9  -1.562576 RNA5SP425  -1.515777 
RNU6-321P  -1.69983 SNORA22  -1.621854 MIR519A2  -1.561094 SNORD53  -1.515103 
FUNDC2P2  -1.699225 TPT1  -1.62056 RN7SKP74  -1.560575 AC092675.4  -1.513919 
RNU6ATAC9P  -1.696918 RN7SKP66  -1.620093 KB-1615E4.3  -1.560134 MIR29B1  -1.513545 
SNORD126  -1.692831 RNU6-1153P  -1.618289 SNORD97  -1.55619 LINC00395  -1.511028 
LOC284632  -1.691533 RNU6-1214P  -1.613901 RNA5SP26  -1.556121 A2MP1  -1.509316 
RNU6-936P  -1.691205 LOC101929721  -1.613342 RNU1-148P  -1.555953 RP1-202O8.2  -1.508923 
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RNU6-216P  -1.690771 SNORD116-27  -1.613098 SEC1P  -1.554985 SNORD27  -1.50708 
LOC101929179  -1.68864 RNU6-1232P  -1.612848 SNORD50A  -1.554408 RNU1-36P  -1.506556 
SNORA53  -1.6871 RNU6-340P  -1.612387 SCARNA14  -1.55319 AA06  -1.505592 
RNU6-926P  -1.685638 RP11-400D2.3  -1.611611 LOC101928203  -1.552899 IGLJ4  -1.5049 
LOC101929492  -1.684451 RNU6-135P  -1.610827 RNU1-100P  -1.550997 RNA5SP285  -1.502506 
SNORD68  -1.68393 PRSS50  -1.610729 FAM90A12P  -1.550666 LOC100133286  -1.501725 
RNU6-195P  -1.681934 SNORA71A  -1.60881 OR10H2  -1.549861 COL5A1-AS1  -1.4986 
SNORD95  -1.67863 RNU6-477P  -1.607807 RNA5SP276  -1.547186 MIR3916  -1.495291 
RNU6-1282P  -1.676166 RN7SKP245  -1.60578 C10orf71-AS1  -1.547131 EPPIN-WFDC6  -1.495039 
RNU6-111P  -1.675299 RNVU1-19  -1.602899 RNU6-458P  -1.546883 RNU1-77P  -1.493345 
RN7SKP80  -1.674602 RNU7-181P  -1.602739 RNU1-109P  -1.546822 RNU6-858P  -1.492999 
ZNF733P  -1.672065 MSTO1  -1.602459 MIR3117  -1.546277 MIR548W  -1.490472 
SPANXA1  // 
SPANXA2  -1.671696 DPRXP4  -1.601893 ARHGAP33  -1.545908 
GNB2L1  // 
SNORD95 -1.487764 
RP11-328J2.1  -1.669505 
TRIM43  // 
TRIM43B  -1.600946 RNA5SP353  -1.545449 LOC101928253  -1.487428 
HNRNPA3P5  -1.662484 SNORA68  -1.59891 SNORD15B  -1.54448 SNORD105  -1.486637 
RNU6-1333P  -1.662442 SNORA76A  -1.597909 YME1L1  -1.544049 ENGASE  -1.48542 
RNU6-1160P  -1.65924 SNORA49  -1.595771 IGHD3-9  -1.543253 RNU6-299P  -1.485356 
RNU6-725P  -1.656535 
RP11-
998D10.7  -1.595044 MIR1197  -1.5432 MRGPRX4  -1.48435 
RNU6-843P  -1.656393 OR51A4  -1.594664 SNORA84  -1.540273 RNU6-723P  -1.478688 
TRAV8-3  -1.656263 SNORD66  -1.594602 SNORD1C  -1.53994 RNU6-712P  -1.47829 
AC005077.5  -1.655751 IGHJ3  -1.592493 RNU6-1326P  -1.53889 MIR1914  -1.475534 
RP11-401I19.1  -1.47521 RNU6-329P  -1.431078 RNA5-8SP4  -1.380494 RNU6-1324P  -1.334093 
MIR4529  -1.474743 POM121L4P  -1.430959 AC093843.1  -1.380175 CTC-428G20.2  -1.334067 
SNORD22  -1.474049 AKR7L  -1.429592 SNORD31  -1.379451 RBMY2FP  -1.333618 
SNORD61  -1.471012 RNU6-826P  -1.429271 MIR4645  -1.378656 MIR133A1  -1.333184 
RNU6-96P  -1.468525 SNORD63  -1.42806 ESRRAP2  -1.376453 RNU6-161P  -1.332612 
RNU6-1186P  -1.467922 RNA5SP290  -1.427372 SNORD54  -1.375895 MIR3201  -1.332206 
RNU6-485P  -1.46765 RNU6-68P  -1.42712 MIR4279  -1.375515 LOC100129055  -1.33146 
RNU6-1272P  -1.467366 MIR4299  -1.424395 AC004878.8  -1.375161 RNU6-1126P  -1.330656 
RNA5SP47  -1.465606 RNU1-103P  -1.421953 MT1F  -1.374429 RNA5SP379  -1.328957 
RP11-703H8.9  -1.465239 RNU6-47P  -1.420429 RNA5SP426  -1.374323 TRAJ18  -1.327793 
LOC93432  -1.465209 RP11-561I11.3  -1.417018 WI2-2373I1.2  -1.370813 LOC101929225  -1.327724 
RNU6-455P  -1.464774 
RP11-
333A23.3  -1.416171 LINC00158  -1.368543 RNU1-33P  -1.326639 
RNU6-1215P  -1.462559 LINC00888  -1.41608 SNORD34  -1.368048 RP11-326C3.7  -1.325996 
MIR3200  -1.461004 RNU6-517P  -1.415486 LOC100507651  -1.365742 MAGEA1  -1.325816 
LOC100506125  -1.460868 RP11-14I17.2  -1.414677 SNORD47  -1.362661 RN7SKP133  -1.323791 
CSHL1  -1.458248 MIRLET7A1  -1.41413 C19orf83  -1.362362 RP11-439C8.2  -1.321852 
RN7SKP220  -1.45798 LRRC7  -1.414008 RNU6-460P  -1.360477 RNU5A-1  -1.321769 
MIR4717  -1.456827 VAMP8  -1.413533 PI4KA  -1.359996 TRAV6  -1.319776 
KRTAP21-3  -1.456229 OR9A2  -1.413156 MIR329-1  -1.358774 KRTAP19-6  -1.318753 
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SNORA69  -1.454423 Z82214.3  -1.412988 SCARNA12  -1.357094 THBS3  -1.318707 
RNU6-1340P  -1.45395 RNU6-136P  -1.411316 RNU6-736P  -1.356191 RP11-253D19.2  -1.318407 
TRAJ14  -1.453895 TRDJ4  -1.410778 SCARNA27  -1.35494 ALS2CL  -1.318334 
RNU6-614P  -1.45243 
RP13-
279N23.2  -1.410335 RNA5SP516  -1.354004 LOC100507445  -1.318316 
CORO6  -1.451607 RNU6-643P  -1.408437 RNU1-130P  -1.353902 RNU6-437P  -1.317509 
MIR128-2  -1.44911 RP11-367F23.1  -1.407998 LOC441455  -1.3532 SNORD69  -1.31708 
RNU6-1143P  -1.448997 MIR4757  -1.40714 RNU6-661P  -1.352811 CBLC  -1.316854 
RNU6-670P  -1.448645 SNORD110  -1.40713 CHEK2P2  -1.352797 RPL13A  -1.315551 
RP11-
356K23.2  -1.448326 RP11-619L12.3  -1.406746 SNORD55  -1.352323 RNA5SP55  -1.315505 
RP11-69I8.2  -1.448006 RNU2-24P  -1.405985 AMY2A  -1.351214 RP11-619J20.1  -1.314092 
SNORA64  -1.447738 RNU6-484P  -1.405973 C20orf203  -1.350766 RN7SKP293  -1.313893 
RNA5SP200  -1.447314 SNORA44  -1.40295 RP4-735C1.6  -1.349779 AC093159.1  -1.312434 
RP11-
100G15.10  -1.446525 MIR4478  -1.402398 RNU6-1085P  -1.349151 RNA5SP359  -1.311811 
LOC101929149  -1.445873 RRP7B  -1.401665 RP11-218D6.4  -1.349141 LOC344967  -1.311756 
RP11-
335O13.8  -1.445769 ZBTB40-IT1  -1.401596 RNU6-916P  -1.348675 RP11-466A19.8  -1.308936 
RNU6-365P  -1.443276 RNU6-901P  -1.401508 TRAJ46  -1.348152 C1QL2  -1.308886 
RNU6-1128P  -1.442919 SNORA8  -1.4001 OR1D5  -1.346529 RN7SKP231  -1.30791 
RP11-
444P10.1  -1.442754 CKM  -1.398651 AC114814.3  -1.346362 LA16c-4G1.3  -1.307112 
SNORD30  -1.442403 PPBPP2  -1.398276 RP11-7I15.4  -1.345577 CTC-295J13.3  -1.306068 
CASP1  -1.442132 RP11-12D16.2  -1.396312 LOC401134  -1.344997 SNORD42A  -1.305418 
RNU6-571P  -1.440864 PIK3C2G  -1.395981 RTP1  -1.344744 RP11-62L18.3  -1.305166 
RNU6-306P  -1.439333 NDUFA1  -1.395013 IGLL3P  -1.344316 SNORD44  -1.30501 
CD274  -1.439302 RP11-501O2.3  -1.392181 MIR197  -1.343828 HMGN2P15  -1.304584 
LOC100506272  -1.438994 STX1B  -1.391365 RNY3P8  -1.343128 RNU6-533P  -1.304116 
RNU6-857P  -1.43899 CBLN4  -1.390128 SEPW1  -1.34295 RP11-716O23.2  -1.303917 
RNU5B-3P  -1.437911 RNU6-1296P  -1.384184 GDPD3  -1.340943 SNORD50B  -1.302566 
OSBPL7  -1.436151 SP7  -1.383531 RNU6-644P  -1.340828 RN7SKP98  -1.302232 
RP11-
465M18.1  -1.435179 SNORD65  -1.382744 SNORD51  -1.339474 SPANXN5  -1.301583 
RNA5SP286  -1.43366 RNU6-240P  -1.382318 SNORA16A  -1.33886 SNHG10  -1.29838 
RN7SKP255  -1.43365 LOC101927993  -1.380501 TERF2IP  -1.334384 RP11-561O23.7  -1.298298 
AC106900.6  -1.297135 MIR4472-1  -1.271227 RNY3P4  -1.234365 LOC100505824  -1.210942 
BMP3  -1.296117 MIR4676  -1.269133 RNU6-1180P  -1.233931 RP11-2C15.1  -1.210685 
MIRLET7E  -1.295968 
RP11-
492A10.1  -1.267418 RNU4-24P  -1.23385 RPS6KA6  -1.210586 
SNORD45A  -1.295218 ID3  -1.266948 RP11-110L15.2  -1.233579 SNORA80B  -1.209547 
RNU6-598P  -1.295017 FAM163B  -1.265288 CHRM2  -1.233242 PER1  -1.208964 
PPP2R2B  -1.293935 LOC401357  -1.264948 LOC102725382  -1.232345 RNU1-104P  -1.208062 
HTR3E  -1.293915 PLCL2-AS1  -1.263744 AL157359.4  -1.230374 MIR499B  -1.207932 
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AC013448.2  -1.293654 SNORD116-26  -1.262974 LINC00682  -1.229954 RP11-1042B17.5  -1.207854 
RNU6ATAC8P  -1.293571 MYL3  -1.262332 HFE2  -1.229625 LOC102724418  -1.207806 
MIR1265  -1.291301 AOX2P  -1.261853 UBL4B  -1.229178 NBPF20  -1.206808 
RNA5SP33  -1.290832 LINC00441  -1.260864 OR4M1  -1.229066 RNU6-1220P  -1.206066 
TRBV3-1  -1.289278 RNU1-75P  -1.260809 AJ006995.3  -1.228893 RP11-202I11.2  -1.205612 
RNU6-406P  -1.289262 RNU6-832P  -1.25974 LOC101928476  -1.228421 SNORA79  -1.20547 
RNA5SP29  -1.286918 MSMO1  -1.258392 RP11-103H7.3  -1.228289 RNA5SP167  -1.205404 
LOC101929448  -1.286815 RNA5SP375  -1.257556 LOC101930276  -1.228257 RNU6-382P  -1.204281 
LOC101929486  -1.285612 RNU6-1140P  -1.256793 
RP11-
445P17.3  -1.228117 RNA5SP153  -1.203897 
ZNF438  -1.285139 RNU6-235P  -1.256619 RNU1-96P  -1.227936 RBMY2EP  -1.20359 
RP11-723G8.2  -1.283441 RNA5SP78  -1.256052 
RPS2  // 
SNORA64  -1.226817 PGM5-AS1  -1.203579 
CTC-558O19.1  -1.282695 LOC101928101  -1.255685 SUPT20HL2  -1.226521 RNU6-1234P  -1.203416 
RNU6-435P  -1.282475 GUCY2C  -1.255471 MIR4480  -1.226263 RN7SKP188  -1.20338 
RP11-
798K23.4  -1.281704 RNU6-672P  -1.254991 SNORA55  -1.225207 RNU6-337P  -1.202742 
RNU6-642P  -1.281183 LOC102725139  -1.252396 RNA5SP291  -1.223385 MIR4679-2  -1.202472 
SNORD116-24  -1.28063 RN7SKP193  -1.251286 LOC100287846  -1.22318 RNU6-71P  -1.200311 
RNA5SP323  -1.280051 RNA5SP214  -1.251056 AF178030.2  -1.22277 IGHA2  -1.200167 
RP11-703I16.1  -1.279417 RNU6-61P  -1.248965 RN7SKP169  -1.22253 SELE  -1.199972 
RP11-88H10.2  -1.278755 GDF2  -1.248716 PLAC9  -1.222171 HBB  -1.199624 
MMP24-AS1  -1.278642 MTRNR2L10  -1.24649 RNU6-1222P  -1.22208 MIR4500  -1.19941 
RNU1-69P  -1.278415 CENPH  -1.246371 RP11-706F1.2  -1.222076 WASH3P  -1.199046 
ANP32C  -1.278181 RNU6-1022P  -1.2462 
RP11-
723D22.3  -1.222019 TUBA3C  -1.197992 
RP11-391J2.3  -1.277996 TTTY11  -1.245406 MKRN7P  -1.221678 RNA5SP122  -1.196966 
SYT14L  -1.277865 SNORD82  -1.245222 RN7SKP106  -1.221658 RP11-166N6.2  -1.195786 
MIR885  -1.277051 KRTAP19-4  -1.244665 PRSS41  -1.221296 MIR548Z  -1.194331 
RP6-102O10.1  -1.276989 RNU6-741P  -1.244382 
RP11-
363D14.1  -1.221007 RNA5SP448  -1.194189 
RN7SKP178  -1.276982 RNU6-1088P  -1.244216 LHX5  -1.219926 MIR887  -1.193932 
LOC101927533  -1.276946 RP11-638I2.4  -1.243709 RNU1-131P  -1.21846 RNU6-316P  -1.193751 
RNU6ATAC21P  -1.276206 MIR526A1  -1.24369 MTRNR2L9  -1.218043 HIST1H3C  -1.192874 
SNORD3D  -1.276009 RN7SKP213  -1.243467 MIR4518  -1.217331 SNORA70  -1.192744 
KRTAP4-2  -1.275503 LINC00701  -1.243217 AC012314.20  -1.216367 RP11-85M11.2  -1.192159 
MIR1266  -1.274446 CXXC4  -1.243035 GIMAP4  -1.216168 RP11-51B23.3  -1.19206 
TRAJ48  -1.274408 LOC101928948  -1.241147 RNU6-1258P  -1.216159 RNU5F-8P  -1.191792 
MIR4797  -1.274054 IGLV@  -1.241075 RNA5SP118  -1.215788 FEM1AP1  -1.191664 
RNA5SP93  -1.273464 FDCSP  -1.239359 ESPN  -1.215297 MIR4530  -1.190321 
LINC00243  -1.27321 MIR1283-2  -1.239161 RNU6-104P  -1.214788 LOC101927853  -1.189856 
LOC101927693  -1.272781 LOC100506236  -1.237688 GFRA4  -1.214442 RP11-740P5.3  -1.189432 
RNA5SP160  -1.27248 RNA5SP89  -1.236488 CDRT15L2  -1.2144 HIST1H2AK  -1.189285 
LOC101927990  -1.272079 PIN4P1  -1.236102 RNU6-1016P  -1.214233 RNU6-1314P  -1.188835 
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LOC101928051  -1.271989 RNA5SP186  -1.23596 PIDD1  -1.213823 SCX  -1.188338 
RP11-
654G14.1  -1.271885 RNA5SP294  -1.23506 MIR4300  -1.211957 RNU6-332P  -1.18641 
RNU6-141P  -1.271668 RNA5SP398  -1.234423 MIR3119-1  -1.211423 RNU6-948P  -1.186265 
RP11-332M4.1  -1.186107 IGLV2-23  -1.167066 SNORD4B  -1.146938 OTOL1  -1.131127 
RP11-1E4.1  -1.186068 RP11-310I24.1  -1.166903 SHD  -1.146882 H2BFXP  -1.130985 
LOC101929014  -1.186052 LOC102723840  -1.166727 MIR1208  -1.146828 LOC100132831  -1.130522 
RNU6-818P  -1.185757 HIST1H2BM  -1.166232 LOC102724732  -1.146812 RNU6-1087P  -1.130156 
DMD-AS3  -1.185358 RP1-150O5.3  -1.166044 RNPEP  -1.146717 RNU6-1074P  -1.130064 
PROSP  -1.184346 RNA5SP191  -1.1659 RNU6-429P  -1.146005 RNU6-689P  -1.129854 
GCG  -1.183988 HCCAT5  -1.165658 HIST1H2BB  -1.145627 RP11-167N4.2  -1.129547 
FLJ25694  -1.183915 SNORD76  -1.16552 MAGEC2  -1.145615 RNU5E-10P  -1.129135 
RP1-155D22.1  -1.183828 SNORD12B  -1.165335 RP11-410L14.2  -1.144323 SNORD125  -1.129085 
MIR4781  -1.183142 FCRL6  -1.164588 LRRC38  -1.143992 AKR7A2  -1.128941 
RN7SKP247  -1.18302 OR52N2  -1.164295 AC004014.3  -1.143632 RP11-103H7.1  -1.128294 
RNA5SP349  -1.182423 RNU6-635P  -1.164096 
RP11-
749H17.1  -1.143362 AC003985.1  -1.128216 
RBM15  -1.181975 MIR3151  -1.163746 LOC284014  -1.142433 DDX12P  -1.128158 
LOC101928769  -1.18157 TRGJP2  -1.163278 LOC102724657  -1.142224 SPANXN3  -1.127808 
RN7SKP189  -1.180633 CCDC162P  -1.163086 RP11-733C7.1  -1.14215 RN7SKP111  -1.1278 
RP11-103C3.1  -1.18022 CD1E  -1.162538 RNA5SP372  -1.142043 FAM72D  -1.127391 
MKRN2OS  -1.18011 RP11-335E6.2  -1.162163 
RP11-
1006G14.2  -1.141971 RNA5SP267  -1.127352 
MKRN3  -1.179627 CTD-2227I18.1  -1.161979 NDUFB7  -1.141343 FEV  -1.127208 
RNU6-556P  -1.178933 RP11-831H9.3  -1.161749 
OVOS2  // 
LOC100509445  -1.141047 RN7SKP112  -1.126749 
LOC102723583  -1.178472 KRTAP1-5  -1.161666 CWH43  -1.139545 RN7SKP137  -1.126413 
FAM72C  -1.177497 SGCZ  -1.160946 LOC101928912  -1.13921 TEX13A  -1.126357 
RP11-
495P10.1  -1.177215 SNHG7  -1.160826 RP11-475J5.6  -1.13914 MIR4658  -1.126135 
LINC00703  -1.177033 AKT3-IT1  -1.160785 RP5-1050E16.2  -1.139097 RNA5SP161  -1.126073 
CYP4F30P  -1.176756 NEFM  -1.160494 RP11-553K8.5  -1.13893 LINC00323  -1.126028 
ACSM2A  -1.176318 MYH7  -1.160304 MIR920  -1.138649 RP11-541F9.2  -1.125956 
LOC100293704 -1.176245 RNA5SP321  -1.159803 RNU2-57P  -1.138343 SMPD4P1  -1.125277 
LOC100507468  -1.175755 RNU6-1229P  -1.158456 MIR3938  -1.138051 GRIP2  -1.124587 
RNU6-1264P  -1.175563 LOC101928138  -1.158345 IFITM4P  -1.137995 RP1-65P5.5  -1.124552 
ZNF99  -1.175443 RP11-382F24.2  -1.158178 ZKSCAN7  -1.137598 VAT1L  -1.124463 
TRAJ28  -1.175228 RNU6-290P  -1.157609 RNU6-326P  -1.137366 TCEAL2  -1.123187 
SNORA34  -1.17507 LOC101929355  -1.156903 MIR4266  -1.136507 SNORD116-15  -1.1224 
RNU7-105P  -1.174662 RNU1-76P  -1.156519 RNU6-775P  -1.136332 FAS-AS1  -1.122333 
HOXC12  -1.174532 RP1-27K12.4  -1.155096 SLC25A24P1  -1.135643 PRAMEF2  -1.121103 
RNA5SP127  -1.173281 SNORD56  -1.155081 CEACAM6  -1.135529 LOC100653061  -1.120833 
AL133249.1  -1.173252 DKKL1  -1.155011 HORMAD1  -1.134761 RNU6-949P  -1.120708 
HMGN3  -1.173061 RNU6ATAC14P  -1.154721 RNU6-1172P  -1.134595 LOC101928733  -1.120607 
234 
 
Gene Symbol Expression Gene Symbol Expression Gene Symbol Expression Gene Symbol Expression 
LOC101929248  -1.172654 RNA5SP62  -1.154299 RNU4-52P  -1.134268 TPSD1  -1.120404 
TRAJ9  -1.172292 FDFT1  -1.153848 RNU1-49P  -1.134013 SNORA19  -1.120378 
MIR551B  -1.172278 NEU2  -1.152528 
RP11-
1149O23.2  -1.133761 RP11-417L19.2  -1.120099 
RP4-781K5.6  -1.172173 MNS1  -1.151992 RNU6-1267P  -1.133724 ZIC4-AS1  -1.119747 
SLC25A3P1  -1.171981 RP11-323I15.5  -1.151817 XAGE-4  -1.133136 MTRNR2L8  -1.118575 
LINC00399  -1.171476 RP11-46F15.2  -1.151035 OR5F1  -1.133113 AC005324.6  -1.118474 
RP11-
756P10.4  -1.171047 RNVU1-14  -1.150844 UBQLN3  -1.133111 RP11-123O22.1  -1.118045 
H1FNT  -1.170616 RNU6-454P  -1.150367 TMEM121  -1.133003 RP3-425P12.1  -1.117977 
HSP90AA4P  -1.170335 OR1D2  -1.149612 SNORA13  -1.132908 RP11-348J24.1  -1.117412 
RP11-875H7.1  -1.169394 MIR1260A  -1.14888 COL4A1  -1.132688 RMRPP5  -1.117245 
RNU6-1191P  -1.167925 SNORD46  -1.14795 
RP11-
386G21.1  -1.132637 OR13C2  -1.116836 
RNA5SP400  -1.167152 LINC00877  -1.147269 RNU6-1315P  -1.131829 AC079630.2  -1.116282 
TUNAR  -1.16713 SNORD36B  -1.147068 RNU6-819P  -1.131727 RP11-269C4.2  -1.115279 
LOC729815  -1.11494 RP11-493L12.5  -1.100847 MIR1537  -1.087574 MIR518D  -1.072417 
RNU6-1063P  -1.114849 RNU6-633P  -1.100539 LINC01419  -1.087495 RNU6-968P  -1.072408 
LOC101927687  -1.114673 RCN3  -1.100386 RNU6-717P  -1.087383 DNAJC22  -1.072158 
RNA5SP42  -1.114594 NEUROD1  -1.100081 RP11-115J16.3  -1.087353 GYS2  -1.071988 
HBCBP  -1.11459 LOC101928076  -1.099562 RNVU1-17  -1.087045 RNU6-1036P  -1.071714 
RNU6-1303P  -1.112328 RP11-80H5.2  -1.099193 WHAMMP3  -1.086941 LOC100130548  -1.070743 
AC011196.3  -1.112159 RNU6-557P  -1.099094 RNU6-208P  -1.086583 OR5AN1  -1.070714 
AC010891.2  -1.112038 LOC100132529  -1.098933 LOC102724890  -1.086336 RP11-566H8.3  -1.070697 
MIR612  -1.111929 CRABP2  -1.098378 LOC102724532  -1.086055 FBLL1  -1.070499 
NPFFR1  -1.111516 OR5AC2  -1.098059 OR51B4  -1.085896 LINC01059  -1.070426 
MT-TH  -1.111122 NDUFB8  -1.097977 C7orf62  -1.085825 LOC102724598  -1.070283 
FREM3  -1.110613 PRM2  -1.09771 LINC00865  -1.085797 RNA5SP209  -1.070251 
MST1  -1.110455 LA16c-2F2.8  -1.09747 LOC641515  -1.085591 UGT2B28  -1.070175 
RNU6-1207P  -1.110223 RNA5SP394  -1.097264 AC004543.2  -1.085458 RP11-236P24.3  -1.069978 
MC3R  -1.109816 HERC2P8  -1.096733 LINC01370  -1.085234 MIR4692  -1.069504 
RNU6-920P  -1.10978 RP11-348J12.2  -1.096678 RNU6-1110P  -1.084857 CNTROB  -1.069484 
SNORD1A  -1.109652 IGLV1-44  -1.096635 RNU6-1141P  -1.084415 RN7SKP149  -1.068874 
LINC01255  -1.109412 RNU6-987P  -1.096034 HIST1H2AJ  -1.084288 RP11-231L11.1  -1.068848 
LCE1F  -1.109255 TP53I3  -1.095708 RP4-806M20.5  -1.083402 RP11-897M7.1  -1.068569 
LOC100129518  -1.109196 MIR708  -1.095684 RP11-108K3.3  -1.083074 RP11-674C21.9  -1.068039 
RP11-434C1.2  -1.108615 LINC00028  -1.095645 RN7SKP55  -1.083016 RP4-800F24.1  -1.068016 
KRTAP1-3  -1.108168 OR6T1  -1.095551 TRAV34  -1.082532 FDPS  -1.067929 
MIR921  -1.107899 RP11-5N11.7  -1.09418 RNA5SP250  -1.082229 MYH6  -1.067564 
RNU6-823P  -1.107697 
RP11-
486O13.2  -1.093819 RP11-100F15.2  -1.081315 PSG11  -1.067463 
RN7SKP260  -1.10768 RNA5SP77  -1.093422 RNA5SP184  -1.081253 RNU6-554P  -1.067318 
RIMS3  -1.107532 
RP11-
114N19.3  -1.092679 LOC102577424  -1.080775 RNU6ATAC26P  -1.067256 
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RNA5SP422  -1.107366 CXCL11  -1.09176 RNU6-339P  -1.080709 COL18A1  -1.067181 
SULT1B1  -1.107189 SETP22  -1.091758 RNU6-994P  -1.079645 CTC-260E6.6  -1.067176 
MIR181A1  -1.106694 ALG9-IT1  -1.09139 RNU6-401P  -1.079633 RP11-640N20.6  -1.067154 
MIR130B  -1.106652 RNU6-303P  -1.091154 RNU6-815P  -1.079153 AC012501.2  -1.067139 
LINC00524  -1.10642 LOC101927827  -1.091151 RNA5SP117  -1.078091 CEBPA-AS1  -1.066669 
FGFR3  -1.106196 NFE4  -1.090716 
RPL23  // 
SNORA21  -1.077639 KRTAP19-2  -1.066636 
RNY4P18  -1.105338 
NEAT1  // 
MIR612  -1.09056 MIR4305  -1.077519 MIR676  -1.066623 
LINCR-0003  -1.105282 LOC100128563  -1.090076 RNA5SP94  -1.077391 OR11H12  -1.066211 
LOC728763  -1.105109 
RP11-
793B23.1  -1.090054 CTC-359M8.1  -1.077101 AC093627.7  -1.066067 
SNORD121A  -1.104963 COX17  -1.089722 LOC102724719  -1.076915 ARGFX  -1.065702 
TUBGCP6  -1.104891 RP1-86D1.4  -1.08969 LOC100287072  -1.076915 RNA5SP249  -1.065422 
GSDMB  -1.104826 RP11-646J21.2  -1.089506 RNU6-107P  -1.076887 LOC100996255  -1.065418 
LOC729739  -1.104826 KRT8P41  -1.089176 MIR4421  -1.076336 TTC23  -1.065333 
TRAV39  -1.104685 LOC101927856  -1.088972 LINC00385  -1.075356 RNU6-1320P  -1.065236 
OR5H2  -1.104651 LINC01339  -1.088888 KRT18P11  -1.074856 RP11-223C24.2  -1.064995 
CST2  -1.104429 
RP11-
297B17.3  -1.088808 RNU6-252P  -1.074378 MAGIX  -1.064843 
RP11-97N5.2  -1.104111 RP4-765H13.1  -1.088528 RP11-4O3.2  -1.074305 MIR649  -1.064615 
AC007680.2  -1.103215 
RP11-
962G15.1  -1.08834 MIR520D  -1.074113 OR5D18  -1.064362 
LOC102723415  -1.102375 LOC102724571  -1.087918 RNU2-17P  -1.073937 RP11-356O9.2  -1.06431 
UBXN7-AS1  -1.101759 OR10A2  -1.087752 FRMD5  -1.07371 KBTBD11-OT1  -1.06423 
LOC100288152  -1.101574 REV3L-IT1  -1.087702 C10orf95  -1.072973 RP11-281A20.2  -1.063663 
ADIRF  -1.101065 RNU6-577P  -1.087682 RNU6-887P  -1.072662 OR5AP2  -1.063521 
CTAGE1  -1.10101 RABGGTB   -1.087615 RNA5SP178  -1.072483 RP11-46A10.2  -1.063303 
LOC101929565  -1.063225 AC006373.1  -1.047684 RNA5SP98  -1.035288 RP11-27P7.1  -1.026798 
OR3A3  -1.062448 UBE2Q2P1  -1.046871 CTD-2555I5.1  -1.035209 AC104076.3  -1.026249 
SERPINA2  -1.061063 LOC101927621  -1.046821 PARP2  -1.035142 TPTE2  -1.025894 
RP11-
507B12.2  -1.060164 RP5-945I17.2  -1.04661 TOP3B  -1.03429 CTD-3105H18.7  -1.02575 
XKR7  -1.059884 NSG1  -1.04656 LOC102723648  -1.034275 RNU6-414P  -1.025447 
AL022344.5  -1.059842 RN7SKP244  -1.046539 RNA5SP435  -1.034025 SNORD42B  -1.02531 
RNU6-777P  -1.059795 RP11-346J10.1  -1.045466 TRIM53AP  -1.033556 GS1-39E22.2  -1.025266 
HES4  -1.059733 C11orf31  -1.045122 SPRR1B  -1.033425 ZDHHC8P1  -1.024843 
TRDJ1  -1.059629 RNA5SP345  -1.044796 PTGIR  -1.033372 SNORD85  -1.024813 
MIR517A  -1.059132 MEF2C  -1.044767 LOC339468  -1.032655 RNU1-140P  -1.02474 
LINC01214  -1.059095 OR52M1  -1.044448 CPA2  -1.032221 RP11-38M15.11  -1.02462 
LOC100507221  -1.058661 PRDM9  -1.043914 C3AR1  -1.032219 SNORD33  -1.02462 
LINC01029  -1.058543 RNA5SP22  -1.04386 RN7SKP32  -1.032111 LOC401010  -1.024059 
TMEM174  -1.058503 PIANP  -1.043601 
SNHG6  // 
SNORD87  -1.0321 ACER1  -1.024032 
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EN1  -1.058173 
RP11-
1258F18.1  -1.043033 RP11-69C17.3  -1.031988 FAM230C  -1.023179 
C10orf40  -1.058135 RNU6-561P  -1.042997 SLC4A1  -1.031795 LOC101928093  -1.022905 
SNORD115-3  -1.057863 NDUFA13  -1.042985 RP11-488L18.8  -1.031354 EMCN-IT1  -1.022894 
KIAA1751  -1.057646 RNA5SP444  -1.042955 RNA5SP174  -1.031338 RP11-4C20.3  -1.022686 
RNU6-972P  -1.057544 RNU6-682P  -1.042631 
RP11-
519G16.5  -1.031301 NAMA  -1.022298 
PMCHL1  -1.057096 PDC  -1.042504 AC018717.1  -1.031196 GS1-18A18.2  -1.021646 
RNU6-456P  -1.057044 LOC101059949  -1.042024 RP11-665J16.1  -1.030928 LILRB4  -1.021543 
RP11-91I20.3  -1.056398 
RP11-
655M14.12  -1.041709 PRSS35  -1.030894 LOC100131047  -1.021496 
CYB5R2  -1.056351 
RP11-
603J24.14  -1.041558 RP11-966I7.3  -1.030056 LOC102724965  -1.021202 
LOC101927347  -1.055578 RNU6ATAC42P  -1.041366 LOC101927577  -1.029664 RP11-360L9.7  -1.021118 
UBTFL1  -1.05526 RN7SKP222  -1.040728 OVOS2  -1.029631 KIF19  -1.020944 
RP11-
388G22.1  -1.05523 ECRP  -1.04065 MPEG1  -1.029628 SPAG8  -1.020942 
RP11-758I14.3  -1.054949 RNU6ATAC22P  -1.040526 C15orf56  -1.029125 GABBR1  -1.020809 
RNA5SP225  -1.05482 AC019186.1  -1.040389 C9orf170  -1.029102 LOC101928306  -1.02051 
ANKRD22  -1.054537 KRT17P2  -1.040019 IFI6  -1.029023 FAM180B  -1.020278 
RNU6-929P  -1.054397 RNU6-767P  -1.039945 PNRC2  -1.028612 RNY4P19  -1.019487 
OR10G8  -1.054378 ARF5  -1.039936 ARL9  -1.028444 RP11-386M24.3  -1.019358 
RP11-278H7.4  -1.05433 RP11-203F8.1  -1.03977 RP11-296L22.8  -1.028401 RP11-536G4.1  -1.019301 
CTD-2562J17.9  -1.053351 
RP11-
557C18.3  -1.039588 ANKRD20A3  -1.028398 RNU6-482P  -1.01884 
AC018866.1  -1.052936 
RP11-
166N17.3  -1.039397 LINC00693  -1.028288 F11-AS1  -1.018728 
AP000442.4  -1.052348 RP11-848D3.5  -1.039364 SPACA7  -1.028056 RNU4-41P  -1.018632 
TRIM36-IT1  -1.052185 RP3-443C4.2  -1.038663 SNCB  -1.027949 AC104623.2  -1.018505 
PI4KAP2  -1.052114 RNU6-283P  -1.038602 MIR3657  -1.02789 RP11-739N10.1  -1.018485 
OR4N3P  -1.051549 RNA5SP496  -1.038537 SNAR-G1  -1.027792 GFI1  -1.018413 
LOC645355  -1.050599 RP11-38H17.1  -1.038371 RN7SKP43  -1.027679 RNU7-185P  -1.018258 
SRGAP2-AS1  -1.050465 IFNA13  -1.03828 SNORD114-28  -1.02749 CXCL3  -1.01806 
RP13-1039J1.3  -1.050298 MYOM1  -1.037585 MVD  -1.027436 MAPK8IP3  -1.017427 
RNU6-654P  -1.050237 FIGNL2  -1.037367 
CTD-
2353F22.1  -1.027405 LOC100505502  -1.017385 
RNU6-696P  -1.049884 RP11-85O21.4  -1.037221 FGD5  -1.027388 LOC101928739  -1.017382 
LOC102724306  -1.049805 KAT2A  -1.03711 AC096732.2  -1.027297 RP11-242P2.2  -1.017372 
TRAJ5  -1.049762 RNU1-105P  -1.037106 LOC101929469  -1.027285 LOC101929167  -1.017026 
RNU6-1057P  -1.049065 RNU6-237P  -1.036794 MIR3188  -1.027155 RNU6-520P  -1.016427 
CD177P1  -1.0486 AC018685.2  -1.036385 RP3-471C18.2  -1.027138 ZPBP2  -1.016347 
CECR9  -1.048271 ZFYVE28  -1.036233 RN7SKP128  -1.026918 AOX3P  -1.016281 
RN7SKP180  -1.047968 RNU6-1271P  -1.036112 AC012442.6  -1.026802 RP11-395B7.2  -1.016147 
RP11-424I19.1  -1.016123 HERC2P5  -1.005152 AC013402.5  -1.010149 CELF5  -1.001704 
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PAN2  -1.015336 LOC102724264  -1.004996 RP11-66A2.1  -1.009919 AL162151.4  -1.001533 
CTD-
2331D11.2  -1.015125 CYP2A6  -1.004496 RNU6-1078P  -1.00969 CYP2D8P  -1.001392 
RPSAP9  -1.014841 RP11-616L12.1  -1.004378 MFI2-AS1  -1.009543 ABHD17AP3  -1.001229 
MSH5  -1.014826 PROL1  -1.00431 RP11-124N3.3  -1.009244 RNU6-1161P  -1.001144 
STAP1  -1.014797 RP11-26L20.3  -1.00425 
RP11-
626H12.1  -1.008894 ZNF295-AS1  -1.000719 
AC006026.13  -1.014654 KRTAP19-3  -1.004213 LOC102724601  -1.007756 RN7SKP39  -1.000528 
HMX3  -1.014539 IVL  -1.004172 RNU4ATAC5P  -1.00758 MIR302E  -1.000511 
OR1L4  -1.014504 RNU1-61P  -1.00411 ZNF366  -1.007047 SCN3A  -1.000505 
OR3A1  -1.014279 
RP11-
624D11.2  -1.00398 RNU6-1279P  -1.006964 RP11-586K2.1  -1.000445 
RP11-
654A16.3  -1.014133 LOC101928150  -1.003845 EEF1DP3  -1.006285 RNU6-171P  -1.000433 
MIR4788  -1.013985 RNU6-491P  -1.003433 CD99  -1.006233 MIR4718  -1.011135 
GSTA3  -1.013298 RP11-27G13.1  -1.002895 
RP11-
627D16.1  -1.005839 RNU2-45P  -1.01109 
AC004009.3  -1.013221 FAM182B  -1.002735 TRAJ43  -1.005798 RP11-807H7.2  -1.010672 
GTF2IRD1P1  -1.013049 RNU6-856P  -1.002672 RNU2-25P  -1.005775 C1orf68  -1.010568 
LINC00624  -1.012981 MIR659  -1.0026 LOC100129722  -1.005705 CTD-2113L7.1  -1.010558 
LOC100506929  -1.012945 RNU6-931P  -1.002547 MIR129-2  -1.005626 RP11-758M4.4  -1.010327 
RP11-10B2.1  -1.012914 RNU6-177P  -1.002358 MIR4760  -1.005454 RLN2  -1.010259 
MIR4764  -1.012856 RPL7A  -1.002318 OR2T4  -1.012336 RNA5SP27  -1.011801 
NOSTRIN  -1.012415 RNU1-20P  -1.001843 RN7SKP64  -1.011893 RP11-353P15.1  -1.01156 
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Table 7.9: List of genes that 1 fold up regulated in K1E7 cells following 
Metformin treatments (0.3 mM) for 6 days. 
Gene Symbol Expression Gene Symbol Expression Gene Symbol Expression Gene Symbol Expression 
PPP1R10  18.396358 RP11-745L13.2  3.583871 EFNB2  2.700318 DENND5B  2.306622 
IPW  18.180253 ZBTB20  3.553499 MMP1  2.699085 MIR616  2.29945 
HCG8  13.96817 LOC100287934  3.497951 IL33  2.677546 AGFG2  2.298074 
IER3  10.379987 LOC100287497  3.454405 RHOQ  2.643028 TNFRSF10D  2.297076 
FLJ22447  8.675055 NT5E  3.449514 DNAJC6  2.634513 RP11-314N13.3  2.288203 
C6orf47  8.49042 CLDN16  3.432416 VEZF1  2.621706 RNU6ATAC18P  2.280939 
PPT2-EGFL8  8.417027 TSC22D2  3.419841 MIR31HG  2.611304 SLC35B3  2.280711 
MTRF1L  7.367797 F8A1  3.344814 ZFP36L2  2.603079 bP-21201H5.1  2.28063 
LOC100132167  7.181866 TRIM25  3.327166 LOC100288637  2.585811 UBL3  2.278935 
LINC01000  6.776727 PLCG2  3.292972 TIGD2  2.5711 RNU2-34P  2.271111 
MIR1236  6.620298 CDYL2  3.284184 RP4-791M13.3  2.561201 ITGB3  2.267268 
TRIM27  6.498174 PCF11  3.221567 RP3-368A4.5  2.550582 MIR590  2.267204 
LOC101927880  6.082773 HCG18  3.214265 EDNRA  2.545605 ST8SIA6  2.265311 
MIR3671  5.918655 LOC728339  3.195197 SERPINE1  2.54529 ERRFI1  2.255162 
PRKXP1  5.87266 MIR573  3.195186 RPL23AP53  2.536122 TOB1  2.250046 
RP11-760D2.12  5.510526 TNKS  3.169761 CASC7   2.533043 TRAK2  2.245783 
LINC00963  5.447429 DKK1  3.154172 CHAC1  2.532166 BMP2K  2.243308 
RNF185  5.364801 PDCD6IP  3.11658 THBD  2.524459 SLC16A6P1  2.240645 
LOC101929475  5.292922 EIF3J  3.106675 SLC7A5  2.517353 SKA3  2.238547 
PARP4  5.132557 DLGAP1-AS2  3.097128 CLDN1  2.491395 LRRC37BP1  2.237285 
LOC100506870  5.036196 VLDLR-AS1  3.078112 OSMR  2.478584 SIRPB1  2.23626 
IL1B  5.019607 RNU7-14P  3.025246 MYPN  2.471146 FOSL1  2.230029 
INTS6  5.013701 HNRNPA1L2  3.018409 FZD1  2.454462 IL11  2.227204 
BRD2  4.959461 LOC100294341  3.009071 EIF5  2.448106 EGFR  2.220315 
PSAT1  4.603824 ULBP1  3.007854 LINC00622  2.438816 CABLES1  2.219924 
DUXAP10  4.565214 CSF3  2.973273 CLGN  2.436664 DOCK11  2.214385 
MIR1184-1  4.477308 CYP24A1  2.962964 PSPC1  2.425345 ZNF836  2.213354 
CD177P1  4.403834 MOB3A  2.923767 SLC1A5  2.419625 MIR4277  2.208876 
PIK3CA  4.385445 TAS2R14  2.922926 TMSB4X  2.406367 ASS1  2.198921 
PTPRJ  4.256055 CTH  2.905041 RP11-360F5.3  2.39891 SRGAP2C  2.198449 
MAT2A  4.234648 LGR5  2.87056 PRKAA2  2.393396 MIR421  2.197534 
AC003092.1  4.226591 LOC90784  2.859262 MIR4521  2.388046 SOCS6  2.192387 
LINC01111  4.225352 KIR2DL5B  2.848919 NPAS2  2.376644 LOC283070  2.192075 
MIR21  4.22201 AMIGO2  2.845933 SLC38A1  2.376627 SLC48A1  2.190653 
HIF1A-AS2  3.994359 LINC01296  2.841038 GEN1  2.373196 DLGAP1-AS1  2.186441 
VLDLR-AS1 3.921012 CDKN2AIPNL  2.812056 USP27X  2.364508 RP11-841O20.2  2.179833 
C10orf12  3.896996 SLC6A9  2.812053 NLRP10  2.363244 ADAMTS5  2.177336 
USP32  3.886046 PAQR5  2.805897 ZNF807  2.3632 LINC00973  2.176555 
CD22  3.859482 AC104135.3  2.790624 RP11-274H2.3  2.362245 ZNF45  2.172775 
ASNSP1  3.846234 PTGS2  2.789166 CDK13  2.351837 ZNF480  2.169903 
KRCC1  3.82766 LOC400743  2.77726 ZNF554  2.351616 RP11-70J12.1  2.169523 
NABP1  3.803141 SMAD2  2.766045 STC2  2.346575 PTPN13  2.163285 
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RP11-3L8.3  3.757711 LINC00641  2.744724 LOC101930106  2.333776 FKTN  2.161884 
SLC7A11  3.726679 IL7R  2.742733 SHISA2  2.333452 DRAM1  2.161508 
LINC01293  3.702518 SLC16A13  2.72888 FOS  2.330317 ZFX  2.160125 
SERTAD4  3.696954 LOC100506178  2.724689 LOC101927841  2.322424 LINC-PINT  2.15821 
LOC101930489  3.677426 LOC729987  2.717962 SLC30A1  2.321284 ZNF770  2.156218 
SLC16A6  3.650859 GABRG1  2.715668 MOCS3  2.316791 ANKRD1  2.151857 
NCOA5  3.631526 ECH1  2.714425 ZBTB38  2.314818 CTB-32H22.1  2.150359 
RFX3  2.143829 IL1R1  2.042979 BCAT1  1.918492 TSPAN2  1.848103 
NCOA7  2.141958 YAE1D1  2.041803 RNF185-AS1  1.916905 MYC  1.845482 
SLC25A32  2.140819 SNX9  2.039378 DEPTOR  1.916657 AKIRIN2  1.845385 
AJUBA  2.14075 LOC100996579  2.03929 FLJ42627  1.91595 LINC00328  1.83894 
NR2F2  2.138533 LINC00969  2.036891 TET1  1.91316 DPY19L3  1.83668 
RP11-265D17.2  2.133485 RP9P  2.035751 PDE1C  1.912923 GPR56  1.836429 
NEO1  2.131532 DDX19B  2.034526 SMOC1  1.910278 ZCCHC8  1.836125 
DGCR8  2.130928 VCAM1  2.032793 ZBED8  1.906282 SLFN5  1.834535 
FZD2  2.130085 KRT80  2.02258 E2F8  1.904929 LMBRD2  1.833772 
TNFAIP6  2.127778 POLI  2.017741 TFAP2C  1.903646 NID2  1.83201 
ZNF566  2.127256 EIF5A2  2.017046 LRIF1  1.903429 RRN3  1.831454 
DUSP1  2.124598 KDM7A  2.013799 GUF1  1.903137 VLDLR  1.831256 
ZC3H12C  2.123501 GTF2A1  2.012097 DDX3X  1.902463 MAN1A2  1.831226 
EMP1  2.123099 DAPK1  2.009512 SNHG1  1.901983 SBNO1  1.829316 
FPR1  2.120273 SLC12A2  2.008491 GARS  1.901695 ASNS  1.828851 
GREM1  2.119657 PANX1  2.004658 PROSER1  1.900411 PLAU  1.828087 
SACS  2.118555 SLC6A15  1.999921 PTCH1  1.90025 RNU6-342P  1.824741 
CHAC2  2.116019 ARHGAP35  1.997141 F3  1.897553 LATS1  1.824263 
SNTB1  2.110157 KCNH1  1.996022 WARS  1.897509 PTGES  1.824161 
CYP4V2  2.109592 VTRNA1-3  1.986014 ELTD1  1.894138 MIR3189  1.819376 
UBASH3B  2.108435 UBE2J1  1.985595 ZYX  1.893617 PRICKLE1  1.81923 
RAB27B  2.104826 TLE1  1.975845 UPF2  1.893116 HTRA1  1.81714 
FAM168B  2.098751 SLC46A3  1.974903 DKFZP586I1420  1.891918 ZNF616  1.814841 
AMD1  2.097939 LOC101928161  1.971175 PTGIS  1.889755 FOXN3-AS1  1.81464 
SGPP2  2.096126 RNU6-737P  1.967519 SLC35B4  1.888547 PM20D2  1.813977 
SEMA7A  2.095867 MURC  1.961502 AC002117.1  1.88551 PMS2CL  1.813099 
MAP3K2  2.09431 HERC2P9  1.960307 BRCC3  1.883176 IL6  1.812095 
RN7SKP103  2.092165 NEDD4  1.959699 ZNF451  1.882136 ANTXR2  1.81045 
INA  2.091255 SOS2  1.954544 DNAJC16  1.879633 ZNF749  1.809319 
LOC100129033  2.090994 TRIB1  1.953029 RNY1P5  1.878979 FAM169A  1.808473 
ARL14EPL  2.089754 RWDD2A  1.947853 CSGALNACT2  1.878331 KLHL5  1.807048 
DUSP4  2.08767 EPC2  1.943185 RP11-51L5.3  1.877737 CHST15  1.806131 
IL6ST  2.085031 GLYR1  1.942764 LOC100288842  1.875847 MIR1305  1.805875 
ALDH1L2  2.082424 SNURF  1.939961 USP34  1.87583 LINC00941  1.80328 
DCLRE1A  2.074959 RNA5SP514  1.939677 TTC39C  1.873594 ZC3HAV1  1.801853 
TPTEP1  2.073601 AF127936.7  1.939403 CREG1  1.872638 CUL3  1.801803 
CD200  2.071668 SLC37A2  1.935587 TINAGL1  1.872494 SRSF8  1.801532 
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SCN9A  2.069506 SLC38A2  1.93174 PTPN21  1.867221 PTPLAD1  1.800976 
SNAI2  2.067916 MXRA7  1.931705 CDR1  1.867099 TXNL4B  1.800952 
SLC7A1  2.060234 ELK3  1.930185 SLC36A4  1.863081 ATE1  1.800444 
RP11-760H22.2  2.059532 ZNF510  1.928199 RP11-350F4.2  1.860596 SEMA3C  1.800292 
MOSPD1  2.057721 DHRS3  1.92713 MTM1  1.858839 IGIP  1.7982 
EPHB2  2.05737 EFR3A  1.926876 BCL2  1.858283 TUBE1  1.798166 
TTPAL  2.056755 PTER  1.925035 BRWD3  1.854428 FBXO28  1.797531 
ZCCHC14  2.055231 PDE4DIP  1.922442 SH2D4A  1.853101 SIN3A  1.794683 
CEACAMP7  2.05205 PHLPP2  1.921791 CDCP1  1.852996 GCSHP3  1.793769 
KCNK3  2.047872 MIR622  1.920585 TIGIT  1.852878 CEP170P1  1.792686 
RNU7-12P  2.046575 FOXE1  1.919704 ITGB8  1.849672 PSPH  1.792622 
RAB23  2.043914 POLR3C  1.918577 ZNF114  1.84827 RP11-152P17.2  1.791818 
CLOCK  1.78992 RCOR3  1.74372 LRRC58  1.701534 SFTA1P  1.6662 
RNU6-552P  1.788636 HIPK2  1.739355 KCNQ1OT1  1.700439 GPR137B  1.666123 
ASB7  1.788473 MIS12  1.739009 ABCC4  1.699939 EP300  1.66553 
GAB1  1.786602 VEGFA  1.737879 AHR  1.699907 LOC644135  1.664838 
RNU7-22P  1.786594 ESCO2  1.736728 SDCBP2-AS1  1.699864 PIGM  1.66414 
MIR548H3  1.784082 TJP1  1.735386 PUS7  1.698751 SLC39A14  1.66384 
MIR645  1.7837 NCOA1  1.735349 NCOA6  1.698281 KIAA1614-AS1  1.661423 
RP11-531A24.5  1.782452 MIR550A2  1.734352 RAD51D  1.698 ZNFX1  1.660288 
ZBTB2  1.78243 SLC35F6  1.734014 HNRNPA1P33  1.69766 TSEN2  1.659682 
IL1A  1.782171 OSBPL6  1.732734 PA2G4P4  1.697442 CHAMP1  1.658388 
ODC1  1.781665 TRIB3  1.732405 SLC25A33  1.696959 RP11-221N13.3  1.658131 
CDC6  1.780991 LOC389906  1.731913 APPBP2  1.695547 FAM135A  1.657188 
CEP19  1.779285 PCNXL4  1.73142 SOAT1  1.695361 DSC3  1.656548 
NRP1  1.77921 SLC9A7P1  1.731332 LGR4  1.694303 POGLUT1  1.656156 
LURAP1L  1.778317 PPT2  1.730819 PTX3  1.693039 TRIM61  1.655637 
VPS4B  1.777982 INTS5  1.73061 SLC30A7  1.692324 SOS1  1.655123 
IFNAR1  1.776111 UTP20  1.730265 MOCOS  1.691342 CLMP  1.654763 
ZSCAN29  1.775774 KLHDC1  1.72936 LOC100507516  1.690573 DOCK9  1.654632 
CREBBP  1.772983 ARHGAP29  1.728854 DOCK7  1.689326 ZCCHC2  1.654386 
EGR1  1.770654 KIAA1549  1.727039 ITGA2  1.688345 ST6GALNAC3  1.653842 
RNF2  1.770441 SNX18  1.726307 VDR  1.686183 UBLCP1  1.653543 
ZNF382  1.770258 NDST1  1.726079 SLC7A2  1.684968 SGPP1  1.653503 
RNF157  1.76798 OXTR  1.726 RMND1  1.684094 SLC1A1  1.653435 
XPOT  1.767514 ARID2  1.725809 TNFRSF12A  1.683306 SPIN3  1.652619 
BRCA2  1.767387 SDAD1  1.725691 H1F0  1.683254 ERCC6L2  1.650905 
PARP8  1.765333 SLC35A4  1.724311 ZNF280C  1.682776 REPS1  1.650871 
ZNF543  1.761874 AJAP1  1.724183 RNU6-795P  1.682551 NUAK1  1.650607 
MGC27345  1.760415 RP11-290L1.3  1.723926 PLEKHA3  1.68216 DAZL  1.650314 
CYP20A1  1.760145 ADAM12  1.719408 RNA5SP462  1.682087 KAT6B  1.648313 
ZDHHC5  1.757528 DIS3L  1.718074 RC3H2  1.681834 RB1CC1  1.64733 
TRIM24  1.757328 MMGT1  1.717454 MT-TL2  1.678737 HGSNAT  1.647241 
JUN  1.75647 SLCO4A1  1.715966 OTUD4  1.678462 KCNMA1  1.646335 
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RPL23AP32  1.756319 TAF2  1.715794 FOXN2  1.678402 PLLP  1.645048 
MIR1299  1.7563 ETV4  1.714928 ARHGEF28  1.677537 LOC645553  1.643692 
RNU7-193P  1.756214 RRAGC  1.714511 RNU6-917P  1.677435 RP11-449J1.1  1.643619 
COQ10A  1.75581 PDE12  1.713194 RP5-1087E8.3  1.677424 LA16c-60G3.8  1.643028 
C18orf8  1.754843 PAPPA2  1.712624 USP7  1.676185 PMEPA1  1.642315 
SGPL1  1.754667 RASGRF1  1.710491 METTL4  1.675794 ZDBF2  1.64205 
B3GALTL  1.75428 ME1  1.709676 PTPRK  1.674733 USP6NL  1.642002 
NBEAP1  1.752546 RMND5A  1.708225 DNAJC13  1.674005 DHRS13  1.64177 
AGL  1.751588 C3  1.708101 SLC38A4  1.673228 ZWILCH  1.640371 
SLC1A4  1.751068 
RP11-
389O22.1  
1.707705 EOGT  1.672845 NCK2  1.640021 
MEIS3P1  1.749582 APOLD1  1.707253 KLF5  1.669997 NEDD4L  1.639741 
RALGPS2  1.748452 ZKSCAN2  1.704567 TMEM171  1.669907 WASF1  1.639088 
ZNF280B  1.748173 CCDC68  1.70398 LINC00294  1.66893 SESN2  1.638715 
ZBTB44  1.747966 MIR548V  1.7036 AP000695.6  1.66886 FBXL3  1.638045 
N4BP2  1.747314 INTS7  1.702671 LOC101060691  1.667846 USP53  1.638026 
CLSTN2  1.74692 ADM2  1.702531 LINS  1.667118 ARHGAP12  1.636429 
LOC284926  1.74582 C1orf109  1.702395 TCP11L2  1.666627 MIR614  1.636091 
SPEN  1.636081 FBXO32  1.601066 RNU7-50P  1.570298 ASAP2  1.544552 
CPPED1  1.635599 KIF5B  1.600403 CYP4F26P  1.569256 FNTA  1.543467 
RABEP1  1.634311 LAMB3  1.600055 JMY  1.568123 STAM  1.543034 
SLC7A6  1.633565 RPP40  1.599206 SLC7A5P1  1.56807 TIAM1  1.542935 
VAMP4  1.632099 C7orf31  1.598038 GOPC  1.567827 LMBR1  1.542913 
AFF1  1.63109 SRGAP1  1.597572 SSH1  1.567811 DUSP6  1.542131 
VGLL3  1.630561 TMX1  1.597531 OTUD1  1.567602 SLC16A3  1.541486 
IFNE  1.629674 SLC30A6  1.596849 LOC101926917  1.564761 IRF2BP2  1.541025 
ZNF37BP  1.629388 CDH4  1.596599 ORC5  1.564005 SIRPD  1.540921 
RP11-11N9.4  1.628769 NFAT5  1.596037 DSC2  1.563897 RP11-473I1.9  1.540698 
RP11-63P12.7  1.626747 SHC3  1.595951 EML4  1.563746 KIAA1644  1.539797 
ANGPTL2  1.625912 RAPGEF3  1.595901 AP4E1  1.563739 BICC1  1.539705 
LOC100506255  1.625411 AP5M1  1.595544 ASH1L  1.563651 RP11-692D12.1  1.539357 
USP38  1.62488 ZNF786  1.595516 RIN2  1.562456 MIR3142  1.539357 
STXBP5  1.623868 SIK2  1.594961 MMP24-AS1  1.561526 LINC00476  1.538922 
USP24  1.623373 ZNF571  1.594173 SLC30A9  1.560926 NGF  1.538579 
SPPL2A  1.622904 CAPN7  1.593797 DPP4  1.560828 SLC38A7  1.538341 
RNU6-1065P  1.62259 LARP4  1.593684 RCHY1  1.560376 LOC101930415  1.537579 
STAM2  1.621963 NOP2  1.593 C17orf80  1.559804 ZC3H11A  1.537399 
ADAM1A  1.621258 DHRS7B  1.589735 FMNL2  1.558952 SIM2  1.537254 
HELQ  1.62117 IRS2  1.589264 PAIP2  1.558525 TNRC6C  1.536722 
RAI14  1.620979 HEATR1  1.58843 SFMBT1  1.558096 ANKRD28  1.536264 
SMIM2-AS1  1.620877 NRIP1  1.587883 MIR1224  1.558043 ROCK2  1.535472 
AC003092.2  1.619539 RPS6KA5  1.587711 ROR1  1.557849 SLITRK4  1.53484 
BAZ1B  1.61838 RIOK1  1.5874 TOE1  1.557604 ACTR3BP2  1.534471 
ZNF768  1.618169 GPATCH8  1.585807 PRR14L  1.556856 KIAA1033  1.533985 
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ABHD5  1.616489 LRRC15  1.584497 ERCC4  1.556852 ZNF557  1.533238 
LOC101927287  1.616235 ZNF148  1.583097 RMI1  1.556851 CRTC3  1.532527 
LINC01355  1.615884 RRP1B  1.581985 LITAF  1.556808 TMEM170B  1.531543 
CLCN3  1.615855 ZDHHC21  1.581645 ZNF613  1.556659 ACSL1  1.53126 
ANAPC1  1.615255 RN7SKP233  1.581046 ARHGAP21  1.555701 ZZZ3  1.53123 
LIMS3-LOC440895  1.613074 GPR84  1.580709 CDK8  1.554758 ETHE1  1.531097 
PBDC1  1.612459 WRN  1.580576 HIPK3  1.554418 PAK2  1.530761 
IL24  1.612094 ZNF620  1.579919 BACH1-IT2  1.552076 SEPT7P2  1.530563 
DCLK1  1.611458 CCNYL1  1.579247 DOLK  1.551975 ZNF284  1.529801 
AGPAT9  1.610974 RBM26-AS1  1.57797 LEPREL1  1.551631 GFPT2  1.529722 
LOC100130428  1.610967 ZFYVE9  1.577871 DDAH1  1.551444 TTPA  1.52919 
PKN2  1.610821 LACC1  1.577764 DHX32  1.551334 GTF2IRD2B  1.528708 
PWARSN  1.610572 CLEC2D  1.577601 DOCK5  1.551318 ZNF594  1.528352 
SYDE2  1.610369 FAM89B  1.576516 NCOA3  1.551199 IFIT5  1.528192 
FOXD1  1.610332 PXK  1.576018 RP11-21L19.1  1.551136 FTSJ1  1.527039 
PKD2  1.609927 RP11-864G5.3  1.575954 RP5-864K19.4  1.551076 TPTE2P5  1.526762 
C5orf22  1.609657 FTX  1.575772 SLC35A5  1.549874 TBCEL  1.526207 
CHTF8  1.607349 PLAT  1.573257 FLJ31306  1.549423 SNX2  1.524556 
GTF2H1  1.606428 MT1E  1.572997 LOC100128281  1.548419 ALKBH1  1.523901 
ATF1  1.606089 RAB4A  1.572824 N4BP1  1.547936 LIFR  1.522688 
CPT2  1.605741 BTBD7  1.572024 AKAP11  1.54672 RNY4P16  1.522136 
FAM49A  1.605301 CCNJ  1.571715 C2orf42  1.546037 CHST11  1.520704 
MBTPS2  1.601968 RP11-115J23.1  1.571193 PLAGL2  1.545879 GPATCH2L  1.517324 
FAM208B  1.517152 JAM2  1.493546 C21orf91  1.467402 TAB3  1.439521 
SRSF6  1.51683 FLJ38717  1.493111 TNFAIP2  1.463938 PPIP5K1  1.439348 
LONRF3  1.516118 ENTPD7  1.492494 JAGN1  1.463534 EVI5  1.439308 
ZBTB24  1.515437 SERPINB2  1.492354 STOX1  1.462698 ARL6  1.438975 
RNU6-729P  1.51534 CTSO  1.491522 AC002480.4  1.462223 RBBP6  1.438948 
MBLAC2  1.514796 SGOL1  1.491217 ZXDB  1.4618 SHMT2  1.437801 
TRAPPC10  1.513891 RPF2  1.490045 ZNF614  1.461071 SLC31A1  1.436611 
AGPAT5  1.513805 DCAF10  1.489306 OSBPL8  1.460799 LOC101929787  1.436437 
TAS2R20  1.51367 ZNF189  1.489108 DSCC1  1.460642 KIAA0430  1.43625 
AP000695.4  1.513253 SUCO  1.488958 CNIH3  1.460501 BRWD1  1.436022 
MAFIP  1.51291 LBR  1.487698 ERN1  1.460311 C5orf30  1.436002 
TMEM184C  1.512569 INHBB  1.487305 RP11-394J1.2  1.460249 RALGAPA2  1.435998 
SCN8A  1.512562 TMEM104  1.487042 IL31RA  1.459969 MCTP1  1.435791 
WAPAL  1.512239 CAMSAP2  1.486762 UBIAD1  1.458976 ZNF70  1.435748 
RP11-337C18.8  1.5121 ATMIN  1.486534 UBE3A  1.458512 LOC101929705  1.435428 
LOC645513  1.511724 ABHD3  1.486331 TP53BP2  1.457955 ZNF319  1.434824 
NIPA1  1.51135 SNAP29  1.48632 UCN2  1.457804 SENP6  1.43459 
MTMR9  1.511248 TGFBR2  1.486215 ANKH  1.457617 RP11-428P16.2  1.434176 
PRKCI  1.510416 APBB1IP  1.486064 WIPF1  1.456883 SLC9A8  1.433236 
UBXN2B  1.509993 LOC100129034  1.484602 ADCY9  1.456601 GPT2  1.432408 
IL18  1.509688 LOC100131691  1.484523 INO80D  1.456383 EIF4G2  1.432407 
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TSTD2  1.509433 MRPL42  1.4832 TRAM1  1.455212 POLR1B  1.431811 
CPEB4  1.509287 CIRH1A  1.483088 PPP2R3C  1.45486 TMEM216  1.431442 
CDC14A  1.50894 TMEM127  1.483064 NEDD1  1.454665 ABLIM3  1.430771 
RNU6-945P  1.508327 SRXN1  1.482562 EEFSEC  1.454555 BACE1-AS  1.429879 
STAMBPL1  1.507999 SQSTM1  1.48098 FLG-AS1  1.454022 TMX3  1.429562 
RN7SKP97  1.507858 ADAMTS12  1.480737 CTNS  1.453683 SCAF4  1.427791 
C9orf41  1.507848 DGKE  1.479801 SLC27A4  1.453395 SMOX  1.427552 
SMEK2  1.507516 FAM217B  1.477998 KIAA0513  1.452723 ENOX2  1.427221 
RAB22A  1.507414 ACVR2A  1.477882 DNER  1.452283 RP11-283G6.3  1.426543 
SLC38A9  1.50712 RAD50  1.477428 DCLRE1C  1.451439 CLCN5  1.426277 
NPC1  1.506433 AKAP12  1.476506 ZNF658  1.450561 ZSWIM7  1.42614 
E2F5  1.506412 LOC731157  1.476149 ERCC6  1.449839 RP11-432J22.2  1.426051 
IFNA5  1.505934 USP1  1.475617 TMEM170A  1.447485 MYO9A  1.42569 
ESCO1  1.505563 SF3B4  1.474387 MKKS  1.447453 AC073046.25  1.425458 
ATP13A3  1.504597 HSCB  1.473746 UBAP1  1.446822 BCOR  1.42543 
LINC00997  1.504594 LOC100132705  1.473384 ASUN  1.446407 HAUS6  1.425339 
MIR4706  1.503593 AGGF1  1.473243 LOC100506083  1.446051 KCNIP3  1.425308 
LRRC8D  1.502046 AGO3  1.473011 ZNF268  1.445874 ZBTB40  1.424618 
FTSJ2  1.498982 ELOVL4  1.47185 ZFHX3  1.445201 CTR9  1.424035 
TIFA  1.498214 ALDH1B1  1.471296 GLIPR2  1.445102 ZMYM4  1.423858 
HIST1H2AB  1.498048 DPP8  1.470887 ELF1  1.444913 
NDUFC2-
KCTD14  
1.423383 
USP10  1.49792 RP11-7F17.7  1.470376 DCBLD2  1.444389 CEP120  1.422738 
C1QTNF1  1.497697 FBXL4  1.470242 RP11-154D6.1  1.443486 RNU6-623P  1.421597 
SRSF1  1.496238 C3orf35  1.469421 ITPR2  1.442371 KIAA1804  1.421583 
G0S2  1.495243 CD3EAP  1.46873 WDR66  1.441458 SMG1  1.420775 
GPR65  1.495142 ANKS6  1.46872 TIMM22  1.441366 TCAIM  1.420272 
BDKRB2  1.4942 TMEM192  1.468279 RIPK1  1.440426 SLIT2  1.419477 
PKI55  1.493913 RP11-253E3.3  1.467753 SLC16A1-AS1  1.4398 CDA  1.419115 
Z83851.4  1.418785 TSPAN14  1.397822 TANC2  1.377635 CPTP  1.35766 
EFTUD1  1.418691 PAX8  1.39734 MDC1-AS1  1.377512 TNPO1  1.35742 
CUL5  1.417213 DCP1A  1.397011 EPHB1  1.376693 CCDC138  1.357252 
CAB39  1.417188 TULP4  1.396604 SESN3  1.376296 HOMER1  1.356849 
EVA1A  1.417142 IARS  1.395456 RNU4-9P  1.376138 FAM86DP  1.356761 
KCNIP1  1.416818 MTMR10  1.39508 SCARA3  1.37603 PSMD5  1.356013 
SLC15A4  1.416405 STC1  1.394048 CBL  1.375654 RFX8  1.355878 
MKL2  1.415597 LCMT2  1.393982 FNIP1  1.375525 SPAST  1.355427 
KIRREL  1.415589 CNOT1  1.393839 EPS15L1  1.375502 PREX1  1.355376 
TUBD1  1.415307 MED1  1.393589 GAS6-AS2  1.375053 EML5  1.355225 
ANPEP  1.414548 MTF1  1.393486 RNU7-96P  1.374904 RNY4P17  1.354979 
USP32P2  1.412629 RNU6-302P  1.39337 GULP1  1.373886 SH3BP4  1.354902 
SLC9A6  1.412229 USP12  1.393049 OPN3  1.373862 CLN8  1.35482 
ZNF652  1.411916 LOC100289650  1.392468 HELZ  1.373503 DNAJC10  1.354256 
RSPRY1  1.411847 ENTPD5  1.390745 ZNF644  1.373026 CDC42BPA  1.354214 
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ABTB2  1.411704 ABHD6  1.390414 PEA15  1.372827 DMXL1  1.354016 
TRAM2  1.411283 OCLN  1.390171 NARS2  1.372602 AARS  1.35386 
RAB6A  1.410723 ADAL  1.389439 
CTD-
2555O16.2  
1.372595 AMTN  1.353526 
IFIT1  1.41058 ERGIC1  1.389249 NEXN  1.372481 RP11-344N10.5  1.353261 
ASXL2  1.410483 SLC2A1  1.389242 IFT88  1.37248 QRSL1  1.35304 
KIAA0196  1.410328 TARS  1.388617 SUPT20H  1.371767 RSC1A1  1.352768 
RNF144B  1.410226 RP4-816N1.7  1.387688 NQO1  1.37156 CNST  1.352705 
COG2  1.410165 PRKG2  1.386621 LOC100507530  1.37091 CDK19  1.352417 
MORC3  1.410057 HERPUD2  1.385828 SRR  1.370899 LINC00337  1.352363 
MAFG-AS1  1.409312 PHF3  1.385753 SMIM13  1.370502 NHEJ1  1.352306 
FAM208A  1.408428 MCIDAS  1.385696 RP6-206I17.1  1.369637 ANKRD40  1.35228 
TROVE2  1.40791 KLF10  1.385686 CINP  1.369414 RPS6KB1  1.351969 
LYSMD3  1.407643 MRPL45  1.385385 MOB1B  1.368512 MYCBP2  1.351784 
CITED2  1.407412 ZBED4  1.384752 TEX2  1.368378 LOC102723919  1.351293 
IGKV1-17  1.407109 COMMD2  1.384052 PEX12  1.367892 OGFRL1  1.350403 
LOC389831  1.406581 ALG2  1.383817 KDSR  1.367024 TTC30A  1.350185 
TBX20  1.406547 LAMC2  1.383816 TXLNG  1.366143 TRNT1  1.349976 
ZMYND11  1.406281 PALB2  1.3832 SLC35E1  1.366058 ATP2B1  1.349907 
MCM8  1.405027 TOR1B  1.382883 GDA  1.366039 UBE4B  1.349833 
ZFR  1.40438 TMEM43  1.382754 GPAM  1.365405 MTDH  1.349667 
TBL1XR1  1.404047 RALGAPA1  1.382259 PIGW  1.365229 NANS  1.349066 
HKDC1  1.403702 RFXAP  1.381933 RN7SKP88  1.364836 UTP15  1.348905 
APBB2  1.403631 MYO5A  1.381926 ELK4  1.364247 TMEM185B  1.348299 
OR2A1-AS1 1.402576 CPN2  1.381566 RPRD2  1.364145 RAD17  1.348068 
SLK  1.401072 RAB3B  1.381192 MAP3K15  1.363872 EDA2R  1.34788 
FASTKD3  1.401027 LOC101927326  1.380802 MIR4731  1.363169 KDM4D  1.347677 
AFTPH  1.400808 ATP2C1  1.380672 ATG2B  1.362966 PPP2R3A  1.346784 
LOC100134040  1.400583 MALT1  1.380635 HECTD2  1.362786 HEG1  1.346006 
MGC70870  1.400437 FGF2  1.380116 ATP11C  1.361578 WAC-AS1  1.345376 
C9orf64  1.400043 FITM2  1.379964 GSK3B  1.360975 MRFAP1L1  1.345103 
HECTD1  1.399922 PHF23  1.379045 CPM  1.36067 MYO1B  1.343488 
PAG1  1.39979 USP25  1.378394 CCNI  1.359333 CD44  1.342396 
ZNF689  1.399228 TMEM194A  1.378307 SLCO3A1  1.358797 FAM126A  1.342287 
CGRRF1  1.397822 AAED1  1.377967 GPS2  1.358376 MEX3C  1.341886 
RP11-685N10.1  1.34174 RP11-513D5.2  1.323929 DNAJC1  1.304436 RP11-632F7.3  1.282305 
CCDC6  1.341476 PLEKHG7  1.32384 S1PR1  1.304211 TENM3  1.282008 
WASL  1.341432 KCTD9  1.323602 PRKAA1  1.304198 LOC729218  1.281832 
ZSCAN30  1.341231 CHUK  1.323417 DNASE2  1.304134 MIR4798  1.281799 
LINC01234  1.340526 RPL7AP28  1.323188 GOSR1  1.302506 USP8  1.281727 
DEGS1  1.340292 
RP13-
143G15.4  
1.321899 FOXF2  1.302422 LDOC1L  1.281366 
RP11-513I15.6  1.33992 FAM89A  1.321229 NF1  1.302028 MIR4252  1.281248 
ANKRD42  1.339382 CEP104  1.321101 MLXIP  1.299884 NEK7  1.28095 
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FOXC1  1.338869 
CTD-
2116N20.1  
1.319868 NEGR1  1.299653 GPRC5C  1.280754 
SPDL1  1.338263 CDC42EP2  1.319571 CNOT10  1.29961 GRB10  1.279955 
YIPF4  1.33817 RNF6  1.319421 MAP1B  1.298814 LMLN  1.278812 
GNPNAT1  1.3379 PTDSS1  1.318813 BMP2  1.29877 NT5C2  1.278628 
TAPT1-AS1  1.337838 TST  1.318697 CA5B  1.298759 CCNT1  1.278534 
FAM13B  1.337773 AASDHPPT  1.318649 POLR3B  1.297936 DFFA  1.27826 
ACTBL2  1.337643 THRB  1.317908 MARS2  1.297518 SLC30A4  1.277958 
NSAP11  1.337141 LIAS  1.317793 SLC35G2  1.297178 PTPN12  1.277798 
RNU6-960P  1.336786 BRPF3  1.317766 FHOD3  1.295922 C6orf15  1.277282 
SH3RF1  1.336614 HIPK1  1.31711 CCDC50  1.295272 AXL  1.27711 
SETD7  1.336279 MED13  1.316936 SIRPA  1.29397 SLC35A3  1.276942 
ABCE1  1.336252 ZNF592  1.31685 AP5B1  1.293766 RARG  1.276789 
ARL13B  1.335781 PLCE1-AS1  1.316719 HNRNPA0  1.293626 SLC1A3  1.276714 
GS1-259H13.2  1.334701 PCGF5  1.316559 CASD1  1.293487 DFNA5  1.276496 
PIK3C2A  1.334699 USP42  1.31652 C5  1.293263 CLIP4  1.276099 
GTF3C4  1.334464 MBNL2  1.31573 KAT2B  1.292993 LOC102724851  1.275713 
PPARA  1.334194 TTC13  1.315128 LOC100507577  1.292849 EHBP1  1.275111 
PHGDH  1.332714 C12orf49  1.314833 LOC100287072  1.29271 PAPD4  1.274444 
NNT  1.332005 TBRG1  1.314255 SPATA2  1.292363 RNA5SP140  1.273958 
MIR548H2  1.331638 ZNF41  1.313755 XPR1  1.291301 PRKD3  1.273607 
LPXN  1.331593 ZNF2  1.312331 FAM118B  1.291298 LOC647859  1.273436 
CCND1  1.331442 OSBPL11  1.312193 FAF2  1.291179 ARMCX2  1.272956 
ATL3  1.331154 HRK  1.311553 PIKFYVE  1.291116 MIR181B2  1.272752 
CTBP1-AS2  1.330835 RAD23A  1.311351 C4BPB  1.29109 VKORC1L1  1.272721 
RPAP2  1.330816 CTD-2647L4.4  1.310436 ARRB2  1.288526 LOC399815  1.27123 
RAB42  1.330498 TMEM179B  1.3104 C5orf51  1.287892 ARHGEF6  1.270944 
CENPBD1  1.33032 ZRANB1  1.310215 CPSF2  1.287741 CSNK2A3  1.270937 
C9orf85  1.330045 LINC01433  1.309855 NOP58  1.286867 AP000704.5  1.270723 
IREB2  1.328996 GDAP2  1.30978 FASTKD2  1.286672 LINC01128  1.270707 
AGTPBP1  1.328773 LOC100506498  1.309323 MTSS1L  1.286026 FAM86MP  1.27036 
ZBTB25  1.328566 NIFK  1.309274 SH3PXD2B  1.285991 NUPL1  1.27013 
ASF1A  1.328137 FBXO10  1.309248 C9orf91  1.285711 POLR1A  1.270009 
TMEM57  1.328053 NSMAF  1.307543 PRICKLE2  1.284794 CDY2A  1.269933 
PNPLA8  1.328029 ZNF287  1.30638 DOCK4  1.28444 R3HCC1L  1.269795 
TMEM131  1.327636 LOC389602  1.306207 SLC25A13  1.283959 DBT  1.269508 
CSRP2BP  1.32684 PORCN  1.305967 RNU6-1029P  1.283948 POP1  1.269235 
RNU6-811P  1.324877 LDLRAD3  1.305433 TMEM38B  1.283293 BVES  1.269155 
MYO6  1.324826 FAM122A  1.305241 NCR3LG1  1.282793 PNO1  1.269093 
PLOD2  1.324691 HSDL1  1.304901 SHISA9  1.28279 SMCHD1  1.268471 
MEPCE  1.324318 DUSP14  1.304681 UTP14A  1.282785 ZNHIT6  1.267512 
PMAIP1  1.324242 FAM20C  1.304663 SPRTN  1.282696 PID1  1.267384 
PDCD4  1.267007 MTFMT  1.252153 HEATR5A  1.237303 MTRR  1.222764 
ITGA1  1.266801 ZHX2  1.251953 BCL2L13  1.236654 DDX21  1.222337 
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RAP1GDS1  1.266561 SLC39A6  1.251279 BCL10  1.236285 DCP1B  1.222283 
LOC441461  1.266259 ST3GAL1  1.250956 MTHFD2  1.236262 FAM60A  1.221706 
AGO4  1.266108 AC083899.3  1.250718 ASNSD1  1.236098 SLC26A2  1.221702 
USP46  1.26549 NIPAL2  1.249977 PARD3  1.235664 ZNF507  1.221636 
UBE2Q2  1.264791 RNU6-529P  1.249405 TSHZ3  1.235443 CSNK1G3  1.221174 
DIP2A-IT1  1.264347 NSRP1  1.249174 UBE2Q1  1.235297 PITPNA  1.221104 
TPT1-AS1  1.264112 WDR3  1.2491 MIR29C  1.234988 NOC3L  1.220807 
EXOSC5  1.263763 PRUNE2  1.248993 MIR25  1.234177 FAM175B  1.220637 
LINC00665  1.263449 ABHD17C  1.248225 RPL13P5  1.233943 ZNF250  1.22022 
RN7SKP268  1.262646 
RP13-
631K18.5  
1.247942 B4GALT1  1.233482 RAP2CP1  1.22014 
CAND1  1.261895 FAM86C2P  1.247877 PRKACB  1.232335 MTSS1  1.219847 
EBLN3  1.261489 LOC101927116  1.247255 NBEAP3  1.232326 DBNDD2  1.219742 
KIAA2026  1.261036 ZBTB14  1.246778 LARP4B  1.232262 C19orf12  1.219582 
WDR52  1.260824 AP1G1  1.246598 SLC3A2  1.232218 PAPOLA  1.219228 
TXNRD1  1.260633 ARMC9  1.246482 XPO4  1.231575 IGLV1-40  1.218093 
RNF180  1.260188 KANK2  1.246212 LOC101926941  1.231571 SPG20OS  1.217874 
SH2B3  1.259427 FAM172A  1.246062 MSRB3  1.229298 TAS2R30  1.217598 
C1orf43  1.258509 RAB29  1.246003 NBPF25P  1.229284 MIR619  1.217316 
C10orf25  1.258493 S100PBP  1.245932 NRROS  1.229123 TMCC3  1.217264 
FUS  1.258299 GPRC5A  1.245853 CDC42EP1  1.228986 SLC35F5  1.217257 
TMEM156  1.258235 ZXDC  1.245675 PDGFA  1.228909 TRAPPC6B  1.216899 
EYA4  1.258229 RNU6-918P  1.245514 ZMIZ1  1.228337 SNRNP27  1.216372 
IDH3A  1.257843 ANAPC16  1.245506 RGL1  1.228333 TMEM251  1.216016 
CYP2E1  1.257577 CHIC2  1.245393 AC005037.3  1.228261 USP28  1.215901 
CCDC183-AS1  1.257362 MIR654  1.245265 ROCK1  1.227693 ABLIM1  1.215288 
ARSG  1.257157 SEL1L3  1.244993 HIST1H3E  1.227191 
RCN1  // 
DKFZp686K1684  
1.215097 
FCHO2  1.257116 MIR28  1.244726 KLF11  1.227113 JOSD1  1.214777 
CASK  1.257036 SH3BP5  1.244549 ELOVL6  1.226487 ARID5B  1.214632 
CLHC1  1.256684 SVILP1  1.243699 LOC100130876  1.226435 USP13  1.214518 
DERL2  1.256662 C1orf233  1.243295 HSD17B1  1.226434 TBC1D9  1.214425 
TOX2  1.256455 USO1  1.242737 QPRT  1.226337 DHRSX  1.214255 
PNMA1  1.256104 CTC-378H22.2  1.242624 LOC101929099  1.225724 ZNF75A  1.214061 
RP1-101K10.6  1.255986 RP11-3D4.2  1.242155 DNAJC15  1.225457 TNFRSF9  1.21388 
DDX58  1.255924 MAGI2-AS3  1.242126 CRISPLD2  1.225358 INHBA  1.213716 
GPR125  1.255797 FBN2  1.241543 SIGMAR1  1.224755 DAGLB  1.213689 
GALK2  1.255154 DUSP5  1.240768 PSKH1  1.224735 RAPGEF1  1.213506 
KLC1  1.255046 FADS1  1.239585 RPAP3  1.224445 ACVR1  1.213268 
RP11-351I24.1  1.254619 PTPN14  1.239482 RHOF  1.224033 SLC41A2  1.212879 
USP37  1.254497 NUFIP1  1.239115 ZBTB8A  1.223982 BTBD9  1.212075 
MFSD12  1.254488 ATP11B  1.239058 AVL9  1.223962 LINC00869  1.211897 
LRRC16A  1.254376 HTR1D  1.238856 UBTD2  1.223876 MIR513A1  1.211702 
TMTC3  1.254323 THEM4  1.238752 HS2ST1  1.223783 NEK4  1.210802 
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PHF20L1  1.253891 40787 1.238633 GFRA1  1.223758 VANGL1  1.210203 
SACM1L  1.25388 CYBRD1  1.238534 MIR3665  1.223498 ANKRD13C  1.210118 
GNA11  1.253196 NCKAP1  1.237966 AC046143.3  1.223093 SUZ12  1.20985 
LPHN1  1.252801 SUV420H1  1.237663 QTRTD1  1.223072 KIAA0895  1.209691 
MID2  1.252505 
RP11-
196H14.3  
1.237447 CASC10  1.222906 TMEM181  1.209391 
RNU7-110P  1.209082 C9orf69  1.191625 LOC441155  1.177516 PPAPDC2  1.162867 
UBE3B  1.208612 TMEM158  1.191173 ADRB2  1.177481 KYNU  1.162838 
SMARCAD1  1.208563 PTPLB  1.191061 OXSR1  1.176901 RNU6-575P  1.162829 
ABCC3  1.208132 C10orf88  1.19039 DOCK1  1.176159 COX11  1.162503 
SLC25A46  1.207225 RRM2B  1.190326 SDE2  1.175604 ARHGAP5  1.162473 
MBNL1  1.206768 TMEM65  1.189977 ABCF2  1.175166 ZNF252P  1.161729 
WDR44  1.206263 NAIP  1.189938 COA5  1.175128 MET  1.160669 
IGF2BP3  1.206069 CUL1  1.189618 CBX4  1.174959 CDC42EP3  1.159961 
ANO6  1.20494 ZNF106  1.189083 PCNX  1.174474 MIR4267  1.159837 
TCP11L1  1.204884 FZD7  1.188988 PCMTD2  1.174383 TRMT6  1.15969 
GGCX  1.204642 LOC286437  1.188696 RPS6KA3  1.174154 ZNF691  1.159623 
RBBP8  1.204619 AC068286.1  1.18866 MKX  1.173955 DNAJB6  1.159166 
SLC25A24  1.204276 PPIF  1.188158 KDM6A  1.173641 NET1  1.158782 
ZNF33B  1.204197 PLEKHM2  1.188137 CLPTM1  1.17348 DTX2  1.158476 
IFNGR2  1.204166 LOC100130691  1.188121 RNASEH2B  1.173388 TSSK3  1.158318 
PMS2  1.203154 ERBB2IP  1.188052 CRK  1.173317 MKNK2  1.157744 
ZNF639  1.202794 ZFP91  1.187847 PPP6C  1.172981 ANGPTL4  1.157629 
CARS  1.202684 SYT14  1.187793 RNU6-14P  1.172817 RP11-380G5.2  1.157627 
WDR35  1.201383 MTHFD1  1.18765 UEVLD  1.17274 SNX16  1.157533 
LOC283588  1.201145 IFT80  1.187563 DYM  1.172058 LIMA1  1.157411 
PSMD11  1.200916 TRIM33  1.187343 FBXW11  1.171923 CENPN  1.157365 
MID1IP1-AS1  1.200117 RNF13  1.187103 LRRC37A2  1.171518 GOLPH3  1.157338 
SEPSECS  1.199973 GSPT1  1.186137 IFT22  1.17139 EMC3-AS1  1.157287 
HN1  1.199955 EID2  1.186032 PDE7A  1.170772 BMPER  1.156802 
PSME3  1.199867 AP000525.9  1.185137 SPG20  1.170411 40422 1.156366 
PHF10  1.199867 GNG5  1.184033 HLTF  1.170099 LOC100506731  1.156114 
ZBTB1  1.199388 ANKIB1  1.183669 TMEM51  1.169978 GAS5-AS1  1.155622 
BNC1  1.19934 RNU6-433P  1.183633 AC099850.1  1.168921 WDR36  1.155442 
DMWD  1.199128 NF2  1.182665 BMPR2  1.168816 ACOT9  1.155421 
ABCA1  1.198888 HIST1H3G  1.181867 CTCF  1.168534 BACH2  1.154412 
HARBI1  1.198329 UGGT2  1.181745 RICTOR  1.168482 TPCN1  1.15436 
CGGBP1  1.198012 IMPAD1  1.181364 IQCK  1.167128 SLC43A3  1.153918 
LL0XNC01-
250H12.3  
1.197312 AGFG1  1.180855 RNA5SP273  1.166593 URB2  1.153669 
RNA5SP385  1.197249 SVIL  1.180845 TIA1  1.166474 DNAJA1  1.153498 
GDF15  1.196983 RP11-111F5.3  1.180587 PPIAL4B  1.165843 BTF3L4  1.153433 
ZBTB6  1.196409 FBXO30  1.180522 MIR570  1.165805 ANKRD29  1.153361 
CYP2U1  1.196261 MEF2A  1.180388 RNA5SP518  1.165734 PTP4A1  1.153284 
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EIF1  1.196059 TRMT10B  1.180234 SPOPL  1.165389 RP11-534L6.5  1.153017 
ZFAND4  1.195863 AMMECR1  1.180056 FAM129A  1.165364 CSTF1  1.152742 
SKIL  1.194692 AKR1B1  1.17997 YTHDF3  1.165095 EIF4EBP1  1.152489 
ZC3H8  1.194567 UPF3B  1.179664 UBXN2A  1.164813 KIF13A  1.152246 
FER1L6  1.194371 MAP4K4  1.17963 ZNF146  1.164143 FBXO27  1.152027 
PPAPDC1A  1.193984 MICALL1  1.179585 GNPDA1  1.164097 MPND  1.151698 
SLC16A2  1.193177 TRIM8  1.179527 MED17  1.16408 STARD7-AS1  1.151366 
ADARB1  1.193156 KRAS  1.179191 AC011431.1  1.164036 PGPEP1  1.15128 
BNIP3L  1.193043 MIR181A2HG  1.17842 MAD2L1BP  1.163841 PTRH2  1.150957 
ATP6V1C1  1.191967 BCAS2  1.178262 EPB41L5  1.163647 RNU6-773P  1.150469 
ELP3  1.191934 RUNX2  1.177764 LINC00862  1.163275 ULBP3  1.150421 
LIG4  1.191653 SWAP70  1.177602 SRP68  1.163083 SAAL1  1.150105 
SPATS2L  1.150043 NME6  1.139001 EPS15  1.127541 RP11-167J8.3  1.115795 
SIMC1  1.15001 EIF3A  1.138884 CRTAP  1.127383 UBR3  1.115533 
UBN2  1.149361 GPR135  1.137787 KRT81  1.12729 CXCL8  1.115484 
CLDN12  1.149292 NFKB1  1.137588 MKLN1-AS  1.127214 AC074183.4  1.115421 
VWA8  1.14928 RPS15A  1.13749 GUCY1A2  1.127138 MIR635  1.115166 
RNF111  1.148862 HS3ST3A1  1.137358 FAR1  1.126691 EXOC6B  1.115004 
STK17A  1.148815 
RP11-
164P12.4  
1.137196 MLLT10  1.126639 RSPH3  1.114905 
RBMS2  1.148534 ZNF462  1.137151 EDEM3  1.126477 ST6GALNAC6  1.114749 
CBS  1.148142 LINC00571  1.136974 HDAC3  1.126308 CTTNBP2NL  1.114207 
ATP6V0A2  1.148034 ANXA3  1.136294 B4GALT5  1.125836 CYB5D2  1.113995 
LOC646021  1.147895 RP11-274J7.2  1.136063 CD109  1.125768 VAPB  1.113919 
PROSER2  1.147765 NAA50  1.135538 RP11-597A11.6  1.125601 CA2  1.113616 
SCGB2B2  1.147726 CCDC97  1.135475 MAPKAP1  1.125463 PPM1D  1.113607 
ATM  1.147129 FBXL20  1.135372 API5  1.125218 NCOA2  1.112979 
AAK1  1.146837 HS3ST3B1  1.135113 NLK  1.124262 BAMBI  1.11279 
GREB1L  1.146646 SECISBP2L  1.134974 SEMA3A  1.12405 YIF1B  1.112776 
C6orf47-AS1  1.145754 GPR19  1.134513 PDZD8  1.123656 LOC101929709  1.112739 
CASP2  1.145662 PRMT3  1.134328 MGAT2  1.123486 ALKBH8  1.112432 
LIN54  1.145547 CLIC4  1.13422 RAB3GAP2  1.12347 SERPINE2  1.11233 
DTX2P1-UPK3BP1-
PMS2P11  
1.145451 ARAP3  1.133921 PRPF38A  1.12331 PHTF2  1.112097 
LINC01138  1.14535 C11orf54  1.133727 FAM111B  1.123259 MUL1  1.111976 
ARHGEF2  1.144842 PSPN  1.133387 KLRAP1  1.123175 LOC101928829  1.111831 
KLF6  1.144343 DLAT  1.133384 LOC648987  1.122836 CCDC92  1.111703 
BCL7B  1.144297 UBQLN2  1.133272 RP1-239B22.5  1.122569 AATF  1.111575 
KLHL42  1.144188 NFIB  1.133065 RNF138  1.12246 UCHL3  1.111541 
WBP4  1.143998 RAB32  1.132704 MIR32  1.122211 PARD6B  1.111228 
CROCCP3  1.14353 NAA35  1.132389 BTBD11  1.121493 TMEM133  1.111102 
DDX60  1.143424 CCDC25  1.13234 PXDC1  1.121307 FANCF  1.111033 
TAB2  1.142764 ABCA3  1.132339 SCRN3  1.120481 SPECC1L  1.110972 
EPM2A  1.142717 NUDT4P1  1.13203 NFATC3  1.120435 TMEM209  1.110964 
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XYLT1  1.142325 LBX2-AS1  1.131711 PARP16  1.12043 LINC01123  1.110957 
FJX1  1.142096 RN7SKP78  1.131569 DENND4A  1.120086 GNAO1  1.110914 
APPL2  1.141867 GALNT3  1.130654 FZD6  1.119793 RP11-486O13.4  1.110518 
DGCR14  1.141474 CDK6  1.130502 TTC7B  1.119772 RGMB  1.110488 
TCF20  1.141228 TET3  1.130275 BAG2  1.119551 ZNF774  1.109881 
AC092835.2  1.141221 HPS5  1.129808 SIK3  1.119452 CCSER2  1.109473 
TNPO3  1.141127 RN7SKP16  1.12965 ARL4C  1.119257 C17orf51  1.109151 
DHX36  1.141038 TTC3  1.129451 MOSPD2  1.119215 LOC284581  1.109146 
NRBP1  1.140706 KRIT1  1.12929 NPAT  1.119093 S100A10  1.108997 
PLAC8  1.140652 GLRX2  1.129184 DCAF5  1.118853 KLF12  1.108645 
APLF  1.140586 HIVEP2  1.128968 FCHSD2  1.118744 ASAP1  1.108091 
PHC1  1.140343 GSE1  1.128762 TMEM220  1.118481 NTNG1  1.107978 
CARF  1.1403 CTBP2P4  1.128686 MTMR6  1.118059 USP47  1.107689 
TRIM32  1.140169 RDH10  1.128678 ETS1  1.117641 CLCF1  1.107433 
SYNCRIP  1.140052 CNOT4  1.128653 WDR45  1.117377 ERI2  1.107385 
MTMR12  1.139652 SMAD4  1.128574 FGF5  1.117219 SAMD12-AS1  1.107364 
PLEKHA1  1.139347 MICAL2  1.128242 AMPD3  1.116797 TESK1  1.107248 
ZMPSTE24  1.139193 RP1-102E24.8  1.127832 LOC101929530  1.116647 SAV1  1.10693 
RP11-655C2.3  1.139036 TAS2R10  1.127757 RAB11FIP2  1.115894 HBEGF  1.106894 
CNKSR3  1.106533 PROSC  1.097967 C10orf76  1.08664 FRMD4A  1.077572 
LINC00649  1.106533 DDX39B  1.097922 GATSL2  1.086633 VAC14  1.077465 
FAF1  1.106465 DIRAS1  1.097335 MIR194-2  1.085933 SKA1  1.077417 
PROS1  1.106442 CHST12  1.097299 LRPPRC  1.085694 ZNF227  1.077297 
KIAA0232  1.106028 LTV1  1.097053 RSU1  1.085645 PCM1  1.077112 
ID1  1.105908 SCYL2  1.096558 
RP4-
633O19__A.1  
1.085593 SNX13  1.07689 
AGPS  1.105707 HSPH1  1.09645 RNU6-1082P  1.084957 LINC00152 1.076841 
FAM160B1  1.105698 STK38  1.096049 STAG2  1.084898 CHD7  1.076735 
RNU1-59P  1.105653 SGTB  1.09587 SGMS1  1.084851 SIK3-IT1  1.076573 
HEXB  1.105566 SCAF8  1.095584 IER5L  1.08452 GATM  1.076364 
BCL9L  1.105416 LOC100131802  1.094507 WSB1  1.084314 ZNF611  1.076339 
NCKAP5  1.105376 BPGM  1.094147 DHX33  1.084245 IDS  1.075225 
MEGF9  1.105347 SATB2  1.093986 TMEM38A  1.084038 CHRAC1  1.075221 
SHFM1  1.10534 STAG1  1.093921 PLEKHA5  1.084024 TRIOBP  1.07493 
QPCT  1.10497 MIR3661  1.093792 SUCLG2-AS1  1.083719 SCAMP4  1.074507 
NUDT5  1.104941 RIPK2  1.093525 KIAA1109  1.083635 SENP5  1.07438 
CACHD1  1.104747 LYPD1  1.093163 JPX  1.083561 RP11-156E6.1  1.074365 
KIAA1551  1.104735 TFB2M  1.09303 CA5BP1  1.083429 MAN1A1  1.074194 
POLR3H  1.104442 MIR505  1.093008 FRMD6  1.083305 CDC42SE2  1.074153 
CNPPD1  1.104413 QSER1  1.092504 C6orf120  1.083059 PARG  1.073691 
MFHAS1  1.104322 ARMCX6  1.092022 TP53TG3B  1.08254 KGFLP1  1.073446 
ZBTB41  1.10419 SOCS4  1.091869 RNF19B  1.082477 ITGA3  1.07325 
BBS7  1.103919 CDK9  1.091706 ARFGEF1  1.082429 MIR3065  1.073166 
EIF4G3  1.103182 TOR1A  1.091165 FOXN3  1.082022 MON1B  1.07308 
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ZNF518A  1.103043 ADSL  1.09114 THOC5  1.08174 GIT2  1.072817 
C7orf69  1.102933 MRS2  1.09101 RP11-314A15.2  1.081535 ENAH  1.072564 
AMMECR1L  1.102521 TMEM69  1.090937 NR1D2  1.081347 CBLL1  1.072515 
SRGAP2  1.102267 FLRT2  1.090806 AC159540.1  1.081275 UTP11L  1.072504 
GADD45A  1.101968 GGTLC2  1.090462 SH3GLB1  1.08106 PPP3CB-AS1  1.072291 
SLC45A4  1.101847 C7orf49  1.090288 GRPEL2  1.080912 MGA  1.072105 
RP11-561O4.1  1.101638 CERS2  1.09027 F11R  1.080658 RPS6KC1  1.07207 
EGLN1  1.101375 RASSF3  1.090134 S100A16  1.079887 TRIM37  1.071881 
TIMMDC1  1.10124 LOC103344932  1.09008 TTYH3  1.079591 VWA9  1.07142 
LRRC47  1.101196 ZNF117  1.08998 KRTAP5-4  1.079505 EHD2  1.071387 
AC104651.1  1.101104 SLC25A44  1.08994 NHLRC1  1.079456 RAB7A  1.07065 
RPP38  1.100986 RP11-110I1.12  1.089628 LIN7C  1.079289 PIK3R1  1.070531 
TOP3A  1.10088 SIKE1  1.08954 PPAP2A  1.079263 SEC24A  1.070514 
RP11-41O4.1  1.100866 DSP  1.08946 PTPN11  1.0789 TTL  1.070284 
RP11-589M4.1  1.099925 LOC100506548  1.089175 PDS5A  1.07869 NETO2  1.070188 
DIRC2  1.09985 TPRA1  1.089074 LOC286370  1.07851 KIAA1279  1.070149 
ITGAV  1.099826 CCDC30  1.088955 RLF  1.078509 RBM41  1.069826 
AP001347.6  1.099576 NUDT3  1.0881 WDFY3  1.078479 TRIM44  1.069695 
TAS2R3  1.099387 PLGLA  1.08728 RP4-798A10.2  1.078364 PHLDA1  1.069352 
PYGO1  1.099299 XX-C2158C6.3  1.087263 LINC00173  1.078208 SP4  1.068681 
SERTAD2  1.098957 MIR3908  1.087244 LOC100129550  1.078155 LOC374443  1.068677 
NOL10  1.098828 C16orf70  1.087029 PRUNE  1.078087 FAM173B  1.068613 
FAM27E2  1.098296 PPP4R1  1.086909 HPS3  1.078004 CACNG4  1.067932 
DDX1  1.098202 MTOR  1.086826 TLN2  1.077952 XKR6  1.067017 
LYPD8  1.098115 RAB21  1.086698 TAF4B  1.077572 C11orf63  1.0669 
RNA5SP408  1.066541 CCDC144A  1.056366 NNMT  1.045293 SMURF2  1.03542 
LOC642361  1.066369 NRBF2  1.056223 CLTCL1  1.044601 NUB1  1.035416 
SFR1  1.066148 ARNTL2  1.055978 SRGAP2-AS1  1.044546 XRCC1  1.035318 
TTC9  1.065865 ACTR8  1.05587 NIPAL1 1.044533 SPOP  1.035287 
NALCN  1.065732 LOC541472  1.055738 SNX6  1.044426 PTK2B  1.034762 
LINC00667  1.065671 AFAP1L2  1.055313 COA7  1.044337 PPP2R5E  1.034715 
RP11-79P5.2  1.065252 UTP3  1.05515 RPP14  1.044134 TP53RK  1.034383 
SNHG16  1.064456 
RP11-
1103G16.1  
1.05401 SIPA1L3  1.043917 OSER1-AS1  1.034178 
SIRT1  1.064307 POC1B  1.053337 ABL2  1.043878 ZMAT3  1.034008 
EAF1-AS1  1.064305 SERPINB8  1.053288 NIP7  1.043539 RASGRP3  1.033909 
ARMCX4  1.064123 TM4SF19  1.053222 DHCR24  1.0434 PKP2  1.033761 
ECM2  1.064117 TCTN3  1.053118 MAP4K3  1.042916 EIF1AX  1.033625 
SDHAP2 1.064067 ZSCAN16  1.052486 THAP11  1.042817 KIN  1.033324 
ALMS1  1.06395 TOB2P1  1.052085 RP11-521B24.5  1.042659 TMEM128  1.033246 
CD55  1.063918 TPP2  1.05203 CCAR2  1.042598 DUSP28  1.033079 
MIR4755  1.063711 SPIN1  1.051855 DUSP7  1.042415 CCDC71  1.033 
RP11-255A11.2  1.062897 PARP6  1.051795 UGDH  1.042393 IRAK2  1.032947 
LARS  1.062746 GNPDA2  1.051375 BMPR1A  1.042355 CHIC1  1.032846 
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PUM2  1.062678 PXMP2  1.051185 39873 1.041852 SLAIN2  1.032783 
SLTM  1.06208 MIR4720  1.051125 C15orf41  1.041712 ARID4A  1.032755 
MPHOSPH8  1.062064 MIRLET7I  1.051011 PLD1  1.041494 RNU6-126P  1.032519 
NTAN1  1.061977 LRCH2  1.050923 IL4I1  1.041444 TNKS2  1.032335 
E2F3  1.061963 NFE2L1  1.050798 RP11-244F12.2  1.041238 LPGAT1  1.031459 
LOC100652999  1.061818 EZR  1.050743 NSD1  1.041226 ZEB1  1.030765 
IFT52  1.061693 SLC20A1  1.05015 MIR3135B  1.041174 CHD1  1.03045 
TTLL12  1.061507 SLC23A2  1.050085 PTPRE  1.041017 CNBP  1.030424 
ZBED5-AS1  1.061448 DLEU2  1.049873 MPI  1.040881 PPAT  1.029803 
FEM1B  1.061358 EVC  1.049856 ATP2B4  1.040766 MID1  1.029698 
DNAJB12  1.061255 LOC391322  1.049714 DCTN4  1.040687 KPNA4  1.029624 
TRPS1  1.060366 CLASP2  1.049199 OGT  1.039964 ABHD17B  1.02934 
ANAPC13  1.060292 LOC644450  1.048931 TFDP2  1.039193 MIR548T  1.029328 
ARMC10  1.060223 CRYBG3  1.048734 ZSWIM4  1.03902 HSBP1L1  1.029298 
WBP1L  1.060112 ZNF599  1.048114 RNU6-522P  1.038477 LINC00638  1.029131 
LRCH3  1.059565 ENG  1.047819 AHCTF1  1.038189 AC009505.2  1.029033 
TRA2B  1.059162 WNK1  1.047629 AC005014.5  1.03809 PHIP  1.028906 
UHRF1BP1  1.058987 ZNF248  1.047531 MED13L  1.038004 RTN4  1.02878 
GOLGB1  1.058811 PIGA  1.047422 MAP1LC3B2  1.03791 MIR31  1.028379 
AIMP2  1.058612 B3GALT6  1.047388 AC067956.1  1.037718 STIM2  1.028184 
AGO2  1.0586 CTSD  1.047276 PDPK1  1.037567 RECK  1.028112 
SMARCD1  1.058481 LOC101929112  1.04673 WDR82  1.037462 BAZ1A  1.028106 
OTUD6B-AS1  1.058277 NDUFAF1  1.046661 SLC16A7  1.037451 RNU4-36P  1.028102 
SOCS3  1.058039 TMEM67  1.046566 N4BP2L2-IT2  1.037267 FAM171A1  1.027955 
RAB9A  1.057956 TSEN15  1.04639 KIR2DL2  1.036977 C8orf88  1.027698 
R3HDM1  1.057924 MIR761  1.046271 CDKL5  1.036975 NIPBL  1.027488 
GAREM  1.057474 WSB2  1.046048 TLE4  1.036664 GALNT1  1.027039 
ANKRD12  1.056866 EXT1  1.045976 ZCCHC17  1.036627 ITPK1  1.026614 
RAB31  1.056763 SPRY3  1.0459 SAP130  1.036604 ARHGEF12  1.026461 
USP33  1.056645 LINC01184  1.045528 MIR604  1.036479 CHMP2B  1.026359 
SERINC2  1.056583 MIR4632  1.045308 RYK  1.036088 C1orf220  1.026326 
NCOA4  1.026214 MGARP  1.017706 LINC01125  1.007988 TAF15  1.002056 
SMAGP  1.025848 SLC25A43  1.017655 PTPRG  1.007899 GSKIP  1.002001 
CD1B  1.025806 SRP72  1.017619 ALKBH3  1.007641 SLMAP  1.001506 
RWDD2B  1.025698 MIR626  1.017574 SIGLEC15  1.007555 PLK4  1.001422 
GCLM  1.025646 FBXL17  1.016882 SPRY2  1.007523 SHOC2  1.001253 
MME  1.025531 MID1IP1  1.016519 APCDD1L  1.007426 ZNF607  1.001149 
LOC101928020  1.025494 CTBS  1.016315 CCDC47  1.007329 NHS  1.000746 
ENTPD4  1.025298 DICER1  1.015704 SRPR  1.007313 NEK3  1.000699 
C22orf46  1.02507 FAM213B  1.015541 SYNC  1.006925 MAP3K8  1.000412 
IPO5P1  1.024981 NAA30  1.015472 FAM171B  1.006854 VPS54  1.000173 
IGLJ5  1.024974 RP11-25E2.1  1.015232 IL1RL1  1.006651 RP11-503E24.2  1.009823 
ZCCHC5  1.024504 LOC101929302  1.015026 ARHGEF18  1.006321 ZBTB9  1.009682 
SORT1  1.02447 ADRBK2  1.014746 CHKA  1.005964 GPD2  1.009566 
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SLC12A6  1.024335 ANKRD30B  1.014434 RMND5B  1.005693 LHX4-AS1  1.009557 
AP4M1  1.024191 SUPT6H  1.014269 SLC25A40  1.005613 MRPL1  1.009268 
FAM86EP  1.023982 RNA5SP500  1.01416 AVPI1  1.005159 BLM  1.009266 
NIN  1.023958 PLA2G15  1.0139 MIR769  1.005002 NOMO1  1.00926 
GIN1  1.023543 ANKRD16  1.013152 PRLR  1.004958 JAK2  1.009138 
FAM102B  1.023446 NAF1  1.01315 PARP4P2  1.004874 RTP3  1.009128 
IKBIP  1.023278 HOOK3  1.01311 LOC493754  1.004564 IGKV1-39  1.009037 
GCOM1  1.023206 ASCC2  1.013052 SEC11C  1.004172 RAB30  1.008787 
HECW2  1.02298 NT5DC2  1.012766 SP2  1.004115 RNU6-612P  1.008535 
IFIT2  1.02269 MLLT4  1.012762 FZD8  1.004045 CCDC101  1.008173 
LRRC8E  1.022572 RNA5SP70  1.012389 RAP2A  1.003902 ZSCAN5B  1.021091 
TAX1BP1  1.022356 ANTXR1  1.011957 ASPHD2  1.003633 ITCH  1.021067 
FUT11  1.022091 ORMDL1  1.011937 KLF3  1.003607 RBM24  1.020578 
SPTLC2  1.021971 TES  1.0117 PPAP2B  1.003552 STEAP3  1.020562 
LOXL2  1.021858 IDNK  1.011652 LYST  1.003532 CCDC103  1.020159 
VPS72  1.021793 RNA5SP355  1.011604 LSG1  1.003384 FAM200A  1.019979 
NUPR1L  1.021672 SLC22A4  1.01136 WNT5A  1.003003 TBC1D31  1.01983 
PPP3CA  1.021672 BLZF1  1.010509 RNU4ATAC16P  1.002975 GABRE 1.018605 
PAQR7  1.021549 USP31  1.010308 C7orf25  1.002944 SENP1  1.018475 
ARHGAP39  1.021346 MERTK  1.010129 PATZ1  1.002931 ZER1  1.018308 
RGPD1  1.021325 C2CD2  1.01012 PIAS2  1.002699 PYROXD1  1.018254 
RNU2-5P  1.021254 NXPE3  1.010083 ZNF271  1.002689 GNPTAB  1.018109 
ZNF384  1.021249 SRCAP  1.00987 ARHGAP11A  1.002432 RP11-642D21.2  1.018025 
 
 
